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Abstract  
  
Amyotrophic  lateral  sclerosis  (ALS)  is  a  terminal  neurodegenerative  disorder  where  
death   of   the   upper   and   lower  motor   neurons   causes   progressive  muscle   wasting  
and   paralysis.   Currently,   the   approved   treatments   for   ALS   provide   only   a   small  
therapeutic   benefit   to   patients.   A   GGGGCC   repeat   expansion   mutation   that   lies  
within   the   C9orf72   gene   is   causal   of   approximately   40%   of   the   inherited   form   of  
ALS.   The   mutation   has   been   demonstrated   to   cause   haploinsufficiency   of   the  
C9orf72   protein   and   this   loss   of   function   is   hypothesised   to   contribute   to  
pathogenesis   in   C9orf72-­ALS.   Until   recently,   little   was   known   about   the   protein  
function   of   C9orf72.   We   performed   a   yeast   two-­hybrid   screen   to   investigate   the  
C9orf72   interactome  which   identified  binding  between  C9orf72  and  coilin.  Coilin   is  
the   major   protein   component   of   nuclear   suborganelles,   Cajal   bodies,   which   are  
responsible   for   processing   snRNPs   that   form   the   spliceosome.   C9orf72-­ALS  
patients  exhibit  splicing  defects  which  correlate  with  disease  severity.  We  therefore  
hypothesised   that   loss   of   the   C9orf72-­coilin   interaction   leads   to   dysregulation   of  
Cajal  bodies  and  splicing  in  C9orf72-­ALS.    
  
The   aims   of   this   project   were   to   characterise   the   C9orf72-­coilin   interaction   and  
investigate  the  effect  of  C9orf72  on  Cajal  bodies  and  splicing.  C9orf72  was  found  to  
interact  with   coilin   directly   in   vitro   and  within   cells,   suggesting   the   interaction   has  
biological   importance.  Depletion  of  C9orf72   in  HEK293  cells   led   to  an   increase   in  
the   number   of   Cajal   bodies,   and   a   subtle   defect   in   splicing.   In   contrast,   C9orf72  
overexpression   decreased   the   number   of   Cajal   bodies,   but   had   little   effect   on  
splicing.   Interestingly,   investigation   of   Cajal   bodies   in   C9orf72-­ALS   patient  
iAstrocytes  found  patients  exhibited  higher  numbers  of  Cajal  bodies   in  comparison  
to  healthy  controls.  
  
The   work   included   in   this   thesis   uncovered   an   interaction   between   C9orf72   and  
coilin  and  that  depletion  of  C9orf72  can  lead  to  abnormal  numbers  of  Cajal  bodies.  
The   results   support   evidence   for   a   novel,   uncharacterised   role   for   C9orf72   in   the  
nucleus   which   may   be   linked   with   snRNP   processing,   Cajal   bodies   and   splicing.  
Investigation  into  the  function  of  nuclear  C9orf72  will   lead  to  greater  understanding  
of   the   consequences   of   C9orf72   haploinsufficiency   in   ALS   and   may   lead   to  
development  of  better  drug  treatments  for  patients.    
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1   Introduction  
  
1.1   Amyotrophic  lateral  sclerosis  
  
Amyotrophic   lateral   sclerosis   (ALS)   is   a   fatal,   progressive   neurodegenerative  
disorder  categorised  as  a  motor  neuron  disease  (MND),  and  is  caused  by  the  death  
of   upper   and   lower   motor   neurons.   Upper   motor   neurons   are   located   within   the  
motor  cortex  and  brain  stem  and  project  down  to  lower  motor  neurons  found  in  the  
spinal  cord.  Signalling  between  the  upper  and  lower  motor  neurons  is  essential  for  
most  motor   functions.   Loss  of  motor   neurons   in  ALS   leads   to  progressive  muscle  
weakness,   paralysis,   and   eventually   death   (Ravits   and   La   Spada,   2009).   The  
average   life   expectancy   from   diagnosis   is   2-­3   years   and   there   is   currently   no  
effective   treatment.  Riluzole,   the   drug  most   commonly   prescribed   for   treatment   of  
ALS,   has   only   a   moderate   effect   and   increases   life   expectancy   by   2-­3   months  
(Lacomblez  et  al.,  1996).  Approximately  7   in  every  100,000  people  are   thought   to  
suffer   from   the   disease,   with   those   aged   between   50   and   70   at   highest   risk  
(Kurtzke,  1982).  Men  are  also  more  commonly  affected  than  women  (Leblond  et  al.,  
2014).  
  
1.2   Clinical  features  of  ALS  
  
Symptoms   including   muscle   twitching,   wasting   and   weakness,   spastic   dysarthria,  
fatigue,  weight  loss  and  dyspnoea  are  seen  in  ALS,  with  relatively  rapid  progression  
from  symptom  onset   to  death  (Ramirez  et  al.,  2008).  Motor  control  decreases  with  
disease   progression   and   care   is   often   required   throughout   the   duration   of   the  
disease.  Symptom  onset  usually  occurs  distally  in  a  single  limb  (limb-­onset  ALS)  or  
through  speech  and  swallowing  difficulties  (bulbar-­onset  ALS),  with  muscle  wasting  
and   weakness   gradually   spreading   until   the   respiratory   muscles   are   unable   to  
function  (Kiernan  et  al.,  2011).  More  rarely,  ALS  can  present  with  initial  respiratory  
symptoms.   ALS   shares   clinical,   neuropathological   and   genetic   features   with  
frontotemporal   dementia   (FTD)   where   symptoms   include   changes   in   behaviour,  
language,  and  memory,  associated  with  degeneration  of  neurons  in  the  cortex  and  
basal   ganglia.   Approximately   10-­15%   of   patients   diagnosed   with   FTD   go   on   to  
develop   motor   neuron   degeneration,   referred   to   as   FTD-­ALS   (Hodges,   2001).  
Conversely,  approximately  30%  of  ALS  patients  later  develop  cognitive  impairment  
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and   dementia   (Rippon   et   al.,   2006).   As   such,   the   two   diseases   are   said   to   be   at  





1.3   Pathological  features  of  ALS  
  
One   of   the   defining   neuropathological   features   of   both   ALS   and   FTD   is   the  
presence   of   skein-­like,   neuronal   cytoplasmic   inclusions   (NCIs)   of   aggregated  
protein  (Mizusawa,  1993).  The  NCIs  are  ubiquitinated,  but  are  tau-­  and  α-­synuclein  
negative  (Mackenzie  and  Feldman,  2005).  One  of  the  major  proteins  found  in  NCIs  
is   TDP-­43,   which   associates   with   the   inclusions   in   a   hyperphosphorylated   and  
fragmented  form  (Arai  et  al.,  2006;;  Neumann  et  al.,  2006).  The  TDP-­43  NCIs  have  
been   detected   in   glial   cells   as   well   as   neurons,   and   are   distributed   across  many  
different  regions  of  the  CNS,  including  the  spinal  cord,  hippocampus,  frontal  cortex  
and  temporal  cortex  (Arai  et  al.,  2006;;  Neumann  et  al.,  2006).  The  inclusions  are  a  
pathological  hallmark  of  both  sporadic  and  familial  ALS,  with  the  exception  of  SOD1  
fALS,   suggesting   an   underlying   protein   aggregation   disease   mechanism   may   be  
shared  between  both   the  sporadic  and  familial   forms  of  disease  (Mackenzie  et  al.,  
2007;;  Tan  et  al.,  2007).  The  distribution  pattern  of  TDP-­43  proteinopathy  has  been  
shown   to   correlate  with   neuronal   loss   in   ALS   patient   brains.   In   keeping  with   this,  
patients  with   the  most  widespread  TDP-­43  NCIs  perform  worse   in   the  Mini-­Mental  
State  Examination,  which   requires   patients   to   complete   a   questionnaire   and   uses  
patient’s   responses   to   determine   cognitive   ability,   than   patients   with   inclusions  
Figure  1.1.  ALS-­FTD  disease  spectrum.  ALS  and  FTD  are  at  opposite  ends  of  
the  disease  spectrum  with  pure  ALS  at  one  end  and  pure  FTD  at   the  other.   In  
between  is  ALS  with  cognitive  and  behavioural  impairments  (ALS-­CBI)  and  FTD  
with  motor  neuron  degeneration  (FTD-­ALS).    
    
   20  
localised  to  only  a  small  part  of  the  brain  (Brettschneider  et  al.,  2013).  Despite  this  
correlation,  it  is  not  yet  known  whether  the  NCIs  are  causal  of  neurodegeneration.    
  
TDP-­43-­negative   aggregates   are   also   frequently   observed   in   ALS.   Bunina   bodies  
are  small,  eosinophilic  inclusions  found  in  the  spinal  cord  and  brain  stem  of  sporadic  
and   familial   ALS   patients   (Tomonaga   et   al.,   1978).   Bunina   bodies   are   formed  
exclusively  by  the  aggregation  of  the  cystatin  C  and  transferrin  proteins  (Mizuno  et  
al.,  2006;;  Okamoto  et  al.,  1993);;  studies  performing  staining  against  proteins  with  a  
known  propensity  to  aggregate  fail  to  detect  other  protein  components.  The  reason  
for   their   formation   and   biological   significance   to   ALS   however   is   not   well  
understood.    
  
Basophilic   inclusions   (BIs)   appear   as   round,   fragmented   or   irregular-­shaped  
filamentous   inclusions   in   neurons   from   patients   diagnosed   with   juvenile   ALS   and  
more  rarely  adult-­onset  ALS  (Kusaka  et  al.,  1993;;  Matsumoto  et  al.,  1992).  BIs  are  
defined  by   their  pale  staining  appearance  with  haematoxylin  and  eosin   (H&E)  and  
their  strong  reaction  to  Nissl  stain  (Kusaka  et  al.,  1990).  BIs  are  similar  in  size  to  the  
nucleus  and  have  been  observed   in   the  spinal  cord,  motor  cortex,  putamen,   facial  
nucleus   and   thalamus   (Aizawa   et   al.,   2000;;   Kusaka   et   al.,   1990).   Several   RNA-­
binding  and/or  stress  granule  associated  proteins  have  been  found  to  associate  with  
BIs,   including   FUS,   poly(A)-­binding   protein   1,   T   cell   intracellular   antigen   1   and  
ribosomal   protein   S6   (Bäumer   et   al.,   2010;;   Fujita   et   al.,   2008),   suggesting   the  
inclusions   may   be   associated   with   dysfunctional   RNA   processing   and   attenuated  
translation  (Ito,  2014).    
  
1.4   Genetics  of  ALS  
  
ALS  is  predominantly  a  sporadic  disease;;  90%  of  patients  develop  ALS  in  singular,  
random   instances   throughout   a   population.  The   remaining  10%  of  ALS  cases  are  
caused  by   inheritance  of  a  mutation   in  an  ALS-­linked  gene,   referred   to  as   familial  
ALS  (fALS)  (Rowland  and  Shneider,  2001).  There  are  more  than  20  known  genes  in  
which   a   genetic  mutation   can   cause  ALS   and   approximately   68%   of   familial   ALS  
cases   are   now   associated   with   a   mutation   in   one   of   these   genes   (Table   1.1)  
(Renton  et   al.,   2013).  Mutations   in   the  C9orf72,  SOD1,  TARDBP   and  FUS   genes  
are   collectively   causative   for   more   than   half   of   familial   ALS   cases.   Hence,   this  
introduction   will   review   the   disease  mechanisms   of   how   these  mutations  may   be  
pathogenic.   There   are   large   efforts   currently   being   undertaken   to   discover   further  
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ALS-­risk   genes.   For   example,   Project   MinE   is   an   international   collaboration  
between  ALS  research  institutes,  scientists  and  clinicians,  aiming  to  complete  whole  
genome  sequencing  of  15,000  ALS  patients  and  7,500  controls  across  17  countries  
to   increase   the   current   understanding   of   genetic   risks   for   ALS   (Press   Release  




Table  1.1.  ALS-­linked  genes  grouped  by  the  proposed  function  of  the  causal  gene  
Gene   Protein   Reference  
Superoxide  metabolism  
SOD1   Superoxide  dismutase  1   (Rosen  et  al.,  1993)  
RNA  processing  
TARDBP   TDP-­43   (Sreedharan  et  al.,  2008)  
FUS   Fused  in  sarcoma  
(Kwiatkowski    Jr.  et  al.,  2009;;  
Vance  et  al.,  2009)  
SETX   Senataxin   (Chen  et  al.,  2004)  
ANG   Angiogenin   (Greenway  et  al.,  2006)  
MATR3   Matrin-­3   (Johnson  et  al.,  2014)  
HNRNPA1/HNRNPA2B1  
Heterogeneous  nuclear  
ribonucleoprotein  A1  and  
A2B1  
(Kim  et  al.,  2013)  
Trafficking,  autophagy  or  protein  proteostasis  
C9orf72   C9orf72   (DeJesus-­Hernandez  et  al.,  
2011;;  Renton  et  al.,  2011)  
ALS2   Alsin   (Yang  et  al.,  2001)  
FIG4   Polyphosphoinositide  5-­
phosphatase  
(Chow  et  al.,  2009)  




associated  protein  B  
(Nishimura  et  al.,  2004)  
OPTN   Optineurin   (Maruyama  et  al.,  2010)  
SQSTM1   Sequestosome  1   (Fecto  et  al.,  2011)  
VCP   Valosin-­containing  protein   (Johnson  et  al.,  2010)  
UBQLN2   Ubiquilin  2   (Deng  et  al.,  2011)  
SPG11   Spatacsin   (Orlacchio  et  al.,  2010)  
TBK1   TANK-­binding  kinase  1   (Cirulli  et  al.,  2015)  
CHMP2B   Charged  multivesicular  
body  protein  2B  
(Parkinson  et  al.,  2006)  
   22  
  
1.4.1   Superoxide  dismutase  1  
  
Mutations  in  SOD1  account  for  approximately  20%  of  familial  ALS  cases  (Rosen  et  
al.,   1993).   Approximately   140   different   mutations   have   been   identified   within   the  
SOD1  gene,   however   only   20   of   these   have   been   validated   as   causative   of   ALS  
pathogenicity  by  further  research  (Andersen,  2006).  An  X-­ray  crystallography  study  
found   that   the   mutations   are   located   in   non-­catalytically   active   SOD1   protein  
domains   (Deng   et   al.,   1993).   The   normal   function   of   superoxide   dismutase   1  
(SOD1)   is   to   ‘clean   up’   reactive   oxygen   species   (ROS),   metabolising   them   into  
oxygen  and  hydrogen  peroxide,  thus  reducing  oxidative  stress  and  damage  to  cells.  
It  was  originally  debated  whether  a  loss  of  SOD1  enzymatic  activity  or  generation  of  
a  toxic  mutant  SOD1  was  responsible  for  SOD1-­ALS  pathogenicity.  However,  there  
are  studies  which  suggest  SOD1  null  mice  do  not  develop  ALS  clinical  features  and  
that   there   is   no   correlation   between   SOD1   dismutase   activity   and   ALS   severity,  
although  these  results  need  validating  (Bruijn  et  al.,  1998;;  Reaume  et  al.,  1996).  On  
the  other  hand,  mutant  SOD1  protein  has  been  shown   to   form  protein  aggregates  
within   motor   neurons   whose   appearance   correlates   with   both   disease   onset   and  
progression  (Bruijn  et  al.,  1998).  Mutant  SOD1  has  also  been  shown  to  impair  both  
slow   and   fast   axonal   transport   of   cargo   proteins   and   mitochondria   respectively  
(Cleveland   and   Williamson,   1999;;   De   Vos   et   al.,   2007).   The   latter   is   caused   by  
mutant   SOD1   induction   of   PINK1/Parkin-­dependent   Miro1   degradation,   which  
detaches   mitochondria   from   the   molecular   motor   kinesin   1   (Moller   et   al.,   2017).  
Consequently,   a   toxic   gain-­of-­function   from  mutant  SOD1   is   now  accepted  as   the  
major   contributing   factor   to   pathology   in  SOD1-­related  ALS.  Studies   in   transgenic  




protein  tau   (Hutton  et  al.,  1998)  
PFN1   Profilin   (Wu  et  al.,  2012a)  
TUBA4A   Tubulin,  alpha  4A   (Smith  et  al.,  2014)  
DCTN1   Dynactin   (Puls  et  al.,  2003)  
NEFH  
Neurofilament  heavy  
polypeptide   (Figlewicz  et  al.,  1994)  
KIF5A   Kinesin  heavy  chain  factor  5A   (Brenner  et  al.,  2018)  
DNA  damage  
NEK1   Never  in  mitosis  A-­related  
kinase  1  
(Brenner  et  al.,  2016)  
C21orf2   C21orf2   (van  Rheenen  et  al.,  2016)  
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(ASO)  as  a  means  of  reducing  both  wild-­type  and  mutant  SOD1  levels  (Smith  et  al.,  
2006;;  Winer  et  al.,  2013).  The  2006  mouse  study  showed  therapeutic  promise,  with  
good  ASO  penetration  into  the  CNS,  reduced  SOD1  protein  levels  and  an  increase  
in  mouse  survival  rate  (Smith  et  al.,  2006;;  Winer  et  al.,  2013).  Clinical  trials  are  now  
underway   investigating   the   therapeutic   use   of   SOD1-­targeting   antisense  
oligonucleotides  in  humans,  although  these  have  so  far  been  unsuccessful  (Miller  et  
al.,  2013).    
  
1.4.2   TARDBP  
  
After  SOD1,  mutations  in  the  TARDBP  gene  account  for  a  further  5%  of  familial  ALS  
cases  (Sreedharan  et  al.,  2008).  The  TARDBP  gene  encodes  the  Tar  DNA  protein  
of   43   kDa   (TDP-­43)   protein,   a   component   of   the   ubiquitin-­positive,   tau-­   and   α-­
synuclein  negative  protein  inclusions  observed  in  the  CNS  of  ALS  patients  (Arai  et  
al.,   2006).   TDP-­43   is   a   predominantly   nuclear-­localised,   DNA-­   and   RNA-­binding  
protein  which  was  originally  characterised  as  a   transcriptional   repressor  of  an  HIV  
gene,   and   a   splicing   factor   for   the   cystic   fibrosis-­related   gene  CFTR   (Buratti   and  
Baralle,   2001;;   Ou   et   al.,   1995).   Although   TDP-­43   is   mostly   concentrated   in   the  
nucleus,   some   protein   shuttles   to   the   cytoplasm   where   it   binds   mRNA   3’   UTRs,  
influencing  their  stability,  transport  and  translation  (Colombrita  et  al.,  2012;;  Wang  et  
al.,   2008).   In   the   nucleus,   TDP-­43   regulates   RNA   processing   and   splicing   of  
hundreds  of  transcripts  through  an  interaction  with  non-­coding  GU  repeats,  and  has  
also   been   shown   to   regulate   its   own   expression   level   by   enhancing   splicing   of   a  
TDP-­43   intron   (Bhardwaj   et   al.,   2013;;   Polymenidou   et   al.,   2011).   TDP-­43   also  
interacts  with   the  Drosha  complex   to   regulate  microRNA  biogenesis   (Buratti  et  al.,  
2010;;  Kawahara  and  Mieda-­Sato,  2012).    
  
A  number  of  missense  mutations  in  the  TARDBP  gene  have  been  identified  in  both  
sporadic   and   familial   ALS  patients,   and   these  mutations   appear  mostly  within   the  
TDP-­43  C-­terminus  which   is   responsible   for   interactions  with  hnRNPs  and  splicing  
regulation   (Buratti   et   al.,   2005;;   Kabashi   et   al.,   2008).   Mutations   in   the   TARDBP  
gene  are   likely  to  cause  ALS  through  a  toxic  gain-­of-­function  of   the  mutant  protein  
combined  with   loss  of   functional  TDP-­43  from  the  nucleus.  Mutant  TDP-­43  protein  
exhibits  a  higher  propensity  to  form  aggregates  in  comparison  to  wild-­type  TDP-­43  
in  vitro  (Guo  et  al.,  2011;;  Johnson  et  al.,  2009).  This  result   is  also  supported  by   in  
vivo   studies   which   report   overexpressed,   mutant   TDP-­43   more   readily   forms  
neurotoxic  inclusions  in  spinal  cord  tissue  from  transgenic  TDP-­43  mice  and  primary  
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rat  cortical  neurons  (Barmada  et  al.,  2010;;  Kabashi  et  al.,  2010;;  Wils  et  al.,  2010).  
As   such,  mutations   in   the  TARDBP   gene   enhance   the  mislocalisation   of   TDP-­43  
from  the  nucleus  into  cytoplasmic  inclusions.  
  
Studies   in  mice  depleted   in  TDP-­43  would  suggest   that   loss  of  TDP-­43   function   is  
causal  of  ALS;;  TDP-­43  knockout  mice  exhibit   typical  ALS-­clinical  phenotypes  and  
motor   neuron   degeneration   (Iguchi   et   al.,   2013;;   Wu   et   al.,   2012b).   Furthermore,  
abhorrent  splicing  of  mRNA  transcripts  known  to  be  regulated  by  TDP-­43  has  been  
detected   in  ALS   spinal   cord,   suggesting   loss   of   nuclear   TDP-­43   can   disrupt  RNA  
processing   (Xiao   et   al.,   2011).   Indeed,   loss   of   nuclear   TDP-­43   in   patient   derived  
fibroblasts   containing   a   mutation   in   TARDBP   can   lead   to   changes   in   alternative  
splicing  events  (Highley  et  al.,  2014).  Aggregation  of  mutant  TDP-­43  into  NCIs  may  
also  hinder  its  ability  to  perform  cytosolic  functions.  Wild-­type  TDP-­43  is  involved  in  
the  axonal  transport  of  mRNP  granules  to  the  neuronal  dendrite,  and  this  transport  
of   mRNA   is   abolished   in   iPSC-­derived   motor   neurons   from   patients   exhibiting   a  
TARDBP  mutation  (Alami  et  al.,  2014).    
  
1.4.3   Fused  in  sarcoma  
  
Mutations   in   the  FUS   gene   are   responsible   for   approximately   5%   of   familial   ALS  
cases  and  1%  of   sporadic  ALS  cases   (Kwiatkowski     Jr.  et  al.,   2009;;  Vance  et  al.,  
2009).  Like  TDP-­43,   the  FUS  protein   is  an  RNA/DNA  binding  protein   that  shuttles  
between  the  nucleus  and  cytoplasm,  and  has  roles  in  transcription  regulation,  RNA  
processing  and  mRNP  transport  (Wang  et  al.,  2015;;  Yang  et  al.,  2014).  FUS  binds  
nascent   pre-­mRNA   transcripts   at   GGU   sequences   in   a   saw-­tooth   pattern,   and  
directly   facilitates   intron   removal   by   interacting   with   RNA   polymerase   II   and   the  
spliceosome  component  U1  snRNP  (Rogelj  et  al.,  2012;;  Yu  and  Reed,  2015).  FUS  
can   also   interact   with   the   SMN   complex   via   direct   interactions   with   both   the   U1  
snRNP  and  the  SMN  protein  (Yamazaki  et  al.,  2012).  As  well  as  regulating  splicing  
of   other   mRNAs,   FUS   also   has   the   ability   to   regulate   its   own   expression   by  
inhibiting  splicing  of  an  intron  within  the  FUS  transcript  and  thus  targeting  the  mRNA  
for  nonsense-­mediated  decay  (Zhou  et  al.,  2013).  Lastly,  FUS  has  been  shown   to  
interact  with  mRNA  and  mRNPs  in  the  cytoplasm,  aiding  transport  to  distal  parts  of  
neurons  as  a  method  of  translation  regulation  (Fujii  et  al.,  2005).    
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The   pathogenic  FUS  mutations   are   clustered   within   the   C-­terminal   domain   which  
includes  the  RNA-­recognition  motif  and  nuclear  localisation  signal  (Chiò  et  al.,  2009;;  
Drepper   et   al.,   2011).   As   a   result,   mutant   FUS   becomes   mislocalised   to   the  
cytoplasm  (Dormann  et  al.,  2010;;  Gal  et  al.,  2011).  The  mutant  FUS  protein  has  an  
intrinsically  disordered,  prion-­like  structure  which  drives  the  protein  into  cytoplasmic  
aggregates  (Bosco  et  al.,  2010;;  Patel  et  al.,  2015;;  Vance  et  al.,  2009).  It  has  been  
proposed  that  mislocalisation  of  FUS  into  cytoplasmic  aggregates  inhibits  its  ability  
to   autoregulate   its   expression   leading   to   increased   mutant   FUS   levels   and   thus  
exacerbating  its  own  protein  aggregation  (Zhou  et  al.,  2013).    
  
FUS-­ALS   pathogenicity   is   currently   understood   to   involve   both   a   toxic   gain-­of-­
function  combined  with  loss  of  functional  FUS  from  the  nucleus.  Depletion  of  FUS  in  
both   HeLa   cells   and   mouse   brain   leads   to   changes   in   gene   expression   and  
alternative   splicing   events,   and   introduces   premature   stop   codons   in   some  
transcripts   encoding   central   RNA-­binding   proteins   (Lagier-­Tourenne   et   al.,   2012;;  
Sun  et  al.,  2015).  However,  transgenic  ALS-­mutant  FUS  mice  but  not  FUS  knockout  
mice   develop   motor   neuron   degeneration,   suggesting   toxicity   from   the   mutant  
protein  is  required  to  develop  ALS  clinical  phenotypes  (Scekic-­‐Zahirovic  et  al.,  2016;;  
Sharma  et  al.,  2016).  Cytoplasmic  aggregations  of  mutant  FUS  bind  and  sequester  
the  spliceosomal  U1,  U11  and  U12  snRNPs,  preventing  their  import  into  the  nucleus  
for  catalysis  of  intron  splicing  and  worsening  the  defective  splicing  caused  by  loss  of  
nuclear   FUS   (Reber   et   al.,   2016;;   Yu   et   al.,   2015).   In   addition,  mutant   FUS   binds  
more   strongly   to   the   SMN   protein   than   wild-­type   FUS,   which   may   cause   the  
reduction   in   nuclear   Gems   and   snRNAs   observed   in   FUS-­ALS   patient   fibroblasts  
(Sun  et  al.,  2015).  Defective   transport  of  mRNA  to  neural  dendrites   is  also  a   toxic  
consequence   of   the   cytoplasmic   FUS   inclusions.   mRNA   which   encodes   proteins  
essential   for   neurite   growth   and   maintenance,   and   which   under   normal  
circumstances   is   transported   to   and   locally   translated   at   the   neuronal   axon   or  
dendrite,  becomes  sequestered  by  mutant  FUS  in  cytoplasmic  inclusions  leading  to  
neurite  degeneration  (Jun  et  al.,  2017;;  Yasuda  et  al.,  2017).    
  
1.5   Molecular  pathogenesis  of  ALS  
  
There  are  multiple  molecular  pathways  that  appear  to  be  disrupted  in  ALS,  and  it  is  
likely   that   a   complicated   convergence   of   these   eventually   leads   to   motor   neuron  
degeneration.   Proteins   in   which   ALS-­causative   mutations   lie   highlight   RNA  
processing,   autophagy   and   protein   proteostasis,   cytoskeleton   maintenance   and  
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DNA   damage   as   some   of   the   pathways   involved   in   ALS.   In   addition   to   these,  
mitochondrial   dysfunction,   glial   cell   toxicity   and   glutamate   excitotoxicity   have   all  
been   shown   to   have   some   involvement   in   ALS.  Dysfunctional  RNA   processing   in  
ALS  is  reviewed  in  Section  1.7.1.    
  
1.5.1   Autophagy  and  protein  proteostasis  
  
There  are  multiple  indications  that  autophagy  and  protein  proteostasis  are  defective  
in  ALS.  Neuronal  inclusions  of  aggregated  protein  are  common  to  almost  every  ALS  
patient,   and   ALS-­causative   mutations   are   commonly   found   within   genes   that  
regulate  autophagy  and  protein  homeostasis.    
  
Aggregation  of  protein  is  a  common  theme  that  runs  throughout  ALS:  (i)  mutations  
in   TARDBP,   FUS   and   SOD1,   all   lead   to   the   cytoplasmic   aggregation   of   their  
respective  proteins,  (ii)  ubiquitinated  TDP-­43-­positive,  tau-­  and  α-­synuclein-­negative  
inclusions  are  prominent  in  both  sporadic  and  familial  ALS  and  (iii)  p62-­positive  but  
TDP-­43-­negative   cytoplasmic   inclusions   are   an   additional   pathological   hallmark  
specific   to  C9orf72-­ALS  patients   (Al-­Sarraj   et   al.,   2011).  The   improper   removal   of  
these   aggregates,   which   often   contain   the   autophagy   and   ubiquitin   proteasome  
system  (UPS)  signalling  proteins  p62  and  ubiquitin,  implies  there  may  be  underlying  
faults  to  protein  clearance  pathways.    
  
Many   ALS-­causative   mutations   lie   in   genes   which   are   involved   in   autophagy.  
Mutations  in  the  SQSTM1  gene,  which  encodes  the  autophagy  adaptor  p62  protein,  
were  discovered  in  both  familial  and  sporadic  ALS,  and  patients  were  found  to  have  
increased  levels  of  both  p62  and  TDP-­43  (Fecto  et  al.,  2011;;  Teyssou  et  al.,  2013).  
In  2011,  mutations  within  the  UBQLN2  gene  were  discovered  to  be  causative  of  X-­
linked   ALS/dementia   (Deng   et   al.,   2011).   The   normal   function   of   the   Ubiquilin   2  
protein  is  to  recognise  protein  ubiquitin  chains  and  facilitate  protein  degradation  by  
the  proteasome  (Seok  Ko  et  al.,  2004).  ALS-­mutant  forms  of  the  Ubiquilin  2  protein  
impair  global  protein  degradation  by  the  UPS  (Deng  et  al.,  2011).  Lastly,  a  mutation  
in   the   C9orf72   protein,   responsible   for   autophagy   initiation   and   trafficking,   is   the  
most   common   cause   of   familial   ALS   known   to   date,   and   causes   p62   protein  
accumulation   and   impairs   autophagy   (Webster   et   al.,   2016).   The   complete   list   of  
mutations  in  ALS-­linked  genes  associated  with  autophagy,  protein  homeostasis  and  
trafficking  are  detailed  in  table  1.1.    
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Autophagy   works   alongside   the   UPS   to   degrade   cellular   components   such   as  
damaged   organelles   and   protein   aggregates.   Disruption   to   autophagy   in   mice   by  
depletion   of   the   autophagy   gene   Atg7   can   cause   neurodegeneration   and  
development   of   ALS-­like   ubiquitin-­positive   inclusions   (Komatsu   et   al.,   2006).  
Interestingly,  induction  of  autophagy  has  been  shown  to  alleviate  TDP-­43  pathology  
(Barmada  et  al.,   2014).  p62   is   involved   in   the  selective  autophagy  process  and   is  
responsible   for   the   binding   of   ubiquitinated   proteins   targeted   for   autophagosome  
degradation   and  mediating   their   transport   to   the   autophagosome   (Lattante   et   al.,  
2015).   Knockdown   of   p62   in   zebrafish   has   been   shown   to   cause   motor   neuron  
degeneration   and   a   decrease   in   swimming   ability   which   can   be   rescued  with   the  
autophagy   inducer   rapamycin,   suggesting   defective   autophagy   can   be   causal   of  
problems  in  motor  function  in  ALS  (Lattante  et  al.,  2015).  Lastly,  ageing  is  the  best  
known  risk   factor   for  developing  ALS  (Logroscino  et  al.,  2010;;  Uenal  et  al.,  2014).  
Autophagic  clearance  of  proteins  has  been  demonstrated  to  naturally  decrease  with  
age,   and   it   is   thought   that   neurons   are   particularly   susceptible   to   disruptions   to  
autophagy  because  their  inability  to  divide  exacerbates  the  accumulation  of  protein  
(Cuervo   et   al.,   2005;;   Nixon,   2013).   Hence,   one   possibility   is   that   age-­related  
accumulation   of   protein   aggregates   in   ALS   leads   to   the   specific   degeneration   of  
motor  neurons.  
  
1.5.2   Cytoskeleton  maintenance  
  
Mutations   in   several   genes   involved   in   cytoskeleton   maintenance   and   axonal  
transport  have  been  linked  with  ALS  (Table  1.1).  Profilin  is  an  actin-­binding  protein  
that  facilitates  the  polymerisation  of  monomeric  actin  into  filamentous  actin  and  can  
also   regulate   microtubule   dynamics   (Carlsson   et   al.,   1977;;   Nejedla   et   al.,   2016).  
ALS-­linked  mutations   in   the  profilin  gene   lead   to  generation  of  cytoplasmic  protein  
aggregates  composed  of  mutant  profilin,  p62,  ubiquitin  and  TDP-­43,  a  decrease  in  
the  actin-­profilin  interaction,  and  defective  axonal  growth  in  motor  neurons  (Tanaka  
et   al.,   2016;;   Wu   et   al.,   2012a).   ALS-­causative   mutations   in   the   tubulin   alpha-­4A  
gene  provide  further  evidence  that  a  disrupted  cytoskeleton  may  contribute  to  ALS  
pathogenicity.  The  TUBA4A  mutations  interfere  with  the  microtubule  network  due  to  
the   inability   of   tubulin   alpha-­4A   to   properly   form   tubulin   dimers   with   beta-­tubulin  
(Smith   et   al.,   2014).   In   addition,   an   ALS-­linked   mutation   in   the   axonal   transport  
protein   dynactin   has   been   shown   to   hinder   axonal   vesicular   transport   and   induce  
motor  neuron  degeneration   (Laird  et  al.,  2008;;  Puls  et  al.,  2003).  Finally,  a   recent  
study   found   that   splice-­site  mutations   in   the  C-­terminal   of   the  KIF5A   gene,  which  
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expresses   a   neuronal   kinesin  motor   protein   responsible   for   protein   and   organelle  
trafficking  along  microtubules,  can  be  causative  of  ALS  (Brenner  et  al.,  2018).  The  
mutations   are   suggested   to   lead   to   haploinsufficiency   of   the   KIF5A   protein,   and  
disruption   to   the   neuronal   transport   of   KIF5A   cargos   (Brenner   et   al.,   2018).  
Collectively,   the   mutations   implicate   axonal   pathology   and   a   defective   neuronal  
cytoskeleton  may  be  a  primary  cause  of  ALS.    
  
Dysfunctional   axonal   transport   is   also   evident   in   sporadic   ALS   and   variations   of  
familial  ALS  with  mutations   in  non-­cytoskeleton  related  genes.  ALS-­related  mutant  
SOD1,   TDP-­43   and   FUS   proteins   have   all   been   demonstrated   to   interfere   with  
axonal   transport   in   primary   neurons   by   binding   to   and   inhibiting   the   function   of  
proteins  involved  in  this  pathway  (Alami  et  al.,  2014;;  De  Vos  et  al.,  2007;;  Jun  et  al.,  
2017;;   Moller   et   al.,   2017;;   Yasuda   et   al.,   2017).   As   previously   discussed,   axonal  
transport  pathology  has  strong  links  particularly  with  SOD1-­ALS;;  axonal  transport  is  
slowed  in  mice  which  express  an  ALS  mutant  SOD1  protein  and  mutant  SOD1  can  
directly  inhibit  transport  of  mitochondria  (Cleveland  and  Williamson,  1999;;  Moller  et  
al.,  2017).  The  axonal  accumulation  of  mitochondria,  vesicles  and  neurofilaments  in  
motor  neurons   from  ALS  patient  spinal  cord   further   implicates   faults   to   the  axonal  
transport   pathway   as   a   disease   mechanism   (Hirano   et   al.,   1984).   Moreover,  
neurofilament   heavy   polypeptide   is   elevated   in   the  CSF   taken   from  ALS  patients,  
and   an   increase   in   neurofilament   heavy   polypeptide   causes   motor   neuron  
degeneration  in  mice  (Collard  et  al.,  1995;;  Xu  et  al.,  2016).    
  
1.5.3   DNA  damage  
  
DNA   damage   has   been   widely   reported   in   ALS,   suggesting   the   DNA-­repair  
machinery   may   be   disrupted   in   disease.   Oxidative   damage   to   DNA   introduces  
breaks  into  nuclear  and  mitochondrial  DNA,  and  markers  of  oxidative  DNA  damage  
have  been   reported  as  elevated   in  urine  and  CSF   from  ALS  patients,  and   in  ALS  
mouse  models   (Aguirre  et  al.,   2005;;  Bogdanov  et  al.,   2000;;  Ferrante  et  al.,   1997;;  
Warita  et  al.,  2001).    
  
ALS-­linked   mutations   are   also   commonly   found   in   genes   with   roles   in   the   DNA  
damage   response.   The   FUS   protein   is   recruited   to   sites   of   DNA   damage   and  
mediates  the  efficient  repair  of  DNA  breaks,  suggesting  the  mislocalisation  of  FUS  
in  FUS-­ALS  could  lead  to  problems  in  DNA  repair  (Mastrocola  et  al.,  2013;;  Wang  et  
al.,  2013b).  In  addition,  a  repeat  expansion  in  the  C9orf72  gene,  which  is  causal  for  
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familial  ALS,  has  been  shown   to  disturb  ATM-­mediated  DNA   repair,   leading   to  an  
accumulation  of  DNA  double  strand  breaks  (Walker  et  al.,  2017).      
  
In   2016,   two   new   risk   genes   for   ALS  were   discovered:   Nek1   and   C21orf2.   Nek1  
mutations  are  proposed  to  cause  loss-­of-­function  of  the  NIMA-­related  protein  kinase  
1  (Nek1)  protein  (Brenner  et  al.,  2016;;  Cirulli  et  al.,  2015;;  Kenna  et  al.,  2016).  The  
Nek1  protein  has   functions   in  cilium  formation  and  mitochondria  permeability,  both  
of  which  have  been  implicated  in  ALS  (Chen  et  al.,  2009;;  Ma  et  al.,  2011;;  Shalom  et  
al.,  2008).  A  third  function  of  Nek1  is  in  DNA  repair,  and  depletion  of  Nek1  has  been  
reported   to  decrease   the  efficiency  of   the  DNA  damage  response  (Pelegrini  et  al.,  
2010).     Mutations   in   the  C21orf2  gene   in  ALS  also   leads   to   loss-­of-­function  of   the  
C21orf2  protein  (van  Rheenen  et  al.,  2016).  The  C21orf2  protein   interacts  with  the  
Nek1   protein   in   the  DNA   repair   pathway,   and   similar   to  Nek1,   evidence   suggests  
depletion   of   C21orf2   can   impair   homologous   recombination   and   slow  DNA   repair  
(Fang  et  al.,  2015).    
  
1.5.4   Mitochondrial  dysfunction  
  
Mitochondria   are   dynamic   organelles   that   have   essential   roles   in   oxidative  
phosphorylation  and  production  of  ATP,  calcium  signalling,  and  apoptosis.   In  ALS,  
studies   have   found   the  morphology,   functionality   and  degradation   of  mitochondria  
can  be  impaired  by  mutant  ALS  proteins.  The  mutant  SOD1  protein  misfolds  into  a  
structure  that  mediates  its  localisation  and  aggregation  within  mitochondria,  where  it  
has  been  shown  to   induce  mitochondrial  damage  (Kawamata  and  Manfredi,  2008;;  
Vande   Velde   et   al.,   2008).   The   interaction   of   mutant   SOD1   with   mitochondria  
induced  apoptosis  and  disrupted  calcium  homeostasis  and  efficient  ATP  production  
(Ferri  et  al.,  2006;;  Kruman  et  al.,  1999;;  Pasinelli  et  al.,  2004).  In  addition,  transgenic  
mice  expressing  ALS-­linked  mutant  SOD1  have  been  shown  to  exhibit  degenerating  
mitochondria   which   form   vacuoles   in   neuronal   axons   and   dendrites,   defective  
electron  transport  chains  and  mitochondria  respiration  (Mattiazzi  et  al.,  2002;;  Kong  
and  Xu,  1998;;  Wong  et  al.,  1995).  Collectively,   these  studies  are  convincing   for  a  
role  of  mitochondrial  dysfunction  in  SOD1-­ALS.    
  
Mitochondrial   impairment   has   also   been   observed   in   TDP-­43   and  FUS  models   of  
ALS,  suggesting  mitochondria  damage  is  a  molecular  pathway  shared  between  the  
different  subtypes  of  disease.  Overexpression  of  TDP-­43  and  FUS  ALS  mutants  in  
motor   neurons   changed  mitochondria  morphology   and   caused   them   to   shorten   in  
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length  (Tradewell  et  al.,  2012;;  Wang  et  al.,  2013a).  Expression  of   the  pathological  
TDP-­43  25  kDa  fragment  showed  its  localisation  to  mitochondria  where  it  influenced  
the   membrane   potential,   caused   mitochondria   clustering   and   induced   mitophagy  
(Hong   et   al.,   2012).   These   studies   suggest   that   the   TDP-­43   pathology   frequently  
observed  in  ALS  patients  can  damage  neuronal  mitochondria,  which  may  be  either  
causal  or  contributory  to  ALS  pathogenicity.    
  
Finally,   it   has   been   reported   that   the   activities   of   the   respiratory   chain   complexes  
are   reduced   in  post  mortem  spinal   cord   from  ALS  patients  and   that  mitochondrial  
DNA   is   highly   mutated   (Wiedemann   et   al.,   2002).   In   addition,   ATP   levels   and  
respiratory   complex   I   activity   were   likewise   reduced   in   lymphoblast   cells   derived  
from  ALS  patients   (Ghiasi  et  al.,  2012).   iPSC-­derived  motor  neurons  differentiated  
from   C9orf72-­ALS   fibroblasts   display   evidence   of   reduced   mitochondrial  
dysfunction,  including  disrupted  calcium  homeostasis  and  mitochondrial  membrane  
potential.   The   decreased   ATP   production   in   ALS   patients   could   reduce   motor  
neurons’  ability  to  cope  with  stress  and  disruptions  to  molecular  pathways.    
  
1.5.5   Glial  cell  toxicity    
  
ALS  involves  the  selective  neurodegeneration  of  motor  neurons.  However,  evidence  
is   emerging   for   an   important   role   of   glial   cells   in   exacerbating   motor   neuron  
degeneration,  specifically  microglia  and  astrocytes.  Microglia  are  macrophages  that  
mediate   the   immune   response   in   the   central   nervous   system,  whereas  astrocytes  
are  supportive  glial  cells   that   ‘prune’  and  maintain  healthy  synapses  and  neuronal  
circuits  (Prinz  and  Priller,  2014;;  Sofroniew  and  Vinters,  2010).  
  
Neuroinflammation  and  activation  of  microglia  and  astrocytes  is  frequently  observed  
in  ALS.     Reactive  microglia   are  widespread   throughout   the  CNS  of  ALS   patients,  
including   the   spinal   cord   and  motor   cortex   (Henkel   et   al.,   2004;;  Kawamata   et   al.,  
1992;;   Turner   et   al.,   2004).   Activation   of   both   microglia   and   astrocytes   is   also  
commonly   detected   in   SOD1-­ALS   mouse   models   (Hall   et   al.,   1998;;   Kriz   et   al.,  
2002).   In   addition,   ALS   brain   areas   that   exhibited   gliosis   correlated   with   cortical  
thinning   and   changes   to   the   local   neuronal   environment   (Alshikho   et   al.,   2016).  
Interestingly,  activation  of  microglia  has  been  shown  to  occur  prior  to  motor  neuron  
degeneration,   suggesting   neuroinflammation   can   be   an   early   marker   of   ALS  
(Henkel  et  al.,  2006).  
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Interestingly,   ALS   but   not   wild   type   astrocytes   are   toxic   to   motor   neurons.   Co-­
culture  of  astrocytes  expressing  ALS  mutant  SOD1  with  motor  neurons  can  induce  
motor  neuron  degeneration  (Marchetto  et  al.,  2008;;  Nagai  et  al.,  2007).  In  addition,  
astrocytes  from  sporadic  and  familial  ALS  patients  are  also  toxic  to  motor  neurons  
in   co-­culture,   causing  dendrite   shortening  and  neuronal  atrophy   (Haidet-­Phillips  et  
al.,  2011;;  Re  et  al.,  2014).  A  recent  study  suggests  ALS-­astrocytes  secrete  proteins  
that   downregulate   major   histocompatibility   complex   class   I   (MHCI)   molecules   on  
motor  neurons,  which   in   turn   increases  their  susceptibility   to   toxicity   from  killer-­cell  
immunoglobulin-­like   receptors   on   the   astrocytes   (Song   et   al.,   2016).   In   addition,  
wild-­type  glial  cells  are  neuroprotective   to  ALS-­SOD1  motor  neurons   in  a  chimeric  
mouse  model,  and  can  increase  life  expectancy  (Clement  et  al.,  2003).    
  
One  of  the  central  questions  in  ALS  research  is  trying  to  understand  how  a  mutation  
in  an  ALS-­linked  gene,  or  disruption  to  a  molecular  pathway,  leads  to  the  selective  
neurodegeneration   of   motor   neurons   whilst   sparing   other   cells.   These   studies  
suggest   that   glial   cells   in   ALS   can   be   neurotoxic   and   treatments   targeting  
neuroinflammation  or  activated  microglia  and  astrocytes  may  extend  motor  neuron  
survival.   Indeed,   treatment   of   SOD1-­ALS   mice   with   the   anti-­inflammatory   drug  
Minocycline  led  to  a  mild  increase  in  mice  survival  rates  (Kriz  et  al.,  2002).  
  
1.5.6   Glutamate  excitotoxicity  
  
The  glutamate  hypothesis  was  one  of  the  earliest  predicted  mechanisms  involved  in  
ALS  (Epstein  et  al.,  1994;;  Shaw  and  Ince,  1997).  Neuronal  degeneration  can  occur  
from  two  types  of  excitotoxicity:  classic  and  slow.  Classic  excitotoxicity  occurs  from  
the  overstimulation  of  neurons  by  high  levels  of  synaptic  glutamate,  which  causes  a  
disruption   to   calcium   homeostasis   from   the   massive   influx   of   Na+   and   Ca2+   ions  
(Doble,   1999).   Slow   excitotoxicity   involves   an   increased   sensitivity   to   glutamate  
from   the   post-­synaptic   neuron,   and   can   be   caused   by   physical   changes   to   the  
glutamate  receptors  (Doble,  1999;;  Van  Den  Bosch  et  al.,  2006).    
  
Riluzole  is  currently  the  only  approved  treatment  for  ALS  in  the  UK,  and  increases  
ALS  patients’  life  expectancy  by  approximately  2-­3  months  (Lacomblez  et  al.,  1996).  
Riluzole   exerts   an   anti-­excitotoxic   effect   by   inhibiting   voltage-­gated   sodium  
channels  on  pre-­synaptic  neurons,  thus  blocking  their  release  of  glutamate  (Doble,  
1996).  A  secondary  mechanism  of  action  may  also  be  via  the  competitive  binding  of  
Riluzole  to  post-­synaptic  glutamate  receptors,  thereby  preventing  glutamate  binding  
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(Albo  et  al.,   2004;;  Doble,  1996).  The  effectiveness  of  Riluzole   to   treat  ALS,  albeit  
moderately,  suggests  glutamate  excitotoxicity  is  involved  in  ALS.  
  
There   is  evidence  of  glutamate  excitotoxicity   in  both  animal  models  of  ALS  and   in  
ALS  patients.  A  study  in  SOD1-­ALS  mice  found  that  glutamate  levels  were  raised  in  
samples   of   extracellular   fluid   taken   from   the   cortex   (Alexander   et   al.,   2000).  
Increased   levels   of   glutamate   have   also   been   detected   in   the   CSF   of   a   small  
number   of   ALS   patients   (Rothstein   et   al.,   1990;;   Shaw   et   al.,   1995).   In   contrast,  
several  studies   investigating  glutamate   in  ALS  patient  brain  and  spinal  cord   tissue  
have  found  levels  to  actually  be  decreased  (Malessa  et  al.,  1991;;  Tsai  et  al.,  1991).  
Interestingly,   levels   of   the   glutamate   precursor  N-­acetylaspartylglutamate   are   also  
decreased   in  ALS  patient  brain  and  spinal  cord  (Rothstein  et  al.,  1990;;  Tsai  et  al.,  
1991).   Although   contradictory,   the   fluctuating   glutamate   levels   between   studies   is  
suggestive  of  a  role  for  defective  glutamate  signalling  in  ALS.    
  
1.6   Chromosome  9  open  reading  frame  72  
  
The   first  genetic  evidence   for  a  causative   link  between  a  mutation   in  C9orf72  and  
ALS  was  published  in  2000,  and  identified  as  a  region  of  genetic  linkage  in  families  
with  ALS  and  FTLD  on  chromosome  9q21-­q22  (Hosler  et  al.,  2000),  later  confirmed  
and   described   as   a   103-­gene   spanning   region   within   9p13.2-­21.3   (Vance   et   al.,  
2006).  Further  genome-­wide  associated  studies  (GWAS)  narrowed  down  the  gene  
to   chromosome  9p21.2   (Laaksovirta  et   al.,   2010;;  Shatunov  et   al.,   2010).   In  2011,  
two   papers   were   simultaneously   published   describing   the   discovery   of   a  
hexanucleotide  (GGGGCC)  repeat  expansion  within  intron  1  of  chromosome  9  open  
reading   frame   72   (C9orf72)   that   is   the   most   common   genetic   defect   identified   in  
familial  and  sporadic  ALS  and  FTD   to  date,  with  approximately  35-­40%  of   familial  
ALS  and  25%  of  familial  FTD  patients  estimated  to  possess  the  mutation  (DeJesus-­
Hernandez  et  al.,  2011;;  Renton  et  al.,  2011;;  van  Blitterswijk  et  al.,  2012).  
  
In  a  healthy   individual,   less   than  30  GGGGCC  repeats  are  present   in   the  C9orf72  
gene,  whereas  in  an  ALS  or  FTD  patient,  the  repeat  number  can  reach  in  excess  of  
1000   (Renton   et   al.,   2011).   Unlike   other   repeat   expansion   diseases   such   as  
Huntington’s   disease,   where   repeat   number   correlates   with   disease   severity,   this  
does   not   seem   to   be   the   case   in   C9orf72   ALS   (Dols-­Icardo   et   al.,   2014).   Under  
normal  circumstances,  the  C9orf72  gene  undergoes  alternative  splicing  to  produce  
three  mRNA  transcripts  which  encode  two  protein  isoforms:  C9orf72  short  form  (1-­
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222aa)  derived   from   transcript   variant   2  and  C9orf72   long   form   (1-­481aa)  derived  
from   transcript   variants   1   and   3   (Figure   1.2)   (DeJesus-­Hernandez   et   al.,   2011).  
Transcript  variant  1  starts  at  exon  1b,  whereas  transcript  variants  2  and  3  begin  at  
exon   1a.   The   positioning   of   the   GGGGCC   repeat   expansion   therefore   lies   in   the  
promoter   for   transcript   variant   1   and   affects   its   transcription   in   C9orf72-­ALS.   For  
transcript  variants  2  and  3,  the  expansion  lies  downstream  of  exon  1a  within  the  first  
intron,  and  is  therefore  transcribed.    Both  the  short  and  long  isoforms  are  expressed  
to  comparable  levels  across  most  tissues  and  both  are  expressed  at  high  levels   in  













1.6.1   C9orf72  mechanisms  of  disease  
  
Three  mechanisms  of  disease  have  been  proposed  as  to  how  the  C9orf72  mutation  
leads  to  ALS  pathogenicity  (Figure  1.3):  (i)  toxic  gain-­of-­function  from  generation  of  
RNA   foci,   (ii)   toxic   gain-­of-­function   from   generation   of   dipeptide   repeat   proteins  
(DPRs)   and   (iii)   loss-­of-­function   from   haploinsufficiency   of   the   C9orf72   protein.  
There   is  evidence   in  support  of  each  pathomechanism,   therefore   the  mechanisms  
are  likely  non-­mutually  exclusive.    
Figure  1.2.  C9orf72  mRNA  transcripts.  The  location  of  the  repeat  expansion  in  the  C9orf72  gene  is  
shown.   White   boxes   represent   coding   exons;;   shaded   boxes   represent   non-­coding   exons.   The  
C9orf72  gene  produces  3  pre-­mRNA  transcripts.  The  V1  pre-­mRNA   is   transcribed   from  a  promoter  
within  intron  1  and  is  not  transcribed  in  C9-­ALS  due  to  disruption  from  the  repeat  expansion.  The  V2  
and   V3   pre-­mRNAs   are   transcribed   upstream   of   the   repeat   expansion   and   produce   expansion-­
containing   pre-­mRNA.   The   V2   transcript   undergoes   alternative   splicing   to   produce   an   mRNA   that  
terminates  after  exon  5,  which  encodes  the  C9orf72  short  protein  isoform.  The  V3  transcript  encodes  
the  C9orf72  long  protein.  Figure  used  with  permission  from  (DeJesus-­Hernandez  et  al.,  2011).  







Figure  1.3.  C9orf72-­linked  disease  mechanisms.  (1)  Expansion  containing  RNA  
forms  a  stable  G-­quadruplex  secondary  structure  which  binds  and  sequesters  RNA  
binding   proteins   leading   to   dysfunctional   RNA  metabolism.   (2)  GGGGCC   repeat  
RNA   is   exported   from   the   nucleus   to   the   cytoplasm   where   it   undergoes   repeat  
associated   non-­ATG   (RAN)   translation   into   dipeptide   repeat   proteins   which  
aggregate   and   cause   toxicity   possibly   through   disrupted   RNA   metabolism   or  
disruption   to   the  UPS.   (3)  Abortive   transcription  of  C9orf72  caused  by   the   repeat  
expansion   leads   to   reduced   C9orf72   mRNA   levels   and   haploinsufficiency   of   the  
C9orf72  protein.  
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1.6.1.1   Generation  of  RNA  foci  
  
Bidirectional  transcription  of  the  C9orf72  gene  in  the  sense  and  antisense  direction  
generates  RNA   containing   a  GGGGCC  or  CCCCGG  expansion   respectively.   The  
expansion-­containing  RNA  forms  RNA  foci  in  the  nucleus,  and  less  frequently  in  the  
cytoplasm,  which  can  sequester  RNA-­binding  proteins  (Cooper-­Knock  et  al.,  2014;;  
Stopford  et  al.,  2017).  
  
The   sense   RNA   foci   were   originally   detected   in   the   nuclei   of   post-­mortem   spinal  
cord  and  frontal  cortex   tissue  from  C9orf72-­FTLD  patients  (DeJesus-­Hernandez  et  
al.,  2011).  The  presence  of  both  sense  and  antisense  RNA  foci,  approximately  0.2-­
0.5   μm   in   size,   has   since   been   widely   reported   in   C9orf72-­expansion   ALS/FTD  
patients   (Gendron  et  al.,  2013;;  Lagier-­Tourenne  et  al.,  2013;;  Zu  et  al.,  2013).  The  
distribution  pattern  of  RNA   foci   is  widespread;;   foci  have  been  detected   in  cortical,  
hippocampal  and  cerebellar  neurons  from  the  brain,  motor  neurons  from  the  spinal  
cord   and   astrocytes   and  microglia   (Gendron   et   al.,   2013;;   Lagier-­Tourenne   et   al.,  
2013).   There   has   also   been   detection   of   foci   in   peripheral   cells   from   C9orf72  
patients,   such   as   peripheral   blood   leukocytes,   skin-­biopsy   derived   fibroblasts   and  
immortalised  lymphoblasts  (Lagier-­Tourenne  et  al.,  2013;;  Zu  et  al.,  2013).  RNA  foci  
are   typically   numbered   1-­2   per   nucleus,   but   as  many   as   40   foci   per   nucleus   has  
been   observed   (Lagier-­Tourenne   et   al.,   2013).   Sense   and   antisense   foci   can  
localise   within   the   same   cell,   but   sense   foci   are   found   in   greater   frequency   in  
granule   neurons   from   the   cerebellum  whereas  antisense   foci   are  more   commonly  
detected   in  motor   neurons   and   cerebellar   Purkinje   neurons   (Cooper-­Knock   et   al.,  
2015b). 
  
Expansion  containing  sense  RNA  has  been  shown   to   form  a  stable  G-­quadruplex  
secondary   structure  which   increases   in   stability  with   repeat   number   (Fratta   et   al.,  
2012;;   Reddy   et   al.,   2013).   The   C9orf72-­expansion   RNA   G-­quadruplex   is   a   four-­
stranded   structure   formed   by   the   stacking   of   four   guanine   nucleobases   that  
associate  by  Hoogsteen  hydrogen  bonding  within   the   four  planes   (Haeusler  et  al.,  
2014).   The   self-­interaction   between   the  G-­quadruplex   structures   promotes   phase-­
separation   and   accelerates   RNA   foci   formation   (Fay   et   al.,   2017;;   Reddy   et   al.,  
2013).   RNA   foci   can   be   decreased   in   C9orf72   iPSC-­derived   cortical   and   motor  
neurons  by   incubation  with  small  molecules   that  bind  and  stabilise   the  GGGGCC-­
expansion  RNA  in  the  G-­quadruplex  structure  (Simone  et  al.,  2017).    
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RNA  foci  are  a  common  pathological  hallmark  in  neurodegenerative  diseases  where  
repeat   expansion   mutations   are   the   underlying   cause.   Myotonic   dystrophy   and  
spinocerebellar   ataxia   type   8   are   two   examples   of   microsatellite   expansion  
disorders   where  RNA   foci   exert   toxicity   through   the   sequestering   of   RNA   binding  
proteins   (Daughters  et   al.,   2009;;  Davis  et   al.,   1997;;  Taneja  et   al.,   1995).  C9orf72  
GGGGCC-­RNA   has   been   shown   to   bind   the   RNA-­binding   proteins   nucleolin,  
hnRNP  U,  hnRNP  F  and  RPL7  (Haeusler  et  al.,  2014).  C9orf72  RNA  containing  the  
antisense   CCCCGG   sequence   in   a   hairpin   structure   has   likewise   been   shown   to  
interact   with   the   hnRNP   K   protein   (Haeusler   et   al.,   2014).   Furthermore,   co-­
localisation  between  RNA   foci   and  RNA-­binding  proteins   such  as  SF2,  SC35  and  
hnRNP   H   has   been   detected   in   neuronal   cell   lines   and   C9orf72-­ALS   Purkinje  
neurons   (Cooper-­Knock  et  al.,  2015b;;  Lee  et  al.,  2013).  The  GGGGCC  expansion  
RNA  in   its  G-­quadruplex  assembly  has  also  been  found  to  bind  heme  and  alter   its  
oxidative  properties,  although  the  role  this  may  play  in  disease  pathology  is  unclear  
(Grigg  et  al.,  2014).  
  
There   are   several   studies   that   support   RNA   foci   as   a   contributor   to   ALS  
pathogenicity.  First,  they  have  been  shown  to  correlate  with  ALS  clinical  phenotype  
(Cooper-­Knock  et  al.,  2014).  Second,  many  of  the  proteins  that  are  sequestered  by  
RNA  foci  have  functions  in  RNA  processing,  and  splicing  of  the  mRNA  targets  of  the  
sequestered  proteins   is  altered   in  C9orf72-­ALS  patients,   suggesting  RNA   foci   can  
interfere  with  RNA  metabolism   (Cooper-­Knock  et   al.,   2015a;;  Conlon  et   al.,   2016).  
Sequestration  of  the  RNA-­editing  deaminase-­2  (ADARB2)  protein  into  RNA  foci  has  
also   been   shown   to   increase   susceptibility   of   iPSC-­derived   neurons   to   glutamate  
excitotoxicity   (Donnelly   et   al.,   2013).   Finally,   GGGGCC   expansion   RNA   has   also  
been   detected   as   a   component   of   RNA   granules   in   distal   parts   of   iPSC-­derived  
neurons  from  C9orf72  patients,  where  it  has  been  shown  to  interact  with  the  fragile  
X  mental   retardation   protein   (FMRP)   and   locally   influence   translation   and   neurite  
branching  (Burguete  et  al.,  2015;;  Rossi  et  al.,  2015).  These  studies  suggest  multiple  
molecular   pathways   may   be   affected   by   sequestration   of   proteins   by   the   repeat  
expansion  RNA.    
  
1.6.1.2   Dipeptide  repeat  proteins  
  
The  repeat  expansion  resides  in  a  non-­coding  region  of  C9orf72  and  thus  would  not  
be   expected   to   undergo   translation.   However,   dipeptide   repeat   proteins   (DPRs)  
have  been   found   to  accumulate   in  both   the  nucleus  and  cytoplasm  of  ALS  brains,  
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which   are   generated   by   the   unconventional   repeat   associated   non-­ATG   (RAN)  
translation  of   the  expansion-­containing  RNA  (Ash  et  al.,  2013;;  Mori  et  al.,  2013a).  
RAN  translation  has  been  found  to  occur  in  other  repeat  expansion  disorders  such  
as   distal  myopathy   and   spinocerebellar   ataxia   type   8,   and   is   thought   to   require   a  
hairpin  or  G-­quadruplex  secondary  structure  as   is  adopted  by  RNA  containing   the  
C9orf72   repeat   expansion   (Cleary   and   Ranum,   2013;;   Zu   et   al.,   2011).   The   RNA  
structure  is  hypothesised  to  behave  as  an  internal  ribosome  entry  site  (IRES),  which  
recruits   proteins   involved   in   translation   initiation   (Stoneley   and  Willis,   2004).  RAN  
translation  of   the  C9orf72   repeat  expansion  can  be   inhibited  by   treatment  with  G-­
quadruplex-­binding   small   molecules,   supporting   the   theory   that   the   secondary  
structure  may  be  required  for  DPR  generation  (Simone  et  al.,  2017).  RNA  foci  have  
been  detected  in  the  neuronal  cytoplasm,  suggesting  the  expansion-­containing  RNA  
is   exported   from   the   nucleus,   thereby   becoming   available   for   RAN   translation  
(Donnelly   et   al.,   2013).   Exactly   how   the   repeat   expansion   acts   as   a   template   for  
RAN  translation  is  unclear,  and  there  are  conflicting  reports   in  the  literature.  There  
is   evidence   to   suggest   the   C9orf72   transcript   is   processed   normally   as   a  mature  
mRNA   which   is   accurately   spliced   downstream   of   exon   2,   but   displays   intron  
retention  of  the  expansion-­containing  intron  1  (Niblock  et  al.,  2016).  The  expansion-­
containing  RNA  has  been  shown  to  sequester  the  SRSF1  protein  which  functions  in  
mRNA   nuclear   export,   and   this   sequestration   targets   the   RNA   for   export   to   the  
cytoplasm   (Hautbergue   et   al.,   2017).   Inhibition   of   SRSF1   increased   the   nuclear  
retention   of   the   expansion  RNA,   thereby   decreasing  DPR  production   and   toxicity.  
Finally,   one   study   found   that   the   intron   containing   the   GGGGCC   expansion   is  
successfully   spliced   in   the  nucleus  but   rather   than  being  degraded,   is  exported   to  
the  cytoplasm  where  it  can  act  as  the  RNA  template  for  RAN  translation  (Cheng  et  
al.,  2018).   Interestingly,   the   latter  pathway   is   further  upregulated  by  cellular  stress  
that   may   arise   from   DPR   expression,   creating   a   positive   feedback   loop   which  
increases  RAN  translation  of  the  repeat  expansion  and  DPR  generation.    
  
DPR  accumulations  were  first  described  as  being  similar  in  appearance  to  the  TDP-­
43   negative   inclusions   found   in  C9orf72-­ALS  motor   neurons   (Ash   et   al.,   2013).   It  
was  later  discovered  that  the  dipeptide  repeat  proteins  co-­localise  with  ubiquitinated  
p62  positive/TDP-­43  negative  inclusions  (Al-­Sarraj  et  al.,  2011;;  Mann  et  al.,  2013).  
By   raising  antibodies  against   the  DPRs  potentially   encoded  by   consecutive   frame  
reads  in  both  the  sense  and  antisense  direction,  the  C9orf72  repeat  expansion  was  
found  to  produce  the   following  dipeptide  repeat  proteins  via  RAN  translation:  poly-­
GlycineAlanine   (GA);;   poly-­GlycineProline   (GP);;   poly-­GlycineArginine   (GR);;   poly-­
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ProlineAlanine  (PA);;  and  poly-­ProlineArginine  (PR)  (Mori  et  al.,  2013a,  2013b;;  Zu  et  
al.,   2013).   DPRs   have   been   detected   in  multiple   brain   regions   from  C9orf72-­ALS  
patients,  but  are  most  common  in  the  cerebral  cortex,  cerebellum  and  hippocampus  
(Ash  et  al.,  2013;;  Davidson  et  al.,  2014).    
  
Of   the   DPRs,   expression   of   poly-­GA,   poly-­GR   and   poly-­PR   appear   to   instigate  
neuronal   degeneration   and   cell   toxicity   more   readily   than   poly-­PA   and   poly-­GP,  
hence  research  efforts  have  focused  on  these  proteins.  The  poly-­GA  protein  is  the  
most   common   DPR   found   in   cytoplasmic   inclusions   in   C9orf72   ALS/FTD   patient  
tissue,   and   has   been   shown   to   form   insoluble   aggregates   more   readily   than   the  
other  DPRs  (Mori  et  al.,  2013b;;  Yamakawa  et  al.,  2014;;  Zhang  et  al.,  2014).  Poly-­
GA  aggregates  have  also  been  reported  to  have  the  ability  to  propagate  by  cell-­to-­
cell  transmission  in  a  neuroblastoma  cell  line  (Chang  et  al.,  2016).  Expression  of  the  
poly-­GA  protein  forms  p62-­  and  ubiquitin-­positive  cytoplasmic  aggregates  in  primary  
cortical  and  hippocampal  neurons,   induces  ER-­stress  via   inhibition  of   the  ubiquitin  
proteasome   system   and   sequesters   the   Unc119   protein   which   is   responsible   for  
axonal  maintenance  (May  et  al.,  2014;;  Yamakawa  et  al.,  2014;;  Zhang  et  al.,  2014).  
In  addition,  expression  of  a  poly-­GA  construct  in  mice  caused  the  mislocalisation  of  
HR23A,  RanGap1  and  Pom121   into  cytoplasmic  poly-­GA   inclusions   (Zhang  et  al.,  
2016).   Finally,   expression   of   poly-­GA   constructs   in   both   cell   lines   and   primary  
neurons   can   activate   caspase-­3   and   the   apoptosis   pathway,   indicative   of   the  
neurotoxicity  of  poly-­GA  aggregates  (Lee  et  al.,  2017;;  Zhang  et  al.,  2014).    Despite  
this,   there   is  no   correlation  between  poly-­GA  pathology  and  neurodegeneration   in  
C9orf72-­ALS/FTD  patients  (Mackenzie  et  al.,  2013).  
  
Unlike   the   poly-­GA,   poly-­GP   and   poly-­PA   proteins   which   form   large   cytoplasmic  
inclusions,   the   poly-­GR   and   poly-­PR   proteins   migrate   to   the   nucleus   where   they  
associate  with  the  nucleolus  (Kwon  et  al.,  2014;;  Wen  et  al.,  2014).  The  poly-­GR  and  
poly-­PR   proteins   have   been   shown   to   impair   numerous   nuclear   events   including  
nucleocytoplasmic  shuttling  and  RNA  processing.    The  binding  of  poly-­GR  and  poly-­
PR   to   the  nucleolus   induces  nucleolar  stress,   impairs  synthesis  of   ribosomal  RNA  
and  eventually  causes  cell  death  (Kwon  et  al.,  2014;;  Tao  et  al.,  2015).  Studies  have  
shown   the   poly-­PR   protein   interacts   with   the   nuclear   pore   complex   preventing  
nuclear  import  and  export,  and  nucleocytoplasmic  shuttling  appears  to  be  disrupted  
as   a   consequence   of   DPR   expression   (Boeynaems   et   al.,   2016;;   Freibaum   et   al.,  
2015;;  Jovičić  et  al.,  2015;;  Shi  et  al.,  2017).  Finally,  poly-­GR  and  poly-­PR  proteins  
can  interfere  with  RNA  metabolism.  Both  proteins  can  interact  with  the  U2  snRNP,  a  
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component   of   the   major   splicing   machinery,   which   shows   mislocalisation   to   the  
cytoplasm  in  DPR-­expressing  iPSC-­motor  neurons  from  C9orf72-­ALS  patients  (Yin  
et  al.,  2017).  Treatment  of  HeLa  cells  with  poly-­GR  and  poly-­PR  peptides  can  inhibit  
spliceosome   assembly   and   induce   mislocalisation   of   the   U2   snRNP   to   the  
cytoplasm   (Yin   et   al.,   2017).   Moreover,   the   poly-­GR   and   poly-­PR   proteins   have  
been  reported  to  interact  with  the  splicing  factor  protein,  hnRNP  A2,  and  can  cause  
global  alteration  of  mRNA  splicing  events  (Kwon  et  al.,  2014).  Indeed,  proteins  with  
a   high   arginine   content   are   common   regulators   of  RNA  processing   through   direct  
RNA  interactions  (Bayer  et  al.,  2005).    
  
It   is  certain  DPRs  can  be  neurotoxic,  however  most  studies  have  investigated  their  
toxicity   using   overexpression   models.   In   reality,   the   levels   of   DPRs   in   ALS/FTD  
patients  are  low  and  are  detected  in  brain  regions  spared  from  neurodegeneration,  
with  the  exception  of  poly-­GR  pathology  (Davidson  et  al.,  2014;;  Gomez-­Deza  et  al.,  
2015;;   Mackenzie   et   al.,   2015).   Interestingly,   the   poly-­PR   and   poly-­GR   proteins,  
which   demonstrate   the   most   neurotoxicity   experimentally,   have   the   lowest  
abundance  in  the  brain  (Mackenzie  et  al.,  2015).  Thus,  it  is  unlikely  DPR  expression  
is   exclusively   causal   of  C9orf72-­ALS  pathogenicity,   but  may   contribute   along  with  
other  disease  mechanisms.    
  
1.6.1.2.1  C9orf72  gain-­of-­function  animal  models  
 
A   number   of   animal   models   have   been   generated   to   investigate   a   toxic   gain-­of-­
function   in  C9orf72-­ALS  pathogenicity.  The   first  mouse  model   involved  expression  
of  66  repeats  of  the  GGGGCC  expansion  using  viral  mediated  transgenesis,  which  
caused   the   mice   to   present   with   typical   C9orf72-­ALS   clinical   features   such   as  
impaired  motor   function,   neuronal   loss   and   pathological   features   such   as  TDP-­43  
inclusions,   RNA   foci   and   dipeptide   repeat   proteins,   supporting   a   toxic   gain-­of-­
function  mechanism  (Chew  et  al.,  2015).    
  
Subsequently,   four   mouse   models   have   been   generated   expressing   repeat-­
expansion   forms  of  C9orf72   from  bacterial   artificial   chromosome   (BAC)  DNA.  The  
studies  vary  in  their  number  of  GGGGCC  repeats,  the  fragment  of  the  C9orf72  ORF  
expressed,   and   the   length   of   the   flanking   5’   and   3’   UTRs.   All   four   BAC-­C9orf72  
mouse  models  displayed  RNA  foci  and  DPRs  in  distribution  patterns  similar  to  post-­
mortem   tissue   from   C9orf72-­ALS   patients   (Jiang   et   al.,   2016;;   Liu   et   al.,   2016;;  
O’Rourke  et  al.,  2015;;  Peters  et  al.,  2015).  However,  mice  from  the  first  two  studies  
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did  not  exhibit   neuronal   loss  or  develop  ALS-­clinical   phenotypes   (O’Rourke  et   al.,  
2015;;  Peters   et   al.,   2015),  whereas  mice   from   the   latter   studies   developed  motor  
and  behavioural  deficits  and  had  motor  neuron  degeneration  (Jiang  et  al.,  2016;;  Liu  
et  al.,  2016).  There  is  therefore  conflicting  evidence  regarding  RNA  foci  and  DPRs  
and  their  capability  to  cause  ALS  pathogenicity  in  mice.  
  
The   studies   discussed   have   investigated   a   gain-­of-­function   mechanism   from   the  
repeat  expansion  without  narrowing  down  the  individual  contribution  from  RNA  foci  
versus   dipeptide   repeat   proteins.   However,   studies   in   Drosophila   models   favour  
DPRs   as   the   primary   toxic   species.   Expression   of   RNA   containing   36   and   103  
repeats  of  the  GGGGCC  expansion  in  flies  led  to  RNA  foci  and  DPR  formation,  and  
severe  degeneration  of  the  fly  eye  (Mizielinska  et  al.,  2014).  However,  expression  of  
RNA  containing   the  same  amount  of  GGGGCC  repeats  but   interrupted  throughout  
the  sequence  with  stop  codons,  forms  RNA  foci  but  not  DPRs  and  does  not  lead  to  
neurodegeneration,   suggesting   DPRs   are   required   for   toxicity   (Mizielinska   et   al.,  
2014).  In  a  second  Drosophila  model,  160  GGGGCC  repeats  were  expressed  from  
an   intron,   thus   more   accurately   reflecting   C9orf72-­ALS   conditions   (Tran   et   al.,  
2015).  Intronic  expression  of  the  repeat  expansion  led  to  generation  of  sense  RNA  
foci   but   not   DPRs,   and   there   was   no   effect   on   locomotor   abilities   or   signs   of  
neurodegeneration  (Tran  et  al.,  2015).  Collectively,  the  Drosophila  models  suggest  
DPRs  rather   than  RNA  foci  are  more   important   in  ALS  pathogenicity.  This  may  be  
true   only   for   flies   however,   and   similar   experiments   in   other   animal   models   are  
required.    
  
In   contrast,   a   recent   zebrafish  model   supports  RNA   foci   toxicity   as   a   causal   ALS  
pathomechanism.   Injection  of  both  GGGGCC  and  CCCCGG  repeat  RNA   impaired  
axon  growth  and  caused  branching  defects,  but  did  not  generate  DPRs,  suggesting  
toxicity  was  via  a  DPR-­independent  mechanism  (Swinnen  et  al.,  2018).  To  confirm  
this   possibility,   injection   of   repeat   RNA   that   contained   stop   codons   regularly  
throughout   its  sequence  and  therefore  could  not  be  RAN  translated,  was  sufficient  
to   cause   the   same   axonal   defects.   Lastly,   the   study   reported   that   RNA   foci  
sequestered   the  RNA-­binding   protein  Pur-­alpha,   and   overexpression   of   Pur-­alpha  
rescued  axonal  growth  and  reduced  RNA  foci  load  (Swinnen  et  al.,  2018).  A  second  
study   found  expression  of  30   repeats  of  GGGGCC   in  a  Drosophila  model   impairs  
locomotor  function  and  causes  cellular  defects  in  the  eye  (Zhang  et  al.,  2015).  DPR  
proteins   were   not   detected,   and   so   therefore   were   unlikely   to   contribute   to  
neurodegeneration   in   this   model.      Moreover,   the   defects   were   rescued   with  
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RanGAP1  overexpression,  a  protein   involved   in  nucleocytoplasmic  shuttling  which  
has   been   shown   to   bind   C9orf72   repeat   expansion   RNA,   suggesting   RanGAP1  
sequestration  by  RNA  is  the  toxic  mechanism  at  play  (Zhang  et  al.,  2015).  Together,  
these   studies   suggest   neurodegeneration   can   occur   from   an   RNA-­mediated  
mechanism  of  protein  sequestration.    
  
1.6.1.3   Haploinsufficiency  of  C9orf72  
  
The  original  paper  that  described  the  discovery  of  the  C9orf72  repeat  expansion  as  
an  ALS-­causing  mutation  found  that,  in  addition  to  RNA  foci,  C9orf72  mRNA  levels  
were   decreased   in   expansion   containing   cells   and   CNS   tissue,   which   may  
correspond   with   reduced   C9orf72   protein   expression   (DeJesus-­Hernandez   et   al.,  
2011).  This  was  confirmed  in  post-­mortem  tissue  from  ALS/FTLD  patients  where  a  
50%  reduction  in  C9orf72  mRNA  was  described  (Gijselinck  et  al.,  2012),  and  again  
in   frontal   cortex   tissue   and   lymphoblasts   from   ALS/FTLD   patients   (Ciura   et   al.,  
2013).   There   is   a   lack   of   evidence   showing   decreased   C9orf72   protein   levels   in  
disease  tissue,  mainly  due  to  the  difficulty  in  obtaining  a  specific  C9orf72  antibody,  
but   one   group   found   levels   of   the   C9orf72   long   isoform  were   decreased   in   post-­
mortem   frontal   cortex   tissue   from   ALS/FTLD   patients   who   carried   the   C9orf72  
mutation  (Waite  et  al.,  2014).  The  C9orf72  short  isoform  was  not  detected  with  the  
anti-­C9orf72   antibody.   A   second   study   implementing   C9orf72   isoform   specific  
antibodies   found   the  C9orf72   long  protein  was  decreased   in   the   frontal  cortex  and  
temporal  cortex  of  C9orf72-­ALS  patients,  but  not  in  the  motor  cortex  or  cerebellum  
(Xiao   et   al.,   2015).   Surprisingly,   the   C9orf72   short   protein   was   increased   in   the  
frontal  cortex  and  temporal  cortex  of  C9-­ALS  patients  (Xiao  et  al.,  2015).  
  
There   are   several   potential   explanations   for   the   decreased   C9orf72   levels.   First,  
epigenetic  control  of  gene  expression  is  exerted  mainly  through  the  acetylation  and  
methylation   of   histones,   with   trimethylation   of   specific   lysine   residues   on   histone  
tails   playing   a   major   role   in   gene   activation   and   repression   (Barski   et   al.,   2007).  
Trimethylation  of  lysines  9  and  27  on  histone  H3  are  generally  associated  with  gene  
silencing  whereas  similar  methylation  of  lysine  36  on  histone  H3  can  be  linked  with  
activation   (Cao   et   al.,   2002;;   Stewart   et   al.,   2005;;  Wagner   and   Carpenter,   2012).  
Interestingly,  binding  was  found  between  C9orf72  expansion  DNA  with  trimethylated  
lysines  9  and  27  on  histone  H3,  suggesting  the  C9orf72  gene  may  have  decreased  
expression   leading   to   reduced   mRNA   levels   (Belzil   et   al.,   2013).   If   ALS  
pathogenicity   is   caused   via   a   toxic   gain-­of-­function   from   RNA   foci   and   DPRs  
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however,  decreased  gene  expression  would  be  expected  to  be  beneficial.  This  has  
been  supported   in  studies  where  CpG  methylation  of   the  C9orf72  promoter,  which  
works   alongside   histone   modifications   to   reduce   gene   expression,   was   found   to  
correlate  with  decreased  RNA  foci  and  neuronal   loss  (Liu  et  al.,  2014;;  McMillan  et  
al.,  2015).    
  
Perhaps  another  mechanism  of  how  reduced  C9orf72  mRNA  levels  occur  is  through  
the   G-­quadruplex   structure   adopted   by   the   hexanucleotide   repeat   expansion.  
Transcription   of   GGGGCC   repeat   expansion   DNA   was   found   to   lead   to   favoured  
production   of   abortive   and   truncated   transcripts   in   comparison   to   full   length   pre-­
mRNA   in   a   repeat-­number-­   and   structure-­   dependent   manner   (Haeusler   et   al.,  
2014).   Production   of   shortened   ‘abortive’   transcripts   in   favour   of   full   length  
transcripts  in  expansion  carrying  patients  was  additionally  confirmed  in  vivo.  
  
1.6.1.3.1  The  C9orf72  protein  
  
The  C9orf72  protein  is  expressed  throughout  the  grey  matter  of  the  CNS  and  shows  
a  high  level  of  sequence  homology  with  non-­human  primates,  mouse  and  zebrafish  
orthologs,   indicating   that   its   function   is   likely   important   (Suzuki   et   al.,   2013).   To  
support   a   haploinsufficiency   disease  mechanism,   it   is   essential   to   understand   the  
normal   protein   function   of   C9orf72.   Should   C9orf72   play   a   role   in   a   vital   cellular  
function,   reduced   levels   of   the   protein   could   potentially   have   negative  
consequences.   Early   bioinformatics   studies   compared   the   sequence   homology   of  
C9orf72   with   proteins   of   known   function.   PSI-­BLAST   searches   found   that   the  
C9orf72  protein  showed  strong  homology  with  differentially  expressed  in  normal  and  
neoplastic   cells   (DENN)-­domain   and   DENN-­like   proteins,   both   in   its   primary  
sequence   and   predicted   secondary   structure   (Levine   et   al.,   2013;;   Zhang   et   al.,  
2012).   DENN   domain   proteins,   of   which   there   are   17   in   humans,   act   as   guanine  
nucleotide   exchange   factors   (GEFs)   for   Rab   GTPases   (Marat   and   McPherson,  
2010;;  Zhang  et  al.,  2012).  GEFs  allow   the   transfer  of  Rab-­bound  GDP  for  GTP  at  
membrane   specific   locations,   switching   the   Rab   proteins   from   an   inactive   to   an  
active  state  (Cherfils  and  Zeghouf,  2013).  Once  activated,  Rab  proteins  interact  with  
effector  proteins  that  facilitate  Rab-­mediated  endosomal  trafficking  and  recycling  of  
vesicle   incorporated   membrane   proteins   through   the   endosomal   pathway  
(Stenmark,  2009).  Through  its  shared  homology  with  DENN  domain  proteins,  it  was  
hypothesised  C9orf72  would  function  in  similar  pathways.    
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As  mentioned,  two  C9orf72  protein  isoforms  are  generated  by  alternative  splicing  of  
the  C9orf72  gene.  The  C9orf72  long  protein  is  a  481  amino  acid  protein  encoded  by  
exons   2   to   11,   whereas   the   C9orf72   short   protein   is   a   222   amino   acid   protein  
encoded   by   exons   2   to   5.   From   its   structural   similarities  with  DENN  proteins,   the  
C9orf72   protein   is   predicted   to   comprise   three   domains:   an   N-­terminal   longin  
domain,  a  central  DENN  domain  and  a  C-­terminal  dDENN  domain  (Figure  1.4).  The  












In   2014,   one   group   reported   that   C9orf72   co-­localised   and   interacted   with  
autophagy-­   and   endosomal   trafficking-­   related   proteins   such   as   Ubiquilin-­2   and  
Rabs   1,   5,   7   and   11   in   neuronal   cell   lines,   and   loss   of   C9orf72   influenced  
autophagosome   formation   (Farg  et   al.,   2014).  The  C9orf72  protein   has  also  been  
shown  to  interact  with  ULK1,  FIP200  and  ATG13,  which  are  involved  in  forming  the  
autophagy  initiation  complex,  suggesting  C9orf72  has  an  early  role  in  the  autophagy  
pathway  (Webster  et  al.,  2016).  The  same  study  demonstrated  C9orf72   influenced  
the   trafficking   of   the   initiation   complex   to   the   autophagophore   by   behaving   as   an  
effector   protein   for   Rab1a,   and   iNeurons   from   C9orf72   patients   demonstrated  
impairments   in   the   autophagy   pathway   and   p62   accumulation   which   could   be  
rescued  with   exogenous  C9orf72   expression   (Webster   et   al.,   2016).   The  C9orf72  
protein   has   also   been   shown   to   interact   with   autophagy-­related   proteins   SMCR8  
and  WDR41,  and  via  these  interactions  behaves  as  a  GEF  for  Rab8a  and  Rab39b  
to  regulate  autophagy  (Sellier  et  al.,  2016;;  Sullivan  et  al.,  2016).  Collectively,  these  
Figure   1.4.   C9orf72   protein   isoforms.   The   C9orf72   long   protein   is   a   481   amino   acid  
protein   that   contains   a   longin   domain   (23-­151aa),   a   DENN   domain   (212-­322aa)   and   a  
dDENN  domain  (324-­481aa).  The  C9orf72  short  protein   is  a  222  amino  acid  protein   that  
contains  the  longin  domain  (23-­151aa)  and  the  first  10  amino  acids  of  the  DENN  domain.  
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results   suggest  C9orf72   is   a   regulator   of   autophagy   and   haploinsufficiency   of   the  
C9orf72  protein  in  ALS  could  be  causal  of  the  p62  pathology.    
  
C9orf72-­regulation  of   trafficking  may  also  be   important   in  other  pathways.  C9orf72  
has  been  reported  to  interact  with  and  colocalise  with  Rab7L1  at  the  neuronal  golgi  
apparatus,   and   depletion   of   C9orf72   decreased   secretion   of   extracellular   vesicles  
(Aoki   et   al.,   2017).   Therefore,   C9orf72   may   also   be   required   for   trans-­golgi   and  
extracellular  vesicle  trafficking.    
  
1.6.1.3.2  C9orf72  loss-­of-­function  animal  models  
  
  
There  are  mixed  results  from  C9orf72  loss  of  function  animal  models  regarding  the  
contribution  of  C9orf72  haploinsufficiency  to  ALS-­like  neurodegeneration  and  motor  
defects.   Transient   knockdown   of   C9orf72   has   been   successfully   completed   in  
zebrafish   using   morpholino   antisense   oligonucleotides,   leading   to   a   number   of  
pathological  defects   (Ciura  et  al.,  2013).  The  knockdown  had  a  negative  effect  on  
locomotor  activity   in  zebrafish  embryos,  all  of  which  were  rescued  to  normal   levels  
after   reintroduction   of   C9orf72   mRNA,   suggesting   loss   of   the   C9orf72   protein   is  
sufficient  to  cause  a  motor  phenotype.  In  support  of  this  observation,  loss  of  the  C.  
elegans  ortholog  of  C9orf72  led  to  worms  showing  increased  neurodegeneration  of  
GABAergic  neurons  and  onset  of  an  age-­dependent  motor  phenotype  (Therrien  et  
al.,   2013).   Knockout   of   C9orf72   in   mice   can   lead   to   changes   in   p62   levels,  
consistent  with  a  role  in  autophagy,  and  caused  mice  to  develop  an  age-­dependent  
lethality  phenotype,  suggesting  loss  of  C9orf72  can  have  toxic  consequences  (Ji  et  
al.,  2017).    
  
In   contrast,   the   majority   of   C9orf72   loss-­of-­function   animal   models   exhibit   lesser  
effects  and   it  has  been  argued   the  motor  defect  observed   in  zebrafish  may  be  an  
artefact   of   morpholino   off-­target   effects   (Gerety   and   Wilkinson,   2011).   Transient  
knockdown   of   the   C9orf72   mouse   orthologue   using   antisense   oligonucleotides  
(ASOs)  targeting  C9orf72  transcripts  appeared  to  have  no  effect  on  mice.  C9orf72  
RNA   levels   were   reduced   to   30-­40%   after   an   intracerebroventricular   injection   of  
ASOs,  with  no  changes  in  the  mice  seen  behaviourally  or  neuropathologically  up  to  
17   weeks   post   injection   (Lagier-­Tourenne   et   al.,   2013).   Since,   four   C9orf72  
knockout   mouse   models   have   been   developed.   One   of   the   studies   reported   that  
C9orf72   null   mice   present   with   a   subtle   motor   defect   and   weakness   of   the   hind-­
limbs   (Atanasio   et   al.,   2016),   however   no   change   was   observed   in   motor   ability,  
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cognitive  behaviour  or  motor  neuron  degeneration  in  the  other  three  studies  (Jiang  
et   al.,   2016;;   Koppers   et   al.,   2015;;   O’Rourke   et   al.,   2016).   However,   whilst   these  
studies   suggest   C9orf72   haploinsufficiency   is   not   causal   of   ALS-­like  
neurodegeneration,  loss  of  the  C9orf72  protein  interestingly  was  observed  to  induce  
an  immune  response  in  mice  (Atanasio  et  al.,  2016;;  Jiang  et  al.,  2016;;  O’Rourke  et  
al.,   2016).   C9orf72   knockout   mice   exhibited   signs   of   neuroinflammation   including  
enlarged   spleens,   macrophage   accumulation   in   lymph   nodes,   T-­cell   activation,  
autoantibody  production  and  plasma  cell  activation  (Atanasio  et  al.,  2016;;  Jiang  et  
al.,   2016;;   O’Rourke   et   al.,   2016).   These   studies   suggest   haploinsufficiency   of  
C9orf72   may   only   be   one   of   a   number   of   converging   disease   mechanisms   that  
together   cause   ALS   and   introduces   a   potential   new   role   for   C9orf72   in  
neuroinflammation.   Indeed,   the   autophagy   pathway   which   C9orf72   functions   in   is  
linked  with  the  immune  response.  First,  autophagosomes  are  key  modes  of  disposal  
for  invading  microbes  and  pathogens  in  cells  and  is  activated  by  immune  signalling  
(Gutierrez   et   al.,   2004;;   Nakagawa   et   al.,   2004).   Second,   the   autophagy   pathway  
can   influence   the   inflammatory   response.   Various   autophagy   protein   complexes  
have  been  demonstrated  to  suppress  pro-­inflammatory  signals  in  cells  by  inhibiting  
inflammasome   activation,   negative   regulation   of   interferon   signalling   and  
suppression   of   pro-­inflammatory   IL-­1α and   IL-­1β   secretion   (Castillo   et   al.,   2012;;  
Jounai   et   al.,   2007;;   Nakahira   et   al.,   2011;;   Shi   et   al.,   2012).   Disruption   to   the  
autophagy  pathway   through   loss  of   the  C9orf72  protein  may   therefore  explain   the  
hyper-­immune   response   observed   in   C9orf72   null   mice   (Atanasio   et   al.,   2016;;  
O’Rourke  et  al.,  2016).   
  
1.7   C9orf72  in  the  nucleus  
  
Investigation   of   the   C9orf72   protein   has   found   its   distribution   to   be   cell-­wide,  
including  some  nuclear   localisation  (Farg  et  al.,  2014).   Immunofluorescence  of   the  
endogenous  C9orf72  protein  using  isoform-­specific  antibodies  suggests  the  C9orf72  
short  protein  localises  to  the  nuclear  membrane  whereas  the  C9orf72  long  protein  is  
more  diffusively   cytoplasmic   (Xiao  et   al.,   2015).   Interactions  between   the  C9orf72  
short  protein  with  Ran-­GTPase  and  Importin  B1  were  also  reported,  suggesting  the  
nuclear  localisation  may  be  linked  with  a  role  in  nucleocytoplasmic  shuttling  (Xiao  et  
al.,   2015).  Moreover,   a   combination   of   published   and   in   house   proteomic   studies  
has  identified  numerous  interactions  between  C9orf72  and  nuclear  proteins  (Sellier  
et  al.,  2016;;  Sullivan  et  al.,  2016).  Interestingly,  some  of  these  proteins  are  involved  
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in  RNA  processing  and  are  ALS-­linked  genes  themselves,  such  as  senataxin,  TDP-­
43  and  FUS  (Sellier  et  al.,  2016).  
  
The   literature   therefore   suggests   there   may   be   a   not   yet   determined   nuclear  
function   of   the   C9orf72   protein,   with   evidence   suggesting   nucleocytoplasmic  
transport  and  RNA  processing,  both  of  which  are  pathways   implicated   in  C9orf72-­
ALS.  To  this  end,  the  work  completed  towards  this  project  focused  on  determining  a  
nuclear  function  for   the  C9orf72  protein  and  investigated  whether  there  could  be  a  
connection  between  haploinsufficiency  of  nuclear  C9orf72  and  RNA  misprocessing  
in  ALS.    
  
1.7.1   Dysfunctional  RNA  processing  in  ALS  
  
Disruption  to  the  RNA  metabolism  pathway  appears  to  be  shared  between  sporadic  
ALS   and  many   of   the   genetic   varieties   of   familial   ALS,   indicating   that   underlying  
problems   to  RNA  processing  may  be  causal  of  ALS  pathogenicity.  Motor  neurons  
specifically   have   a   high   reliance   on   efficient   transcription   and   splicing   to  maintain  
their   ability   to   send   and   receive   electrical   signals.   Any   disruptions   to   RNA  
processing   therefore   may   have   a   more   detrimental   impact   on   neurons   in  
comparison  to  other  somatic  cells.  
  
The   ALS-­linked   TDP-­43   and   FUS   proteins   both   have   well   known   roles   in   RNA  
processing.  TDP-­43  can  directly  behave  as  a  trans-­acting  splicing  regulator  of  some  
genes,   including   the  CFTR  and  MAPT  genes,   and   can   also   regulate   transcription  
via   interactions   with   DNA   (Buratti   and   Baralle,   2001;;   Gu   et   al.,   2017).  
Mislocalisation   of   TDP-­43   to   the   cytoplasm   in   ALS   patient   derived   fibroblasts  
containing  a  mutation  in  TARDBP  has  been  shown  to  lead  to  changes  in  alternative  
splicing   events   (Highley   et   al.,   2014).   Furthermore,   alternative   splicing   of   mRNA  
transcripts  known  to  be  regulated  by  TDP-­43  were  found  to  be  abhorrently  spliced  
in  ALS  spinal  cord  (Xiao  et  al.,  2011).  Taken  together,  these  studies  suggest  TDP-­
43   pathology   is   one   of   the   contributing   factors   to   the   observed   defects   in   RNA  
processing   in   ALS.   FUS   likewise   has   roles   in   splicing   regulation.   FUS   directly  
interacts   with   pre-­mRNA   transcripts,   the   U1   snRNP   and   the   SMN   complex   to  
regulate   removal   of   introns   (Yamazaki   et   al.,   2012;;   Yu   et   al.,   2015;;   Zhou   et   al.,  
2013).   Depletion   of   the   FUS   protein   can   cause   alternative   splicing   events   on  
transcripts   encoding   other   RNA-­binding   proteins,   potentially   exacerbating   the  
disruption  to  RNA  metabolism  (Sun  et  al.,  2015).  ALS-­linked  mutant  FUS  can  also  
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sequester   both   major   and   minor   snRNPs   into   cytoplasmic   aggregates,   thereby  
decreasing   their   availability   for   splicing   catalysis   and   potentially   downregulating  
global  splicing  (Reber  et  al.,  2016;;  Yu  et  al.,  2015).  
  
Dysfunctional  splicing  is  also  prevalent  in  C9orf72-­ALS,  where  splicing  defects  have  
been   shown   to   correlate   disease   severity   (Cooper-­Knock   et   al.,   2015a).   RNA-­
sequencing  of  cerebellum  and  frontal  cortex  tissue  from  C9orf72-­ALS  patient  brains  
detected   hundreds   of   mis-­splicing   events   (Prudencio   et   al.,   2015).   Interestingly,  
alternative   splicing   was   also   misregulated   in   brains   of   sporadic   ALS   patients,  
although   to   a   much   lower   extent   than   C9orf72   patients.   In   both   C9orf72-­   and  
sporadic-­ALS   patients,   the   alternative   splicing   events   were   approximately   8-­fold  
higher   in   cerebellum   versus   frontal   cortex.   The   most   common   mis-­splicing   event  
was  the  skipping  of  exons,  followed  by  intron  retention  (Prudencio  et  al.,  2015).  This  
study  confirms  the  extensive  dysregulation  to  splicing  in  C9orf72-­ALS.    
  
The  disruption   to  splicing   in  C9orf72-­ALS   is   likely   through  convergence  of  several  
mechanisms.  As  previously   discussed,   the  RNA   foci   formed   from  RNA  containing  
the  GGGGCC   repeat  expansion  can  sequester  RNA  binding  proteins  and  splicing  
factor   proteins.   Indeed,   splicing   factors   are   one   of   the  main   regulatory   bodies   for  
signalling   for   exon   inclusion/removal   during   alternative   splicing,   therefore   their  
sequestration  could  lead  to  the  exon  skipping  events  in  C9orf72-­ALS.  Interestingly,  
the  arginine  DPRs  have  been  shown  to  bind  the  U2  snRNP  and  sequester  it  in  the  
cytoplasm  in  C9orf72-­ALS  motor  neurons,  and  can  also  bind  the  hnRNP  A2  splicing  
factor   to   influence  alternative  splicing  events   (Kwon  et  al.,  2014;;  Yin  et  al.,  2017).  
The  nuclear   function  of   the  C9orf72  protein   is  yet   to  be  determined,  but   there  are  
suggestions   it   interacts   with   RNA-­binding   proteins   and   may   also   function   in  
nucleocytoplasmic   transport   (Blokhuis  et  al.,  2016;;  Sellier  et  al.,  2016;;  Xiao  et  al.,  
2015).  Hence,  the  three  proposed  mechanisms  of  disease  for  C9orf72-­ALS  all  may  
contribute  to  ALS  pathogenicity  through  their  interaction  with,  and  inhibition  of,  RNA  
processing  pathways.  
  
1.7.2   Overview  of  RNA  splicing  
  
Introns   are   non-­coding   sequences   interspaced   between   coding   exons   within   a  
gene.   Transcription   of   genes   produces   an   intron-­containing   pre-­mRNA,   which  
undergoes   spicing   in   the   nucleus   by   the   spliceosome,   before   export   to   the  
cytoplasm   for   translation   into  protein   (Berget   et   al.,   1977;;  Chow  et   al.,   1977).  For  
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some  genes,  all  exons  are  constitutively  expressed  and  only  the  intervening  introns  
are  removed,  generating  a  single  mRNA  transcript.  Alternatively,  certain  exons  may  
be   removed  alongside   introns,   termed  alternative   splicing.  Alternative   splicing   can  
therefore  generate  multiple  mRNA   transcripts,   encoding  different  protein   isoforms,  
from  a  single  gene  (Black,  2003).    
  
The   spliceosome   can   be   classed   as   a   large   multimolecular   complex,   which   is  
composed   of   five   U   snRNPs   and   associated   splicing   factor   proteins   (Will   and  
Luhrmann,  2011).    Introns  contain  specific  sequences  which  recruit  the  spliceosome  
and   signal   for   intron   removal.   These   are   the   5’   and   3’   splice   sites   (ss)  which   are  
located   at   the   exon-­intron   junctions   and   the   branch   point   sequence   which   is  
generally  located  18-­40  nucleotides  upstream  of  the  3’  ss  (Burge  et  al.,  1999).  The  
snRNPs   and   splicing   factors   work   together   in   a   complex,   step-­wise   pathway   to  
catalyse   the   removal   of   introns,   mediated   by   the   RNA-­RNA   interaction   between  
snRNPs   and   pre-­mRNA.   Interestingly,   there   are   two   different   spliceosomes:   the  
major  spliceosome  and  the  minor  spliceosome.  They  differ  in  both  their  composition  
of  U  snRNPs  and  in  the  introns  they  remove.    
  
1.7.2.1   Major  splicing  vs  minor  splicing  
  
The  major  spliceosome  is  composed  from  the  U1,  U2,  U4,  U5  and  U6  snRNPs.  As  
discussed  later,  the  U4,  U5  and  U6  snRNPs  function  in  the  splicing  pathway  as  a  tri-­
snRNP,  which  assembles   in  nuclear  suborganelles  called  Cajal  bodies.  The  major  
spliceosome   catalyses   the   removal   of   major   introns,   otherwise   called   U2-­introns,  
which   make   up   more   than   99%   of   the   introns   in   the   human   genome.   U2-­introns  
contain  dinucleotides  GT  and  AG  at  their  5’  ss  and  3’  ss  respectively,  a  degenerate  
branch  point  sequence  (BPS)  that  can  be  18-­40  nucleotides  upstream  of  the  3’  ss,  
and  a  polypyrimidine  tract  in  between  the  BPS  and  3’  ss  (Gao  et  al.,  2008).    
  
In  contrast,  the  minor  spliceosome  is  composed  from  the  U11,  U12,  U4atac,  U5  and  
U6atac   snRNPs   (Turunen   et   al.,   2013).   Thus,   the   U5   snRNP   is   shared   between  
both   the   major   and   minor   spliceosomes.   The   U11,   U12,   U4atac   and   U6atac  
snRNPs  share  high  levels  of  structural  similarity  with  their  U1,  U2,  U4  and  U6  major  
spliceosome   snRNP   counterparts,   but   differences   in   their   sequences   allows   the  
minor  snRNPs  to  recognise  a  different  subset  of  introns.    
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The  minor   spliceosome   removes   a   rare   type   of   intron,   called   the   minor   intron   or  
U12-­type  intron.  U12-­introns  have  been  discovered  in  approximately  800  genes  and  
make   up   only   0.5%   of   the   introns   in   the   human   genome   (Turunen   et   al.,   2013).  
Genes   typically   contain   only   a   single   U12-­intron,   but   can   contain   more.   For  
example,   the   U12   intron   database   shows   the   spermine   synthase   gene   contains  
three  U12-­introns.  Interestingly,  U12-­introns  are  enriched  in  genes  that  have  roles  in  
voltage   gated   channels   or   in   RNA   processing,   transcription   and   DNA   replication,  
suggesting  minor  splicing  may  have  some  regulatory  control  over  certain  molecular  
pathways  (Burge  et  al.,  1998).    
  
When  U12-­introns  were  originally  discovered,  they  were  termed  ATAC-­introns,  due  
to  the  observation  that  they  contained  AT  and  AC  dinucleotides  at  their  5’  ss  and  3’  
ss  respectively,  and  a  particularly  high  level  of  conservation  at  their  5’  ss,  unalike  to  
U2-­introns   (Jackson,  1991).  However,   it  was   later  discovered   the  majority  of  U12-­
introns  also  have  GT-­AG  splice  sites  (Dietrich  et  al.,  1997;;  Wu  and  Krainer,  1997).  
U12-­introns  are  now  defined  by  a  highly  conserved  sequence  downstream  of  the  5’  
ss,  their  unique  branch  point  sequence,  which  is  optimally  located  approximately  15  
nucleotides  upstream  of  the  3’  ss,  and  their  lack  of  a  polypyrimidine  tract  (Dietrich  et  
al.,  2005;;  Hall  and  Padgett,  1996).  
  
Another  of   the  key  differences  between  the  major  and  minor  spliceosomes   is   their  
efficiency  at  intron  removal.  In  a  Drosophila  cell  line,  splicing  of  a  reporter  U2-­intron  
was  ten-­fold  higher  than  the  splicing  of  an  equivalent  U12-­intron  (Patel  et  al.,  2002).  
Within  the  same  gene,  splicing  of  a  U12-­intron  was  significantly  slower  than  splicing  
of  the  adjacent  U2-­intron  (Patel  et  al.,  2002).  Splicing  occurs  co-­transcriptionally  to  
ensure   efficient   generation   of   mature   mRNA   and   protein   expression.   However,  
genes   containing   U12-­introns   generate   pre-­mRNA   transcripts   in   which   the   U2-­
introns   are   removed   but   U12-­introns   remain,   and   which   can   therefore   regulate  
protein   levels   post-­transcriptionally.   It   has   been   proposed   that   the   slower   intron  
removal  by  the  minor  spliceosome  is  a  consequence  of  the  low  abundance  of  minor  
snRNPs.  All  four  of  the  minor-­spliceosome  specific  snRNPs  are  approximately  100-­
fold   fewer   in   number   in   comparison   to   the   major   spliceosome   snRNPs   (Montzka  
and  Steitz,  1988;;  Tarn  and  Steitz,  1996).  In  support  of  this  hypothesis,  splicing  of  an  
exogenous   reporter   U12-­intron   was   slower   in   a   cell   line   with   low   abundance   of  
minor   snRNPs   in   comparison   to   its   splicing   in   a   cell   line   with   high   abundance   of  
minor   snRNPs   (Pessa   et   al.,   2006).   However,   in   the   same   study,   splicing   of  
endogenous  U12-­introns   in   the  different   cell   lines  was  unchanged,   suggesting   the  
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snRNP  number  does  not  influence  the  rate  of  endogenous  minor  splicing  (Pessa  et  
al.,  2006).  Although,  the  low  abundance  of  the  snRNPs  can  be  a  contributing  factor  
under  conditions  of  high  splicing  demand.  
  
1.8   Cajal  bodies  and  the  spliceosome  
  
In   this   thesis,   the   first   steps   taken   towards   investigating   the   nuclear   function   of  
C9orf72   and   splicing   involved   characterising   an   interaction   between   the   C9orf72  
protein   and   nuclear   protein   coilin.   Coilin   is   the   major   protein   component   and  
structural  scaffold  for  nuclear  suborganelles  called  Cajal  bodies.    
  
1.8.1   Cajal  bodies  
  
Cajal  bodies   (CBs)  were   first  discovered   in  1903  by  Santiago  Ramón  y  Cajal  and  
were  originally  named  nucleolar  accessory  bodies  (Cajal,  1903).  The  Cajal  body  is  a  
spherical,   membraneless   nuclear   suborganelle   with   a   diameter   of   approximately    
0.1-­0.5  µm  (Cajal,  1903;;  Hardin  et  al.,  1969).    
  
The  Cajal  body  is  enriched  in  proteins  and  RNA  responsible  for  snRNP  processing  
and  other  functions  (see  Section  1.8.2).  The  two  major  proteins  that  compose  Cajal  
bodies   are   coilin   and  SMN.  Canonical  Cajal   bodies   refer   to  Cajal   bodies   that   are  
both   coilin-­   and  SMN-­positive   and   are   functionally   involved   in   snRNP  processing.  
However,   non-­canonical  Cajal   bodies   lacking   coilin   or   the  SMN  protein   can   exist,  
termed   residual   and   immature   Cajal   bodies   respectively,   but   these   are   unable   to  
correctly  recruit  snRNPs  (Lafarga  et  al.,  2017;;  Sleeman  et  al.,  2001;;  Tucker  et  al.,  
2001).  
  
How  Cajal  bodies   form  into  membraneless  suborganelles   from  their  nucleoplasmic  
components  is  not  yet  clear.  However,  evidence  supports  an  RNA  nucleation  event,  
where   other   Cajal   body   proteins   and   RNA   assemble   in   an   apparently   random  
manner  (Kaiser  et  al.,  2008;;  Mao  et  al.,  2011a;;  Shevtsov  and  Dundr,  2011).  Once  
formed,  the  weak  interactions  between  the  Cajal  body  proteins,  many  of  which  are  
RNA-­binding  proteins  with   low  complexity  domains,  are   thought   to  be   important   to  
maintaining   the   membraneless   suborganelle   in   a   ‘hydrogel-­like’   phase   within   the  
fluid   nucleoplasmic   environment   (Kato   et   al.,   2012).   Cajal   bodies   have   a   porous  
structure,   where   proteins   may   passively   diffuse   between   Cajal   bodies   and   the  
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surrounding   nucleoplasm,   with   snRNPs   shown   to   spend   as   little   as   30   seconds  
within  the  Cajal  body  (Deryusheva  and  Gall,  2004;;  Dundr  et  al.,  2004).    
  
1.8.2   Cajal  body  function  
  
Cajal   bodies   are   best   known   for   their   role   in   snRNP   processing.   Many   of   the  
proteins   and   RNA   concentrated   in   Cajal   bodies   have   roles   in   the   modification,  
recruitment  or  nucleocytoplasmic  shuttling  of   snRNPs   (Table  1.2).  However,  Cajal  
bodies   are   also   involved   in   the   modification   of   small   nucleolar   RNAs   (snoRNA),  
telomere  maintenance  and  regulating  gene  expression  of  small,  non-­coding  RNAs,  
which  will  be  briefly  covered  below.  
  
Table  1.2.  Cajal  body  proteins  and  RNA  involved  in  snRNP  processing  
   PROTEIN     
Protein  Name   Function   Reference  
Coilin   Cajal  body  scaffold   (Andrade  et  al.,  1991)  
SMN   SMN  complex   (Hebert  et  al.,  2001)  
Gemins   SMN  complex   (Hao  et  al.,  2007)  
Sm  proteins   SMN  complex     (Smoliński  et  al.,  2011)  
SART3   snRNP  recycling   (Stanĕk  et  al.,  2003)  
TGS1   snRNA  m7G  cap  methylation   (Mouaikel  et  al.,  2003)  
PHAX   snRNA  nuclear  export   (Boulon  et  al.,  2004)  
CRM1   snRNA  nuclear  export   (Boulon  et  al.,  2004)  
WRAP53   SMN  complex  recruitment  to  Cajal  bodies   (Mahmoudi  et  al.,  2010)  
Prp3/Prp4   snRNP  recycling   (Schaffert  et  al.,  2004)  
Snurportin1   snRNP  nuclear  import   (Ospina  et  al.,  2005)  
SF3a60/SF3a66   snRNP  nuclear  import   (Nesic  et  al.,  2004)  
U2AF   Splicing  factor   (Carmo-­Fonseca  et  al.,  1992)  
RNA  
RNA  Name   Family   Reference  
U1   snRNA   (Carmo-­Fonseca  et  al.,  1992)  
U2   snRNA   (Carmo-­Fonseca  et  al.,  1992)  
U4   snRNA   (Carmo-­Fonseca  et  al.,  1992)  
U5   snRNA   (Carmo-­Fonseca  et  al.,  1992)  
U6   snRNA   (Carmo-­Fonseca  et  al.,  1992)  
U11   snRNA   (Matera  and  Ward,  1993)  
   52  
  
1.8.2.1   snRNP  maturation    
  
Splicing  is  performed  by  the  spliceosome,  which  refers  to  five  U  snRNPs  and  their  
associated  splicing   factor  proteins   (Will  and  Luhrmann,  2011).  The  U  snRNPs  are  
RNA-­protein  complexes  which  contain  a  U  snRNA  which  catalyses   the   removal  of  
introns   from   pre-­mRNA.   This   section   will   focus   on   the   maturation   pathway   from  
early   U   snRNA   transcription   to   fully   mature   spliceosomal   U   snRNP,   and   the  
relationship   with   Cajal   bodies   in   that   pathway   (Figure   1.5).   It   is   worth   noting,   the  
snRNP  processing   reactions   can   occur   throughout   the  whole   of   the   nucleoplasm,  
but  by  enriching   the  proteins  and  RNA   in  specific  sites   in   the  nucleus  within  Cajal  
bodies,  the  efficiency  of  snRNP  assembly  and  splicing  output  of  the  cell  is  increased  
(Klingauf  et  al.,  2006).    
  
There  are  9  U  snRNAs  that  are  involved  in  splicing:  U1,  U11,  U2,  U12,  U4,  U4atac,  
U5,   U6   and   U6atac.   Similar   to   mRNA,   the   U   snRNA   genes   are   transcribed   by  
polymerase  II,  except  for  U6  and  U6atac  which  are  transcribed  from  a  polymerase  
III  promoter  and  undergo  a  separate  maturation  pathway  (Hernandez,  2001;;  Kunkel  
et  al.,  1986;;  Schramm  and  Hernandez,  2002).  After   transcription,   the  snRNAs  are  
m7G  capped  on  their  5’  end,  and  the  3’  end  undergoes  snRNA  specific  cleavage  by  
the   integrator   complex   (Baillat   et   al.,   2005).   Interestingly,   there   is   also   evidence  
suggesting   a   role   for   the   Cajal   body   protein   coilin   in   the   3’   end   processing   of  
nascent   U   snRNAs,   and   this   might   be   enabled   through   the   association   of   Cajal  
U12   snRNA   (Matera  and  Ward,  1993)  
U4atac   snRNA   (Stanĕk  et  al.,  2003)  
U6atac   snRNA   (Stanĕk  et  al.,  2003)  
SCARNA10   scaRNA   (Jady  and  Kiss,  2001)  
SCARNA5   scaRNA   (Darzacq  et  al.,  2002)  
SCARNA6   scaRNA   (Darzacq  et  al.,  2002)  
SCARNA12   scaRNA   (Darzacq  et  al.,  2002)  
SCARNA7   scaRNA   (Darzacq  et  al.,  2002)  
SCARNA17   scaRNA   (Darzacq  et  al.,  2002)  
SCARNA8   scaRNA   (Darzacq  et  al.,  2002)  
SCARNA13   scaRNA   (Kiss  et  al.,  2002)  
SCARNA4   scaRNA   (Kiss  et  al.,  2004)  
SCARNA1   scaRNA   (Kiss  et  al.,  2004)  
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bodies   with   snRNA   gene   loci   discussed   in   Section   1.8.2.3   (Broome   and   Hebert,  
2012).  
  
snRNA  transcripts  are  bound  by   the  cap-­binding  complex,  phosphorylated  adaptor  
RNA   export   protein   (PHAX)   and   arsenite   resistance   2   (ARS2)   which   bridge   an  
interaction   between   the   snRNA   cap   and   the   chromosome   region   maintenance   1  
(CRM1)  protein  (Fornerod  et  al.,  1997;;  Hallais  et  al.,  2013;;   Izaurralde  et  al.,  1994;;  
Ohno  et  al.,  2000).  There  is  evidence  to  suggest  the  export  complex  assembly  onto  
snRNAs   takes   place   in   Cajal   bodies.   Firstly,   immature   snRNAs   and   the   export  
complex   proteins   are   detected   in   Cajal   bodies,   and   secondly,   inhibition   of   PHAX  
nuclear  export  causes  snRNAs  to  accumulate  in  Cajal  bodies  (Boulon  et  al.,  2004;;  
Smith  and  Lawrence,  2000;;  Suzuki  et  al.,  2010).    
  
In   the   nucleus,   the   CRM1   protein   mediates   an   interaction   between   the   snRNA-­
export  complex  with  the  GTP-­bound  Ran-­GTPase  and  facilitates  nuclear  export  via  
the   nuclear   pore   complex   (Fornerod  et   al.,   1997;;  Ohno  et   al.,   2000).  Once   in   the  
cytoplasm,   the   simultaneous   GTP   hydrolysis   by   Ran-­GTPase   and   the  
dephosphorylation  of  PHAX  releases  the  snRNA  from  the  export  complex  (Kitao  et  
al.,  2008;;  Ohno  et  al.,  2000).  
  
The   cytoplasmic   snRNA   is   next   bound   by   the  SMN   complex,   a   large  multiprotein  
complex   composed  of   the  SMN  protein   and  associated  Gemins   2-­7   (Massenet   et  
al.,  2002;;  Pellizzoni  et  al.,  2002).  The  SMN  complex  recruits  seven  Sm  proteins,  F,  
E,  G,  D1,  D2,  B  and  D3,  and  acts  as  a  platform  for  the  Sm  proteins  to  assemble  into  
a  heteroheptameric  ring  around  the  snRNA  in  an  ATP-­dependent  manner,   forming  
the  core  of  the  snRNP  (Meister  et  al.,  2001;;  Raker  et  al.,  1996).    
  
After  assembly  of  the  Sm  protein  core  on  the  snRNP,  the  SMN  complex  recruits  the  
trimethylguanosine   synthase   1   (TGS1)   protein  which   hypermethylates   the   snRNA  
m7G  cap  to  a  2,2,7-­trimethylguanosine  (m3G)  cap  (Mouaikel  et  al.,  2003).  Together,  
the  snRNP  core  and  m3G  cap  behave  as  nuclear  localisation  signals  and  target  the  
snRNP  for  nuclear  import  (Fischer  and  Lührmann,  1990;;  Fischer  et  al.,  1993).  The  
nuclear   import  complex,  comprising  snurportin  1  and  importin-­β, assembles  on  the  
m3G  cap  and  facilitates  nuclear  import  of  the  snRNPs  (Huber  et  al.,  1998;;  Palacios  
et  al.,  1997).  
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Once  back  in  the  nucleus,  newly  imported  snRNPs  return  to  Cajal  bodies  for  further  
modifications   (Ospina   et   al.,   2005;;   Sleeman   and   Lamond,   1999).   An   interaction  
between   the  SMN  protein  and   coilin   is   thought   to  mediate   recruitment   of   snRNPs  
into  Cajal  bodies  (Hebert  et  al.,  2001).  In  Cajal  bodies,  the  snRNPs  undergo  several  
final   adjustments   to   become   functional   for   pre-­mRNA   splicing.   First,   Cajal   bodies  
are  enriched  in  small  Cajal  body  RNAs  (scaRNAs),  which  catalyse  the  2’-­O-­ribose-­
methylation  and  pseudouridylation  of   the  snRNP,  which   increases  the  stability  and  
protection  of   the  snRNA  (Jady  et  al.,  2003).     Secondly,  U  snRNP-­specific  proteins  
are  assembled  onto  the  complex  (Nesic  et  al.,  2004).  Lastly,  the  mature  U4,  U5  and  
U6  snRNPs  organise  themselves  into  a  U4-­U6  di-­snRNP  and  U4-­U5•U6  tri-­snRNP  
to   become   fully   functional   for   pre-­mRNA  splicing   (Novotny   et   al.,   2011;;  Stanĕk  et  
al.,   2003;;   Stanĕk   and  Neugebauer,   2004).   The   snRNPs   can   then   diffuse   through  
the   nucleoplasm   and   enter   the   splicing   pathway   (Sleeman   and   Lamond,   1999;;  
Spector  and  Lamond,  2011).  
  
As   previously   mentioned,   the   U6   and   U6atac   undergo   a   maturation   pathway  
separate   from   the   other  U   snRNPs   in   that   they   are   transcribed   by   polymerase   III  
and  their  biogenesis  pathway  takes  place  exclusively   in  the  nucleus  (Kunkel  et  al.,  
1986;;  Mroczek  and  Dziembowski,  2013).  The  5’  cap  on  the  U6  and  U6atac  is  a  non-­
nucleotide   gamma-­monomethyl   phosphate   and   the   3’   end   has   a   2’,3’-­cyclic  
phosphate  added   (Lund  and  Dahlberg,  1992;;  Singh  and  Reddy,  1989).  Unlike   the  
other   U   snRNAs,   the   heteroheptameric   ring   on   the   U6   and   U6atac   snRNA   is  
assembled  from  Like-­Sm  (LSm)  proteins  2-­8,  called  the  LSm  complex  (Achsel  et  al.,  
1999;;   Khusial   et   al.,   2005).   The   LSm   complex   is   assembled   separately   in   the  
cytoplasm  and  is  imported  into  the  nucleus  where  it  associates  with  the  3’  end  of  the  
U6/U6atac   snRNA   (Licht   et   al.,   2008;;   Zaric   et   al.,   2005).   Final   U6   snRNA  
modifications   take  place   in   the  nucleolus,  where  small  nucleolar  RNAs  (snoRNAs)  
guide  2’-­O-­ribose-­methylation  and  pseudouridylation  reactions  (Ganot  et  al.,  1999).  
The   mature   U6   snRNP   is   then   recruited   to   Cajal   bodies   by   the   SART3   protein,  
where,   as   mentioned,   it   forms   di-­snRNPs   and   tri-­snRNPs   with   the   U4   and   U5  
snRNPs  (Stanĕk  et  al.,  2003;;  Stanĕk  and  Neugebauer,  2004).  
  
1.8.2.1.1  U4-­U5•U6  tri-­snRNP  assembly  
  
The  mature  U4,  U5  and  U6  snRNPs  are  recruited  into  the  splicing  pathway  as  a  U4-­
U5•U6  tri-­snRNP.  The  localisation  of  the  U4-­U6  di-­snRNP  and  U4-­U5•U6  tri-­snRNP  
within  Cajal   bodies   has   been  widely   reported,   suggesting   they   are   the   location   of  
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assembly  (Schaffert  et  al.,  2004;;  Stanĕk  and  Neugebauer,  2004).  To  begin,  the  U4  
and  U6   snRNPs   form   a   di-­snRNP.   The  U4   and  U6   snRNA   form  RNA-­RNA   base  
pairings,  mediated  by  the  SART3  protein  and  LSm  proteins  (Achsel  et  al.,  1999;;  Bell  
et  al.,  2002;;  Raghunathan  and  Guthrie,  1998).  For  U5  snRNP   integration,   the  U4-­
U6  di-­snRNP  protein  Prp31   interacts  with   the  U5  snRNP  protein  Prp6,   as  well   as  
the  association  of  several  new  proteins  (Liu  et  al.,  2006;;  Makarova  et  al.,  2002).   If  
tri-­snRNP  assembly  fails,   the  SART3  protein  anchors   immature  snRNPs  into  Cajal  
bodies   through   an   interaction   with   coilin,   suggesting   Cajal   bodies   also   act   as   a  
quality   control   step,   only   allowing   fully   functional   snRNPs   to   enter   the   splicing  
pathway  (Novotný  et  al.,  2015).  After  assembly,  the  U4-­U5•U6  tri-­snRNP  enters  the  
splicing  pathway,  where  the  snRNP  interactions  are  broken.  The  individual  snRNPs  
are  then  recycled  back  into  Cajal  bodies  for  reassembly.    






























Figure   1.5.   Maturation   pathway   of   Sm-­like   snRNPs.   The   U   snRNA   is  
transcribed   by   Polymerase   II   and   recruited   to   Cajal   bodies   where   the   export  
complex,   composing   PHAX,   CRM1   and   Ran-­GTPase,   assembles.   The   U  
snRNA   is  exported   to   the  cytoplasm  where   the  export  complex  disassociates.  
The  SMN  complex  binds  the  snRNA,  and  mediates  the  formation  of  the  Sm  ring  
and   cap   hypermethylation   from   a  m7G   cap   to   a   m3G   cap.   The  m3G   cap   and  
snRNP  core  act  as  nuclear   localisation  signals,  and  import  proteins  importin-­β  
(Iβ)  and  snurportin  1  (SNP)  bind  and  mediate  import  into  the  nucleus.  snRNPs  
then   localise   to   Cajal   bodies   where   scaRNA   catalyses   the   2’-­O-­ribose  
methylation  and  pseudouridylation  of  the  snRNAs.  The  snRNPs  then  exit  Cajal  
bodies  to  join  the  spliceosome.  
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1.8.2.2   snoRNA  and  scaRNA  modifications  
  
In  addition   to  snRNA,  Cajal  bodies  are  also  home  to  another   two  families  of  RNA:  
scaRNA   and   snoRNA.   scaRNA   and   snoRNA   share   similar   structures,   both   can  
contain  box  H/ACA  and/or  box  C/D  motifs,  and  functionally  they  both  mediate  the  2’-­
O-­ribose-­methylation   and  pseudouridylation  modifications   of   other  RNA.  However,  
scaRNA  mediates   the  modification   of   snRNPs   in   Cajal   bodies,   whereas   snoRNA  
mediates  the  modification  of  ribosomal  RNA  in  the  nucleolus  (Darzacq  et  al.,  2002;;  
Decatur  and  Fournier,  2003;;  Jady  et  al.,  2003).  
  
Both   scaRNA  and   snoRNA   initially   localise  at  Cajal   bodies  and  are   thought   to   be  
recruited  by  WRAP53  and  PHAX,  respectively  (Boulon  et  al.,  2004;;  Tycowski  et  al.,  
2009).  The  scaRNAs,  which  contain  a  Cajal  body  (CAB)  box  motif,  are  retained   in  
Cajal  bodies  whereas  the  snoRNA,  which  lack  a  CAB  box,  are  quickly  trafficked  to  
the   nucleolus   (Narayanan   et   al.,   1999a,   1999b;;   Richard   et   al.,   2003).   The   exact  
modifications  to  scaRNA  and  snoRNA  that  occur  in  Cajal  bodies  are  unknown,  but  
there   is   evidence   to   suggest   they   undergo   cap   hypermethylation   and   binding   of  
RNA-­specific  proteins  (Pradet-­Balade  et  al.,  2011;;  Verheggen  et  al.,  2002).    
  
1.8.2.3   Chromosome  organisation  and  gene  expression  
  
Cajal   bodies   are   not   static   structures,   but   migrate   within   the   nucleoplasm   where  
they   have   been   shown   to   associate   with   other   nuclear   bodies   and   chromatin  
(Platani   et   al.,   2000,   2002).   Interestingly,   Cajal   bodies   have   been   shown   to  
associate  with  the  genomic  loci  of  several  genes,  including  the  U1  and  U2  snRNAs  
and  histone  gene  clusters   (Frey  et  al.,  1999;;  Frey  and  Matera,  1995;;  Smith  et  al.,  
1995).   Recent   evidence   suggests   the   Cajal   body   can   act   as   a   ‘hub’   for  
chromosomal   organisation,   in   which   the   gene   loci   of   highly   expressed   snRNAs,  
scaRNAs,  and  snoRNAs  form  chromosomal  clusters  (Wang  et  al.,  2016).  Disruption  
of  Cajal   bodies   led   to   a   loss   of   these   gene   clusters   and   a   decrease   in  U   snRNA  
expression  and  snRNP  production,  suggesting  Cajal  bodies  may   influence  splicing  
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1.8.2.4   Telomere  maintenance  
  
Cajal   bodies   have   also   been   implicated   in   telomere  maintenance.   Telomeres   are  
repeated   DNA   sequences   at   the   ends   of   linear   chromosomes   and  which   shorten  
with   each   round   of   cell   division   (Smogorzewska   and   de   Lange,   2004).   After   the  
shortening   of   telomeres   to   a   specific   length,   cells   signal   to   enter   a   state   of  
senescence,   or   undergo   programmed   apoptosis   (McEachern   et   al.,   2000).   To  
counter   telomere   shortening,   they   are   maintained   and   synthesised   by   the  
telomerase  enzyme,  which   is  composed  of  a   telomerase  RNA  and   the   telomerase  
reverse   transcriptase   (TERT)   (Greider  and  Blackburn,  1989;;  Mitchell  et  al.,  1999).  
Both  the  telomerase  RNA  and  TERT  have  been  shown  to   localise   in  Cajal  bodies,  
which  themselves  can  directly  associate  with  telomeres  as  they’re  being  replicated  
(Jady  et  al.,  2005;;  Tomlinson  et  al.,  2006;;  Zhu  et  al.,  2004).  In  addition,  one  of  the  
protein   components   of   Cajal   bodies,   telomerase   Cajal   body   protein   1   (TCAB1),  
recruits   active   telomerase   to   Cajal   bodies   and   its   depletion   can   inhibit   telomere  
synthesis  suggesting  Cajal  bodies  may  be  sites  of  telomerase  assembly  (Venteicher  
et   al.,   2009).   A   second   proposed   role   is   that   Cajal   bodies   are   involved   in   the  
maturation   of   the   telomerase   RNA.   The   telomerase   RNA   is   part   of   the   scaRNA  
family,  and  holds  similar  physical  properties  to  other  scaRNAs  that  target  it  for  Cajal  
body   localisation   and   modification,   such   as   the   H/ACA   box   and   CAB   box   motifs  
(Jady  et  al.,  2004;;  Theimer  et  al.,  2007).    
  
1.8.3   Cajal  body  dynamics  
  
The  appearance  and  number  of  Cajal  bodies  varies  between  cell  and  tissue  types.  
In  neurons,  the  neuronal  size  can  influence  the  number  of  Cajal  bodies,  but  typically  
1-­3  Cajal  bodies  per  nucleus  are  present   (Cajal,  1903;;  Pena  et  al.,  2001).  On   the  
other   hand,   cell   types   from   various   tissues,   for   example   spleen,   stomach   and  
smooth  muscle  cells,  lack  Cajal  bodies  altogether  (Young  et  al.,  2000).    
  
The   number   of   Cajal   bodies   in   the   nucleus   appears   to   be   regulated,   and   can   be  
influenced  by  several   factors.  Cajal  bodies  are  especially  prominent   in  cells  with  a  
high  metabolic  or  transcription  demand,  which  may  be  related  to  an  increased  need  
for   snRNP   production   (Pena   et   al.,   2001;;   Spector   et   al.,   1992).   Inhibition   of  
transcription   leads   to   disassembly   of   Cajal   bodies   and   their   restructuring   into  
nucleolar  caps  (Shav-­Tal  et  al.,  2005),  suggesting  active  transcription  is  required  to  
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maintain   canonical   Cajal   bodies.   Cellular   levels   of   snRNP   can   also   influence   the  
number   of   Cajal   bodies;;   an   increase   in   snRNPs   causes  Cajal   bodies   to   increase  
(Sleeman  et  al.,  2001).  The  effect  of  transcription  and  snRNPs  on  Cajal  bodies  are  
likely   linked,   a   high   transcription   demand   requires   more   snRNPs   for   RNA  
processing.   In   addition,   within   dividing   cells,   Cajal   body   numbers   change   in  
response  to  the  cell  cycle;;  Cajal  bodies  disassemble  during  mitosis  and  reassemble  
in  daughter  cells  during  mid-­G1  (Andrade  et  al.,  1993;;  Carmo-­Fonseca  et  al.,  1993).  
These   changes   could   be   from   the   inhibition   and   restarting   of   transcription   and  
splicing   as   the   cell   progresses   through   cell   division,   or   there   is   also   evidence   to  
suggest   Cajal   bodies   are   regulated   in   the   cell-­cycle   by   post-­translational  
modification  of   the  coilin  protein,  which   is  discussed  later.  Cajal  body  number  may  
also   be   important   developmentally,   as   numbers   of   Cajal   bodies   are   high   during  
early  development  and  decrease  post-­differentiation   (Strzelecka  et  al.,   2010).  The  
response   of   Cajal   bodies   to   factors   such   as   serum   starvation   and   viral   infection  
have   also   led   to   suggested   roles   in   pathways   such   as   the   stress   response  
(Carvalho  et  al.,  1999;;  Platani  et  al.,  2000).  Finally,  overexpression  or  depletion  of  
Cajal  body  components  can  also  regulate  the  number  of  Cajal  bodies.  For  example,  
overexpression  of   the  SmB  protein   leads   to  an   increase   in  Cajal   bodies,  whereas  
SMN  depletion  leads  to  a  decrease  in  Cajal  bodies  (Lemm  et  al.,  2006;;  Sleeman  et  
al.,  2001).  
  
1.8.4   Cajal  bodies  in  disease  
  
Defects  in  Cajal  bodies  have  been  linked  with  a  number  of  diseases,  mainly  through  
their   association   with   the   spliceosomal   snRNPs.   Cajal   body   dysregulation   can  
influence   the   splicing   ability   of   the   cell   and   defective  RNA   processing   has   strong  
links  with  ALS  (Cooper-­Knock  et  al.,  2015a;;  Whittom  et  al.,  2008).  Cajal  bodies  and  
splicing  have  been  implicated  in  spinal  muscular  atrophy  (SMA),  a  disease  similar  to  
ALS  in  which  patients  develop  motor  neuron  degeneration  as  a  result  of  SMN  loss-­
of-­function   (Lefebvre   et   al.,   1995).   Depletion   of   the   SMN   protein   leads   to   loss   of  
canonical  Cajal  bodies  (Lemm  et  al.,  2006;;  Morse  et  al.,  2007).  Disruption  to  Cajal  
bodies  is  observed  in  the  SMN∆7  mouse  model  of  SMA,  involving  relocalisation  of  
Cajal   body   proteins,   specifically   coilin,   to   perinucleolar   caps   which   disrupted  
ribosome   biogenesis   (Tapia   et   al.,   2017).   In   addition,   SMA   patient-­derived  
lymphoblast   cells   lack  Cajal   bodies  and  have   reduced  U4-­U5•U6   tri-­snRNP   levels  
(Boulisfane   et   al.,   2011).  Hence,   disruption   to  Cajal   bodies   caused  by   loss   of   the  
SMN  protein  may  contribute  to  SMA  pathogenicity.      
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Cajal   bodies   have   also   been   linked   with   ALS.   In   the   presence   of   mutant   SOD1,  
Cajal  bodies  are  decreased  and  lack  SMN  and  snRNPs  in  neuronal  cells  (Kariya  et  
al.,   2012).   In   support   of   this,   in   a  mutant   human  SOD1   transgenic  mouse  model,  
loss   of   nuclear   bodies   from   spinal   motor   neurons   correlates   with   age   and   ALS  
disease  progression  (Gertz  et  al.,  2012).    These  studies  suggest  Cajal  bodies  may  
be  dysfunctional  in  SOD1-­related  ALS.  Moreover,  ALS  genes  TDP-­43  and  FUS  also  
have   connections   with   Cajal   bodies.   TDP-­43   forms   intranuclear   inclusions   within  
cells  and  these  inclusions  strongly  colocalise  with  Cajal  bodies  (Wang  et  al.,  2002).  
Further,   knockdown   of   TDP-­43   can   cause   a   marked   decrease   in   the   number   of  
nuclear   gem   structures   (Tsuiji   et   al.,   2013)   and   both   mutant   TDP-­43   and   FUS  
expressing   ALS   patient   fibroblasts   contain   lower   than   normal   numbers   of   nuclear  
bodies,  suggesting  irregular  Cajal  body  number  and/or  function  is  a  theme  that  runs  
throughout  a  number  of  ALS  models  (Yamazaki  et  al.,  2012).  
  
Interestingly,  Cajal  bodies  have  also  been  implicated  in  CAG  repeat  diseases,  such  
as  Huntington’s  disease.  A  common  characteristic  of  CAG   repeat  disorders   is   the  
formation  of   neuronal   intranuclear   inclusions   (NIIs)   in  brains   (DiFiglia  et   al.,   1997;;  
Paulson  et  al.,  1997).  These  NIIs  have  been  shown  to  closely  associate  with  Cajal  
bodies   in   dentatorubral-­pallidoluysian   atrophy   (DRPLA)   transgenic   mouse   brains  
and  it  is  hypothesised  this  may  disrupt  Cajal  bodies  and  cause  cell  death  (Yamada  
et   al.,   2001).   Neurodegenerative   diseases   are   complex   disorders   whose  
mechanisms   of   disease   often   overlap;;   therefore,   it   may   be   that   defective   Cajal  
bodies  play  a  role  in  several  diseases.    
  
1.8.5   Coilin  
  
At  the  beginning  of  this  project,  an  unbiased  yeast  two-­hybrid  screen  was  performed  
with   the   aim   of   identifying   novel   nuclear   protein   interactors   of   the   C9orf72   long  
protein.   The   Cajal   body   protein   coilin   was   identified   several   times   in   the   screen  
indicating  a  probable  interaction  between  C9orf72  and  coilin.    
  
Coilin  is  an  80  kDa  nuclear  protein  that  is  the  major  protein  component  and  marker  
of   Cajal   bodies   (Andrade   et   al.,   1991;;   Bohmann   et   al.,   1995).   Located   on  
chromosome   17,   the   coilin   gene   is   approximately   25   kb   and   is   comprised   of   7  
coding  exons,  which  are  constitutively  expressed  (Chan  et  al.,  1994).   Investigation  
of  the  coilin  sequence  has  revealed  two  nuclear  localisation  signals  (NLS),  a  single  
nucleolar   localisation   signal   (NoLS)   and   an   RG-­box   (Hebert   and   Matera,   2000).  
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However,   the   sequence   does   not   disclose   any   other   structural   motifs   from  which  
function  can  be   inferred  and   the  crystal  structure  of  coilin   is  yet   to  be  determined.  
NMR   methods   have   been   utilised   which   suggest   coilin   is   formed   from   three  
domains:  an  N-­terminal  domain,  a  central  highly  disordered  domain  which  contains  
the   nuclear   and   nucleolar   localisation   signals,   and   the  C-­terminal   region  which   is  
thought  to  contain  an  uncharacteristic  tudor  domain  adjacent  to  the  RG-­box  (Figure  
1.6)  (Shanbhag  et  al.,  2010).  Although  lacking  a  proper  RNA-­binding  domain,  the  N-­
terminal   self-­association   domain   may   contain   an   atypical   RNA-­recognition   motif  
which  allows  it  to  interact  with  RNA  (Bellini  and  Gall,  1998).  The  coilin  RG-­box  is  a  
motif   of   repeated   arginine-­glycine   dipeptides   which   are   often   post-­translationally  
symmetrically   dimethylated   on   the   arginine   residues,   and   which   commonly  
facilitates  protein-­protein  interactions  (Thandapani  et  al.,  2013).  The  tudor  domain  is  
a  barrel-­like  fold  that  preferentially  binds  symmetrically  dimethylated  arginines  within  
RG-­boxes  (Sprangers  et  al.,  2003).  Interestingly,  the  Sm  proteins  and  SMN  protein  
also  contain  an  RG-­box  and  tudor  domain,  respectively.  Symmetrical  dimethylation  
of   the  RG-­box  on   the  SmB,  SmD1  and  SmD3  proteins   is   central   to  an   interaction  
between  the  Sm  protein  RG-­box  and  the  SMN  protein  tudor  domain  (Brahms  et  al.,  
2000,  2001).  Although  sequence  conservancy   is   low,   the   three  domains   in  human  
coilin  have  also  been  described   for  plant  coilin,  suggesting   the  structure   is  shared  




Figure  1.6.  Coilin  protein  domains.  The  coilin  protein  contains  an  N-­terminal  domain   for  
self-­association   (1-­92aa),   a   central   disordered   region   (92-­392aa),   an   RG-­box   motif   (392-­
420aa)  and  an  atypical  tudor  domain  (460-­560aa).  The  red  arrows  indicate  the  domains  with  
which  coilin-­interacting  proteins  or  RNA  associate  with.    
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1.8.5.1   Coilin  function  
  
Coilin  is  the  most  commonly  used  marker  for  Cajal  bodies.  As  is  frequently  seen  for  
nuclear   body   proteins,   coilin   self-­interacts   via   its   conserved   N-­terminal   domain  
(Hebert  and  Matera,  2000).  This  self-­interacting  domain,  combined  with  the  NLS,  is  
essential  for  canonical  Cajal  body  formation  (Hebert  and  Matera,  2000).  Coilin  has  
also   been   shown   to   mediate   many   of   the   protein-­protein   and   protein-­RNA  
interactions   in   Cajal   bodies,   helping   to   scaffold   the   nuclear   body.   Studies   have  
shown   coilin   is   symmetrically   dimethylated   on   the   arginine   residues   in   its  RG-­box  
which   interacts  with   the   tudor   domain   on   the  SMN  protein   to   recruit   snRNPs   into  
Cajal   bodies   (Boisvert   et   al.,   2002;;   Hebert   et   al.,   2001;;   Tucker   et   al.,   2001).   In  
addition,  coilin  associates  with  Sm  proteins  and  snRNPs  via  an  interaction  between  
the  Sm-­fold  on  Sm  proteins  and  the  tudor  domain  on  coilin  (Xu  et  al.,  2005).  Coilin  
has   also   been  widely   documented   to   interact  with  multiple   snoRNA,   scaRNA  and  
telomerase   RNA   and   may   be   directly   involved   in   the   processing   of   these   RNAs  
within  Cajal  bodies  (Enwerem  et  al.,  2015;;  Machyna  et  al.,  2014;;  Poole  et  al.,  2016).  
The   literature   therefore   suggests   that   the   main   function   of   coilin   is   to   form   the  
‘structural  scaffold’  of  Cajal  bodies  and  enrich  and  recruit   the  proteins   required   for  
snRNP  assembly.    
  
Indeed,   coilin   is   essential   for   Cajal   body   formation.   Numerous   studies   have  
investigated   the   essential   nature   of   coilin   through   its   knockdown   and   knockout   in  
both   cell   and   animal   models.   HeLa   cells   depleted   of   coilin   have   decreased   cell  
proliferation   and   splicing   efficiency   but   still   show   viability   (Lemm   et   al.,   2006;;  
Whittom  et  al.,  2008).  Similarly,  Drosophila  coilin  null  mutants  show  full  viability  but  
lose  the  ability  to  form  Cajal  bodies  (Liu  et  al.,  2009).  In  zebrafish,  coilin  is  essential  
for  embryogenesis;;  coilin  knockdown  led  to  decreased  cell  proliferation  and  embryo  
lethality  (Strzelecka  et  al.,  2010).  In  addition,  Cajal  body  integrity  was  lost  (although  
some   residual   Cajal   bodies   remained)   and   the   spliceosomal   snRNPs   dispersed  
from  foci,  leading  to  decreased  snRNP  assembly  and  defective  splicing  (Strzelecka  
et   al.,   2010).   Interestingly,   embryo   viability   was   rescued  with   injections   of  mature  
snRNPs,   suggesting  coilin   knockdown  caused  a  downstream  effect  where  snRNP  
assembly  was  reduced  due  to  Cajal  body  loss,  which  in  turn  impacted  the  embryos  
ability   to   efficiently   perform   splicing   (Strzelecka   et   al.,   2010).   Finally,   in   a  mouse  
study,   coilin  was   shown   to   be  essential   for   canonical  Cajal   body   formation.  Coilin  
knockout  mice  lacked  Cajal  bodies  containing  SMN  and  snRNPs,  but  residual  Cajal  
bodies  containing  fibrallarin  did  remain  (Tucker  et  al.,  2001).  The  homozygous  coilin  
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knockout   mutants   additionally   showed   decreased   viability   (Tucker   et   al.,   2001).  
From  the  loss-­of-­function  coilin  studies  it  appears  coilin  is  essential  for  correct  Cajal  
body   formation   and   loss   of   Cajal   bodies   can   affect   viability   in   varying   degrees   of  
severity,   from  no  effect   in  Drosophila   to  embryo   lethality   in  zebrafish.  The  strength  
of   the   phenotype   for   Cajal   body   disruption   may   be   dependent   on   the   splicing  
demand   of   the   organism,   explaining   the   severe   phenotype   observed   in   zebrafish  
during  embryo  development.  
  
Manipulating   the   coilin   protein   has   been   shown   to   influence   splicing.   Both  
expression  levels  and  post-­translational  modifications  of  coilin  have  been  shown  to  
have   an   effect   on   the   splicing   efficiency   of   cells   (Whittom   et   al.,   2008).   Coilin  
depletion  caused  decreased  splicing  of  an  intron  from  an  artificial  reporter  whereas  
hypomethylation   of   coilin   increased   splicing   (Whittom   et   al.,   2008).   However,   as  
Cajal   bodies   are   sites   of   snRNP   maturation,   and   coilin   is   the   major   protein  
component  of  Cajal  bodies,   the  effect  on  splicing   is   likely  explained  by  Cajal  body  
regulation.   In   contrast,   a   study   in   Arabidopsis   thaliana   reported   coilin   loss-­of-­
function   mutants   led   to   increased   splicing   of   an   artificial   reporter,   purportedly   by  
influencing   the  gene  expression  of   a   small   number   of   stress-­genes   (Kanno  et   al.,  
2016).  More  work  is  required  to  understand  if  there  is  a  direct  relationship  between  
coilin  and  splicing.      
  
Although   coilin   concentrates   in   Cajal   bodies,   it   is   found   predominantly   dispersed  
throughout  the  nucleoplasm  of  cells  and,  as  not  all  cells  contain  Cajal  bodies  but  do  
have   nucleoplasmic   coilin,   there   are   suggestions   of   additional   functions   for   coilin  
(Lam   et   al.,   2002;;   Young   et   al.,   2000).   Coilin   has   been   shown   to   bind   double  
stranded   DNA   and   contains   DNA-­dependent   RNase   activity   with   which   it   can  
process   snRNA   3’   ends   (Broome   and   Hebert,   2012).   In   the   same   study,   coilin  
depletion  led  to  accumulation  of  immature  U  snRNAs,  suggesting  coilin  may  directly  
be  involved  in  snRNA  3’  end  processing.  Another  interpretation  however,  is  that  loss  
of  coilin  disrupts  Cajal  bodies  and  their  association  at  snRNA  gene  loci,  and  the  loss  
of   the   interaction   may   influence   snRNA   processing.   There   is   also   evidence   that  
coilin  plays  a  part  in  the  DNA  damage  response.  UV-­irradiation  causes  Cajal  bodies  
to   disassemble   and   interestingly,   coilin   is   one  of   the   first   proteins   recruited   to   the  
DNA  breaks  (Bártová  et  al.,  2014;;  Cioce  et  al.,  2006).  In  addition,  coilin  redistributes  
to   the  nucleolus   in   response   to  cisplatin-­induced  DNA  damage,  where   it  has  been  
shown   to   inhibit   rRNA   biogenesis   by   interacting   with   the   RPA-­194   subunit   of  
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Polymerase  I  (Gilder  et  al.,  2011).  Collectively,  these  studies  indicate  nucleoplasmic  
coilin  has  Cajal  body-­independent  functions.    
  
1.8.5.2   Post-­translational  modifications  of  coilin  
  
Coilin   is   a   phosphoprotein   that   undergoes   many   post-­translational   modifications  
which   can   regulate   its   localisation   and   formation   of   Cajal   bodies.   Coilin   contains  
segments  of  serine  rich  sequences  and  undergoes  phosphorylation,  often   in  a  cell  
cycle   dependent   manner   (Carmo-­Fonseca   et   al.,   1993;;   Chan   et   al.,   1994).  
Proteomics   approaches   have   shown   coilin   to   contain   a   minimum   of   11   potential  
phosphorylation  sites   in   its   sequence   (Beausoleil   et  al.,   2006;;  Olsen  et  al.,   2006).  
Phosphorylation  of  coilin  has  been  shown  specifically  to  increase  during  the  mitosis  
phase   of   the   cell   cycle   and   the   phosphorylation   state   of   coilin   is   able   to   regulate  
Cajal   bodies   and   protein   interactions   (Carmo-­Fonseca   et   al.,   1993).   SMN,   for  
example,  shows  preferential  binding  for  dephosphorylated  coilin,  whereas  the  SmB  
protein  shows  a  higher  affinity  of  binding   to  a  phosphorylated  coilin   (Toyota  et  al.,  
2010).  Overexpression  of  a  dephosphorylated  coilin  mimic  in  cells  caused  a  loss  of  
canonical  Cajal   body   formation   and   uncharacteristic   localisation,   suggesting   coilin  
phosphorylation   is   a   prerequisite   for   Cajal   body   formation   (Hearst   et   al.,   2009).  
However,   in   the   same   study   it   was   shown   that   hyperphosphorylation   of   all   11  
phosphorylation  sites  also  caused  Cajal  body  disassembly,  thus  there  may  be  an  ‘in  
the   middle’   phosphorylation   state   that   favours   Cajal   body   formation.   The  
hyperphosphorylation  state  of  coilin  when  entering  the  mitosis  stage  of  the  cell  cycle  
may  then  be  responsible  for  the  disassembly  of  Cajal  bodies.  
  
Methylation  of   coilin   can  also   regulate   its   function  and   localisation.  As  mentioned,  
coilin   can   be   symmetrically   dimethylated   on   its   arginine   residues   in   the   RG-­box  
motif,  which  enhances   the   interaction  with   the  SMN  protein   (Boisvert   et   al.,   2002;;  
Hebert   et   al.,   2001).   Inhibition   of   coilin   methylation   weakens   the   coilin-­SMN  
interaction,  and  causes  SMN  to  localise  into  nuclear  gems  instead  of  Cajal  bodies,  
suggesting  the  methylation  state  of  coilin  may  be  the  reason  some  cell  lines  display  
nuclear  gems  but  not  Cajal  bodies  (Hebert  et  al.,  2002).  An  MCF7  cell   line  lacking  
the  5’  methylthioadenosine  phosphorylase  (MTAP)  enzyme  has  been  used  to  study  
the  effect  of  hypomethylation  on  coilin  localisation.  The  cell  line  has  increased  levels  
of   MTAP   which   inhibits   protein   arginine   methyltransferases   (PRMT),   thus  
decreasing  coilin  methylation.  In  this  cell  line,  hypomethylated  coilin  accumulates  in  
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the  nucleolus  whereas  methylated  coilin  remains  in  canonical  Cajal  bodies  (Tapia  et  
al.,   2010).   Of   course,   the   PRMTs   will   catalyse   the   methylation   of   target   proteins  
other   than   coilin,   and   you   cannot   rule   out   an   indirect   effect   of   this   on   coilin  
mislocalisation.  Lastly,  a  HeLa  cell  line  that  expresses  a  hypomethylated  version  of  
coilin,   was   found   to  more   efficient   at   splicing   a   reporter   intron   than   normal   HeLa  
cells  expressing  methylated  coilin,   suggesting  coilin  methylation  and   its  effects  on  































   66  
1.9   Summary,  hypothesis  and  project  aims  
  
The  GGGGCC  hexanucleotide  repeat  expansion  in  the  C9orf72  gene  is  the  leading  
cause   of   amyotrophic   lateral   sclerosis.   Three   non-­mutually   exclusive   disease  
mechanisms   have   been   proposed,   including   haploinsufficiency   of   the   C9orf72  
protein.  The  C9orf72  protein  has  roles  in  autophagy  and  endosomal  trafficking,  but  
little   is  currently  known  about  the  nuclear  function  of  C9orf72.  The  C9orf72  protein  
exhibits  nuclear  localisation  and  interacts  with  nuclear  proteins,  indicating  there  may  
be  an  essential  nuclear  function  that  is  not  yet  understood.  Characterisation  of  this  
nuclear   function   could   lead   to   better   understanding   of   C9orf72-­linked   disease  
mechanisms  and  development  of  more  effective  treatments.    
  
Unto  this  end,  the  interaction  between  C9orf72  and  coilin  was  investigated.  Coilin  is  
the  major   protein   component   of   Cajal   bodies   (CBs),   nuclear   suborganelles   which  
act  as  sites  of  splicing  machinery  maturation  and  assembly.  C9orf72  ALS  patients  
have   splicing   defects   that   correlate   with   disease   severity   and   disruption   to   Cajal  
bodies   has   been   implicated   in   several   neurodegenerative   disorders.   We  
hypothesised   that   haploinsufficiency   of   the   C9orf72   protein   in   ALS   leads   to  
dysregulation  of  Cajal  bodies  and  downstream  splicing.  
  
The  project  aims  were  therefore:  
1.   To  characterise  the  C9orf72-­coilin  interaction  
2.   To  investigate  how  C9orf72  regulates  Cajal  bodies  and  splicing  
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2   Materials  and  Methods  
  
2.1   Materials  
  
Materials  were  obtained  from  Sigma  unless  otherwise  stated.  
  
2.1.1   Stock  solutions  
  
2.1.1.1   Purchased  stock  solutions  
  





Ethylenediaminetetraacetic  acid  (EDTA)  (0.5  M)  
Ethylene  glycol-­bis(β-­aminoethyl  ether)-­N,N,N',N'-­tetraacetic  acid  (EGTA)  (0.25  M)  
Ethidium  bromide  (10  mg/ml)  
Foetal  bovine  serum  (FBS)  
Formaldehyde  (37-­40%)  
Glacial  acetic  acid  (100%)  
Glycerol  (100%)  
HEPES,  pH  7.9  (1  M)  
Methanol  (100%)  
Nuclease  free  water  
Normal  goat  serum  (NGS)  
NP-­40  (100%)  
Pen/Strep  (5000  U/ml  penicillin,  5000  U/ml  streptomycin)  
Propan-­2-­ol  
Poly-­L-­Lysine  (0.1%  w/v)  
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2.1.1.2     Stock  solutions  prepared  in  house  
  
The  following  were  prepared  in  dH2O  unless  otherwise  stated:  
  
Ammonium  persulfate  (APS)  (10%  w/v)    
Ampicillin  (100  mg/ml)    
Bovine  Serum  Albumin  (BSA)  (100  mg/ml)    
Chloramphenicol  (34  mg/ml)  dissolved  in  ethanol  
Dithiothreitol  (DTT)  (0.1  M)    
Isopropyl  β-­D-­1-­thiogalactopyranoside  (IPTG)  (0.5  M)    
Kanamycin  (100  mg/ml)  
L-­glutamine  (200  mM)  
Magnesium  chloride  (1  M)  
Phosphate  buffered  saline  (PBS)  (137  mM  NaCl,  2.7  mM  KCl,  10  mM  Na2HPO4,  1.8  
mM  KH2PO4)  
Polyethylenimine  (1  mM)  
Potassium  chloride  (4  M)  
Sodium  dodecyl  sulfate  (SDS)  (10%  w/v)  
Sodium  chloride  (5  M)  
Sodium  pyruvate  (100  mM)  
Tris  buffered  saline  (TBS)  (50  mM  Tris-­HCl,  150  mM  NaCl)  
Tris-­HCl  (1.5  M,  pH  8.8)  
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2.1.2   Molecular  biology  reagents  
  
2.1.2.1   Vectors  and  expression  plasmids  
  
The   vectors   and   expression   plasmids   used   throughout   the   project   are   detailed   in  
Table  2.1  and  Table  2.2.  
  
Table  2.1.  Backbone  vectors  
Vector   Expression   Supplier  
pCI-­neo   Mammalian   Promega  
pCI-­neo-­myc   Mammalian   Promega  –  modified  in  house  by  Dr  Kurt  De  Vos  
pCI-­neo-­FLAG   Mammalian   Promega  –  modified  in  house  by  Dr  Kurt  De  Vos  
pCI-­neo-­mCherry   Mammalian   Promega  –  modified  in  house  by  Dr  Kurt  De  Vos  
pRK5   Mammalian   BD  Biosciences  
pGEX6p1   Bacterial   GE  Healthcare  Life  Sciences  
PL-­SIN-­PGK-­cPPT-­WHV  
(pLenti-­VOS)   Viral  
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Table  2.2.  Plasmids  used  for  protein  expression  







myc-­C9orf72S   pRK5   In  house:  Dr  Matthew  
Walsh  and  Dr  Adrian  
Higginbottom  
pRK5-­myc-­C9orf72L   myc-­C9orf72L   pRK5   In  house:  Dr  Matthew  
Walsh  and  Dr  Adrian  
Higginbottom  
pCB6-­P120   P120  minigene   pCB6   Prof  Richard  Padgett,  
Cleveland  Clinic    
pLenti-­VOS-­
mVenus-­C9orf72S  




mVenus-­C9orf72L   pLenti-­VOS   In  house:  Dr  
Annekathrin  Moeller  







pLenti-­VOS   In  house:  Dr  
Annekathrin  Moeller.  







pLenti-­VOS   In  house:  Dr  
Annekathrin  Moeller.  




b-­Galactosidase   pRSV   Addgene  (#24058)  
pCI-­neo-­myc-­coilin   myc-­coilin   pCI-­neo   This  project  (Section  
2.2.1.12)  




mCherry-­coilin   pCI-­neo   This  project  (Section  
2.2.1.12)  
pEGFP-­coilin   EGFP-­coilin   pEGFP-­C3   Addgene  (#36906)  








GST-­C9orf72L   pGEX6p1   In  house:  Dr  
Christopher  Webster  
  
   71  
2.1.2.2   Reagents  for  E.Coli  bacterial  cultures  
  
LB  broth  and  LB  agar  were  purchased  in  powder  form.  
  
LB  broth  (Miller)  powder  components  were:    
10  g/L  Tryptone  
10  g/L  NaCl  
5  g/L  Yeast  extract  
  
For   LB   broth   reconstitution,   25   g   LB   broth   was   dissolved   in   1   L   of   dH2O   and  
autoclaved.   LB   broth   was   supplemented   with   either   100   µg/ml   ampicillin   or   100  
µg/ml  kanamycin.  
  
LB  agar  (Miller)  powder  components  were:  
15  g/L  Agar  
10  g/L  Tryptone  
10  g/L  NaCl  
5  g/L  Yeast  extract  
  
For   LB   agar   reconstitution,   40   g   LB   agar   was   dissolved   in   1   L   of   dH2O   and  
autoclaved.   LB   agar   was   supplemented   with   either   100   µg/ml   ampicillin   or   100  
µg/ml  kanamycin.  
  
Antibiotics  were  added  upon  cooling  of  the  LB  agar/broth  to  approximately  60  °C.    
  
  
2.1.2.3   Reagents  for  small-­scale  preparation  of  plasmid  DNA  
  
For  plasmid  purification  from  E.Coli,  the  NucleoSpinÒ  Plasmid  Kit  (Macherey-­Nagel)  
was  used.    
  
The  following  reagents  were  included  with  the  kit:  
  
NucleoSpinÒ  plasmid  columns  
Collection  tubes  
Resuspension  buffer  A  with  RNase  A  supplementation  
Lysis  buffer  A2  
Neutralisation  buffer  A3  
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Wash  buffer  AW  
Wash  buffer  A4  
Elution  buffer  AE  
  
2.1.2.4   Reagents  for  genomic  DNA  extraction  
  
QuickExtractä  DNA  extraction  solution  (Lucigen)  
  
2.1.2.5   Reagents  for  C9orf72  exon  2  and  coilin  cloning  
  
2.1.2.5.1  Primers  for  generation  of  C9orf72  exon  2  and  coilin  fragments  
  
C9orf72  exon  2  was  amplified  from  genomic  DNA  using  the  primers  below.  A  XhoI-­
coilin-­NotI   product  was   generated   from   the   pEGFP-­coilin   plasmid   using   a   forward  
and  reverse  primer  which  contained  the  XhoI  and  NotI  cut  site  sequence  on  their  5’  
and  3’  ends  respectively.    
  
C9orf72  exon  2  forward:  5’-­AAATCATTTGGGGTTTTGATGG-­3’  
  
C9orf72  exon  2  reverse:  5’-­TGTAAAACGACGGCCAGTACCA-­3’  
  
XhoI-­coilin  forward:  5’-­CTCGAGATGGCAGCTTCCGAGACG-­3’  
  
NotI-­coilin  reverse:  5’-­GCGGCCGCTCAGGCAGGTTCTGTACTTGA-­3’  
	  
  
2.1.2.5.2  Reagents  for  Phusion®  High-­Fidelity  PCR  
  
PCR  amplification  of  C9orf72  exon  2  and  coilin  was  performed  using  the  Phusionâ  
High-­Fidelity  DNA  polymerase  (New  England  BioLabs):    
  
5X  PhusionÒ  HF  buffer  
10  mM  dNTPs  
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2.1.2.6   Reagents  for  agarose  gel  electrophoresis  
  
1x  Tris-­Acetate  (TAE)  buffer:  
40  mM  Tris  
20  mM  Glacial  acetic  acid  




DNA  loading  buffer  (Bioline)  
  
2.1.2.7   Reagents  for  extraction  of  DNA  bands  from  agarose  gels  
  
DNA   was   excised   and   purified   from   agarose   gels   using   the   GenElute™   Gel  
Extraction  Kit  (Sigma).    
  
The  following  reagents  were  included  with  the  kit:  
GenElute™  binding  column  G  
Collection  tubes  
Gel  solubilisation  buffer  




In  house  reagents  included:  
100%  Propan-­2-­ol  
  
2.1.2.8   Reagents  for  subcloning  C9orf72  exon  2  and  coilin  PCR  
products  into  the  pCR™-­Blunt  II-­TOPO®  vector  
  
The  C9orf72  exon  2  and  coilin  DNA  products  were   ligated  into  the  pCR™-­Blunt  II-­
TOPO®   vector   using   the   Zero   Blunt®   TOPO®   PCR   cloning   kit   (Thermo   Fisher  
Scientific).    
  
The  ligation  was  performed  using  the  reagents  provided  in  the  manufacturers  kit:  
  
10  ng/µl  linearised  pCR™-­Blunt  II-­TOPO®  vector  in:  
50%  (v/v)  Glycerol  
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50  mM  Tris-­HCl,  pH  7.4  
1  mM  EDTA  
2  mM  DTT  
0.1%  (v/v)  Triton-­X100  
100  µg/ml  BSA  
30  µM  Bromophenol  blue  
  
Salt  solution:  
1.2  M  NaCl  
0.06  M  MgCl2  
  
2.1.2.9   Reagents  for  transformation  of  XL10-­Gold®  Ultracompetent  
cells  
  
XL10-­Gold®  Ultracompetent  cells  
XL10-­Gold®  b-­Mercaptoethanol  
  
2.1.2.10   Reagents  for  colony  PCR  
  
Coilin  was  amplified  from  pCR™-­Blunt  II-­TOPO®-­coilin  using  the  following  primers:  
  
XhoI-­coilin  forward:  5’-­CTCGAGATGGCAGCTTCCGAGACG-­3’  
NotI-­coilin  reverse:  5’-­GCGGCCGCTCAGGCAGGTTCTGTACTTGA-­3’  
  
PCR  amplification  of  the  coilin  insert  used  the  following  reagents:  
  
5X  FIREPol®  Master  Mix  Ready  to  Load  (Solis  Biodyne)  which  contained:  
FIREPol®  DNA  polymerase    
5X  reaction  buffer  B  (0.5  M  Tris-­HCl,  0.1  M  (NH4)2SO4,  0.1%  Tween-­20  (v/v))  
7.5  mM  MgCl2  




2.1.2.11   Reagents  for  restriction  enzyme  digestion  of  DNA  
  
The   coilin   insert   was   excised   from   the   pCR™-­Blunt   II-­TOPO®   vector   using   the  
following  FastDigest  reagents  from  Thermo  Fisher  Scientific:  
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FastDigest  Green  Buffer  (10X)  
FastDigest  XhoI  enzyme  
FastDigest  NotI  enzyme  
  
2.1.2.12   Reagents  for  coilin  ligation  into  pCI-­neo-­tag  vectors  
  
The  Quick  Ligation™  Kit  (New  England  BioLabs)  was  used  to  perform  the  ligation  of  
XhoI-­coilin-­NotI   into   linearised  pCI-­neo-­tag   vectors  which   had  been  previously   cut  
with  XhoI  and  NotI.  
  
The  kit  reagents  included:  
  
Quick  Ligase  Reaction  Buffer  (2X)  
Quick  T4  DNA  ligase  
  
2.1.2.13   Reagents  for  site-­directed  mutagenesis  
  
2.1.2.13.1   Primers  for  generation  of  siRNA  resistant  pRK5-­myc-­
C9orf72  
  
Primers   used   in   the   first   round   of   mutagenesis   introduced   two   T>C   base   pair  
changes   at   T439   and   T445   in   the   C9orf72   cDNA   sequence   using   missense  
mutations   in   the  primers.  The  primers  were  used   to  mutate   the  C9orf72  siRNA  #2  
binding   site   within   the   pRK5-­myc-­C9orf72S   and   pRK5-­myc-­C9orf72L   plasmids.  
Primers   used   in   the   second   round   of  mutagenesis   introduced   four   T>C  base   pair  
changes   at   T703,   T709,   T715   and   T718   in   the   C9orf72   cDNA   sequence   using  
missense  mutations   in   the  primers.  The  primers  were  used   to  mutate   the  C9orf72  
siRNA  #D  binding  site  within   the  C9orf72  siRNA  #2   resistant  pRK5-­myc-­C9orf72S  
and   pRK5-­myc-­C9orf72L   plasmids.   Primers   were   designed   using   the   online  
QuikChange  Primer  Design  Program.  
  
C9orf72  T439C,  T445C  forward:  
5’-­GACAAGACAAAAAACTTTACGTCTATGGCACCACTCTCTGCATTTCG-­3’  
  
C9orf72  T439C,  T445C  reverse:  
5’-­CGAAATGCAGAGAGTGGTGCCATAGACGTAAAGTTTTTTGTCTTGTC-­3’  
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2.1.2.13.2         PCR  reagents  for  site-­directed  mutagenesis  
  
PCR  was  performed  using  the  QuikChange  Lightning  Site-­Directed  Mutagenesis  Kit  
(Agilent):  
  
10X  QuikChange  Lightning  Reaction  Buffer  
dNTP  mix  
QuikSolution  Reagent    
QuikChange  Lightning  Enzyme  
Dpn  I  enzyme  
  
2.1.2.14   Sequencing  primers  
  
The   SP6   primer   was   used   to   sequence   C9orf72   exon   2   in   the   pCRÔ-­Blunt   II-­





Coilin  was  sequenced  in  the  pCRÔ-­Blunt  II-­TOPOÒ  vector  using  the  SP6  primer  and  
four  primers  within  the  coilin  sequence  spaced  approximately  400  base  pairs  apart  
to  ensure  full  coverage.  
  
SP6:  5’-­ATTTAGGTGACACTATAG-­3’  
Coilin  sequencing  1:  5’-­GGAGGGTGAAGAAACTGAACC-­3’  
Coilin  sequencing  2:  5’-­GATGAATCTATCAGTGATGGTCCC-­3’  
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Coilin  sequencing  3:  5’-­TCCCTGCTAGTTTAGGAAGAGG-­3’  
Coilin  sequencing  4:  5’-­ACCTGCCTTGAGAGAACCTG-­3’  
  
2.1.2.15   Reagents  for  expression  of  GST-­proteins  in  Rosetta  pLysS  
cells  
  
GST-­protein   expression   was   induced   in   Rosetta   pLysS   bacteria   cells   (Novagen)  
transformed  with  the  pGEX6p1  expression  plasmids  detailed   in  table  2.2  using  the  
following  reagents:  
  
Terrific  Broth  (TB):  
24  g/L  Yeast  extract  
20  g/L  Tryptone  
0.4%  (v/v)  Glycerol  
17  mM  KH2PO4  
72  mM  K2HPO4  
  
TB  supplemented  with  100  µg/ml  ampicillin  and  34  µg/ml  chloramphenicol  
TB  supplemented  with  100  µg/ml  ampicillin  
0.5  mM  IPTG  
  
2.1.3   Cell  culture  and  transfection  
  
2.1.3.1   Reagents  for  subculturing  of  HEK293  cells  
  
Complete  DMEM  media:  
DMEM  (with  4.5  g/L  glucose)    
10%  Foetal  bovine  serum  (Life  Science  Production)  





2.1.3.2   Reagents  for  culturing  rat  primary  neurons  
  
Poly-­L-­Lysine  (0.1%  w/v  in  H2O)    
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Complete  Neurobasal  Medium:  
Neurobasal  medium  (Thermo  Fisher  Scientific)  
2%  B-­27  supplement  (Thermo  Fisher  Scientific)  
100  IU/ml  penicillin    
100  mg/ml  streptomycin    
2  mM  L-­glutamine  (Lonza)  
  
2.1.3.3   Reagents  for  subculturing  iAstrocytes  
  




DMEM  (with  4.5  g/L  glucose)    
100  IU/ml  penicillin    
100  mg/ml  streptomycin    
10%  Foetal  bovine  serum  (Life  Science  Production)  
0.2  %  N-­2  Supplement  (Thermo  Fisher  Scientific)  
  
2.1.3.4   Reagents  for  plasmid  DNA  transfection  
  
Opti-­MEM  Reduced  Serum  Media  (Thermo  Fisher  Scientific)  
Polyethylenimine  (PEI)  
LipofectamineÒ  2000  Reagent  (Thermo  Fisher  Scientific)  
  
2.1.3.5   Reagents  for  siRNA  transfection  
  
Opti-­MEM  Reduced  Serum  Media  (Thermo  Fisher  Scientific)  
LipofectamineÒ  RNAiMAX  Reagent  (Thermo  Fisher  Scientific)  
  
MISSION  siRNA  Universal  Negative  Control  #1    
C9orf72  #2  siRNA:  GUGCUAUAGAUGUAAAGUU  
C9orf72  #D  siRNA:  GAUCAGGGUCAGAGUAUUA  
Coilin  #1  siRNA:  GGAACAACAUCUUCCAGUU  
Coilin  #2  siRNA:  CAUCUACUAUUAUCCAGAA  
Coilin  #3  siRNA:  CAGAGAAAUUACCAACUGA  
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2.1.4   Reagents  for  biochemical  methods  
  





Radioimmunoprecipitation  (RIPA)  buffer:  
100  mM  Tris-­HCl,  pH  6.8  
150  mM  NaCl  
1  mM  EDTA  
1  mM  EGTA  
1  mM  DTT  
0.1%  (w/v)  SDS  
0.5%  (w/v)  sodium  deoxycholate  
1%  (v/v)  NP40  
Halt  Protease  Inhibitor  Cocktail  (Thermo  Fisher  Scientific)  
  
2.1.4.2   Reagents  for  nuclear  fractionation  
  
Hypotonic  lysis  buffer:  
10  mM  HEPES,  pH  7.9  
1.5  mM  MgCl2  
10  mM  KCl  




2.1.4.3   Reagents  for  Bradford  protein  assay  
  
Bovine  Serum  Albumin  (100  mg/ml)  
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2.1.4.4   Reagents  for  preparation  of  samples  for  SDS-­PAGE  
electrophoresis  
  
5X  Laemmli  buffer:  
250  mM  Tris-­HCl,  pH  6.8  
10%  (w/v)  SDS  
0.5%  (w/v)  Bromophenol  blue  
50%  (v/v)  Glycerol  
25%  (v/v)  b-­mercaptoethanol  
  
2.1.4.5   Reagents  for  immunoprecipitation  
  
1  µg  of  antibody  (Table  2.3)  
Protein  G  Sepharose  4  Fast  Flow  (GE  Healthcare)  
RIPA  buffer  
2X  Laemmli  buffer  
  
Table  2.3.  Immunoprecipitation  antibodies  
IP  antibody   Protein  pull  down   Antibody  species   Supplier  
Anti-­coilin  
(ab87913)  
Coilin   Mouse   Abcam  
Anti-­myc  
(9B11)  
myc-­C9orf72   Mouse   Cell  Signalling  
  
  
2.1.4.6   Reagents  for  in  vitro  GST-­binding  assay  
  
In  vitro  production  of  35S-­coilin:  
Reticulocyte  from  the  T7  TnT®  Quick  Coupled  Transcription/Translation  System  
(Promega)  
35S-­methionine  (Perkin  Elmer)  
  
RB100  buffer:  
25  mM  HEPES,  pH  7.5  
100  mM  KOAc  
10  mM  MgCl2  
1  mM  DTT  
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0.05%  (v/v)  Triton-­X100  
10%  (v/v)  Glycerol  
  
Pull  down:  
Glutathione  Sepharose  High  Performance  (GE  Healthcare)  
  
GSH  elution  buffer:  
50  mM  Tris-­HCl,  pH  7.5  
100  mM  NaCl  
40  mM  reduced  glutathione  
  
Radioactivity  detection:  
Whatman  filter  paper  
BAS  Storage  Phosphor  Screen  (GE  Healthcare)  
  
2.1.4.7   Reagents  for  SDS-­PAGE  electrophoresis  
  
10%  resolving  gel:  
10%  (w/v)  acrylamide  
375  mM  Tris-­HCl,  pH  8.8  
0.1%  (w/v)  SDS  
0.1%  (w/v)  APS  
0.01%  (v/v)  TEMED    
  
6%  stacking  gel:  
6%  (w/v)  acrylamide  
125  mM  Tris-­HCl,  pH  6.8  
0.1%  (w/v)  SDS  
0.06%  (w/v)  APS  
0.3%  (v/v)  TEMED  
  
SDS-­PAGE  running  buffer:  
25  mM  Tris-­HCl    
190  mM  glycine  
0.1%  (w/v)  SDS  
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2.1.4.8   Reagents  for  coomassie  staining  of  polyacrylamide  gels  
  
Coomassie  Brilliant  Blue  G250  stain:  
1  g/L  Coomassie  Brilliant  Blue  
50%  (v/v)  Methanol  
10%  (v/v)  Glacial  acetic  acid  
  
Destain  solution:  
30%  (v/v)  Methanol  
10%  (v/v)  Glacial  acetic  acid  
  
2.1.4.9   Reagents  for  electrophoretic  transfer  of  proteins  
  
Transfer  buffer:  
25  mM  Tris-­HCl  
190  mM  Glycine  
20%  (v/v)  Methanol  
  
Whatman  filter  paper  
Nitrocellulose  blotting  membrane  0.45  µm  pore  (Amersham)  
  
Ponceau  S  stain:  
0.1%  (w/v)  Ponceau  S  
5%  (v/v)  Glacial  acetic  acid  
  
2.1.4.10   Reagents  for  immunoblot  of  nitrocellulose  membrane  
  
TBST:  
0.1%  (v/v)  Tween-­20  in  TBS  
  
Blocking:  
5%  milk  (MARVEL)  in  TBST  
  
Antibodies  used  for  immunoblot  are  detailed  in  Table  2.4.  
  
   83  
Table  2.4.  Immunoblot  antibodies  
  
  
2.1.4.11   Reagents  for  chemiluminescent  protein  detection    
  
SuperSignal™  West  Pico  PLUS  Chemiluminescent  Substrate  components:  
SuperSignal™  West  Pico  PLUS  Luminol/Enhancer  Solution  
SuperSignal™  West  Pico  PLUS  Stable  Peroxide  Solution  
  
Hyperfilm  ECL  (Amersham)  
  
Developing  solution  (Ilford  Hypam)  
Fixing  solution  (Ilford  Hypam)  
  
2.1.4.12   Reagents  for  RNA  extraction  
  
TRIzol™  reagent  (Ambion)  
Chloroform  
Propan-­2-­ol  















Anti-­coilin   Rabbit   ProteinTech   10976-­1-­AP   1:1000  















































Anti-­mouse-­HRP   Goat   Dako   P0447   1:5000  
Anti-­rabbit-­HRP   Goat   Dako   P0448   1:5000  
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75%  Ethanol  
Nuclease  free  water  
  
2.1.4.13   Reagents  for  RT-­PCR  generation  of  cDNA  
  
10X  DNase  I  Buffer  (New  England  BioLabs)  
DNase  I  enzyme  (New  England  BioLabs)  
25  mM  EDTA  
Oligo  dT(18)  primer  (Thermo  Fisher  Scientific)  
dNTPs  solution  mix  (New  England  BioLabs)  
  
The  following  are  supplied  with  the  SuperScriptÒ  III  Reverse  Transcriptase  (Thermo  
Fisher  Scientific):  
DTT  
5X  First  Strand  Buffer    
SuperScriptÒ  III  Reverse  Transcriptase  (200  U/µl)  
  
2.1.4.14   Reagents  for  qPCR  
  
5X  HOT  FIREPol  EvaGreenÒ  dye  (Solis  Biodyne)  
Nuclease  free  water  
  
The   following   primers   (100   µM   stock)   were   used   in   qPCR   to   measure   relative  
mRNA  levels:  
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2.1.4.15   Reagents  for  PCR  amplification  of  the  pCI-­neo  and  P120  
introns  
  
FIREPol®  Master  Mix  Ready  To  Load  
Nuclease  free  water  
  
Primers  for  amplification  of  the  pCI-­neo  intron:  
pCI-­neo  forward:  5’-­TCACTAGAAGCTTTATTGCGGTAG-­3’  
pCI-­neo  reverse:  5’-­TGTATCTTATCATGTCTGCTCGAAG-­3’  
  
Primers  for  amplification  of  the  P120  intron:  
P120  forward:  5’-­TGGATGAGGAACCATTTGTG-­3’  
P120  reverse:  5’-­AGAACGAGACCGCCCTTC-­3’  
  
2.1.5   Reagents  for  microscopy  
  
2.1.5.1   Reagents  for  immunofluorescence  
  
PBS  
4%  (w/v)  Formaldehyde  in  PBS  
0.2%  (v/v)  Triton-­X100  in  PBS  
5%  (v/v)  Normal  goat  serum  in  PBS  
Hoechst  33342    
Fluorescence  mounting  media  (Dako)  
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Antibodies  used  in  immunofluorescence  are  detailed  in  table  2.5.  
  
  
Table  2.5.  Immunofluorescence  antibodies  
  
2.1.5.2   Reagents  for  the  proximity  ligation  assay  
  
In  house  PLA  reagents:  
PBS  
4%  Formaldehyde  in  PBS  
0.2%  Triton-­X100  in  PBS  
5%  Normal  goat  serum  in  PBS  
Hoechst  33342  
Fluorescence  mounting  media  (Dako)  
  
The  following  DuolinkÒ  PLA  technology  reagents  were  used  (Sigma):  
  
  


















































Anti-­mouse-­AF488   Donkey   Thermo  Fisher  
Scientific  
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DuolinkÒ  PLA  Probe  Anti-­Mouse  MINUS:  
5X  PLA  Probe  Anti-­Mouse  MINUS  
1X  Blocking  Solution  
1X  Antibody  Diluent  
  
DuolinkÒ  PLA  Probe  Anti-­Rabbit  PLUS:  
5X  PLA  Probe  Anti-­Rabbit  PLUS  
1X  Blocking  Solution  
1X  Antibody  Diluent  
  
DuolinkÒ  In  Situ  Detection  Reagents  Orange:  
5X  Ligation  Solution  
1X  Ligase  
5X  Amplification  Solution  
1X  Polymerase  
  
DuolinkÒ  In  Situ  Wash  Buffers,  Fluorescence:  
Wash  Buffer  A  
Wash  Buffer  B  
  
Antibodies  used  in  PLA  are  detailed  in  table  2.6.  
  
Table  2.6.  PLA  antibodies  
Antibody   Species   Supplier   Dilution  
Anti-­coilin  (10976-­
1-­AP)  
Rabbit   ProteinTech   1:1000  
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2.2   Methods  
  
2.2.1   Molecular  biology  methods  
  
2.2.1.1   Plasmid  growth  from  bacterial  glycerol  stocks  
  
Bacterial   glycerol   stocks   were   used   for   long-­term   plasmid   storage.   500   µl   of  
bacterial  culture  was  combined  with  500  µl  of  sterile  50%  glycerol  and  stored  at  -­80  
°C.    
  
To  recover  bacteria  from  glycerol  stocks,  a  sterile  loop  was  used  to  remove  frozen  
bacteria,  which  were  then  streaked  onto  LB  agar  plates  containing  the  appropriate  
antibiotic.  The  plates  were  incubated  at  37  °C  for  16  hours.  A  sterile  loop  was  used  
to  pick  a  single  colony  for  inoculation  into  1  ml  LB  broth  containing  the  appropriate  
antibiotic.  The  bacterial  culture  was  shaken  at  220  rpm  at  37  °C  for  8  hours.  50  µl  of  
the   1   ml   culture   was   inoculated   into   5   ml   LB   broth   containing   the   appropriate  
antibiotic  and  shaken  at  220  rpm  at  37  °C  for  16  hours.    
  
2.2.1.2   Small-­scale  preparation  of  plasmid  DNA  
  
For   plasmid   purification,   the   NucleoSpin®   Plasmid   Kit   from   Macherey-­Nagel   was  
used   following   the   manufacturers   protocol.   E.Coli   were   pelleted   from   the   5   ml  
bacterial  culture  by  centrifugation  at  4,000  rpm  for  10  minutes  at  RT  in  a  Sigma  1-­15  
PK  centrifuge  using  a  12124   rotor.  The  LB  broth  was  discarded  and   the  bacterial  
pellet   resuspended   in   250  µl   resuspension   buffer  A1.   The   bacteria  were   lysed   by  
addition  of  250  µl  of   lysis  buffer  A2  and   incubation  at  RT   for  5  minutes.  300  µl  of  
neutralisation   buffer   A3  was   added   and   the   lysate   centrifuged   at   11,000   g   for   10  
minutes   to   pellet   protein,   genomic   DNA   and   cell   debris.   The   plasmid-­containing  
supernatant   was   applied   to   the   NucleoSpin®   Plasmid   column   to   bind   DNA   to   the  
silica  membrane  and  subjected  to  centrifugation  at  11,000  g  for  1  minute.  The  run-­
through  was  discarded  and  the  membrane  washed  with  500  µl  wash  buffer  AW  by  
centrifugation   at   11,000   g   for   1   minute.   The   run-­through   was   discarded   and   the  
membrane  washed  with  600  µl  wash  buffer  A4  by  centrifugation  at  11,000  g   for  1  
minute.  The  run-­through  was  discarded  and   the  membrane  dried  by  centrifugation  
at   11,000   g   for   2   minutes.   The   plasmid   DNA   was   eluted   by   addition   of   50   µl   of  
elution  buffer  AE  and  centrifugation  at  11,000  g  for  1  minute.    
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2.2.1.3   Genomic  DNA  extraction  
  
Genomic  DNA  was   extracted   from   the  C9orf72  CRISPR-­edited   cell   lines  B2,  B17  
and  B12  for  sequencing  of  C9orf72  exon  2.  Cells  were  pelleted  by  centrifugation  at  
400   g   for   4   minutes   at   4   °C.   Cells   were   washed   by   resuspension   in   PBS   and  
pelleted  by  centrifugation  at  14,000  rpm  for  30  seconds  at  4  °C  in  a  Sigma  1-­15  PK  
centrifuge   using   a   12124   rotor.   100   µl   of  QuickExtract™  DNA   extraction   Solution  
(Lucigen)   was   added   to   cells   and   vortexed   for   15   seconds.   The   solution   was  
incubated  at  65  °C  for  2  hours  then  99  °C  for  2  minutes.  DNA  was  stored  at  4  °C.  
  
  
2.2.1.4   DNA  quantification  
  
The   concentration   and   quality   of   DNA   samples   were   determined   using   the  
NanoDrop  1000  spectrophotometer  (Thermo  Fisher  Scientific)  which  measured  the  
absorbance  of  the  samples  at  260  nm  and  280  nm.  The  concentration  of  the  DNA  in  
ng/µl   is   based  on   the  A260;;   a  DNA  sample  with   concentration  1   ng/µl   and  a  1   cm  
path  length  has  A260  =  50.  The  ratio  of  A260/A280  was  used  as  an  assessment  of  DNA  
purity  where  a  ratio  of  ~1.8  was  taken  as  pure  DNA.    
  
  
2.2.1.5   PCR  amplification  of  C9orf72  exon  2  and  coilin  to  generate  
blunt-­ended  products  
  
The   C9orf72   exon   2   fragment   to   be   sequenced   was   generated   using   Phusion®  
High-­Fidelity   DNA   polymerase   (New   England   BioLabs),   the   primers   described   in  
Section  2.1.2.5.1  and  genomic  DNA  extracted   from  B2,  B17  and  B12  cells  as   the  
DNA   template.   A   XhoI-­Coilin-­NotI   product   for   cloning   into   pCI-­neo-­tag   expression  
vectors  was  generated  using  Phusion®  High-­Fidelity  DNA  polymerase,   the  primers  
described  in  Section  2.1.2.5.1  and  the  pEGFP-­coilin  plasmid  as  the  template.    
  
A  20  µl  reaction  mix  was  prepared  as  below:  
  
12.4  µl  Nuclease-­free  water  
4  µl  5X  Phusion®  HF  buffer  
0.4  µl  10  mM  dNTPs  
1  µl  10  µM  Forward  primer  
1  µl  10  µM  Reverse  primer  
1  µl  Template  DNA  (5  ng/µl)  
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0.2  µl  Phusion®  DNA  polymerase    
  
The  reaction  was  subjected  to  the  following  thermocycling  conditions:    
  
Table  2.7.  Thermocycling  conditions  for  Phusion®  High-­Fidelity  PCR  
Step   Cycles   Temp   Time  











30  s  C9orf72  exon  2  /  
60  s  coilin  
Final  extension   1   72  °C   10  mins  
  
  
2.2.1.6   Agarose  gel  electrophoresis  of  DNA  
  
A  1-­2%  (w/v)  agarose  gel  was  prepared  by  dissolving  agarose  in  boiling  TAE  buffer.  
Upon  cooling,  1  µl  of  ethidium  bromide  was  added  per  100  ml  before  pouring   into  
casting   apparatus   containing   a   horizontal   comb.   The   gel   was   placed   into   a  
Geneflow   Horizontal   Gel   Tank,   immersed   in   TAE   buffer   and   samples   loaded.   If  
required,  DNA  loading  buffer  (Bioline)  was  diluted  1  in  5  with  DNA  sample.  A  nucleic  
acid  molecular  weight  marker  (Hyperladder,  Bioline)  was  loaded  for  determination  of  
DNA  bands  in  sample  wells.  The  gel  was  subjected  to  electrophoresis  at  120  V  for  
approximately  40  mins  and  bands  visualised  using  the  Syngene  G:Box  Chemi  XRQ.  
  
2.2.1.7   Gel  extraction  of  DNA  
  
DNA   extraction   from   agarose   gels   was   performed   using   the   GenElute   Gel  
Extraction   Kit   (Sigma).   DNA   bands   were   visualised   on   a   UV   transilluminator   and  
excised  from  the  gel  using  a  scalpel.  The  gel  slice  was  weighed  and  solubilised  in  3  
gel  volumes  of   the  Gel  Solubilisation  Buffer  by   incubation  at  60  °C  for  10  minutes,  
with  vortexing  every  2  minutes.  A  binding  column  containing  a  silica  membrane  was  
placed  into  a  collection  tube  and  prepared  for  DNA  binding  by  addition  of  500  µl  of  
the  Column  Preparation  Solution  and  centrifugation  at  16,000  g   for  1  minute.  The  
run-­through  was   discarded.   1   gel   volume   of   100%   propan-­2-­ol   was   added   to   the  
solubilised   gel   solution   and  mixed   until   homogenous.   The   solubilised   gel   mixture  
was  added  to  the  binding  column  and  centrifuged  at  16,000  g  for  1  minute.  The  run-­
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through  was  discarded.  The  silica  membrane  was  washed  by  addition  of  700  µl  of  
Wash  Solution  to  the  binding  column  and  centrifuged  at  16,000  g  for  1  minute.  The  
run-­through  was  discarded  and  the  membrane  was  dried  by  centrifugation  at  16,000  
g   for   1   minute.   DNA   was   eluted   by   addition   of   20   µl   of   Elution   Solution   and  
centrifugation   at   16,000   g   for   1   minute.   DNA   concentration   was   measured   as  
detailed  in  Section  2.2.1.4.    
  
2.2.1.8   Subcloning  into  the  pCR™-­Blunt  II-­TOPO®  vector  
  
The  blunt-­ended  C9orf72  exon  2  and  XhoI-­Coilin-­NotI  products  were  subcloned  into  
the   pCR™-­Blunt   II-­TOPO®   vector   using   the   Zero   Blunt®   TOPO®   PCR   cloning   kit  
(Thermo  Fisher  Scientific)  following  the  manufacturers  protocol.  The  pCR™-­Blunt  II-­
TOPO®   plasmid   is   provided   linearised   and   bound   by   virus   DNA   topoisomerase   I  
enzyme  at  the  3’  end.  Briefly,  the  system  functions  by  site-­specific  cleavage  of  the  
DNA  product  by  topoisomerase  I  followed  by  formation  of  a  covalent  bond  between  
the  3’  phosphate  of  the  DNA  and  a  tyrosyl  residue  in  topoisomerase  I.  The  bond  is  
then   broken   by   attacking   of   the   cleaved   5’   hydroxyl,   removing   the   enzyme   and  
ligating  the  DNA  into  the  plasmid  (Shuman,  1994).  
  
The  6  µl  ligation  reaction  was  prepared  as  follows:  
4  µl  gel  extracted/purified  blunt-­ended  DNA  product  
1  µl  salt  solution  
0.5  µl  sterile  water  
0.5  µl  linearised  pCR™-­Blunt  II-­TOPO®  vector  
  
The  reaction  was   incubated  at  RT  for  15  minutes  before  transformation   into  XL10-­
Gold®  Ultracompetent  Cells.  
  
2.2.1.9   Transformation  of  XL10-­Gold®  Ultracompetent  Cells  
  
XL10-­Gold®   Ultracompetent   Cells   (Stratagene)   exhibit   the   Hte   phenotype   which  
lends   to   increased   transformation   efficiency   of   ligated   plasmids.   An   empty  
eppendorf  and  an  aliquot  of  cells  were  chilled  on  ice  until  the  cells  had  thawed.  A  20  
µl   aliquot   of   cells   was   removed   into   the   chilled   eppendorf   and   1   µl   of   b-­
mercaptoethanol  was  added.  The  b-­mercaptoethanol  was  mixed  into  cells  by  gentle  
swirling   of   the   pipette   tip   in   the   cells   and   incubated   on   ice   for   1   minute.   2   µl   of  
ligated  plasmid  was  added  to  cells  and  mixed  by  gentle  swirling  of  the  pipette  tip  in  
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the  cells  and  incubated  on  ice  for  30  minutes.  The  cells  were  heat  shocked  at  42  °C  
for  exactly  30  s  then  placed  on  ice  for  2  minutes.  180  µl  of  LB  broth  was  added  to  
cells  and  incubated  at  37  °C  for  1  hour  with  shaking  at  220  rpm.  The  200  µl  bacterial  
culture  was  split  into  a  50  µl  and  150  µl  aliquot  and  spread  onto  two  LB  agar  plates  
that   incorporated   the   antibiotic   for   which   the   bacteria   expressed   resistance.   The  
plates  were   incubated  at  37  °C  for  16  hours.  Colonies  containing   the  pCR™-­Blunt  
II-­TOPO®  vectors  with  C9orf72  exon  2  insert  were  selected  for  plasmid  purification  
as   described   in   Section   2.2.1.2   for   sequencing   as   described   in   Section   2.2.1.14.  
Colonies  containing  pCR™-­Blunt   II-­TOPO®  vectors  with  coilin   insert  were  selected  
for  colony  PCR  screening.  
  
2.2.1.10   Colony  PCR  screening  of  bacterial  colonies  
  
Colonies   were   selected   for   the   coilin   insert   by   colony   PCR.   The   following   10   µl  
reaction   was   prepared   in   a   0.2   ml   PCR   tube   using   primers   described   in   Section  
2.1.2.10:  
  
2  µl  5X  FIREPolÒ  Master  Mix  Ready  to  Load  (Solis  Biodyne)  
0.3  µl  Forward  primer  
0.3  µl  Reverse  primer  
7.4  µl  Sterile  water  
  
A  bacterial  colony  was  picked  with  a  sterile  pipette   tip  and  streaked  onto  a  replica  
plate  which  was  incubated  at  37  °C  for  8  hours.  The  residual  bacteria  on  the  pipette  
tip  was  transferred  to  the  reaction  tubes  by  swirling  the  pipette  tip   in  the  PCR  mix.  
The  reactions  were  subjected  to  the  following  thermocycling  conditions:  
  
Table  2.8.  Thermocycling  conditions  for  colony  PCR  
Step   Cycles   Temp   Time  
Bacteria  lysis/Initial  
denaturation  











Final  extension   1   72  °C   10  mins  
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The  PCR  mix  was   subjected   to  DNA  agarose  gel   electrophoresis   as   described   in  
Section   2.2.1.6   for   analysis   of   DNA   bands.   Colonies   which   contained   the   coilin  
insert   were   picked   from   the   replica   plate   for   plasmid   purification,   sequencing   and  
restriction  enzyme  digest.  
  
2.2.1.11   Restriction  enzyme  digest  of  DNA  
  
pCR™-­Blunt   II-­TOPO®-­coilin   plasmids   with   the   correct   coilin   sequence   was  
digested   with   XhoI   and   NotI   restriction   enzymes   (Thermo   Fisher   Scientific)   for  
cloning   into   the   required  expression   vectors.   The   following  20  µl   restriction   digest  
reaction  was  prepared:    
  
3.4  µl  pCR™-­Blunt  II-­TOPO®  with  coilin  insert  (0.584  µg/µl)  
2  µl  FastDigest  Green  Buffer  
13.6  µl  Sterile  water  
0.5  µl  FastDigest  XhoI  enzyme  
0.5  µl  FastDigest  NotI  enzyme  
  
The  reactions  were  incubated  at  37  °C  for  10  minutes.  The  total  20  µl  reaction  mix  
was  loaded  onto  an  agarose  gel  and  subjected  to  electrophoresis  for  separation  of  
the   vector   and   coilin   insert.   The   coilin   insert   was   gel   extracted   as   described   in  
Section  2.2.1.7  for  ligation  into  expression  vectors.  
  
2.2.1.12   Ligation  of  coilin  insert  into  pCI-­neo-­tag  expression  
vectors  
  
The  purified  coilin  insert  was  ligated  into  pCI-­neo-­myc,  pCI-­neo-­FLAG  and  pCI-­neo-­
mCherry   expression   vectors.   The   vectors   had  previously   been  digested  with  XhoI  
and  NotI  and  were  stored  linearised  and  dephosphorylated  at  -­20  °C.  The  Quick  T4  
DNA   Ligase   (New   England   BioLabs)   was   used   to   perform   the   following   ligation  
reaction  which  required  a  3:1  molar  ratio  of  insert  to  vector:  
  
50  ng  pCI-­neo-­tag  vector  (5.5  kb)  
50  ng  coilin  insert  (1.8  kb)  
10  µl  Quick  Ligase  Reaction  Buffer  
Up  to  19  µl  with  sterile  water  
1  µl  Quick  T4  DNA  Ligase  
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The  reactions  were  incubated  at  RT  for  10  minutes  before  transformation  into  XL10-­
Gold®  Ultracompetent  Cells  as  described  in  Section  2.2.1.9  and  purified.    
  
  
2.2.1.13   Site-­directed  mutagenesis  of  pRK5-­myc-­C9orf72  
  
Site-­directed   mutagenesis   was   performed   using   the   QuikChange   Lightning   Site-­
Directed  Mutagenesis  Kit  (Agilent).  Two  rounds  of  mutagenesis  were  performed;;  the  
first   round  of  mutagenesis  was  performed  on   the  pRK5-­myc-­C9orf72S  and  pRK5-­
myc-­C9orf72L   plasmids   using   the   primers   described   in   Section   2.1.2.13.1.   The  
second   round   of  mutagenesis  was   performed   on   the  mutant   pRK5-­myc-­C9orf72S  
and   pRK5-­myc-­C9orf72L   plasmids   using   the   primers   described   in   Section  
2.1.2.13.1.    
  
The  mutagenesis  reactions  were  prepared  as  follows:  
  
39  µl  Sterile  water  
5  µl  10X  QuikChange  Lightning  Reaction  Buffer  
1  µl  pRK5-­myc-­C9orf72  vector  (25  ng/µl)  
1.25  µl  Forward  primer  (100  ng/µl)  
1.25  µl  Reverse  primer  (100  ng/µl)  
1  µl  dNTP  mix  
1.5  µl  QuikSolution  Reagent    
1  µl  QuikChange  Lightning  Enzyme  
  
The  reactions  were  subjected  to  the  following  thermocycling  conditions:  
  
Table  2.9.  Thermocycling  conditions  for  QuikLightning  Site-­Directed  Mutagenesis  
Step   Cycles   Temp   Time  










Final  Extension   1   68  °C   5  mins  
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After  mutagenesis,  2  µl  of  DpnI   restriction  enzyme  was  added   to   the   reaction  mix  
and   incubated   at   37   °C   for   5   minutes   to   digest   the   parent   plasmid   DNA.   The  
mutated   plasmid   was   transformed   into   XL10-­Gold®   Ultracompetent   cells,   purified  
and  sequenced.  
  
2.2.1.14   DNA  Sequencing  
  
DNA   sequencing   was   outsourced   to   The   University   of   Sheffield   Core   Genomic  
Facility.  10  µl  of  100  ng/µl  DNA  and  10  µl  of  100  pmol/µl  sequencing  primers  were  
supplied   to   the   facility   per   sequencing   reaction.   The   primers   used   for   sequencing  
are   described   in   Section   2.1.2.14.   The   sequencing   files   were   analysed   using  
4Peaks  (Nucleobytes)  and  Serial  Cloner  (Serialbasics)  software.    
  
2.2.1.15   Expression  of  GST-­tagged  proteins  in  Rosetta  pLysS  cells  
  
GST-­control   and  GST-­tagged  C9orf72   proteins  were   expressed   in  Rosetta   pLysS  
bacterial  cells  transformed  with  the  pGEX6p1  expression  plasmids  detailed  in  table  
2.2.  A  sample  of  the  cells  was  removed  from  glycerol  stocks  and  inoculated  into  20  
ml   Terrific   Broth   containing   ampicillin   and   chloramphenicol   antibiotics.   The  
pGEX6p1  vector   carries   resistance  against  ampicillin  and   the  Rosetta  pLysS  cells  
contain  a  plasmid  which  carries  chloramphenicol   resistance.  The  bacterial  cultures  
were  grown  at  37  °C   for  16  hours  with  shaking  at  220   rpm.  10  ml  of   the  bacterial  
culture  was  added  to  750  ml  Terrific  Broth  containing  ampicillin  antibiotic  and  mixed  
well   until   homogenous.   1   ml   of   this   culture   was   removed   into   a   cuvette   for  
measurement   of   the   A600   using   the   WPA   Spectrawave   S1200   Visible  
Spectrophotometer  (Biochrom  Ltd).  The  750  ml  culture  was  incubated  at  37  °C  with  
shaking  at  220  rpm  and  1  ml  samples  removed  at  30  minute   intervals   to  measure  
the  A600.  When  the  A600  reached  0.7,  750  µl  of  0.5  M  IPTG  (final  concentration  0.5  
mM)  was  added  to  induce  GST-­protein  expression  and  the  culture  incubated  37  °C  
with  shaking  at  220  rpm  for  3  hours.  The  bacteria  were  pelleted  by  centrifugation  at  
4,000   g   at   RT   for   20  mins   and   stored   at   -­20   °C   before   use   in   the   in   vitro   GST-­
binding  assay  described  in  Section  2.2.3.5.    
  
2.2.2   Cell  culture  and  transfection  
  
2.2.2.1   Subculturing  of  HEK293  cells  
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HEK293  cells  were  grown  in  20  ml  of  complete  DMEM  at  37°C/5%  CO2  in  T75  cell  
culture   flasks   and   sub-­cultured   twice   per  week  when   cells   reached   approximately  
90%   confluency.   Media   was   removed   and   cells   washed   with   PBS.   Cells   were  
detached  from  the  flask  by  addition  of  2  ml  of  Trypsin/EDTA  solution  and  incubation  
at  37°C/5%  CO2   for  2  minutes.  The   trypsin  was  neutralised  by  addition  of  8  ml  of  
complete  DMEM  and  triturated  to  create  a  single  cell  suspension.  A  volume  of   the  
10   ml   cell   suspension   was   seeded   into   new   flasks   as   stock   cells   or   into   the  
appropriate   cell   culture   vessel   for   experimental   purposes   as   described   in   Table  
2.10.   For   immunofluorescence   experiments,   cells   were   seeded   onto   glass  
coverslips  in  a  24-­well  plate.  
  













Stock  flasks   T75  flask   1   19   20  
Plasmid  
transfection  
24-­well  plate   1.2   10.8   12  
6-­well  plate   1.5   10.5   12  
10  cm  dish   1.5   8.5   10  
siRNA  
transfection  
24-­well  plate   0.3   11.7   12  
  
  
2.2.2.2   Preparation  of  rat  primary  neurons  
  
Rat   primary   neurons   were   prepared   by   Miss   Rebecca   Cohen.   Rat   cortical   and  
hippocampal   neurons   were   isolated   from   E18   Sprague   Dawley   rat   embryos  
(Charles  River)  and  seeded  onto  poly-­L-­lysine  coated  coverslips   in  a  24-­well  plate  
at   approximately   190,000   cells   per   well.   Neurons   were   cultured   in   complete  
neurobasal  media   at   37°C/5%  CO2,   and  maintained  by   replacement   of   half   of   the  
media  with  fresh  media  at  5,  8  and  12  days  in  vitro  (DIV).    
  
2.2.2.3   Seeding  of  iAstrocyte  cell  lines  
  
iAstrocyte   cells   were   differentiated   from   neural   progenitor   cells   (NPCs)   converted  
from  healthy  or  C9orf72-­ALS  patient  skin  fibroblasts  by  Dr  Laura  Ferraiuolo  (Meyer  
et   al.,   2014).   The   human   skin   fibroblasts   were   obtained   by   Prof   Dame  Pamela   J  
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Shaw   and   informed   consent   was   acquired   from   all   subjects   prior   to   collection   of  
samples   (Study   number   STH16573,   Research   Ethics   Committee   reference  
12/YH/0330).  The  demographics  of  the  cell  lines  is  detailed  in  table  2.11.  
  
Table  2.11.  iAstrocyte  cell  line  patient  demographics  
Cell  
line  
ALS-­type   Sex   Age  at  biopsy  
collection  (years)  
Ethnicity   Onset  to  death  
(months)  
155   Non-­ALS  control   M   40   Caucasian   -­  
209   Non-­ALS  control   F   69   Caucasian   -­  
3050   Non-­ALS  control   M   55   Caucasian   -­  
78   C9-­ALS   M   66   Caucasian   31.7  
183   C9-­ALS   M   50   Caucasian   27  
201   C9-­ALS   F   66   Caucasian   19.4  
  
  
The   iAstrocytes   were   grown   in   iAstrocyte   media   at   37°C/5%   CO2   in   cell   culture  
flasks.   Media   was   removed   and   for   seeding,   cells   were   washed   with   PBS   and  
detached  from  the  flask  by  addition  of  1  ml  of  AccutaseÒ  and  incubation  at  37°C/5%  
CO2  for  2  minutes.  The  AccutaseÒ  was  quenched  by  addition  of  3  ml  of   iAstrocyte  
media  and  the  cell  suspension  centrifuged  at  200  g  for  4  minutes  at  RT.  The  media  
was  removed  and  the  cells  resuspended  in  3ml  of  fresh  iAstrocyte  media  by  gently  
pipetting   up   and   down.   10   µl   of   cell   suspension  was   removed   and   the   cell   count  
determined  using  a  hemocytometer.  The  iAstrocyte  cell  suspension  was  diluted  and  





2.2.2.4   Plasmid  DNA  transfection  
    
Cells   were   seeded   such   that   they   were   at   70%   confluency   for   next-­day   plasmid  
transfection.  HEK293  and   iAstrocyte  cells  were   transfected  using  polyethylenimine  
(PEI)   and   Lipofectamine   2000   (Invitrogen)   transfection   reagents   respectively.  
HEK293  cells  were  transfected  using  a  PEI  to  DNA  ratio  of  3:1  and  iAstrocytes  were  
transfected  using  a  Lipofectamine  2000  to  DNA  ratio  of  2:1.    
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Table  2.12.  Plasmid  transfection  of  HEK293  cells  with  PEI  





DNA  per  well  
(µg)  
DNA  Opti-­MEM  
volume  per  well  
(µl)  
24-­well  plate   1.5   25   0.5   25  
6-­well  plate   6   100   2   100  
10  cm  dish   60   500   10   500  
  
  




2000  per  well  
(µl)  
Lipofectamine  2000  





volume  per  well  
(µl)  
24-­well  plate   1   25   0.5   25  
  
  
The   stated   volume  of   transfection   reagent  was  added   to  Opti-­MEM,   vortexed  and  
incubated   at  RT   for   5  minutes.   Separately,   the   plasmid  DNA  was   diluted   in  Opti-­
MEM.  The  diluted  transfection  reagent  was  added  to  the  diluted  DNA  and  incubated  
at   RT   for   20   minutes.   The   transfection   mix   was   added   drop-­wise   onto   cells   and  
incubated  at  37°C/5%  CO2   for  6  hours.  The   transfection  media  was  removed   from  
cells   and   replaced   with   fresh   complete   DMEM   or   iAstrocyte   media.   Cells   were  
incubated  at  37°C/5%  CO2  for  24  hours  to  allow  for  protein  expression  before  fixing  
or  harvesting.    
  
2.2.2.5   siRNA  transfection  
  
HEK293  cells  were  seeded  such   that   they  were  at  approximately  40%  confluency  
for  next-­day  siRNA  transfection.  Dry  siRNA  was  dissolved  in  sterile  water  to  give  a  
100   µM   stock   siRNA.   The   stock   siRNAs   were   diluted   1   in   10   in   sterile   water   to  
generate  10  µM  siRNAs  which  were  used  for  transfections.  siRNA  was  transfected  
into   cells   using   Lipofectamine   RNAiMax   reagent   (Invitrogen)   following   the  
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24-­well  plate   0.6   25   0.6   25  
  
  
The   stated   volume   of   Lipofectamine  RNAiMax  was   added   to  Opti-­MEM,   vortexed  
and  incubated  at  RT  for  5  minutes.  Separately,  the  siRNA  was  diluted  in  Opti-­MEM.  
The  diluted  Lipofectamine  RNAiMax  was  added  to  the  diluted  siRNA  and  incubated  
at   RT   for   20   minutes.   The   transfection   mix   was   added   drop-­wise   onto   cells   and  
incubated  at  37°C/5%  CO2   for  6  hours.  The   transfection  media  was  removed   from  
cells  and  replaced  with   fresh  complete  DMEM.  After  96  hours,  cells  were   fixed   for  
immunofluorescence  or  harvested  for  protein  or  RNA.  If  the  experiment  required  it,  
plasmid   transfection  was  performed  72  hours   post   siRNA   transfection.  Cells  were  
fixed   for   immunofluorescence   or   harvested   for   protein   or   RNA   24   hours   post  
plasmid  transfection.    
  
2.2.2.6   Viral  transduction  of  rat  primary  neurons  
  
Rat   primary   neurons   were   transduced   by   Miss   Rebecca   Cohen   at   5   DIV.  
Neurobasal  media  was   removed  and  cells   received  4   transducing  units  per  cell  of  
lentivirus   construct   diluted   in   250   µl   complete   neurobasal   media.   Cells   were  
incubated  at  37°C/5%  CO2   for  16  hours  before   the  media  was  replaced  with  a  1:1  
mix   of   fresh   complete   neurobasal   media   and   conditioned   complete   neurobasal  
media.   Neurons   were   incubated   at   37°C/5%   CO2   for   7   days   before   fixing   for  
immunofluorescence  or  harvested  for  protein  or  RNA.    
  
2.2.3   Biochemical  Methods  
  
2.2.3.1   Whole  cell  lysis  
  
Media   was   removed   and   cells   washed   with   PBS.   Cells   were   detached   from   the  
culture  vessel  by  addition  of  Trypsin/EDTA  solution  for  full  coverage  of  the  cells  and  
incubation   at   37°C/5%   CO2   for   2   minutes.   The   cells   were   harvested   and   trypsin  
quenched  by  addition  of  DMEM.  The  cell  suspension  was  centrifuged  at  400  g  for  4  
minutes  at  4  °C  to  pellet  cells.  Cells  were  washed  by  removal  of  media  and  gentle  
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resuspension  in  PBS.  Cells  were  pelleted  by  centrifugation  at  400  g  for  4  minutes  at  
4  °C.  Cells  were  lysed  by  resuspension  in  RIPA  buffer  and  incubation  on  ice  for  30  
minutes.  Lysates  were  clarified  by  centrifugation  at  14,000  rpm  for  30  mins  at  4  °C  
in  a  Sigma  1-­15  PK  centrifuge  using  a  12124  rotor  and  the  supernatant  transferred  
to  a  fresh  tube.  
  
2.2.3.2   Nuclear  fractionation  
  
Media   was   removed   and   cells   washed   with   PBS.   Cells   were   detached   from   the  
culture  vessel  by  addition  of  Trypsin/EDTA  solution  for  full  coverage  of  the  cells  and  
incubation   at   37°C/5%   CO2   for   2   minutes.   The   cells   were   harvested   and   trypsin  
quenched  by  addition  of  DMEM.  Cells  were  pelleted  by  centrifugation  at  400  g  for  4  
minutes  at  4  °C.  The  media  was  removed  and  cells  washed  by  gentle  resuspension  
in  PBS.  If  a  total  lysate  sample  was  required,  one  third  of  the  PBS  cell  suspension  
was   removed  and  whole  cell   lysis  performed.  The   remaining  PBS  cell   suspension  
was  centrifuged  at  400  g  for  4  minutes  at  4  °C  to  pellet  cells.  The  PBS  was  removed  
and   the   pellet   washed   quickly   with   hypotonic   lysis   buffer   to   remove   residual   salt.  
The   hypotonic   lysis   buffer   lyses   the   cell   membrane   but   leaves   the   nuclear  
membrane   intact.  The  cell   pellet  was  gently   resuspended   in  hypotonic   lysis  buffer  
and  incubated  on  ice  for  30  minutes  to  lyse  the  cell  membrane.  Nuclei  were  pelleted  
by  centrifugation  at  4,000  rpm  for  3  minutes  at  4  °C  in  a  Sigma  1-­15  PK  centrifuge  
using   a   12124   rotor.   The   supernatant   ‘cytoplasmic   fraction’   was   transferred   to   a  
fresh  eppendorf.  The  nuclear  pellet  was  washed  twice  with  hypotonic  lysis  buffer  by  
gentle   resuspension   and   centrifugation   at   4,000   rpm   for   3   minutes   at   4   °C   in   a  
Sigma  1-­15  PK  centrifuge  using  a  12124  rotor   to  remove  any  residual  cytoplasmic  
fraction.   The   nuclear   pellet   was   lysed   by   resuspension   in   RIPA   buffer   and  
incubation  on  ice  for  30  minutes.  The  nuclear   lysate  was  clarified  by  centrifugation  
at  14,000  rpm  for  30  mins  at  4  °C  in  a  Sigma  1-­15  PK  centrifuge  using  a  12124  rotor  
and  the  supernatant  transferred  to  a  fresh  eppendorf.  
  
2.2.3.3   Bradford  protein  assay  
  
The  Bradford  protein  assay  was  used   to  measure   the  protein  concentration  of  cell  
lysates  following  whole  cell  lysis  or  nuclear  fractionation  (Bradford,  1976).  Bradford  
reagent   was   diluted   1   in   5  with  water   and   used   to  make   a   1   in   100   dilution   of   1  
mg/ml   BSA.   Two-­fold   serial   dilutions   of   BSA   were   completed   on   a   96-­well   flat-­
bottom   plate   to   produce   a   standard   curve   ranging   from   1000   ng/ml   to   0.5   ng/ml.  
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Lysates   were   diluted   1   in   100   in   diluted   Bradford   reagent   and   two-­fold   serial  
dilutions  completed  on  the  96-­well  plate.  The  final  volume  in  each  well  was  100  µl  
and  diluted  Bradford   reagent  alone  was  used  as  a  blank.  The  A595  was  measured  
using  the  PHERAstar  FS  plate  reader  (BMG  Labtech)  and  the  A595  of  the  blank  was  
subtracted   from   the   A595   of   standards   and   samples.   The   standard   curve   was  
generated  by  plotting  the  A595  against  protein  concentration  and  the  gradient  of  the  
curve   measured.   The   protein   concentration   of   lysates   was   determined   using   the  
equation:  concentration  =  (A595  x  curve  gradient  x  dilution  factor).    
  
2.2.3.4   Immunoprecipitation  
  
For  input  samples,  lysates  were  diluted  in  water  and  5X  Laemmli  buffer  to  a  1mg/ml  
protein  concentration  in  a  final  volume  of  50  µl  (e.g.  10  µl  lysate  at  5  mg/ml  +  10  µl  
5X  Laemmli  +  30  µl  water).  The  remaining  lysate  was  used  for  immunoprecipitation  
(IP).  IP  samples  were  diluted  in  RIPA  buffer  to  have  a  minimum  of  1  mg  total  protein  
in  a  final  volume  of  750  µl  (e.g.  200  µl  lysate  at  5  mg/ml  +  550  µl  RIPA  buffer).  1  µg  
of  antibody  for  protein  immunoprecipitation  was  added  per  IP  sample  and  incubated  
for  16  hours  at  4  °C  with  agitation.  A  50%  slurry  of  Protein  G  Sepharose  beads   in  
RIPA  buffer  was  prepared.  30  µl  of   the  bead  slurry  was  added  per   IP  sample  and  
incubated   for   3   hours   at   4   °C   with   agitation.   The   beads   were   pelleted   by  
centrifugation  at  3,000  g  for  3  mins  at  4  °C.  The  supernatant  was  discarded  and  the  
beads  washed  five  times  by  gentle  resuspension   in  RIPA  buffer  and  centrifugation  
at   3,000  g   for   3  mins   at   4   °C.  After   the   final  wash,   care  was   taken   to   remove  all  
residual  supernatant  from  the  beads  using  a  gel-­loading  tip.  Protein  was  eluted  from  
the  beads  by  addition  of  25  µl  of  2X  Laemmli  buffer  and  boiling  for  5  minutes  at  100  
°C.  The  complete  25  µl  elution  was  analysed  by  immunoblot.    
  
2.2.3.5   In  vitro  GST-­binding  assay  
  
35S-­methionine  radiolabeled  coilin  was  generated  using  the  T7  TnT®  Quick  Coupled  
Transcription/Translation  System   (Promega)   from   the  pCI-­neo-­myc-­coilin   construct  
which  contained  a  T7  promoter.  The  10  µl  reaction  was  prepared  as  follows  behind  
a  plastic  shield  to  protect  against  radiation:  
  
1.5  µl  pCI-­neo-­myc-­coilin  plasmid  (333  ng/µl)  
0.5  µl  35S-­Methionine  (PerkinElmer)  
8  µl  Reticulocyte  lysate  
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The   reaction   was   incubated   at   37   °C   for   90   minutes.   Frozen   Rosetta   pLysS  
bacterial  cells  expressing   the  GST-­tagged  proteins  were  weighed   into  eppendorfs.  
GST,  GST-­C9orf72S  and  GST-­C9orf72L  cells  were  weighed  out  at  0.1  g,  0.2  g  and  
0.3  g  respectively  due  to  differences  in  protein  expression.  1  ml  of   ice-­cold  RB100  
buffer   was   added   and   cells   lysed   by   sonication   until   no   visible   clumps   remained.  
The  lysates  were  centrifuged  at  17,000  g  for  5  minutes  at  4  °C  to  pellet  cell  debris.  1  
ml  of  the  clarified  lysate  was  transferred  to  separate  tubes  containing  30  µl  of  50%  
glutathione-­agarose  (GSH)  bead  slurry  in  RB100  buffer.  The  lysates  were  incubated  
with   the   beads   for   30   minutes   at   4   °C   with   agitation.   Beads   were   pelleted   by  
centrifugation  at  500  g  for  1  minute  at  4  °C  and  the  bacteria  lysate  discarded.  The  
beads  were  washed   twice   by   resuspension   in  RB100   buffer   and   centrifugation   at  
500  g  for  1  minute  at  4  °C.  Beads  were  resuspended  in  500  µl  RB100  buffer  and  8  
µl  of  the  35S-­coilin  reticulocyte  reaction  was  added  and  incubated  for  1  hour  at  4  °C  
with   agitation.   Beads  were   pelleted   and  washed   twice   by   resuspension   in  RB100  
buffer  and  centrifugation  at  500  g  for  1  minute  at  4  °C.  Care  was  taken  to  remove  
any   residual   liquid  and  proteins  eluted  by  adding  40  µl   of  GSH  elution  buffer   and  
incubating   at   RT   for   10   minutes   with   frequent   agitation.   The   GST   control   was  
prepared  for  immunoblot  by  taking  1  µl  of  the  GST  elution  and  adding  15  µl  of  GSH  
elution  buffer  and  4  µl  of  5X  Laemmli  buffer.  For  GST-­C9orf72S  and  GST-­C9orf72L,  
immunoblot   samples   were   prepared   by   diluting   16   µl   of   elution   with   4   µl   of   5X  
Laemmli   buffer.   Input   samples   were   prepared   by   diluting   0.5   µl   of   the   35S-­coilin  
reticulocyte  reaction  in  15.5  µl  of  GSH  elution  buffer  and  4  µl  of  5X  Laemmli  buffer.  
The   whole   of   the   20   µl   samples   were   subjected   to   SDS-­PAGE   electrophoresis  
followed  by  coomassie  staining  of  the  gel  for  GST-­protein  visualisation.  The  gel  was  
dried  and  backed  onto  Whatman  filter  paper  and  exposed  to  a  Phosphor  Screen  for  
14  days.  A  Typhoon  Phosphor  Imager  was  used  to  detect  radioactivity  and  digitise  
results.    
  
2.2.3.6   SDS-­PAGE  electrophoresis  
  
Protein  samples  were  boiled  at  100  °C  for  5  minutes  in  Laemmli  buffer  to  denature  
proteins   for   SDS-­PAGE  electrophoresis.   A   10%  polyacrylamide   resolving   gel  was  
prepared.   After   the   resolving   gel   had   set,   a   6%   polyacrylamide   stacking   gel   was  
prepared   on   top   of   it   with   a   10-­   or   15-­well   comb   depending   on   the   number   of  
samples   to   be   run.   The   gel   was   placed   into   a   Mini-­PROTEAN   Tetra   Cell   tank  
(Biorad)   and   immersed   in   running   buffer.   Protein   samples  were   loaded   into   wells  
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and   subjected   to   electrophoresis   at   100   V   for   approximately   2   hours.   3   µl   of  
Precision  Plus  Protein  All  Blue  Standard  was  loaded  as  a  molecular  weight  marker.    
  
2.2.3.7   Coomassie  staining  of  polyacrylamide  gels  
  
After   SDS-­PAGE   electrophoresis   of   the   samples   from   the   in   vitro   GST-­binding  
assay,   the  polyacrylamide  gel  was  stained  with  Coomassie  G-­250  by  heating   in  a  
microwave   for   15   s   and   incubating   at   RT   for   20   minutes   with   agitation.   The  
Coomassie  was   replaced  with   destain   solution   and  microwaved   for   15   s.   The   gel  
was  incubated  in  destain  at  RT  for  20  minutes  and  the  destain  replaced  with  fresh  
destain  solution  every  20  minutes  until  the  GST-­proteins  were  clearly  visible  and  the  
gel   clear.   The   gel  was   dried   and   backed   onto  Whatman   paper   and   exposed   to   a  
Phosphor   Screen   for   14   days.   A   Typhoon   Phosphor   Imager   was   used   to   detect  
radioactivity  and  digitise  results.  
  
2.2.3.8   Electrophoretic  transfer  of  proteins  
  
For   immunoblotting,   proteins   were   electrotransferred   from   the   polyacrylamide   gel  
onto   nitrocellulose   membrane.   The   gel   and   nitrocellulose   membrane   were  
sandwiched   in   a   gel   holder   cassette   as   follows:   sponge,   2   filter   papers,  
polyacrylamide  gel,  nitrocellulose  membrane,  2  filers  papers,  sponge.  The  cassette  
was   orientated   into   a   Mini   Trans-­Blot   Cell   (Biorad)   such   that   the   protein   transfer  
from   gel   to   nitrocellulose   was   aligned   with   the   electric   current   from   the   cathode  
towards  the  anode.  The  cassette  was  submerged  in  transfer  buffer  and  subjected  to  
100   V   for   a   1   hour   transfer   or   30   V   for   a   16   hour   transfer.   The   membrane   was  
stained  with  Ponceau  S  for  protein  detection  and  to  allow  for  more  accurate  cutting  
of  the  membrane  if  required.      
  
2.2.3.9   Immunoblot  of  nitrocellulose  membrane    
  
Membranes  were  blocked   in  5%  milk   in  TBST   for  1  hour  at  RT.  Primary  antibody  
was  diluted  in  5%  milk  in  TBST  and  added  to  the  membrane  for  1  hour  at  RT  or  for  
16   hours   at   4   °C.   The  membrane  was  washed   three   times  with   10  minute   TBST  
incubations  with  rocking.  HRP-­conjugated  secondary  antibody  was  diluted  in  TBST  
and  added   to   the  membrane   for  1  hour  at  RT.  The  membrane  was  washed   three  
times   with   10   minute   TBST   incubations   with   rocking.   Protein   detection   was  
performed  by  incubation  of  the  blot  with  SuperSignal  West  Pico  Chemiluminescent  
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Substrate   for   five   minutes   before   placement   into   a   film   cassette.   The   substrate  
oxidises   luminol   in   the   presence   of   HRP   and   peroxide   thus   generating   a  
chemiluminescent  signal  proportionate  to  the  amount  of  HRP  present  which  can  be  
detected   by   autoradiograph   film.      The   following   steps   were   completed   in   a   dark  
room.  Autoradiograph  Hyperfilm   (Amersham)  was  positioned  above   the  blot   in   the  
cassette.  Exposure  time  varied  from  1  s  to  1  hour  depending  on  the  band  intensity.  
The  film  was  placed  into  developing  solution  for  1  minute,  rinsed  quickly  with  water  
and   placed   into   fixing   solution   for   2  minutes.   The   film  was   air-­dried   and   scanned  
onto  a  computer  for  analysis.    
  
2.2.3.10   Quantification  of  protein  and  DNA  bands  using  
densitometry  
  
Densitometry   was   performed   on   protein   and   DNA   bands   using   ImageJ   software  
(Abràmoff  et  al.,  2004).  A  box  was  drawn  around  the  band  to  be  analysed  using  the  
rectangular  selection.  For  measuring  band  densitometry   in  the  splicing  assays,  the  
box  was  drawn  around  both  the  upper  unspliced  band  and  the  lower  spliced  band.  
Histograms  for  each  band  were  generated  by  selecting  analyse  >  gels  >  plot  lanes.  
A   straight   line   was   drawn   level   to   the   background   signal   and   the   area   under   the  
histogram  was  measured  by  selection  with   the  wand   tool.  This  area  was   taken  as  
representative  of  protein  level.  Protein  bands  were  normalised  to  the  housekeeping  
protein  GAPDH  which  was  included  as  a  loading  control.    
  
2.2.3.11   RNA  extraction  
  
Cells  were  washed  once  with  PBS  and   lysed   in  200  µl  TRIzol™   reagent   (Thermo  
Fisher  Scientific)  per  well  of  a  24-­well  plate  following  the  manufacturers  protocol.  40  
µl  of  chloroform  was  added  and  lysates  shaken  immediately  for  15  s.  Samples  were  
incubated  at  RT  for  10  minutes  before  centrifugation  at  12,000  g  for  15  minutes  at  4  
°C.   Centrifugation   separates   the   sample   into   three   distinct   liquid   phases:   a   lower  
phenol-­chloroform  mix  that  contains  protein,  a  middle  interphase  that  contains  DNA  
and   an   upper   aqueous   phase   containing   RNA.   The   upper   aqueous   phase   was  
removed   into  a  new  RNA-­free  tube.  100  µl  of  100%  propan-­2-­ol  was  added  to   the  
aqueous   phase   and   mixed   by   gentle   flicking   to   precipitate   RNA.   The   mix   was  
incubated  at  RT  for  ten  minutes  before  centrifugation  at  12,000  g  for  10  minutes  at  4  
°C  to  pellet  the  RNA.  The  supernatant  was  discarded  and  the  RNA  pellet  washed  by  
addition   of   200   µl   of   75%   ethanol   and   brief   vortexing.   The   RNA  was   pelleted   by  
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centrifugation  at  7,500  g   for  5  minutes  at  4  °C.  The  ethanol  was  removed  and  the  
pellet  air  dried  for  10  minutes.  The  RNA  was  resuspended  in  9  µl  of  nuclease  free  
water  by  pipetting  up  and  down  and   incubating  at  60  °C  for  15  minutes.  The  RNA  
concentration   and   quality   was   determined   using   the   NanoDrop   1000  
spectrophotometer  by  measuring   the  absorbance  at  260  and  280  nm.  An  A260/A280  
of  ~2.0  was  taken  as  pure  RNA.    
  
2.2.3.12   RT-­PCR  generation  of  cDNA  
  
The  RNA  was   reverse   transcribed   to  produce  cDNA  which  could  be  quantified  by  
qPCR.     2  µg  of  RNA  was  prepared   in  8  µl  of  nuclease   free  water.  1  µl  of  DNaseI  
buffer  was  added  to  the  RNA  and  mixed.  1  µl  of  DNAase  I  enzyme  was  added  and  
incubated   at   37   °C   for   10   minutes   to   remove   DNA   contamination.   The   DNase   I  
enzyme  was  inactivated  by  addition  of  1  µl  of  25  mM  EDTA  and  incubating  at  75  °C  
for  10  minutes.  2  µl  of  25  mM  dNTP  mix  and  1  µl  of  Oligo(dT)18  primer  was  added  
to   the   RNA   and   incubated   at   65   °C   for   5  minutes   to   prime   the   RNA.   4   µl   of   5X  
reverse  transcriptase  buffer  and  2  µl  of  0.1  M  DTT  was  added  and  incubated  at  25  
°C  for  5  minutes.  cDNA  was  transcribed  by  addition  of  0.5  µl  SuperScript  III  enzyme  
and  incubation  at  50  °C  for  1  hour.  The  reaction  was  inactivated  by  incubation  at  75  
°C  for  15  minutes.  cDNA  was  stored  at  4  °C.  
  
2.2.3.13   qPCR  
  
The  cDNA  was  quantified  by  qPCR  using  HOT  FIREPol  EvaGreen®  dye  and  gene-­
specific  primers  at  an  optimised  dilution  (detailed  in  Section  2.1.4.14).  The  following  
20  µl  reactions  were  prepared:  
  
11  µl  Nuclease  free  water  
4  µl  HOT  FIREPol  EvaGreen®  qPCR  mix  
2  µl  Forward  primer  at  optimised  dilution  
2  µl  Reverse  primer  at  optimised  dilution  
1  µl  of  1  in  10  dilution  of  cDNA    
  
Each  cDNA  sample  was   run   in   triplicate  on   the  CFX96  Real-­Time  PCR  Detection  
System  (Biorad).  The  qPCR  thermocycling  conditions  were  as  follows:  
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Table  2.15.  Thermocycling  conditions  for  qPCR  
Step   Cycles   Temp   Time  









The  Ct  values  from  the  cDNA  triplicates  were  averaged  and  normalised  to  GAPDH  
or  RPL19  mRNA  levels  for  human  or  rat  mRNA  respectively.      
  
2.2.3.14   PCR  amplification  of  the  pCI-­neo  intron  
  
The  pCI-­neo   intron  was  PCR  amplified  using  FIREPol®  DNA  polymerase,   primers  
described  in  Section  2.1.4.15  and  either  pCI-­neo  plasmid  or  cDNA  from  cells  as  the  
DNA  template.  The  following  10  µl  reactions  were  prepared:  
  
6.8  µl  Nuclease  free  water  
2  µl  FIREPol®  Master  Mix  Ready  To  Load  
0.1  µl  Forward  primer  (100  µM)  
0.1  µl  Reverse  primer  (100  µM)  
1  µl  pCI-­neo  plasmid  (100  ng/µl)  OR  1  in  10  dilution  of  cDNA  
  
cDNA  was  run  in  triplicate  and  subjected  to  the  following  thermocycling  conditions:  
  
Table  2.16.  Thermocycling  conditions  for  pCI-­neo  intron  amplification  
Step   Cycles   Temp   Time  
Initial  Denaturation   1   95  °C   3  mins  
Denaturation  



















Final  Extension   1   72  °C   10  mins  
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The   whole   10   µl   reaction   was   loaded   onto   an   agarose   gel   and   subjected   to  
electrophoresis.  Unspliced  and  spliced  DNA  bands  were  quantified  as  described  in  
Section  2.2.3.10.    
  
2.2.3.15   PCR  amplification  of  the  P120  intron  
  
The   P120   intron   was   PCR   amplified   using   FIREPol®   DNA   polymerase,   primers  
described  in  Section  2.1.4.15  and  either  P120  minigene  plasmid  or  cDNA  from  cells  
as  the  DNA  template.  The  following  10  µl  reactions  were  prepared:  
  
6.8  µl  Nuclease  free  water  
2  µl  FIREPol®  Master  Mix  Ready  To  Load  
0.1  µl  Forward  primer  (100  µM)  
0.1  µl  Reverse  primer  (100  µM)  
1  µl  P120  minigene  plasmid  (100  ng/µl)  OR  1  in  10  dilution  of  cDNA  
  
cDNA  was  run  in  triplicate  and  subjected  to  the  following  thermocycling  conditions:  
  
Table  2.17.  Thermocycling  conditions  for  P120  intron  amplification  
Step   Cycles   Temp   Time  























Final  Extension   1   72  °C   10  mins  
  
The   whole   10   µl   reaction   was   loaded   onto   an   agarose   gel   and   subjected   to  
electrophoresis.  Unspliced  and  spliced  DNA  bands  were  quantified  as  described  in  
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2.2.4   Microscopy  
  
2.2.4.1   Immunofluorescence  
  
Cells   were   plated   onto   13   mm   glass   coverslips   for   immunofluorescence  
experiments.     Media  was   removed  and   cells  washed  gently  with  PBS.  Cells  were  
fixed  with  4%   formaldehyde   in  PBS   for  20  minutes.  Cells  were  washed   twice  with  
PBS   to   remove   formaldehyde.  Cells  were  permeabilised  with  0.2%  Triton-­X100   in  
PBS   for   3  minutes.   Cells   were  washed   twice  with   PBS   to   remove   the   Triton   and  
blocked  with   5%  Normal  Goat  Serum   (NGS)   in  PBS   for   1   hour.  Primary   antibody  
was  diluted  in  5%  NGS  in  PBS  (Table  2.5)  and  incubated  with  cells  for  1  hour  at  RT.  
Cells  were  washed  three  times  with  PBS  to  remove  primary  antibody.  Fluorophore-­
conjugated  secondary  antibody  and  DNA  stain  Hoechst  33342  were  diluted   in  5%  
NGS   in  PBS  and   incubated  with   cells   for   1   hour   at  RT.  Cells  were  washed   three  
times  with  PBS  to  remove  secondary  antibody.  Coverslips  were  mounted  onto  glass  
microscope  slides  using  fluorescence  mounting  medium.  Slides  were  stored  at  4  °C  
before   visualisation   with   a   63x   Plan   Apochromat   1.4NA   objective   on   a   Zeiss  
Axioplan   2   microscope   installed   with   a   Zyla   4.2   sCMOS   camera.   Images   were  
collected   using   MicroManager   1.4   software   and   analysed   using   ImageJ   software  
(Edelstein  et  al.,  2014).  
  
2.2.4.2   Proximity  Ligation  Assay  
  
The  proximity   ligation  assay  was  performed  using   the  DuoLinkÒ  PLA  Technology  
reagents   (Sigma)   following   the  manufacturers   protocol.  Cells  were   plated   onto   13  
mm  glass  coverslips   for  PLA  experiments.     Media  was  removed  and  cells  washed  
gently   with   PBS.   Cells   were   fixed   with   4%   Formaldehyde   in   PBS   for   20  minutes  
then   washed   twice   with   PBS   to   remove   formaldehyde.   Cells   were   permeabilised  
with  0.2%  Triton-­X100  in  PBS  for  3  minutes  then  washed  twice  with  PBS  to  remove  
Triton.   Cells   were   blocked   using   the   Blocking   Solution   for   30   minutes   at   37   °C.  
Primary   antibody   was   diluted   in   5%  NGS   in   PBS   (Table   2.6)   and   incubated   with  
cells   for   1   hour   at   RT.   Cells   were   washed   twice   with   Wash   Buffer   A   to   remove  
primary   antibody.   Secondary   PLA   probes   were   diluted   in   Antibody   Diluent   and  
incubated  with  cells   for  30  minutes  at  37   °C.  Cells  were  washed   twice  with  Wash  
Buffer  A  to  remove  PLA  probes.  The  PLA  probes  were  ligated  by  incubation  of  cells  
with   the  PLA   ligation   reagents   for   30  minutes   at   37   °C.  Cells  were  washed   twice  
with  Wash  Buffer  A  and  rolling  circle  amplification  initiated  by  incubation  of  cells  with  
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the  PLA  amplification  reagents   for  100  minutes  at  37  °C.  Cells  were  washed  once  
with  1X  Wash  Buffer  B  and   incubated  with  Hoechst  33342  diluted   in  0.01X  Wash  
Buffer  B   for  15  minutes   to  stain  nuclei.  Cells  were  washed  once  with  0.01X  Wash  
Buffer   B   and  mounted   onto   glass  microscope   slides   using   fluorescence  mounting  
medium.   Images   were   recorded   as   described   in   Section   2.2.4.1.   Cells   were  
selected   for   image  capture   if   they  were  GFP-­positive  by  searching  on   the  488  nm  
channel.    
  
2.2.4.3   Cajal  body  quantification  
  
Images  were  opened  on  ImageJ  software  for  analysis.  Cajal  bodies  were  manually  
quantified   by   counting   the   number   of   coilin   foci   per   nucleus.   For   non-­transfected  
cells,  10  cells  were  selected  randomly  per  field  of  view  for  Cajal  body  quantification.  
For   transfected   cells,   Cajal   bodies   were   counted   in   cells   which   had   appropriate  
expression   shown   by   immunofluorescence   using   an   antibody   against   the  
transfected  protein.  
  
2.2.4.4   PLA  signal  quantification  
  
Images  were   opened   on   ImageJ   software   for   analysis.   A   region   of   interest   (ROI)  
was  drawn  around  either  the  whole  cell  on  the  GFP  channel  or  the  nucleus  on  the  
DAPI   channel.  On   the  PLA  signal   channel,   the  brightness  and  contrast  of   images  
was   edited   by   setting   the  minimum   and  maximum   display   range   to   a   determined  
value  such  that  PLA  signals  appeared  as  bright  visible  puncta  with  no  background  
signal.   The  ROI  was   transferred   onto   the   PLA   signal   channel   and   the   number   of  
PLA  signals  contained  within  the  ROI  were  manually  counted.    
  
2.2.4.5   Performing  statistical  tests  
  
All  statistical  tests  were  performed  using  Prism  7  software  (GraphPad  Software  Inc.,  
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3   Optimisation  and  development  of  tools  for  
the  project  
  
3.1   Introduction  
  
A  GGGGCC  hexanucleotide   repeat   expansion   in   the  C9orf72   gene   is   the   leading  
cause   of   familial   ALS.   The   mutation   is   thought   to   cause   disease   via   three   non-­
mutually   exclusive  mechanisms:   haploinsufficiency   of   the  C9orf72   protein   (loss   of  
function),   generation   of   toxic   RNA   foci   and   dipeptide   repeat   proteins   (gain   of  
function).   Decreased   levels   of   C9orf72   mRNA   and   protein   in   ALS   patient   brains  
support   haploinsufficiency   of   the   C9orf72   protein   as   a   disease   contributor.   There  
have   been   recent   advancements   in   understanding   the   cellular   functions   and  
localisation  of  the  C9orf72  protein,  but  a  role  for  C9orf72  in  the  nucleus  is  yet  to  be  
discovered.    
  
The   aim   of   this   project   was   to   increase   understanding   of   the   nuclear   function   of  
C9orf72.   To   do   this,  C9orf72   protein   overexpression   and   knockdown   experiments  
were  frequently  used  to  look  at  the  effect  of  C9orf72  on  Cajal  bodies  and  splicing.  In  
addition   to   transient  C9orf72  knockdowns,  a  stable  C9orf72  knockout  cell   line  was  
used.  This  chapter  describes  the  characterisation  of  these  CRISPR/Cas9  generated  
C9orf72   mutant   cell   lines,   and   the   development   and   optimisation   of   tools   used  
throughout  the  project.    
  
3.2   Results  
  
3.2.1   Characterisation  of  stable  C9orf72  knockout  cell  lines  
  
Haploinsufficiency  of   the  C9orf72  protein   is  one  of   three  mechanisms  proposed   to  
contribute  to  ALS  pathogenesis.  In  trying  to  understand  what  the  function  of  C9orf72  
might  be,  it  can  be  useful  to  knockdown  the  C9orf72  protein  and  probe  what  effect  
this  has  on  different  cellular  pathways.  This  helps  inform  not  only  the  pathway  which  
C9orf72  may  be  involved  in,  but  also  pinpoints  what  might  be  occurring  in  disease.  
Transient   knockdown   of   C9orf72   can   be   achieved   with   some   efficiency   by  
transfection  of  cell  lines  with  C9orf72-­targeting  siRNAs.  However,  siRNAs  can  have  
off-­target   effects   and   the   acute   nature   of   transfections   is   not   as   representative   of  
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physiological   conditions   as   a   stable   knockout.   For   these   reasons,   we   used  
CRISPR/Cas  9  genome  editing  to  try  and  establish  a  C9orf72  knockout  cell  line.    
  
Dr   Christopher   Webster   co-­transfected   HEK293   cells   with   two   Cas9   nickase  
plasmids.  Each  plasmid  expressed  the  Cas9  nickase  enzyme,  puromycin  resistance  
and   different   C9orf72   exon   2   complimentary   guide   RNAs   (gRNA).   The   gRNAs  
associate  with  the  Cas9  nickase  and  target  the  enzyme  to  the  C9orf72  exon  2  DNA.  
After   DNA   binding,   each   nickase   cuts   a   single   DNA   strand   creating   a   ‘nick’;;  
together,  these  two  nicks  create  a  double  strand  break  (DSB).  The  DSB  is  repaired  
by  inefficient  non-­homologous  end  joining  which  introduces  errors  into  the  genome  
via   insertions   or   deletions   (INDELs)   of   base   pairs   (Mali   et   al.,   2013;;   Ran   et   al.,  
2013).    If  the  inserted  or  deleted  base  pairs  lead  to  a  frame  shift  in  the  open  reading  
frame  (ORF),  a  premature  stop  codon   is  often   introduced.  Premature  stop  codons  
signal   to   the   cells   nonsense-­mediated   decay   surveillance   pathway   to   target   the  
mRNA   for   degradation,   thereby   preventing   translation   and   creating   a   loss-­of-­
function   mutant   (Hug   et   al.,   2016).   Having   two   gRNAs   targeting   C9orf72   exon   2  
increased   the   specificity   of   the  gene  editing   technology,   and  was  hypothesised   to  
lead  to  loss  of  both  the  short  and  long  C9orf72  protein  isoforms.  Cells  were  selected  
for   successful   transfection   by   growth   in   puromycin   containing   media.   Living   cells  
were  seeded  at   increasing  dilutions  until   isogenic  cell  colonies  were  apparent.  Cell  
cultures  were  scaled  up  from  these  colonies  and  were  preliminarily  screened  by  Dr  
Christopher  Webster   for   C9orf72   mRNA   levels   as   measured   by   RT-­qPCR.   From  
this,  three  clones  were  selected  for  further  characterisation:  B2,  B17  and  B12.    
  
To  determine  if  the  C9orf72  gene  in  the  B2,  B17  and  B12  cell  lines  was  successfully  
edited,   I   performed   DNA   sequencing   of   C9orf72   exon   2.   HEK293   cells   are  
pseudotriploid  and  therefore  contain  three  copies  of  the  C9orf72  gene  (Bylund  et  al.,  
2004;;   Lin   et   al.,   2014).   Genomic   DNA   was   extracted   from   the   C9orf72   edited  
CRISPR   lines.  A  PCR  amplifying  C9orf72  exon  2  was  performed  on   the   genomic  
DNA  using  the  Phusion  High-­Fidelity  DNA  polymerase  to  create  a  C9orf72  exon  2  
blunt-­ended   product.   The   PCR   product   was   resolved   on   an   agarose   gel   and   gel  
extracted  and  purified.  The  blunt-­ended  C9orf72  exon  2  product  was  ligated  into  the  
pCR-­Blunt   II-­TOPO   vector   and   transformed   into   XL10-­Gold   Ultracompetent   cells.  
Since  HEK293  cells  are  triploid,  each  pCR-­Blunt  II-­TOPO-­C9orf72  exon  2  construct  
was   hypothesised   to   contain   one   of   three   possible   C9orf72   exon   2   sequences.  
Plasmid   DNA  was   purified   from   bacterial   colonies   and   sequenced   using   the   SP6  
forward   primer   located   in   the   pCR-­Blunt   II-­TOPO   vector   which   would   give   full  
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sequencing  coverage  of  the  C9orf72  exon  2  (Figure  3.1).  We  sequenced  9  colonies  
per  stable  cell  line.  If  we  did  not  detect  an  appropriate  ratio  of  alleles  representing  a  















Figure  3.1.  Cloning  of  CRISPR  edited  C9orf72  exon  2  for  sequencing.  The  C9orf72  exon  
2  was  amplified  from  genomic  DNA  extracted  from  the  C9orf72  knockout  CRISPR  cell  lines  
and  ligated  into  the  pCR-­Blunt  II-­TOPO  vector.  Constructs  were  transformed  into  XL10-­Gold  
Ultracompetent  cells  before  minipreparation  of  plasmid  DNA   for  sequencing  of   the  C9orf72  
exon  2  insert.  
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For   the  B2  CRISPR   line,   nine   colonies  were   successfully   sequenced   (Table   3.1).  
Out   of   the   nine   colonies   sequenced,   5   colonies   exhibited   a   +2/-­4   bp   mutation  
(Figure   3.2),   2   colonies   a   -­10   bp   mutation   (Figure   3.3)   and   2   colonies   a   -­35   bp  
mutation   (Figure   3.4).   This   suggests   all   three   copies   of   C9orf72   in   the   B2   clone  
were  successfully  edited  and  each  had  acquired  a  different   INDEL  mutation.     The  
three  mutant  C9orf72  sequences  were  aligned  with  the  wild-­type  C9orf72  sequence  
and  all  three  mutations  were  found  to  lead  to  a  frameshift   in  the  C9orf72  ORF  and  
coded   for  premature  stop  codons   (Figure  3.2-­3.4).  Therefore,   it  was  hypothesised  
based   on   sequence   that   the   B2   clone   should   have   no   translated  C9orf72   protein  
and  was  a  stable  C9orf72  knockout  cell  line.  
  
    
B2  mutation   Number  of  colonies  with  mutation  




+2/-­4  bp   5   55.5   Yes  
-­10  bp   2   22.2   Yes  
-­35  bp   2   22.2   Yes  
  
Table  3.1.  C9orf72  exon  2  mutations  in  the  B2  CRISPR  line.  Plasmids  from  nine  bacteria  
colonies  were  successfully  sequenced   for   their  C9orf72  exon  2   insert.   In   the  nine  C9orf72  
sequences  returned,  three  INDEL  mutations  recurred:  +2/-­4  bp,  -­10  bp  and  -­35  bp.  All  three  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
             |||||||||||||      ||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CACTTCATAGAGTAA----TGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  476 
               L  H  R  V  M      I  D  *  H  I  *  S  G  K  E  E  Y  G   
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  477   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  536 
             C  I  R  K  D  K  K  M  S  R  R  L  S  *  K  A  Q  R  E  W   
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  537   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  596 




               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  597   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  656 
             C  F  H  L  *  N  H  T  V  F  L  K  K  *  I  *  L  I  Q  Y   
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  657   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  705 
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Figure   3.2.   Sequence   alignment   of   B2   +2/-­4   bp   mutant   with   wild-­type   C9orf72.   The  
sequence  of  wild-­type  C9orf72  exons  2-­5  (Seq_1)   is  aligned  with  the  sequence  of  C9orf72  
exons  2-­5  from  the  B2  +2/-­4  bp  mutant  (Seq_2).  Exon  2  (red),  exon  3  (blue),  exon  4  (green)  
and  exon  5  (orange)  are  shown.  The  translated  amino  acid  sequence  is  shown  above  and  
below   the   sequence   alignment   for   wild-­type   C9orf72   and   B2   C9orf72   respectively.  
Premature  stop  codons  are  labelled  with  an  asterisk  (pink).  The  B2  INDEL  is  highlighted  in  
yellow.  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
             |||||||||||||||||||||||||||||          ||||||||||||||||||||| 
Seq_2  421   CACTTCATAGAGTGTGTGTTGATAGATTA----------TCCGGAAAGGAAGAATATGGA  470 
               L  H  R  V  C  V  D  R  L            S  G  K  E  E  Y  G   
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  471   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  530 
             C  I  R  K  D  K  K  M  S  R  R  L  S  *  K  A  Q  R  E  W   
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  531   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  590 
             K  I  R  V  R  V  L  F  Q  C  L  L  E  K  *  F  L  *  W  N   
 
 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  591   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  650 
             C  F  H  L  *  N  H  T  V  F  L  K  K  *  I  *  L  I  Q  Y   
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  651   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  699 
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Figure   3.3.   Sequence   alignment   of   B2   -­10   bp   mutant   with   wild-­type   C9orf72.   The  
sequence  of  wild-­type  C9orf72  exons  2-­5  (Seq_1)  is  aligned  with  the  sequence  of  C9orf72  
exons  2-­5  from  the  B2  -­10  bp  mutant  (Seq_2).  Exon  2  (red),  exon  3  (blue),  exon  4  (green)  
and  exon  5  (orange)  are  shown.  The  translated  amino  acid  sequence  is  shown  above  and  
below   the   sequence   alignment   for   wild-­type   C9orf72   and   B2   C9orf72   respectively.  
Premature  stop  codons  are  labelled  with  an  asterisk  (pink).  The  B2  INDEL  is  highlighted  in  
yellow.  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
             |                                   |||||||||||||||||||||||| 
Seq_2  421   C-----------------------------------TAATCCGGAAAGGAAGAATATGGA  445 
                                                  N  P  E  R  K  N  M  D  
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  446   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  505 
              A  *  G  K  T  R  K  C  P  E  D  Y  L  R  R  H  R  E  N  G  
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  506   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  565 
              R  S  G  S  E  Y  Y  S  N  A  Y  W  R  S  D  S  C  N  G  T  
 
 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  566   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  625 
              A  F  I  Y  E  I  T  Q  C  S  *  R  N  R  Y  S  *  Y  S  T  
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  626   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  674 
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Figure   3.4.   Sequence   alignment   of   B2   -­35   bp   mutant   with   wild-­type   C9orf72.   The  
sequence  of  wild-­type  C9orf72  exons  2-­5   (Seq_1)   is   aligned  with   the   sequence  of  C9orf72  
exons  2-­5  from  the  B2  -­35  bp  mutant  (Seq_2).  Exon  2  (red),  exon  3  (blue),  exon  4  (green)  and  
exon  5  (orange)  are  shown.  The  translated  amino  acid  sequence  is  shown  above  and  below  
the  sequence  alignment   for  wild-­type  C9orf72  and  B2  C9orf72   respectively.  Premature  stop  
codons  are  labelled  with  an  asterisk  (pink).  The  B2  INDEL  is  highlighted  in  yellow.  
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For  the  B12  CRISPR  line,  fifteen  colonies  were  successfully  sequenced  (Table  3.2).  
Out   of   the   fifteen   colonies   sequenced,   5   colonies   exhibited   a   -­31   bp   mutation  
(Figure  3.5)  and  10  colonies  a  +48  bp  mutation  (Figure  3.6),  suggesting  two  copies  
of   the   C9orf72   gene   had   acquired   the   same   48   bp   insertion   mutation.   The   two  
mutant   C9orf72   sequences   were   aligned   with   the   wild-­type   C9orf72   sequence   to  
determine  whether   the  mutations  created  premature  stop  codons   (Figure  3.5-­3.6).  
The  48  bp  insertion  mutant  introduced  novel  amino  acids  into  the  C9orf72  sequence  
but   did   not   create   a   frameshift   or   premature   stop   codon.   The   -­31   bp   mutant   did  
create  a  premature  stop  codon.  Hence,   it  was  assumed  two  copies  of   the  C9orf72  
gene  could  produce  potentially  functional  C9orf72  protein  and  therefore  the  B12  cell  
line  could  not  be  used  as  a  C9orf72  loss-­of-­function  cell  model.  
  
  
B12  mutation   Number  of  colonies  with  mutation  




-­31  bp   5   33.3   Yes  
+48  bp   10   66.6   No  
  
Table   3.2.   C9orf72   exon   2   mutations   in   the   B12   CRISPR   line.   Plasmids   from   fifteen  
bacteria  colonies  were  successfully  sequenced  for  their  C9orf72  exon  2  insert.  In  the  fifteen  
C9orf72  sequences  returned,  two  INDEL  mutations  recurred:  -­31  bp  and  +48  bp.  Only  the  -­
























   121  
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCtTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  H 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
                                            ||||||||||||||||||||||||||||| 
Seq_2  421   -------------------------------ACATATAATCCGGAAAGGAAGAATATGGA  449 
                                              I  *  S  G  K  E  E  Y  G   
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  450   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  509 
             C  I  R  K  D  K  K  M  S  R  R  L  S  *  K  A  Q  R  E  W   
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  510   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  569 
             K  I  R  V  R  V  L  F  Q  C  L  L  E  K  *  F  L  *  W  N   
 
 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  570   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  629 
             C  F  H  L  *  N  H  T  V  F  L  K  K  *  I  *  L  I  Q  Y   
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  630   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  678 
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Figure   3.5.   Sequence   alignment   of   B12   -­31   bp   mutant   with   wild-­type   C9orf72.   The  
sequence   of   wild-­type   C9orf72   exons   2-­5   (Seq_1)   is   aligned   with   the   sequence   of   C9orf72  
exons  2-­5  from  the  B12  -­31  bp  mutant  (Seq_2).  Exon  2  (red),  exon  3  (blue),  exon  4  (green)  and  
exon  5  (orange)  are  shown.  The  translated  amino  acid  sequence  is  shown  above  and  below  the  
sequence   alignment   for   wild-­type   C9orf72   and   B12   C9orf72   respectively.   Premature   stop  
codons  are  labelled  with  an  asterisk  (pink).  The  B12  INDEL  is  highlighted  in  yellow.  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R                   
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCC------------------  462 
             ||||||||||||||||||||||||||||||||||||||||||                   
Seq_2  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCATGAAGTTGTTGATAGAT  480 
               L  H  R  V  C  V  D  R  L  T  H  I  I  H  E  V  V  D  R  L 
 
 
                                             K  G  R  I  W  M  H  K  E  R 
Seq_1  463   ------------------------------GGAAAGGAAGAATATGGATGCATAAGGAAA  492 
                                           |||||||||||||||||||||||||||||| 
Seq_2  481   TAACACATATAATCCATGAAGTTGATATCCGGAAAGGAAGAATATGGATGCATAAGGAAA  540 
               T  H  I  I  H  E  V  D  I  R  K  G  R  I  W  M  H  K  E  R 
 
 
               Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E  D  Q  G  Q 
Seq_1  493   GACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGGAAGATCAGGGTC  552 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   GACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGGAAGATCAGGGTC  600 
               Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E  D  Q  G  Q 
 
 
               S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L  L  S  S  M 
Seq_1  553   AGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAACTGCTTTCATCTA  612 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   AGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAACTGCTTTCATCTA  660 
               S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L  L  S  S  M 
 
 
               K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L  N  D  D  D 
Seq_1  613   TGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTACTCAATGATGATG  672 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   TGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTACTCAATGATGATG  720 
               K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L  N  D  D  D 
 
 
               I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  673   ATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||| 
Seq_2  721   ATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  757 
               I  G  D  S  C  H  E  G  F  L  L  X   
 
Key:  
Exon  2                          INDEL  
Exon  3                          *  premature  stop  codon  
Exon  4  
Exon  5  




For   the  B17  CRISPR  line,  nine  colonies  were  successfully  sequenced  (Table  3.3).  
Out  of  the  nine  colonies  sequenced,  3  colonies  exhibited  a  -­23  bp  mutation  (Figure  
3.7)   and   6   colonies   a   -­27   bp  mutation   (Figure   3.8),   suggesting   two   copies   of   the  
C9orf72   gene   had   acquired   the   same   27   bp   deletion   mutation.   The   two   mutant  
C9orf72  sequences  were  aligned  with  the  wild-­type  C9orf72  sequence  to  determine  
whether   the  mutations  created  premature  stop  codons  (Figure  3.7-­3.8).  The  27  bp  
deletion  mutant  removed  amino  acids  from  the  C9orf72  sequence  but  did  not  create  
a   frameshift   or   premature   stop   codon.   The   -­23   bp  mutant   did   create   a   premature  
stop   codon.   Two   copies   of   the  C9orf72   gene   could   produce   potentially   functional  
C9orf72  protein  and  therefore  the  B17  cell  line  could  not  be  used  as  a  C9orf72  loss-­
of-­function  cell  model.  
  
  
B17  mutation   Number  of  colonies  with  mutation  




-­23  bp   3   33.3   Yes  
-­27  bp   6   66.6   No  
  
Table   3.3.   C9orf72   exon   2   mutations   in   the   B17   CRISPR   line.   Plasmids   from   nine  
bacteria  colonies  were  successfully  sequenced   for   their  C9orf72  exon  2   insert.   In   the  nine  
C9orf72  sequences  returned,  two  INDEL  mutations  recurred:  -­23  bp  and  -­27  bp.  Only  the  -­








Figure   3.6.   Sequence   alignment   of   B12   +48   bp   mutant   with   wild-­type   C9orf72.   The  
sequence  of  wild-­type  C9orf72  exons  2-­5  (Seq_1)   is  aligned  with  the  sequence  of  C9orf72  
exons  2-­5  from  the  B12  +48  bp  mutant  (Seq_2).  Exon  2  (red),  exon  3  (blue),  exon  4  (green)  
and  exon  5  (orange)  are  shown.  The  translated  amino  acid  sequence  is  shown  above  and  
below   the   sequence   alignment   for   wild-­type   C9orf72   and   B12   C9orf72   respectively.  
Premature  stop  codons  are  labelled  with  an  asterisk  (pink).  The  B12  INDEL  is  highlighted  in  
yellow.  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
             ||||||||||||||||||||||                       ||||||||||||||| 
Seq_2  421   CACTTCATAGAGTGTGTGTTGA-----------------------AAGGAAGAATATGGA  457 
               L  H  R  V  C  V  E                         R  K  N  M  D  
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  458   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  517 
              A  *  G  K  T  R  K  C  P  E  D  Y  L  R  R  H  R  E  N  G  
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  518   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  577 
              R  S  G  S  E  Y  Y  S  N  A  Y  W  R  S  D  S  C  N  G  T  
 
 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  578   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  637 
              A  F  I  Y  E  I  T  Q  C  S  *  R  N  R  Y  S  *  Y  S  T  
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  638   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  686 
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Figure   3.7.   Sequence   alignment   of   B17   -­23   bp   mutant   with   wild-­type   C9orf72.   The  
sequence  of  wild-­type  C9orf72  exons  2-­5  (Seq_1)   is  aligned  with  the  sequence  of  C9orf72  
exons  2-­5  from  the  B17  -­23  bp  mutant  (Seq_2).  Exon  2  (red),  exon  3  (blue),  exon  4  (green)  
and  exon  5  (orange)  are  shown.  The  translated  amino  acid  sequence  is  shown  above  and  
below   the   sequence   alignment   for   wild-­type   C9orf72   and   B17   C9orf72   respectively.  
Premature  stop  codons  are  labelled  with  an  asterisk  (pink).  The  B17  INDEL  is  highlighted  in  
yellow.  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
             |||||||||                           |||||||||||||||||||||||| 
Seq_2  421   CACTTCATA---------------------------TAATCCGGAAAGGAAGAATATGGA  453 
               L  H  I                             I  R  K  G  R  I  W  M 
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  454   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  513 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  514   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  573 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
 
 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  574   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  633 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  634   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  682 
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The  sequencing  results  suggested  clone  B2  was  the  only  CRISPR  line  to  contain  a  
mutation  in  all  three  C9orf72  alleles  predicted  to  generate  a  premature  stop  codon.  
Both   B12   and   B17   were   predicted   to   have   two   copies   of   the   C9orf72   gene   from  
which   a  mutant   C9orf72   protein   could   be   translated.   To   investigate   this,   C9orf72  
mRNA   and   protein   levels   were   measured   in   the   CRISPR   cell   lines.   To   quantify  
C9orf72  mRNA  levels,  RNA  was  extracted  from  cells  and  an  RT-­qPCR  performed,  
data  shown  in  figure  3.9A.  Primers  used  in  the  qPCR  targeted  C9orf72  exon  4  and  
exon  6  and  therefore  were  C9orf72  long  isoform  specific.  B17  C9orf72  mRNA  levels  
were  comparable  to  those  seen  in  the  HEK293  control.  B2  was  the  only  clone  that  
appeared   to   have   reduced   C9orf72   mRNA,   with   a   50%   reduction.   Interestingly,  
C9orf72   mRNA   in   the   B12   CRISPR   line   was   measured   at   approximately   10-­fold  
higher   than   in   control   HEK293   cells   (Figure   3.9A).   To   investigate   the   effect   on  
C9orf72   protein   level   in   the   CRISPR   lines,   whole   cell   lysate   was   prepared   and  
subjected  to  SDS-­PAGE  electrophoresis.  Protein  was  transferred  onto  nitrocellulose  
membrane   and   blotted   for   C9orf72   using   an   anti-­C9orf72   antibody   (Proteintech,  
25757-­1-­AP).  The  C9orf72  protein  was  detected  with  an  observed  size  of  50  kDa  in  
the   HEK293   cell   control,   but   was   absent   in   the   B17,   B2   and   B12   CRISPR   lines  
(Figure  3.9B).  A  smaller,  unknown  37  kDa  protein  was  detected   in   the  B12  clone,  
labelled  with  an  asterisk.  The  anti-­C9orf72  antibody,  which  reportedly  recognises  an  
epitope  within  the  C9orf72  N-­terminal,  did  not  detect  a  C9orf72  short  protein  isoform  
in   any   of   the   clones,   which   has   a   predicted   molecular   weight   of   25   kDa.   The  
immunoblot  suggests  all  three  clones  lack  the  full   length  C9orf72  long  protein.  The  
B2   clone   contained   three   predicted   loss-­of-­function   mutations   and   had   both   an  
observed   knockdown   in   both   C9orf72   mRNA   and   protein.   Taken   together,   these  
results  strongly  suggest  this  cell  line  was  a  loss-­of-­function  C9orf72  mutant  and  was  
the   only   clone   taken   forward   for   future   use   in   experiments   as   a   stable   C9orf72  
knockout  cell  model.    
  
Figure  3.8.   Sequence  alignment  of  B17   -­27  bp  mutant  with  wild-­type  C9orf72.   The  
sequence  of  wild-­type  C9orf72  exons  2-­5  (Seq_1)  is  aligned  with  the  sequence  of  C9orf72  
exons   2-­5   from   the   B17   -­27   bp   mutant   (Seq_2).   Exon   2   (red),   exon   3   (blue),   exon   4  
(green)  and  exon  5   (orange)  are   shown.   The   translated  amino  acid   sequence   is   shown  
above   and   below   the   sequence   alignment   for   wild-­type   C9orf72   and   B17   C9orf72  
respectively.  Premature  stop  codons  are  labelled  with  an  asterisk  (pink).  The  B17  INDEL  
is  highlighted  in  yellow.  
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3.2.2   Characterisation  of  C9orf72  targeting  siRNAs  
  
The   stability   of   the  C9orf72   knockout   in   the  B2  CRISPR   line   is   useful   for   probing  
long-­term  effects   of   a   loss   of   the  C9orf72   protein.  However,   there   is   the   potential  
that   the   cells   compensate   for   the   loss   of   the   C9orf72   protein   by   upregulation   of  
other   proteins   and/or   pathways.   Therefore,   throughout   the   project   transient  
knockdown   of   C9orf72   in   cell   lines   was   also   performed   to   look   at   more   acute  
effects.  For  these  knockdowns,  two  C9orf72  siRNAs  were  used:  C9orf72  siRNA  #2  
and  C9orf72  siRNA  #D  (Webster  et  al.,  2016).  These  siRNA  were  used  in  a  pooled  
1:1  mix  for  C9orf72  knockdown,  unless  otherwise  stated  as  used  individually.  Until  
recently,   commercially   available   anti-­C9orf72   antibodies   were   nonspecific   and  
unable   to   detect   the   low   levels   of   endogenous   C9orf72   in   cells.   Hence,   after  
C9orf72   siRNA   transfections,   C9orf72   knockdown   was   confirmed   by   measuring  
C9orf72  mRNA   levels  by  RT-­qPCR,  and   is   the   technique   included   throughout   this  
project.  However,  a  new  rabbit  anti-­C9orf72  antibody  was   recently  made  available  
which  can  detect  endogenous  C9orf72  long  protein.  mRNA  can  be  a  good  indicator  
of  knockdown  but   it  does  not  directly   infer  the  protein   level  (Schwanhäusser  et  al.,  
A   B  
Figure   3.9.   C9orf72   mRNA   and   protein   levels   in   C9orf72   CRISPR   lines.   (A)   Relative  
C9orf72   mRNA   levels   as  measured   by  RT-­qPCR.  Data   represent  mean   ±   SEM;;  One-­way  
ANOVA  with  Dunnett’s  test,  ****  p  ≤  0.0001.  n=3  triplicates  from  one  experiment.  (B)  C9orf72  
immunoblot   of   whole   cell   lysate   from  C9orf72  CRISPR   lines.   Blots  were   probed  with   anti-­
C9orf72  (25757-­1-­AP)  and  anti-­GAPDH.  Asterisk  notes  smaller,  unknown  protein  of   interest  
at  37  kDa  present  in  the  B12  cell  line.  
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2011).   Therefore,   the   new   anti-­C9orf72   antibody  was   used   to   detect   endogenous  
C9orf72  levels  following  C9orf72  siRNA  transfection  for  comparison  with  measured  
C9orf72  mRNA  levels  by  RT-­qPCR.  HEK293  cells  were  transfected  with  either  non-­
targeting  control  (NTC),  C9orf72  #2,  C9orf72  #D,  or  C9orf72  pool  siRNA.  To  look  at  
C9orf72  mRNA   levels,   RNA  was   extracted   and   an   RT-­qPCR   performed.   C9orf72  
mRNA   was   reduced   relative   to   the   NTC   by   approximately   40%   for   both   C9orf72  
siRNAs  when  used   individually,  and  approximately  50%  for  C9orf72  siRNA  pooled  
(Figure   3.10A).   For   C9orf72   protein   levels,   whole   cell   lysates   were   prepared   and  
subjected   to   SDS-­PAGE   and   immunoblot   using   the   anti-­C9orf72   antibody.   The  
endogenous  C9orf72   long   protein   was   detected   in   the  NTC   and  was   significantly  
decreased   in   all   C9orf72   siRNA   transfected   samples   (Figure   3.10B).   The   level   of  
reduction   of   the   C9orf72   protein   after   C9orf72   siRNA   transfection   appeared  
significantly   greater   than   the   apparent   40-­50%   reduction   in   C9orf72   mRNA.  
Consequently,   the   C9orf72   mRNA   levels   measured   throughout   the   project   as  

















A   B  
Figure  3.10.  C9orf72  mRNA  and  protein  levels  following  C9orf72  siRNA  transfection.  
(A)  HEK293  cells  were  transfected  with  NTC,  C9orf72  #2,  C9orf72  #D  or  C9orf72  pooled  
siRNA.  Relative  C9orf72  mRNA  levels  were  measured  by  RT-­qPCR.  Data  represent  mean  
±  SEM;;  One-­way  ANOVA  with  Dunnett’s  test,  *  p  ≤  0.05,  **  p  ≤  0.01.  n=3  triplicates  from  
one  experiment.   (B)  C9orf72   immunoblot  of  HEK293  whole  cell   lysate   following  C9orf72  
siRNA  transfection.  Blots  were  probed  with  anti-­C9orf72  (25757-­1-­AP)  and  anti-­GAPDH.  
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3.2.3   Generation  of  siRNA  resistant  myc-­C9orf72  constructs  
  
One  method   of   reducing  C9orf72   protein   levels   in   cell   lines  was   through  C9orf72  
siRNA   transfection.   After   knockdown,   rescue   experiments   were   performed   to  
confirm   specificity.   The   aim  was   to   reintroduce  C9orf72   into   cells.   The   constructs  
frequently   used   for  C9orf72  overexpression  were  pRK5-­myc-­C9orf72S  and  pRK5-­
myc-­C9orf72L   which   expressed   N-­terminal   myc-­tagged   C9orf72   short   and   long  
protein  under  a  CMV  promoter   respectively.   It  was  hypothesised   that   the  C9orf72  
siRNA   in   cells   would   target   the   transfected   myc-­C9orf72   and   prevent  
overexpression.   Thus,   site-­directed   mutagenesis   was   performed   on   the   myc-­
C9orf72  constructs  to  mutate  the  C9orf72  #2  and  #D  siRNA  binding  sites  to  provide  
siRNA  resistance  and  allow  for  use   in  rescue  experiments.  The  C9orf72  #2  siRNA  
binding   site   was   located   within   the   C9orf72   exon   2   and   the   C9orf72   #D   siRNA  
binding  site  spanned  the  junction  between  exon  3  and  exon  4.  Thymine  nucleotides  
were   selected   for  mutagenesis   to   cytosines,  with   care   taken   to   ensure   the   amino  
acid   sequence   was   unchanged.   Both   myc-­C9orf72   short   and   long   constructs  
underwent  a  first  round  of  site-­directed  mutagenesis  to  generate  two  T>C  mutations  
within   the  C9orf72   #2   siRNA  binding   site.  After  mutagenesis,   the   constructs  were  
transformed   into   XL10-­Gold   Ultracompetent   cells   and   the   plasmid   purified.   The  
plasmid   was   sequenced   using   the   SP6   primer   to   confirm   successful   mutation.  
Successfully   mutated   plasmids   underwent   a   second   round   of   site-­directed  
mutagenesis  to  generate  four  T>C  mutations  within  the  C9orf72  #D  siRNA  binding  
site.   As   before,   constructs   were   transformed   into   XL10-­Gold  Ultracompetent   cells  
and  plasmids  miniprepped.  The  constructs  were  sequenced  with  the  SP6  primer  to  
confirm  both   siRNA  binding   sites  were  mutated.  The   final   sequence  of   the   siRNA  
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               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
Seq_1  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATATCTCCGGAGCATTTGGATAATGTGACAGTTGGAATGCAGTGATGTCGACTCTTTGCC  60 
               I  S  G  A  F  G  *  C  D  S  W  N  A  V  M  S  T  L  C  P 
 
 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
Seq_1  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CACCGCCATCTCCAGCTGTTGCCAAGACAGAGATTGCTTTAAGTGGCAAATCACCTTTAT  120 
               P  P  S  P  A  V  A  K  T  E  I  A  L  S  G  K  S  P  L  L 
 
 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
Seq_1  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TAGCAGCTACTTTTGCTTACTGGGACAATATTCTTGGTCCTAGAGTAAGGCACATTTGGG  180 
               A  A  T  F  A  Y  W  D  N  I  L  G  P  R  V  R  H  I  W  A 
 
 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
Seq_1  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   CTCCAAAGACAGAACAGGTACTTCTCAGTGATGGAGAAATAACTTTTCTTGCCAACCACA  240 
               P  K  T  E  Q  V  L  L  S  D  G  E  I  T  F  L  A  N  H  T 
 
 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
Seq_1  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCTATAGATGTAAAGTTTTTTG  300 
             ||||||||||||||||||||||||||||||||||||||||#|||||#||||||||||||| 
Seq_2  241   CTCTAAATGGAGAAATCCTTCGAAATGCAGAGAGTGGTGCCATAGACGTAAAGTTTTTTG  300 
               L  N  G  E  I  L  R  N  A  E  S  G  A  I  D  V  K  F  F  V 
 
 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
Seq_1  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TCTTGTCTGAAAAGGGAGTGATTATTGTTTCATTAATCTTTGATGGAAACTGGAATGGGG  360 
               L  S  E  K  G  V  I  I  V  S  L  I  F  D  G  N  W  N  G  D 
 
 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
Seq_1  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ATCGCAGCACATATGGACTATCAATTATACTTCCACAGACAGAACTTAGTTTCTACCTCC  420 
               R  S  T  Y  G  L  S  I  I  L  P  Q  T  E  L  S  F  Y  L  P 
 
 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
Seq_1  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CACTTCATAGAGTGTGTGTTGATAGATTAACACATATAATCCGGAAAGGAAGAATATGGA  480 
               L  H  R  V  C  V  D  R  L  T  H  I  I  R  K  G  R  I  W  M 
 
 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
Seq_1  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   TGCATAAGGAAAGACAAGAAAATGTCCAGAAGATTATCTTAGAAGGCACAGAGAGAATGG  540 
               H  K  E  R  Q  E  N  V  Q  K  I  I  L  E  G  T  E  R  M  E 
 
 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
Seq_1  541   AAGATCAGGGTCAGAGTATTATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
             ||||#|||||#|||||#||#|||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   AAGACCAGGGCCAGAGCATCATTCCAATGCTTACTGGAGAAGTGATTCCTGTAATGGAAC  600 
               D  Q  G  Q  S  I  I  P  M  L  T  G  E  V  I  P  V  M  E  L 
 
 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
Seq_1  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   TGCTTTCATCTATGAAATCACACAGTGTTCCTGAAGAAATAGATATAGCTGATACAGTAC  660 
               L  S  S  M  K  S  H  S  V  P  E  E  I  D  I  A  D  T  V  L 
 
 
               N  D  D  D  I  G  D  S  C  H  E  G  F  L  L  X   
Seq_1  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   TCAATGATGATGATATTGGTGACAGCTGTCATGAAGGCTTTCTTCTCAA  709 




C9orf72  #2  siRNA  binding  site  
C9orf72  #D  siRNA  binding  site  
Mutated  T>C  base    
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The   sequencing   results   confirmed   both   siRNA   binding   sites   in   the   myc-­C9orf72  
constructs   were   successfully   mutated.   To   test   their   functionality   for   rescue  
experiments,   the   constructs   were   expressed   in   cells   after   C9orf72   siRNA  
transfection   and   compared   against   non-­siRNA   resistant   myc-­C9orf72   expression.  
HEK293  cells  were  transfected  with  NTC,  C9orf72  #2,  C9orf72  #D  or  C9orf72  pool  
siRNA.  72  hours  post  knockdown,  cells  were  transfected  with  pCI-­neo  (empty  vector  
control),   myc-­C9orf72S,   myc-­C9orf72S   siRNA   resistant,   myc-­C9orf72L   or   myc-­
C9orf72L   siRNA   resistant   constructs.   24   hours   post   overexpression,   whole   cell  
lysates  were  prepared  and  subjected  to  SDS-­PAGE  and  immunoblot  with  anti-­myc  
antibody  to  probe  myc-­C9orf72  expression   levels.   Interestingly,  myc-­C9orf72S  and  
myc-­C9orf72L   were   detected   in   C9orf72   siRNA   treated   samples,   but   to   slightly  
lower  levels  than  in  the  NTC  sample,  suggesting  there  was  only  a  small  effect  of  the  
siRNA  on  plasmid  expression  (Figure  3.12A).  This  was  likely  due  to  the  strength  of  
the   expression   from   the   CMV   promoter.   Both   myc-­C9orf72S   and   myc-­C9orf72L  
siRNA  resistant  constructs  appeared  to  express  myc-­C9orf72  to  a  higher  level  than  
the   non-­siRNA   resistant   constructs.   Importantly,   the   levels   of   the   myc-­C9orf72  
siRNA   resistant   proteins   were   not   reduced   in   C9orf72   siRNA   treated   samples  
versus   NTC,   suggesting   they   were   resistant   to   siRNA   (Figure   3.12A).   C9orf72  
knockdown   in   the   experiment   was   confirmed   to   be   between   40-­50%   by   RNA  
extractions   followed   by   RT-­qPCR   (Figure   3.12B).   The   siRNA   resistant   myc-­
C9orf72S   and   myc-­C9orf72L   constructs   were   therefore   taken   forward   for   use   in  







Figure   3.11.   Sequence   alignment   of   siRNA   resistant   C9orf72   with   wild-­type   C9orf72.  
The   sequence   of   wild-­type   C9orf72   exons   2-­5   (Seq_1)   is   aligned   with   the   sequence   of  
C9orf72   exons   2-­5   from   the   siRNA   resistant   mutant   (Seq_2).   The   translated   amino   acid  
sequence   is   shown   above   and   below   the   sequence   alignment   for   wild-­type   C9orf72   and  
siRNA   resistant   C9orf72   respectively.   The   C9orf72   #2   binding   site   is   shown   in   blue.   The  
C9orf72  #D  binding  site   is  shown   in  purple.  Site-­directed  mutagenesis  was  performed  within  
these   binding   sites   to   introduce   a   T>C   base   pair   change   (red).   Base   pair   mismatches   are  
shown  with  a  #.  







































Figure  3.12.   Expression  of  myc-­C9orf72  siRNA   resistant  constructs.   (A)  myc-­C9orf72  
and  myc-­C9orf72  siRNA  resistant  constructs  were  expressed  in  HEK293  cells  following  NTC  
or  C9orf72  siRNA  transfection.  Anti-­myc  immunoblot  of  whole  cell  lysate  shows  myc-­C9orf72  
protein   levels.   Blots   were   probed   with   anti-­myc   (9B11)   and   anti-­GAPDH.   (B)   C9orf72  
knockdown  was   confirmed   by  RT-­qPCR.  Data   represent   mean   ±   SEM;;   One-­way   ANOVA  
with  Dunnett’s  test,  *  p  ≤  0.05,  **  p  ≤  0.01.  n=3  triplicates  from  one  experiment.  
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3.2.4   Expression  of  tagged-­coilin  proteins  
  
To  establish  a  function  for  C9orf72,  it’s  relationship  with  coilin  was  examined.  Coilin  
is   a   nuclear   protein   that   localises   to   Cajal   bodies,   which   are   involved   in   the  
assembly  of  the  cells  splicing  machinery,  where  it  acts  as  a  scaffolding  protein.  The  
interaction   between   C9orf72   and   coilin   is   described   in   Chapter   4   and   the  
involvement   of  C9orf72   in  Cajal   bodies   and   splicing   is   investigated   in  Chapters   5  
and  6  respectively.  To  investigate  the  behaviour  and  relationship  between  coilin  and  
C9orf72   in   cells,   a   GFP-­coilin   construct   was   obtained   for   coilin   overexpression.  
Coilin  was  subcloned  from  the  pEGFP-­C3  backbone  vector   into  pCI-­neo-­myc,  pCI-­
neo-­FLAG  and  pCI-­neo-­mCherry  vectors  to  allow  for  a  selection  of  different  tagged-­
coilin   proteins   for   expression   experiments   and   sequenced   to   confirm   the   coilin  
protein  sequence  had  not  mutated  during  the  subcloning  process.  To  test  for  correct  
expression,   the   constructs   were   transfected   into   HEK293   cells   and   analysed   by  
western  blot  and   immunofluorescence.  For   immunoblot,  HEK293  cells  were  either  
non-­transfected  or   transfected  with  GFP-­,  myc-­,  FLAG-­,  or  mCherry-­coilin.     Whole  
cell   lysates   were   prepared   and   subjected   to   SDS-­PAGE   electrophoresis   and  
proteins   transferred   to   nitrocellulose  membrane.  The  blot  was   cut   such   that  GFP-­
coilin,   myc-­coilin,   FLAG-­coilin   and   mCherry-­coilin   samples   were   separate   and  
received   anti-­GFP,   anti-­myc,   anti-­FLAG   and   anti-­mCherry   antibodies   respectively.  
All   antibodies   detected   their   respective   tagged-­coilin   protein   at   correct   molecular  
weights   which   were   absent   in   non-­transfected   samples,   suggesting   each   coilin  
protein  had  a   functional   tag.  A  second   immunoblot  was  performed  on  all   samples  
using   an  anti-­coilin   antibody.   The  antibody   detected   endogenous   coilin   in   all   non-­
transfected   samples   and   the   overexpression   of  GFP-­,  myc-­,   FLAG-­   and  mCherry  
coilin  (Figure  3.13).  Together  these  blots  suggest  the  tagged-­coilin  constructs  were  



























The   immunoblots   confirmed   the   tagged-­coilin   proteins   of   the   expected   molecular  
weight   were   expressed.   As   mentioned,   coilin   localises   strongly   to   Cajal   bodies  
which   appear   as   bright   nuclear   spots   (Cioce   and   Lamond,   2005).   To   investigate  
correct   localisation   of   the   tagged-­coilin,   an   immunocytochemistry   experiment   was  
performed.  HEK293  cells  were  transfected  with  GFP-­coilin,  myc-­coilin,  FLAG-­coilin  
or  mCherry-­coilin.   Cells   were   fixed   and   immunostained   using   anti-­GFP,   anti-­myc,  
anti-­FLAG  and  anti-­mCherry  antibodies  respectively.  All  tagged-­coilin  proteins  were  
successfully   detected   with   their   respective   antibodies   (Figure   3.14).   However,   all  
were   expressed   diffusively   throughout   the   nucleus   and   distinct   Cajal   bodies  were  
not   detected,   suggesting   these   proteins   were   unable   to   localise   to   Cajal   bodies.  
Therefore,   these   constructs   were   unsuitable   for   experiments   where   Cajal   bodies  










Figure  3.13.  Tagged-­coilin  constructs  expressed  in  HEK293  cells.  GFP-­,  myc-­,  FLAG-­
,   and   mCherry-­coilin   constructs   were   transfected   into   HEK293   cells   and   analysed   for  
correct   tagged-­protein   expression   by   immunoblot   with   anti-­GFP,   anti-­myc   (9B11),   anti-­
FLAG  and  anti-­mCherry  antibodies  respectively.  Immunoblot  with  anti-­coilin  was  included  
as  control.  



















3.2.5   Optimisation  of  an  anti-­coilin  antibody  for  Cajal  body  
immunostaining  
  
Overexpressed   tagged-­coilin   localised   to   the   nucleus   but   not   Cajal   bodies,  
suggesting  endogenous  coilin  immunostaining  should  be  used  as  a  marker  of  CBs.  
Consequently,  a  rabbit  anti-­coilin  antibody  was  acquired  and  tested  in  HEK293  cells  
for  Cajal  body  detection.  Cells  were  fixed  and  immunostained  using  the  antibody  at  
dilutions  ranging  from  1  in  50  to  1  in  1000.  All  dilutions  immunostained  Cajal  bodies,  
imaged  as  bright  green  foci  (Figure  3.15).  At  lower  dilutions,  there  was  cytoplasmic  
signal,  nucleoplasmic  coilin  staining  and  Cajal  body  staining.  The  1  in  1000  dilution  
effectively  detected  coilin   localised   in  CBs  and   therefore   this  dilution  was  selected  
for  use  in  future  experiments.    
Figure  3.14.  Tagged-­coilin  localises  in  the  nucleus  but  not  Cajal  bodies.  GFP-­,  myc-­,  
FLAG-­,   and  mCherry-­coilin   constructs  were   transfected   into  HEK293  cells   and  analysed  
for  correct  tagged-­protein  expression  by  immunostaining  with  anti-­GFP,  anti-­myc  (9B11),  
anti-­FLAG  and  anti-­mCherry  respectively  (green).  Scale  bar  =  10  µm.  
















































Figure   3.15.   Optimisation   of   a   rabbit   anti-­coilin   antibody   for   Cajal   body  
immunostaining.   HEK293   cells   were   fixed   and   immunostained   using   a   rabbit   anti-­coilin  
antibody  at  varying  dilutions  for  Cajal  body  (green  foci)  visualisation.  Scale  bar  =  10  µm.  
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3.2.6   Optimisation  of  coilin  siRNAs  
  
For  coilin  knockdown,  siRNA  transfections  were  used.  Three  commercially-­available  
coilin-­targeting   siRNAs   were   purchased   and   optimised   to   determine   which  
combination  of  siRNAs  produced  the  most  effective  knockdown  of  both  coilin  protein  
and   mRNA.   HEK293   cells   were   transfected   with   NTC   siRNA   as   a   control.   Cells  
were   also   transfected   with   individual   coilin   1,   2   and   3   siRNA   and   pooled  
combinations   thereof.   To   probe   coilin   protein   knockdown,   cell   lysates   were  
subjected   to   SDS-­PAGE   and   immunoblotted   with   anti-­coilin   antibody.   All   coilin  
siRNAs   reduced   coilin   protein   levels   (Figure   3.16A).   Relative   coilin   protein   levels  
were  quantified  by  normalisation   to   the  GAPDH   loading  control  and  are  presented  
relative  to  the  NTC  (Figure  3.16B).  Individually,  the  coilin  1  and  3  siRNAs  were  most  
effective   for   coilin   protein   knockdown,   and   siRNAs   1+3   and   2+3   were   the   best  
pooled   combinations.   An   RT-­qPCR   was   also   performed   on   RNA   extracted   from  
siRNA   transfected   cells   to   look   at   coilin   mRNA   levels.   In   agreement   with   the  
immunoblot,  all  siRNAs  decreased  coilin  mRNA  levels,  and  pooled  siRNAs  1+3  and  
2+3  were   best   (Figure   3.16C).   The   pooled   combination   of   coilin   siRNAs   1   and   3  
effectively  knocked  down  both  coilin  mRNA  and  protein  and  therefore  was  selected  
as   the   combination   for   future   coilin   knockdowns.   To   determine   if   the   pooled  
combination   of   coilin   siRNAs   1+3   caused   Cajal   body   loss,   HEK293   cells   were  
transfected   with   either   NTC   or   coilin   1+3   siRNA.   Cells   were   fixed   and  
immunostained  using  an  anti-­coilin  antibody  to  mark  Cajal  bodies.    Cells  transfected  
with  the  pooled  coilin  siRNA  had  no  apparent  nuclear  CBs,  which  were  present  in  all  
















































A   B  
C   D  
Figure   3.16.   Optimisation   of   coilin   siRNA.   (A)   Anti-­coilin   immunoblot   of   HEK293   whole   cell  
lysates   following   transfection   of   individual   and   pooled   combinations   of   coilin   #1,   #2   and   #3  
siRNAs.   Blots   were   probed   with   anti-­coilin   and   anti-­GAPDH.   (B)   Relative   coilin   protein   levels  
quantified   from   (A).  Coilin   protein  was  normalised   to  GAPDH  and   is   shown   relative   to  NTC.   (C)  
Relative  coilin  mRNA  levels  as  measured  by  RT-­qPCR.  All  data  represent  mean  ±  SEM;;  One-­way  
ANOVA  with  Dunnett’s  test,  *  p  ≤  0.05,  **  p  ≤  0.01,  ***  p  ≤  0.001,  ****  p  ≤  0.0001.  n=3  experiments.  
(D)  HEK293  cells  transfected  with  NTC  or  Coilin  1+3  pooled  siRNA  and  immunostained  with  anti-­
coilin  (green).  Scale  bar  =  10  µm.  
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3.3   Discussion  
  
The  aim  of   this  chapter  was   to  describe   the  process  of  generating  and  optimising  
tools   utilised   throughout   the   project.   This   included   characterising   a   C9orf72  
knockout  CRISPR  cell   line,  optimising  new  siRNAs  and  antibodies  and  generating  
siRNA   resistant   protein   constructs.   The   C9orf72   knockout   CRISPR   line   was  
generated  to  investigate  the  effect  of  C9orf72  loss  of  protein  in  a  stable  model  and  
to  compliment   transient  knockdown  experiments.  Exon  2  of   the  C9orf72  gene  was  
targeted   for  mutation  using  CRISPR/Cas9  nickase   technology,  and   three  cell   lines  
generated   from   this   were   characterised   for   loss   of   C9orf72   in   three   ways:  
sequencing   of   the  mutation,  measuring   C9orf72  mRNA   levels   and   immunoblot   of  
the   C9orf72   protein.   The   B2   clone   had   INDEL   mutations   in   each   copy   of   the  
C9orf72  gene  which  were  predicted  to  lead  to  premature  stop  codons,  the  C9orf72  
mRNA   showed   a   50%   reduction   and   an   anti-­C9orf72   antibody   did   not   detect  
C9orf72   protein.   Newly   transcribed   mRNA   may   not   have   been   targeted   for  
nonsense-­mediated   decay   at   the   time   of   RNA   extraction,   explaining   the   C9orf72  
mRNA   levels.   It   is   unlikely,   with   the   number   of   premature   stop   codons   found  
downstream  of   the   INDELs,   to   translate   into   full-­length  protein.  We  were   therefore  
confident  in  implementing  B2  as  a  new  C9orf72  knockout  cell  line.  
  
The  B17  and  B12  clones  however,  showed  inconsistencies  across  their  results.  B17  
was  found  to  have  two  mutations  in  the  C9orf72  gene,  a  23  bp  and  27  bp  deletion.  
The  27  bp  deletion  was  found  twice  as  often  than  the  23  bp  deletion,  hence  it  was  
probable  that  two  copies  of   the  C9orf72  gene  had  both  acquired  the  same  INDEL.  
The   -­27   bp   mutant   caused   the   deletion   of   nine   amino   acids   from   the   C9orf72  
protein,  but  did  not  lead  to  a  frameshift  in  the  ORF.  Therefore,  it  was  assumed  the  
B17   line   had   two   copies   of   the   C9orf72   gene   that   could   be   transcribed   and  
translated  to  produce  a  C9orf72  mutant  protein  lacking  amino  acids  129-­138,  which  
are   located  within   the  N-­terminal   longin  domain.  C9orf72  mRNA   levels   in   the  B17  
clone   were   comparable   with   the   HEK293   control,   as   in-­frame   mRNA   transcripts  
could   still   be   generated   from   two   copies   of   the   C9orf72   gene.   Interestingly,   the  
immunoblot  of  the  B17  clone  did  not  detect  C9orf72  protein,  even  though  we  would  
expect   a   9   amino   acid   deletion.   The   epitope   of   the   anti-­C9orf72   antibody   is  
described  as  the  N-­terminal  of  C9orf72.  Therefore,  if  the  deleted  amino  acids  in  the  
B17  -­27  bp  INDEL  mutant,  specifically  the  VDRLTHI  residues,  form  all  or  part  of  the  
anti-­C9orf72  epitope,  the  protein  would  be  undetectable  by  immunoblot.  
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Similarly,   the  B12  clone  had  a  +48  bp  mutation   that  occurred   in   two  copies  of   the  
C9orf72  gene  which  did  not  produce  a  premature  stop  codon  mutation  but  led  to  the  
insertion  of  16  novel  amino  acids  into  the  C9orf72  sequence.  It  may  be  possible  that  
the   INDEL  mutation   stabilised,   or   inhibited   destabilisation,   of   the   C9orf72  mRNA,  
leading  to  the  ten-­fold  higher  levels  of  B12  C9orf72  mRNA  versus  HEK293  control.  
The  higher  mRNA  levels  could  also  be  clone  specific  as  opposed  to  a  direct  effect  
of   the   INDEL   mutation.   The   immunoblot   contradicted   the   qPCR   data   with   no  
detectable  C9orf72  protein.  As  before,   this   result  could  occur   if   the  +48  bp   INDEL  
had  disrupted  the  epitope  recognised  by  the  anti-­C9orf72  antibody.  Interestingly,  the  
B12  clone  had  an  additional  protein  band  at  37  kDa,  which  was  absent  in  HEK293  
cells   and   the   other   CRISPR   lines,   suggesting   the   48   bp   insertion   was   leading   to  
generation   of   a   smaller   C9orf72   isoform   that   was   still   detectable   with   the   anti-­
C9orf72   antibody.   The   inserted   base   pairs   could   insert   a   novel   splice   site   from  
which  a  new  C9orf72  isoform  can  be  alternatively  spliced.  If  alternative  splicing  was  
occurring  from  this  novel  splice  site,  it  would  produce  a  C9orf72  protein  lacking  the  
first   N-­terminal   139   amino   acids   and   the   predicted   molecular   weight   of   this   new  
isoform   would   be   37.6   kDa,   fitting   with   the   detected   protein   on   the   immunoblot.  
Interestingly,   the   48   bp   insertion   codes   for   residues  VDRLTHI,  which  would   allow  
the   anti-­C9orf72   antibody   to   recognise   and   bind   if   this   is   indeed   the   antibody  
epitope.  
  
The  aim  was  to  take  forward  a  stable  C9orf72  knockout  cell  model  and  as  such,  the  
B17  and  B12  clones  were  not  investigated  further.  However,  the  B12  clone  could  be  
an   interesting   cell  model   for   future  experiments   if   it   is   indeed  expressing  a   stable  
C9orf72   Dlongin   mutant.   To   test   these   hypotheses,   mutagenesis   could   be  
undertaken   on   a   C9orf72   construct   to   substitute   the   residues   predicted   to   be  
involved  in  the  anti-­C9orf72  antibody  epitope,  to  confirm  the  lack  of  protein  detected  
on   the   immunoblot   was   for   this   reason.   Unfortunately,   other   C9orf72   antibodies  
which  may  target  other  epitopes  are  not  specific  or  sensitive  enough  yet  to  perform  
another   immunoblot   with.   Redesign   of   qPCR   primers   could   inform   as   to   whether  
alternative   splicing   is   occurring  at   the   insertion  mutation.   If   alternatively   spliced,   a  
forward   primer   in   the   sequence   upstream   of   the   insertion   should   not   amplify  
product.    
  
The   discrepancy   between  C9orf72  mRNA   and  C9orf72   protein   levels   seen   in   the  
CRISPR   lines  was  also  seen   for  cells   transfected  with  C9orf72  siRNA.  Due   to   the  
lack   of   suitable   C9orf72   antibodies   for   most   of   the   duration   of   the   project,  
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knockdown   of   C9orf72   was   confirmed   by   measuring   mRNA   levels.   On   average,  
knockdown   of  C9orf72  mRNA  was   between   40-­70%.  At   the   end   of   the   project,   a  
new  anti-­C9orf72   antibody   became  available  which   could   detect  C9orf72   and   this  
antibody   was   tested   on   HEK293   cells   transfected   with   C9orf72   siRNAs   for  
comparison   with   mRNA   levels.   In   all   knockdown   conditions,   the   reduction   in  
C9orf72   mRNA   was   approximately   50%   whereas   the   C9orf72   immunoblot  
suggested  there  was  a  much  greater  loss  of  protein.  At  the  point  of  cell  harvest,  the  
RT-­qPCR  will  detect  C9orf72  out-­of-­frame  mRNA  which  has  not  yet  been  targeted  
by   the  RNA-­Induced  Silencing  Complex   (RISC)   for  degradation   thus  mRNA   levels  
may  not   correlate  with   protein   levels.   In   addition,   transcription   of  C9orf72  may  be  
highly   active   but   followed   by   slow   translation   and/or   high   protein   turnover.   This  
would  explain  the  low  C9orf72  protein  levels  described  in  the  literature  (Waite  et  al.,  
2014;;  Xiao  et  al.,  2015).  The  non-­correlation  between  mRNA  and  protein  levels  has  
been  examined   further   in  other  studies   (Schwanhäusser  et  al.,  2011;;  Vogel  et  al.,  
2010).   In   the   context   of   the   project,   it   is   possible   that   the   C9orf72   knockdowns  
measured  as  reduction   in  C9orf72  mRNA  are  underestimating   the  actual  effect  on  
C9orf72  protein  levels.      
  
Of   note,   the   anti-­C9orf72   antibody   did   not   detect   an   endogenous   C9orf72   ‘short’  
isoform   thought   to   be   translated   from   the   alternatively   spliced   V2   transcript  
(DeJesus-­Hernandez   et   al.,   2011).   The   short   isoform   is   terminated   at   exon   5,  
therefore  contains   the  same  N-­terminus  as   the   long   isoform   for   recognition  by   the  
antibody.   There   has   been   debate   in   the   C9orf72   research   community   as   to   the  
existence  of   the  C9orf72  short   isoform,  and   the   immunoblot  with   this  anti-­C9orf72  
antibody   would   support   there   only   being   one   C9orf72   protein   in   the  HEK293   cell  
line.  Other  groups  have  shown  detection  of   the  short   isoform   in  patient   tissue  but  
not  cell   lines  (Waite  et  al.,  2014;;  Xiao  et  al.,  2015),  suggesting  it’s  expression  may  
be  cell-­specific.    
  
This   chapter   also   detailed   the   generation   of   tagged-­coilin   protein   constructs   for  
expression  in  cells.  Coilin  was  subcloned  into  four  different  expression  vectors  such  
that  it  was  tagged  with  GFP,  myc,  FLAG  or  mCherry  on  the  N-­terminal.  Immunoblot  
of   these   proteins   confirmed   successful   expression   of   the   proteins   which   had   the  
expected  molecular  weights  and  were  detected  by  antibodies  recognising  their  tags  
(Figure  3.13).  Endogenous  coilin  localises  to  the  nucleus,  where  approximately  70-­
80%   of   it   is   dispersed   throughout   the   nucleoplasm   and   the   remaining   is  
concentrated   in   Cajal   bodies   (Lam   et   al.,   2002).   The   tagged-­coilin   constructs  
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correctly   localised   to   the   nucleus   but   did   not   appear   to   form  Cajal   bodies   (Figure  
3.14).  One  reason  for  this  could  be  because  of  the  location  of  tag.  The  N-­terminal  of  
coilin   is   defined   as   the   ‘self-­association   domain’,   without   which   it   cannot   interact  
with   itself   or   form   canonical   Cajal   bodies   (Hebert   and   Matera,   2000).   If   the   N-­
terminal   tag   is   affecting   the   proper   folding   or   interactions   between   the   self-­
association   domains,   then   the   tagged-­coilin   would   be   unable   to   localise   to   Cajal  
bodies.    To  determine  whether  Cajal  bodies  still  exist  in  these  cells,  immunostaining  
with  another  Cajal  body  marker  such  as  SMN  would  be  required.  The  C-­terminal  of  
coilin  is  responsible  for  mediating  protein-­protein  interactions  with  other  Cajal  body  
proteins,   such   as   the   SMN   and   Sm   proteins,   suggesting   this   is   also   not   an   ideal  
location   for  a   tag   (Hebert  et  al.,  2001).  This   is  supported  by   the  observance  of  an  
unusual  staining  pattern  of  a  coilin-­GFP  protein   in  HeLa  cells   (Hebert  and  Matera,  
2000).  On  the  other  hand,  it  may  be  the  overexpression  of  coilin  itself  that  leads  to  
the  disassembly  of  Cajal  bodies.  It  was  described  by  Hebert  &  Matera  in  2000  that  
GFP-­coilin  could  be  seen  in  Cajal  bodies  in  low-­expressing  cells.  Supporting  this,  a  
stable  GFP-­coilin  HeLa  cell   line,  where   the  GFP-­coilin  was  expressed   to  a  similar  
level  as  endogenous  coilin,  was  generated  in  which  Cajal  bodies  were  successfully  
formed.  The  GFP-­coilin  was  noted  as  having  the  same  biochemical  and  localisation  
patterns   as   endogenous   coilin   (Platani   et   al.,   2000).   These   data   suggest   coilin  
expression   can   affect   Cajal   bodies.   Accordingly,   for   all   experiments   where   there  
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4   C9orf72  interacts  with  nuclear  protein  coilin  
  
4.1   Introduction  
  
In   this   chapter,   the   nuclear   localisation   of   C9orf72   was   investigated.   Often,   a  
protein’s  function  is  closely  linked  with  its  localisation  in  a  cell.  The  exact  localisation  
of   endogenous   C9orf72   has   thus   far   been   difficult   to   determine,   with   studies  
reporting   different   localisation   patterns   that   vary   between   cell   and   tissue   types.  
Contributing   to   the   problem   is   a   lack   of   antibodies   recognising  C9orf72  with   high  
specificity   or   the   ability   to   distinguish  between   the   short   and   long   isoforms,  which  
may  have  different  functions.  However,  in  2015,  C9orf72  isoform-­specific  antibodies  
were   generated   which   suggested   the   endogenous   short   isoform   localised   to   the  
nuclear   envelope   whereas   the   long   isoform   appeared   cytoplasmic   (Xiao   et   al.,  
2015).    Both  isoforms  showed  nuclear  localisation  when  overexpressed  in  cell  lines.    
  
Moreover,  proteomic  analysis  studies  undertaken  by  various  groups  have  identified  
potential   protein   interactors   of  C9orf72   (Blokhuis   et   al.,   2016;;   Sellier   et   al.,   2016;;  
Sullivan   et   al.,   2016).   Nuclear   proteins   appear   frequently   throughout   the   list   of  
proteins   included   in   the   C9orf72   interaction   network   (See   appendix).   Taken  
together,  these  studies  suggest  C9orf72  has  some  nuclear  involvement.  
  
In   addition   to   probing   C9orf72   localisation,   a   yeast   two-­hybrid   (Y2H)   screen   was  
conducted  to  identify  novel  C9orf72  protein  interactors  which  produced  multiple  hits  
for   an   interaction   between   C9orf72   and   nuclear   protein   coilin.   Two   Y2H   screens  
were   outsourced   and   performed   by   staff   at   the   proteomics   facility   at   the  German  
Cancer  Research  Centre:  1)  A  complete  human  brain  random  library  screened  with  
both   short   and   long   C9orf72   isoforms   and   2)   A   human   full-­length   cDNA   library  
screened   with   C9orf72   long   isoform   only.   The   latter   screen   identified   two   protein  
interactions  only,  one  of  which  was  coilin  and   the   results  of  which  are   included   in  
this   chapter.   Hits   from   the   other   screen   are   referenced   in   the   appendix.   The  
interaction  between  C9orf72  and  coilin  was  confirmed  using  an  in  vitro  GST-­binding  
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4.2   Results  
  
4.2.1   Exogenous   C9orf72   short   and   long   isoforms   localise   to   the  
nucleus  in  HEK293  cells  
  
To  investigate  C9orf72  localisation  after  protein  overexpression,  myc-­C9orf72  short  
(S)  or  long  (L)  plasmid  constructs  were  transfected  into  HEK293  cells.  pCI-­neo  was  
transfected   as   an   empty   vector   control.   After   transfection,   cells   were   fixed   and  
immunostained   using   an   anti-­myc   antibody   to   investigate   the   localisation   of   myc-­
C9orf72.   Both   myc-­C9orf72S   and   myc-­C9orf72L   showed   similar   staining   and  
localised   to   both   the   nucleus   and   cytoplasm   in   all   transfected   cells   (Figure   4.1A).  
However,  the  strength  of  nuclear  localisation  varied  from  cell  to  cell  for  both  C9orf72  
isoforms.  Thus,  cells  were  categorised  as  either   ‘Equal’,   ‘Nuclear’  or   ‘Cytoplasmic’  
accordingly  and  quantified  (Figure  4.1B).  Myc-­C9orf72S  showed  equal,  nuclear  and  
cytoplasmic   localisation   in   approximately   40%,   30%   and   30%   of   cells   analysed  
respectively.   Myc-­C9orf72L   showed   a   similar   distribution   with   equal,   nuclear   and  
cytoplasmic   localisation   in   approximately   60%,   20%   and   20%   of   cells   analysed  
respectively.   Myc-­C9orf72S   appeared   to   show   more   preference   towards   distinct  
cytoplasmic  or  nuclear   localisation   in  comparison  to  myc-­C9orf72L  which  exhibited  
diffusive   localisation   in   a   higher   proportion   of   cells.   Overall,   the   subcellular  
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Immunostaining   against   myc-­C9orf72   in   HEK293   cells   showed   both   the   C9orf72  
short  and  long  protein  localised  in  the  nucleus  and  cytoplasm  when  overexpressed.  
To  validate  the  immunofluorescence  results,  a  nuclear  fractionation  was  undertaken  
on  HEK293  cells  to  investigate  the  localisation  of  myc-­C9orf72  in  total,  cytoplasmic  
or   nuclear   fractions.  As  before,   cells  were   transfected  with   pCI-­neo   (empty   vector  
control),   myc-­C9of72S   or   myc-­C9orf72L.   Cells   were   harvested   and   a   sample  
removed   and   lysed   in  RIPA   buffer   for   the   ‘total’   cell   fraction.   The   remaining   cells  
were   lysed   in   hypotonic   lysis   buffer   which   breaks   down   the   cell   membrane   but  
leaves  the  nuclear  membrane  intact.  The  nuclei  were  pelleted  and  the  supernatant  
collected  as  the  ‘cytoplasm’  fraction.  The  nuclear  pellet  was  lysed  in  RIPA  buffer  to  
produce   the   ‘nuclear’   fraction.   Myc-­C9orf72   localisation   across   the   fractions   was  
examined  by   immunoblot.  To  confirm  successful  nuclear   fractionation,  SSRP1  and  
actin  were  used  as  nuclear  and  cytoplasm  markers  respectively.  SSRP1  is  a  protein  
component   of   the   Facilitates   Chromatin   Transcription   (FACT)   complex   and   binds  
DNA   at   nucleosomes   (Röttgers   et   al.,   2000).   Actin   is   a   microfilament   protein  
involved   in  cytoskeleton  shaping   (Stricker  et  al.,  2010).   In  all   transfected  samples,  
SSRP1  was  absent   in   the  cytoplasm   fraction  and  enriched   in   the  nuclear   fraction,  
suggesting   the   cytoplasm   fraction  was   free   of   nuclear   contamination   (Figure   4.2).  
Conversely,   actin   was   detected   in   both   the   nuclear   and   cytoplasmic   fractions,  
suggesting  unlysed  cells  remained  or  there  was  some  cytoplasmic  contamination  of  
the  nuclear  fraction.  To  look  at  myc-­C9orf72  localisation,  an  anti-­myc  antibody  was  
used.  Myc-­C9orf72L  was  detected  in  total,  cytoplasmic  and  nuclear  fractions.  Myc-­
C9orf72S  was  likewise  detected  in  all  fractions,  however  the  protein  level  appeared  
highest   in   the   nuclear   fraction   (Figure   4.2).   The   results   support   the  
immunofluorescence  data,  suggesting  C9orf72  localises  to  both  the  cytoplasm  and  
nucleus.  
  
Figure  4.1.  myc-­C9orf72  localisation  is  varied  within  the  HEK293  cell  population.  
(A)   HEK293   cells   were   transfected   with   pCI-­neo   (control),   myc-­C9orf72S   or   myc-­
C9orf72L  and  immunostained  using  an  anti-­myc  antibody  (9B11)  (green).  myc-­C9orf72  
localisation   was   categorised   as   ‘Equal’,   ‘Cytoplasmic’   or   ‘Nuclear’;;   Representative  
images   are   shown.   Scale   bar   =   10   µm.   (B)   Percentage   of   cells   exhibiting   equal,  
cytoplasmic   or   nuclear   localisation   of   myc-­C9orf72S   and   myc-­C9orf72L.   Data  
represent   mean   ±   SEM;;   Two-­way   ANOVA   with   Sidak’s   test,   ***   p   ≤   0.001.   n=3  
experiments  (20  cells  per  experiment).  

















4.2.2   The   C9orf72   short   isoform   localises   to   nuclear   speckles   in   rat  
cortical  neurons  
  
Myc-­C9orf72   was   shown   to   localise   to   both   the   nucleus   and   cytoplasm   when  
overexpressed  in  HEK293  cells.  However,  while  useful  to  understand  the  location  of  
C9orf72  in  this  cell  line  to  gain  information  about  function,  the  location  of  C9orf72  in  
primary  neurons  holds  more  importance  in  the  context  of  ALS.  For  this  reason,  the  
localisation   of   C9orf72   was   also   investigated   in   primary   rat   cortical   neurons.  
Neurons   were   prepared   and   transduced   by   Miss   Rebecca   Cohen.   At   5   DIV,  
neurons   were   transduced   with   pLenti   virus   expressing   GFP   (control),   mVenus-­
C9orf72S   or  mVenus-­C9orf72L   and   fixed   at   12   DIV.   Both  mVenus-­C9orf72S   and  
mVenus-­C9orf72L   localised   to   the   nucleus,   cytoplasm   and   dendrites   of   neurons,  
suggesting   C9orf72   localises   evenly   throughout   the   whole   cell   (Figure   4.3A).  
Interestingly,   mVenus-­C9orf72S   but   not   mVenus-­C9orf72L   localised   to   nuclear  
speckles   in   many   transduced   neurons.   Confocal   microscope   imaging   showed  
clearly   the   localisation   of   mVenus-­C9orf72S   in   nuclear   speckles   in   a   subset   of  
cortical  neurons  (Figure  4.3B).  The   images  show  that   in  neurons,   the   two  C9orf72  
isoforms  have  different  localisation  patterns.  
  
  
Figure   4.2.   C9orf72   localises   to   both   the   cytoplasm   and   nucleus   in   HEK293   cells.  
HEK293  cells  were  transfected  with  pCI-­neo  (control),  myc-­C9orf72S  or  myc-­C9orf72L  and  
subjected  to  nuclear  fractionation.  Total  (T),  cytoplasmic  (C)  and  nuclear  (N)  fractions  were  
immunoblotted   using   anti-­myc   antibody   (9B11)   to   investigate   myc-­C9orf72   subcellular  
localisation.   Anti-­SSRP1   and   anti-­actin   antibodies  were   used   as   nuclear   and   cytoplasmic  
markers  respectively.  





































Figure  4.3.  mVenus-­C9orf72S  forms  nuclear  speckles  in  rat  cortical  neurons.  (A)  5  DIV  
rat   cortical   neurons   were   transduced   with   GFP   (control),   mVenus-­C9orf72S   or   mVenus-­
C9orf72L.  Neurons  were  fixed  at  12  DIV  and  imaged  for  mVenus-­C9orf72  localisation  (green).  
Scale  bar  =  10  µm  (B)  Confocal  microscope  image  of  mVenus-­C9orf72S  localised  in  nuclear  
‘speckles’.   Scale   bar   =   10   µm.   Neurons   were   prepared   and   transduced   by   Miss   Rebecca  
Cohen.  
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4.2.3   A   yeast   two-­hybrid   screen   identified   coilin   as   a   C9orf72  
interacting  protein  
  
The   function  of  C9orf72   in   the  nucleus   is  unknown.   It  has  been  hypothesised   that  
the  short  C9orf72  protein  may  be  involved  in  nucleocytoplasmic  shuttling  due  to  its  
localisation   at   the   nuclear   envelope   in   certain   cell   types   (Xiao   et   al.,   2015).  
Identifying   protein   interactors   can   increase   understanding   of   a   protein’s   potential  
function.   Thus,   a   yeast   two-­hybrid   (Y2H)   screen   was   conducted,   with   special  
attention   paid   to   novel   nuclear   protein   interactors   of   C9orf72.      The   screen   was  
outsourced   to   the   Protein   Interaction   Screening   of   the  Genomics   and   Proteomics  
Core   Facilities,   German   Cancer   Research   Centre,   Heidelberg,   Germany   and  
involved   screening   a   human   full-­length   cDNA   library   using   C9orf72L   as   the   bait  
protein.   Briefly,   C9orf72L   was   cloned   into   the   bait   vector   pGBKT7,   for   yeast  
expression  of  a  C9orf72L  protein  tagged  at  its  N-­terminal  end  with  the  transcription  
factor  GAL4  DNA  binding-­domain.   The   cDNA   library  which  was   screened   against  
contained  full-­length  ORFs  expressing  ‘prey’  proteins  fused  with  the  corresponding  
GAL4   activation   domain.   If   the   bait   and   prey   proteins   interact,   GAL4   becomes  
functional  and  facilitates  transcription  from  a  reporter  gene.    The  screen  selected  for  
high-­confidence  interactions  only  by  rejecting  prey  proteins  that:  1)  only  had  a  single  
hit   against  C9orf72L  and   therefore   lacked   reproducibility   or   2)  were   ‘promiscuous’  
prey  proteins  that  are  commonly  pulled  down  in  Y2H  screens  due  to  their  tendency  
to  bind  to  numerous  different  proteins.    The  Y2H  identified  two  proteins  as  C9orf72L  
interactors:  coilin  and  synapsin  III  (Table  4.1).  Coilin  had  5  hits  and  synapsin  III  had  
37  hits;;  both  were  predicted  to  be  biologically  significant.  The  interaction  with  coilin,  
which   is   a   nuclear   protein,   was   taken   forward   for   further   investigation   to   gain   a  
better  understanding  of  the  role  of  C9orf72  in  the  nucleus.  The  C9orf72  interaction  






























































































































































C9orf72L	   SYN3	   37	   0	   37	   0	   0	   1	   synapsin	  III	  
C9orf72L	   COIL	   5	   0	   5	   0	   0	   1	   coilin	  
  
Table  4.1  Coilin  and  synapsin  III  interact  with  C9orf72L.  A  Y2H  screen  used  C9orf72L  as  
bait   protein   and   screened   a   human   full-­length   cDNA   library.   Proteins   isolated   more   than  
once  and  a  prey  promiscuity  less  than  4  were  identified  as  positive  hits.  Prey  promiscuity  is  
defined   as   prey   that   are   repeatedly   identified   in   several   screens   due   to   their   non-­specific  
binding  of  bait  proteins.  
  
4.2.4   C9orf72  and  coilin  directly  interact  in  vitro  
  
Coilin   is   a   nuclear   protein   and   is   the   major   protein   component   of   nuclear  
suborganelles   called   Cajal   bodies.   It   is   thought   to   mediate   protein-­protein  
interactions   within   Cajal   bodies,   thus   acting   as   a   scaffolding   protein.   The   Y2H  
screen   suggested   coilin   is   a   protein   interactor   of   C9orf72L.   To   confirm   the  
interaction  and  to  determine  if  the  interaction  is  direct,  an  in  vitro  GST-­binding  assay  
was   performed.   GST,   GST-­C9orf72S   or   GST-­C9orf72L   protein   was   expressed   in  
Rosetta™  pLysS  competent  cells  as  the  C9orf72  does  not  express  well  in  bacterial  
systems  and  these  cells  are  designed  to  enhance  expression  of  eukaryotic  proteins  
that   contain   rare   codons.   Glutathione   sepharose   added   to   bacterial   lysates   for  
protein   immobilisation.   35S   radiolabelled   coilin   was  made   in   vitro   using   a   coupled  
transcription/translation   reticulocyte   system   by   incorporating   35S-­methionine  
residues,   although   it   is   worth   noting   coilin   has   only   2   methionines   in   its   protein  
sequence   and   hence  may   only   have  minimal   labelling.   35S-­coilin   reticulocyte   was  
incubated   with   the   GSH   before   elution   with   excess   glutathione.   Samples   were  
subjected   to   SDS-­PAGE   electrophoresis   and   the   pull-­down   was   confirmed   by  
coomassie  staining.  35S-­coilin  was  detected  using  a  phosphoimager.  The  GST  pull  
down   was   successful,   with   GST,   GST-­C9orf72S   and   GTS-­C9orf72L   observed   by  
coomassie   staining   at   the   correct   molecular   weights   (Figure   4.4).   The   additional  
protein   bands   were   previously   characterised   by   Dr   Chris   Webster   using   mass  
spectrometry  and  were  identified  as  bacterial  chaperone  proteins  CH60  and  DnaK.  
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35S-­coilin  was  pulled  down  with  both  C9orf72  short  and  long  protein  but  not  with  the  



























4.2.5   C9orf72  interacts  with  coilin  in  HEK293  cells  
  
The   in   vitro   GST-­binding   assay   showed   C9orf72   directly   interacts   with   coilin.  
However,  while  confirming  the  proteins  can  bind  in  vitro,  the  assay  is  limited  in  that  
it  cannot  be  concluded  from  the  results  if  the  interaction  is  physiologically  relevant.  
For  this  reason,  a  co-­immunoprecipitation  experiment  was  performed  to  investigate  
the   interaction   between   the   C9orf72   proteins   and   coilin   in   cells.   Myc-­C9orf72S/L  
was   transfected   into   HEK293   cells.   pCI-­neo   was   included   as   an   empty   vector  
control.   Whole-­cell   lysates   were   prepared   and   a   sample   removed   to   confirm  
transfections   were   successful   (Inputs).   Anti-­coilin   antibody   was   added   to   the  
remaining  lysate  before  addition  of  Protein  G  sepharose  beads  for  coilin  pull-­down.  
Figure   4.4.   Coilin   directly   binds   to   C9orf72   in   vitro.   GST-­,   GST-­C9orf72S   or   GST-­
C9orf72L  was  expressed  and  purified  from  Rosetta  pLysS  competent  cells  and  a  pull  down  
performed   using   GSH   beads.   GST-­C9orf72   protein   expression   was   confirmed   by  
Coomassie  staining  (lower  panel).  Recombinant  
35
S-­coilin  was  produced  in  vitro  (input)  and  
incubated  with   the  GST-­C9orf72  pull  down.  Eluted  proteins  were  subjected   to  SDS-­PAGE  
electrophoresis  and  
35
S-­coilin  detected  by  phosphor  imaging  (top  panel).  
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Beads   were   washed   and   proteins   were   eluted   by   addition   of   Laemmli   buffer   and  
boiling.   Samples   were   subjected   to   SDS-­PAGE   electrophoresis   for   protein  
separation   and   transferred   to   a   nitrocellulose  membrane   for   immunoblotting.  Anti-­
coilin  and  anti-­C9orf72  antibodies  were  used  for  detection  of  endogenous  coilin  and  
myc-­C9orf72S/L  respectively.  Endogenous  coilin  was  detected  in  the  pCI-­neo,  myc-­
C9orf7S   and   myc-­C9orf72L   transfected   ‘Input’   samples.   Myc-­C9orf72S   and   myc-­
C9orf72L   were   likewise   detected   in   their   input   samples   confirming   successful  
overexpression   (Figure  4.5A).  Coilin  protein   levels  were  considerably   increased   in  
the   IP   samples,   showing   successful   immunoprecipitation.   In   these   samples,  myc-­
C9orf72S   and   myc-­C9orf72L   were   both   co-­immunoprecipitated   with   coilin,  
suggesting   the   interaction   between   C9orf72   and   coilin   does   occur   in   the   cellular  
environment.  It  appeared  myc-­C9orf72S  was  pulled  down  more  than  myc-­C9orf72L,  
however   there   also   appeared   to   be   greater   expression   of  myc-­C9orf72S   vs  myc-­
C9orf72L  in  the  input  samples  thus  there  was  more  protein  available  for  interaction.  
To  support  this  result,  the  experiment  was  performed  in  reverse.  HEK293  cells  were  
transfected  with  pCI-­neo  or  myc-­tagged  C9orf72  short  or  long  protein  and  subjected  
to  nuclear  fractionation,  to  enrich  for  nuclear  proteins.  As  before,  a  sample  of  lysate  
was   removed   for   inputs.   To   remaining   lysate,   a   pull-­down   of   myc-­C9orf72   was  
performed  by  incubation  with  an  anti-­myc  antibody  followed  by  addition  of  Protein  G  
sepharose   beads.   Proteins   were   eluted   and   subjected   to   SDS-­PAGE   and  
immunoblot   with   anti-­coilin   and   anti-­myc   antibodies.   Endogenous   coilin   and  myc-­
C9orf72S   and   myc-­C9orf72S   were   detected   as   expected   in   the   input   samples  
(Figure   4.5B).   Both   myc-­C9orf72S   and   myc-­C9orf72L   were   enriched   in   the   IP  
samples,  confirming  successful  immunoprecipitation.  Endogenous  coilin  was  pulled  
down   with   both   C9orf72   isoforms,   but   as   seen   in   Figure   4.5A,   this   interaction  
appeared   to   be   stronger   with   the   C9orf72   short   isoform.   Together,   the   two   co-­
















































4.2.6   C9orf72  and  coilin  are  at  close  proximity  in  both  the  nucleus  and  
the  cytoplasm  
  
The  previous  sections  in  this  chapter  have  shown  that  C9orf72  localises  to  both  the  
nucleus  and  cytoplasm,  and  interacts  with  coilin.  Next,  the  localisation  of  where  the  
C9orf72  and  coilin  proteins  interact  was  investigated.  To  do  this,  a  proximity  ligation  
assay   was   implemented,   which   can   visualise   protein-­protein   interactions   in   situ  
B  
A  
Figure   4.5.   Endogenous   coilin   and  myc-­C9orf72   interact   in   cells.   HEK293   cells  
were   transfected   with   pCI-­neo   (control),   myc-­C9orf72S   or   myc-­C9orf72L.  
Immunoprecipitation  of  endogenous  coilin  was  performed  on  whole  cell  lysate  using  an  
anti-­coilin   antibody   (A)   or   immunoprecipitation   of   myc-­C9orf72   was   performed   on  
HEK293  nuclear  fractions  using  an  anti-­myc  antibody  (9B11)  (B).  For  coilin  detection,  
the  top  blots  were  probed  using  an  anti-­coilin  antibody.  For  myc-­C9orf72  detection,  the  
bottom  blots  were  probed  using  anti-­C9orf72  (sc-­138763)  (A)  or  anti-­myc  (9106)  (B).  
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(Figure  4.6).  Briefly,  primary  antibodies  recognising  the  two  proteins  of  interest,  one  
raised   in  mouse  and   the  other   in   rabbit,  are   incubated  on   fixed  and  permeabilised  
cells.   Secondary   antibodies   are   then   added,   called   PLA   probes,   which   are  
conjugated   to  DNA  oligonucleotides.  Next,   hybridising   oligonucleotides,  which   are  
complimentary  to  the  PLA  probe  oligonucleotides,  are  added  and  ligated  to  form  a  
closed,   circularised   DNA   product.   This   circular   DNA   then   acts   as   a   template   for  
DNA   polymerase   to   perform   rolling   circle   amplification,   generating   a   large   DNA  
concatemer   at   the   site   of   the   protein-­protein   interaction.   Fluorescent   hybridisation  
probes,   complimentary   to   the  DNA   amplicon,   are   added  which   bind   to   produce   a  
single   fluorescent  spot  (PLA  signal),  allowing  the   location  of   the  protein   interaction  
to   visualised   by   microscopy.   For   the   proximity   ligation   assay   to   produce   a   PLA  
signal,  the  two  proteins  of  interest  must  be  within  40  nm,  therefore  the  assay  is  only  




The  proximity  ligation  assay  was  used  to  investigate  where  in  the  cell  myc-­C9orf72  
and  endogenous  coilin  are  in  close  proximity.     HEK293  cells  were  transfected  with  
pCI-­neo   or   myc-­tagged   C9orf72   short   or   long   protein.   Immunostaining   of   myc-­
C9orf72   in   the   PLA   protocol   was   not   possible,   therefore   in   addition   to   these  
Figure  4.6.  The  proximity  ligation  assay.  Primary  antibodies  raised  in  different  species  are  
added   against   target   proteins.   Secondary   antibodies   conjugated   to   oligonucleotides   (PLA  
probes)  bind  to  the  primary  antibodies.  Hybridisation  oligonucleotides  bind  to  the  PLA  probes  
and   form   a   circular   DNA   template   which   undergoes   rolling   circle   amplification.   The   RCA  
generates  a  DNA  concatemer  with  up   to  1000   repeats  of   the  sequence.  Fluorescent  probes  
bind  the  DNA  product  and  concentrate  at  the  site  of  the  protein-­protein  interaction,  producing  
a  single  fluorescent  PLA  signal  which  can  be  visualised  using  fluorescence  microscopy.  
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transfections,  cells  received  10%  GFP  of  total  DNA  transfected.  It  was  hypothesised  
that   GFP   transfected   cells   would   be   co-­transfected   with   myc-­C9orf72,   therefore  
GFP  positive  cells  could  be  selected  for  analysis  of  their  PLA  signals,  ensuring  we  
were  only  analysing  cells  overexpressing  C9orf72.  Cells  were   fixed,  permeabilised  
and   used   for   either   immunofluorescence   or   PLA.   Immunofluorescence   cells   were  
immunostained   using   an   anti-­myc   antibody   to   confirm   successful   myc-­C9orf72  
transfection.  Cells   successfully   expressed  myc-­C9orf72S,  myc-­C9orf72L  and  GFP  
(Figure  4.7A).  The  co-­transfection  efficiency  of  GFP  and  the  myc-­C9orf72  proteins  
was  quantified  as  the  percentage  of  GFP-­positive  cells  which  also  expressed  myc-­
C9orf72.   GFP   and   myc-­C9orf72L   had   100%   co-­transfection   efficiency,   whereas  
myc-­C9orf72S   was   only   co-­transfected   in   60%   of   GFP-­transfected   cells   (Figure  
4.7B).    
  
For  PLA,  cells  received  either  no  antibody,  anti-­coilin  antibody,  anti-­myc  antibody,  or  
both   anti-­coilin   and   anti-­myc   antibody.   The   PLA   protocol   was   completed   as  
described   above   and   PLA   signals   viewed   by   fluorescence   microscopy.   All  
transfected  cells  which  received  no  primary  antibody,  had  no  detected  PLA  signals  
(Figure  4.7C).  Likewise,   transfected  cells  which   received  anti-­coilin  antibody  alone  
did   not   generate   PLA   signals   (Figure   4.7D).   Cells   which   were   myc-­C9orf72S   or  
myc-­C9orf72L   but   not   pCI-­neo   transfected,   and  which   received   anti-­myc   antibody  
had   some   PLA   signals   (Figure   4.7E).   Cells   which   were   myc-­C9orf72S   or   myc-­
C9orf72L   but   not   pCI-­neo   transfected,   and   received   both   anti-­coilin   and   anti-­myc  
antibodies  had  increased  PLA  signals  located  in  both  the  nucleus  and  cytoplasm  of  
the  cells  (Figure  4.7F).  The  PLA  signals  were  quantified  per  cell  (Figure  4.7G),  per  
nucleus   (Figure   4.7H)   or   per   cytoplasm   (Figure   4.7I).   Although   some   background  
PLA  signals  were  generated   in  myc-­C9orf72  cells  with  only   the  anti-­myc  antibody,  
there  were  significantly  more  PLA  signals  in  myc-­C9orf72  cells  which  received  both  
antibodies,  suggesting  the  PLA  detected  close  proximity  between  C9orf72  and  coilin  
(Figure  4.7G/H/I).  Both  the  images  and  quantification  showed  approximately  half  of  
the  total  PLA  signals  were  in  the  nucleus,  suggesting  the  interaction  occurs  equally  



















































































































































































































































































Figure   4.7.   Coilin   and   C9orf72   are   in   close   proximity   in   both   the   nucleus   and   the  
cytoplasm.   HEK293   cells   were   co-­transfected  with   pCI-­neo   (control),   myc-­C9orf72S   or  myc-­
C9orf72L  +  GFP.  (A)  Cells  were  fixed  and  immunostained  using  an  anti-­myc  antibody  to  confirm  
successful  co-­transfection  of  myc-­C9orf72  (red)  with  GFP  (green).  (B)  Co-­transfection  efficiency  
quantified   as   percentage   of   GFP-­positive   cells   co-­transfected   with   myc-­C9orf72S   and   myc-­
C9orf72L.  Data  represent  mean  ±  SEM.  n=4  experiments  (20  cells  per  experiment).  (C-­F)  Cells  
were   fixed  and  a  proximity   ligation  assay  performed  using  no  primary  antibody   (C),  anti-­coilin  
antibody  (D),  anti-­myc  antibody  (E),  or  anti-­coilin  and  anti-­myc  antibodies  (F).  GFP  transfected  
cells   (green)  were  selected   for  visualisation  of  PLA  signals   (white)   representative  of  an   in  situ  
protein-­protein  interaction.  Scale  bar  =  10  µm.  (G-­I)  Quantification  of  the  number  of  PLA  signals  
per   cell   (G),   per   nucleus   (H)   or   per   cytoplasm   (I).   Data   represent   mean   ±   SEM;;   Two-­way  
ANOVA  with  Tukey’s  test,  *  p  ≤  0.05,  ***  p  ≤  0.001,  ****  p  ≤  0.0001.  n=3  experiments  (20  cells  
per  experiment).  
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4.3   Discussion  
  
In   this  chapter,  C9orf72  was   found   to   localise   to   the  nucleus  and   interact  with   the  
nuclear   protein   coilin.   The   nuclear   localisation   of   C9orf72  was   shown   in   both   the  
HEK293  cell   line  and  primary  rat  cortical  neurons.  At   the   time,  antibodies   that  can  
successfully  detect  endogenous  C9orf72  by   immunofluorescence  were  unavailable  
and   so   overexpression   of   the   C9orf72   protein   was   used.   The   discussion   of   the  
nuclear   localisation   of   C9orf72   in   this   chapter   refers   only   to   the   overexpressed  
protein.   High   levels   of   exogenous   C9orf72   expression   may   lead   to   abnormal  
distribution  of  the  protein  in  cells.  Both  short  and  long  C9orf72  isoforms  localised  to  
both   the  nucleus  and  cytoplasm,  and  analysis  of   their  protein  sequence   reveals  a  
lack  of  a  nuclear  localisation  signal  (NLS),  suggesting  the  proteins  do  not  enter  the  
nucleus   by   active   nuclear   transport   through   the   nuclear   pore   complex.   The  
threshold  for  passive  diffusion  through  the  nuclear  pore  complex  is  predicted  to  be  
between   30-­60   kDa,   allowing   the   short   isoform   (25   kDa)   and   possibly   the   long  
isoform  (50  kDa)  to  cross  the  nuclear  membrane  in  this  way  (Timney  et  al.,  2016).  
Based  on  antibody  staining,   the  endogenous  short   isoform  appears  more  nuclear,  
whereas   the   long   isoform   is   cytoplasmic   (Xiao  et  al.,   2015).  Further   studies  using  
additional   antibodies   are   needed   to   confirm   this   observation.   We   suggest   entry  
could  be  via  passive  diffusion  and  the  overexpression  of  the  C9orf72  proteins  in  our  
studies  drives  the  long  isoform  into  the  nucleus.    
  
The   short   C9orf72   isoform   showed   more   of   a   distinct   nuclear   or   cytoplasmic  
localisation   in   comparison   to   the   long   isoform   which   was   more   commonly   found  
diffusively  through  the  whole  cell  (Figure  4.1B).  In  addition,  the  short  isoform  formed  
nuclear   speckles   in   rat   cortical   neurons.   The   nucleus   has   many   nuclear   bodies,  
such  as  Cajal   bodies,  gemins,  PML  bodies  and  paraspeckles  which  all   have   their  
own  distinct  protein  make-­up   (Mao  et  al.,   2011b).  The  C9orf72S  nuclear   speckles  
did  not  exhibit   the  staining  pattern   that  would  be  expected   for  Cajal  bodies,  which  
are  usually  found  numbered  1-­2  in  primary  neurons.  To  determine  the  identity  of  the  
speckles,   immunostaining   with   antibodies   recognising   protein  markers   of   different  
nuclear   bodies   could   be   used.   The   localisation   and   formation   of   nuclear   speckles  
seen  only  for  the  short  C9orf72  isoform  is  consistent  with  a  specific  nuclear  role  for  
this  isoform  of  C9orf72.  
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Studies  into  the  biological  function  of  C9orf72  have  so  far  focused  on  its  role  in  the  
cytoplasm   and   involvement   in   trafficking   and   autophagy   (Sellier   et   al.,   2016;;  
Webster  et  al.,  2016).  However,  many  of  the  protein  interactors  of  C9orf72  identified  
in  proteomic  analysis  studies  were  found  to  be  nuclear  proteins,  and  we  and  others  
have  shown  there  is  likely  a  nucleus-­associated  function.  The  proteomic  screens  of  
C9orf72   completed   to   date   have   mostly   identified   C9orf72   protein   interactors   by  
immunoprecipitation   of   C9orf72   followed   by   mass   spectrometry   analysis   of   its  
binding  partners.  The  proteins  identified  using  this  method  may  not  directly  interact  
with  C9orf72  however,  but  are  pulled  down  as  part  of  the  same  protein  complex.  In  
this  project,  an  unbiased  yeast   two-­hybrid  screen  was  performed   to   look   for  novel  
C9orf72  protein   interactors  using  a  different  approach.  The  yeast  two-­hybrid  assay  
suggested  there  was  an  interaction  between  C9orf72L  and  coilin.  Coilin  is  the  major  
protein   component   of   Cajal   bodies,   where   it   scaffolds   and   interacts   with   proteins  
involved   in   processing   of   the   splicing  machinery,   such   as   the  SMN  protein,   small  
nuclear   ribonucleoproteins   (snRNPs)   and   Sm   proteins.   Loss   of   the   SMN   protein  
caused   by   a   mutation   in   the   SMN1   gene   leads   to   the   development   of   Spinal  
Muscular  Atrophy  (SMA).  SMA  has  similarities  to  ALS,  characterised  by  the  death  of  
the  lower  motor  neurons  and  muscular  atrophy,  and  is  the  leading  genetic  cause  of  
death  in  infants  (Burghes  and  Beattie,  2009).  Loss  of  nuclear  bodies  has  also  been  
observed   in  TDP-­43  and  FUS-­related  ALS   (Yamazaki  et  al.,  2012).  This  suggests  
that   there   could   be   a   link   between   Cajal   body   proteins   and   motor   neuron  
degeneration,   hence   the   interaction   between   C9orf72   and   coilin   was   investigated  
further.    
  
The  interaction  with  coilin  was  investigated  using  three  different  approaches.  An   in  
vitro  GST-­binding  assay  confirmed  there  was  a  direct   interaction  between  C9orf72  
and  coilin,  and  the  co-­immunoprecipitation  experiments  and  proximity  ligation  assay  
suggested  the  interaction  was  biologically  relevant.  The  35S-­coilin  bands  detected  in  
the  GST-­binding   assay   pull   downs  were   faint   relative   to   the   input,   suggesting   the  
interaction  may  be  weak.  The  weakness  of  the  signal  could  have  also  been  due  to  
the   low   level   of   35S   radiolabelling   of   the   recombinant   coilin   protein.   To   radiolabel  
coilin,   35S-­methionine   was   added   to   the   in   vitro   coupled   transcription/translation  
system   for   incorporation   into   coilin.   Analysis   of   the   coilin   amino   acid   sequence  
shows   there  are  only   three  methionine   residues  spread   throughout   the  576-­amino  
acid  sequence  (Figure  4.8).  As  such,  even  with  100%  efficient  labelling  of  coilin,  the  
amount  of  35S  incorporated  would  be  low,  and  therefore  difficult  to  detect.  A  way  to  
increase   radiolabelling   of   coilin   would   be   to   use   35S-­cysteine   in   addition   to   35S-­
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methionine   (Chen   and   Casadevall,   1999).   Coilin   contains   12   cysteine   residues  
(Figure   4.8)   therefore   labelling   with   35S-­cysteine   would   increase   the   strength   of  
radioactive   signal   for   detection.  Unfortunately,   commercially   available   35S-­cysteine  
products  are  unsuitable   for   in  vitro   translation,  and   in  house  attempts  at   its  use   in  
such  experiments  have  found   its   radiolabelling  efficiency   to  be  weak,   therefore  we  
were  unable  to  take  this  approach  in  the  GST-­binding  assay.    
  
   MAASETVRLRLQFDYPPPATPHCTAFWLLVDLNRCRVVTDLISLIRQRFGFSSGAFLGLY 
   LEGGLLPPAESARLVRDNDCLRVKLEERGVAENSVVISNGDINLSLRKAKKRAFQLEEGE 
   ETEPDCKYSKKHWKSRENNNNNEKVLDLEPKAVTDQTVSKKNKRKNKATCGTVGDDNEEA 
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   KESPSSSSESESCDESISDGPSKVTLEARNSSEKLPTELSKEEPSTKNTTADKLAIKLGF 
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   HPVSCVVNRSTDNQRQQQLNDVVKNSSTIIQNPVETPKKDYSLLPLLAAAPQVGEKIAFK 
   LLELTSSYSPDVSDYKEGRILSHNPETQQVDIEILSSLPALREPGKFDLVYHNENGAEVV 
   EYAVTQESKITVFWKELIDPRLIIESPSNTSSTEPA 
 
Co-­immunoprecipitation   experiments   between   overexpressed   myc-­C9orf72   and  
endogenous  coilin  confirmed  the  interaction  occurred  in  HEK293  cells.  The  Co-­IPs  
showed   coilin   was   pulled   down   with   myc-­C9orf72   and   vice   versa.   Both   proteins  
were  pulled  down  after  immunoprecipitation  of  the  other,  suggesting  the  interaction  
is   genuine   and   not   an   artefact   of   the   experiment.   The   amount   of   co-­
immunoprecipitated  protein  was  similar  for  both  Co-­IPs  also,  confirming  the  strength  
of  the  interaction.  Unfortunately,  an  IgG  only  control  was  omitted  from  the  anti-­coilin  
IP.  Inclusion  of  the  IgG  control  would  have  given  more  confidence  that  myc-­C9orf72  
was  not  binding  to  the  beads.  
  
Figure   4.8.   Coilin   protein   sequence.   The   coilin   amino   acid   sequence   is   shown.  
Methionine  residues  that  were  S35  radiolabelled  in  the  GST-­binding  assay  are  highlighted  
in   yellow.   Cysteine   residues   that   can   additionally   be   35S   radiolabelled   are   highlighted   in  
turquoise.  
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The  proximity  ligation  assay  was  used  to  investigate  where  in  the  cell  C9orf72  and  
coilin  were  in  close  proximity.  There  were  similar  numbers  of  PLA  signals  generated  
with   transfection   of   both   myc-­C9orf72S   and   myc-­C9orf72L,   suggesting   coilin  
interacts  with  both  C9orf72  isoforms  equally.  However,  the  co-­transfection  efficiency  
of  myc-­C9orf72S  with  GFP  was  found  to  be  only  60%.  Therefore,  40%  of  the  cells  
analysed   were   unable   to   generate   PLA   signals   as   they   were   not   co-­transfected.  
This  will  have  decreased  the  mean  PLA  signals  per  cell  and  thus  underestimate  the  
interaction   between   coilin   and  C9orf72S.  Because   coilin   is   a   nuclear   protein,   one  
might   think   that  coilin  would   interact  more  strongly  with   the  C9orf72  short   isoform,  
which   has   a   stronger   nuclear   presence   than   C9orf72   long.   Interestingly,   the   PLA  
showed   that   coilin   and   C9orf72   were   in   close   proximity   in   both   the   nucleus   and  
cytoplasm.   This   result   was   unexpected,   as   coilin   has   been   shown   to   have   two  
nuclear   localisation   signals  and  has  not   been  detected   in   the   cytoplasm   in  any  of  
our   or   others’   experiments   by   western   blotting   or   immunofluorescence   (Carmo-­
Fonseca  et  al.,  1993).  One  study  has  described  the  shuttling  of  coilin  between  the  
nucleus   and   cytoplasm   in  Xenopus  oocytes,   suggesting   there   could   be   some   low  
levels  of  coilin  in  the  cytoplasm,  but  there  is  a  lack  of  evidence  for  a  shuttling  coilin  
protein  in  a  human  cell  model  (Bellini  and  Gall,  1999).  Coilin  interacts  with  multiple  
proteins   and   RNAs   in   the   SMN   complex   which   shuttles   between   the   nucleus,  
cytoplasm   and   Cajal   bodies   (Hebert   et   al.,   2001;;   Toyota   et   al.,   2010;;   Xu   et   al.,  
2005).   C9orf72S   has   also   been   suggested   to   have   a   role   in   nucleocytoplasmic  
shuttling  due   to   its   localisation  pattern  and   interactions  with  nuclear  pore  complex  
proteins  Importin  b1  and  Ran-­GTPase  (Xiao  et  al.,  2015).  Therefore,  the  interaction  
between   C9orf72   and   coilin  may   be   facilitating   trafficking   of   proteins   and/or   RNA  
complexes   between   the   nucleus   and   cytoplasm.   Coilin   has   also   been   shown   to  
undergo  degradation  by  the  ubiquitin  proteasome  system  in  the  cytoplasm.  Coilin  is  
ubiquitinated   by   the   Mdm2   ubiquitin   ligase   in   the   nucleus   and   exported   to   the  
cytoplasm  where  it   is  targeted  to  the  proteasome  for  degradation  (Cantarero  et  al.,  
2015).  The  close  proximity  between  C9orf72  and  coilin   in   the  cytoplasm  may   then  
be  linked  with  coilin  protein  degradation.  Additionally,  coilin  will  also  be  available  for  
binding  by  C9orf72  after  it’s  translation  in  the  cytoplasm.    
  
Of  note,  PLA  signals  were  also  generated  in  cells  which  were  transfected  with  myc-­
C9orf72   but   only   received   anti-­myc   antibody,   suggesting   there   was   some   non-­
specific   binding   of   the   rabbit   secondary   PLA   probe   to   myc-­C9orf72.   These   non-­
specific   PLA   signals   were   significantly   less   in   number   versus   the   PLA   signals  
generated  in  cells  which  received  both  anti-­myc  and  anti-­coilin  antibody,  suggesting  
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we   could   detect   true   C9orf72-­coilin   interactions   in   cells   which   received   both   anti-­
myc   and   anti-­coilin   antibodies.   It   should   be   taken   into   consideration   that   some   of  
these  PLA  signals  would  be  generated   from   the  non-­specific   binding  of   the   rabbit  
PLA   probe   to   myc-­C9orf72   and   do   not   represent   a   genuine   C9orf72-­coilin  
interaction.    
  
When   these   experiments   were   conducted,   antibodies   recognising   endogenous  
C9orf72   were   not   available   and   so   the   interaction   was   confirmed   using  
overexpressed  myc-­C9orf72.  Now,  an  anti-­C9orf72  antibody  is  available  which  was  
shown   in   the   previous   chapter   to   successfully   detect   C9orf72,   and   these  
experiments  could  be   repeated   to   investigate   the   interaction  between  endogenous  
C9orf72  and  coilin.  Apart   from   the   in  vitro  GST-­binding  assay,   the   interaction  was  
investigated   in   the   HEK293   cell   line,   which   was   beneficial   for   confirming   that   the  
interaction  does  take  place  in  vivo.  However,  the  C9orf72  mutation  causes  death  of  
motor  neurons,  and  to  determine  if  the  C9orf72-­coilin  interaction  is  relevant  in  ALS,  
the   Co-­IP   and   PLA   experiments   could   also   be   performed   on   a   primary   neuron  
culture.   It   would   be   especially   interesting   to   perform   the   PLA   on   the   rat   cortical  
neurons  in  which  mVenus-­C9orf72S  forms  nuclear  speckles,  to  see  if  an  interaction  
with  coilin  is  localised  to  these  speckles.    
  
By   using   different   methods   to   study   the   interaction,   it   imparts   confidence   the  
interaction  is  real  and  likely  has  a  biological  function.  Coilin  has  an  N-­terminal  self-­
association   domain,   a   central   highly   disordered   region   and   a   C-­terminal   tudor  
domain  which  facilitates  protein-­protein  interactions.  It  would  therefore  be  predicted  
that   the   interaction   with   C9orf72   is   taking   place   via   the   C-­terminal   domain.  
Conversely,   both  C9orf72   isoforms  were   shown   to   interact   with   coilin,   suggesting  
coilin   binding   is   on   the   C9orf72   N-­terminal   longin   domain.   A   Dlongin-­C9orf72  
construct   could   be   generated   and   used   in   the  Co-­IP   experiments   to   confirm   this.  
The   PLA   results   suggest   this   is   both   a   nuclear   and   cytoplasmic   interaction.  
However,  coilin   is  best  known  for   its  role   in  scaffolding  Cajal  bodies.  Spliceosomal  
snRNPs   undergo   a   complicated   processing   pathway   that   moves   between   the  
nucleus,   Cajal   bodies   and   cytoplasm,   described   in   detail   in   section   1.8.2.1   and  
reviewed   in   (Matera  and  Wang,  2014).  The   role  of  Cajal  bodies   in   this  pathway   is  
thought   to   involve   snRNP   remodelling   and  maturation.   Therefore,   it   could   be   that  
C9orf72   is   involved   in   the   processing   or   trafficking   of   splicing   machinery  
components,   and   encounters   coilin   in   this   pathway.   The   immunofluorescence  
experiments   suggest   C9orf72   is   not   enriched   in   Cajal   bodies   but   the   consensus  
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view   is   that   Cajal   bodies   concentrate   spliceosome   components   to   increase  
efficiency   of   the   processing   reactions,   but   that   these   also   occur   throughout   the  
nucleoplasm   at   a   slower   rate   (Klingauf   et   al.,   2006;;   Pena   et   al.,   2001).   This   is  
supported   by   the   fact   CBs   are   non-­essential   and   are   absent   in   certain   cell   types  
(Tucker   et   al.,   2001;;   Young   et   al.,   2001).   Also,   the   protein   components   of   Cajal  
bodies   are   predominantly   dispersed   throughout   the   nucleus,   and   not   all   coilin-­
interacting   proteins   exhibit   concentrated   localisation   in  Cajal   bodies   (Cantarero   et  
al.,  2015;;  Ogg  and  Lamond,  2002).  The  next  chapter  explores  what  effect  C9orf72  
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5   C9orf72  influences  Cajal  body  numbers  
  
5.1   Introduction  
  
Coilin   is   the   major   protein   component   of   nuclear,   membrane-­less   suborganelles  
called  Cajal   bodies.   They  measure  approximately   0.1-­0.5  μm   in   diameter   and   the  
number  of  Cajal  bodies  per  nucleus  varies  by  cell  type,  but  typically  is  between  0-­10  
(Ogg  and  Lamond,  2002).  Cajal  bodies  are  dynamic  structures  and  the  number  and  
size  of  Cajal  bodies  has  been  shown   to  be  affected  by  many   factors  such  as  cell  
cycle   and   the   transcriptional   activity   of   cells.   For   example,  Cajal   bodies   are  more  
numerous  in  cells  with  a  higher  transcription  and  splicing  demand,  such  as  neurons  
and   transformed   cell   lines   (Pena   et   al.,   2001;;   Spector   et   al.,   1992;;   Young   et   al.,  
2001).   
  
Cajal   bodies   are   involved   in   the   processing   and   maturation   of   the   small   nuclear  
ribonucleoproteins   (snRNPs)   that   make   up   the   splicing   machinery.   snRNPs   go  
through   a   complicated   pathway   of   modifications   in   the   nucleus   and   cytoplasm  
before   they   are   fully   functional;;   it   has   been   proposed   that   snRNPs   enter   Cajal  
bodies   twice   during   this   pathway   where   RNP-­remodelling   and   RNA-­processing  
takes  place,  discussed  in  detail  in  Section  1.8.2.1.  Cajal  bodies  can  be  visualised  by  
immunofluorescence  using  antibodies  against  coilin  and  SMN,  the  two  major  protein  
markers  of  Cajal  bodies.  Coilin  acts  as  a  scaffolding  protein  which  mediates  protein-­
protein  and  protein-­RNA  interactions  between  the  Cajal  body  components,  allowing  
snRNP  processing  to  occur  efficiently  (Boisvert  et  al.,  2002;;  Hebert  et  al.,  2001;;  Xu  
et  al.,  2005).  Coilin   localisation  within  Cajal  bodies   is  essential   for  canonical  Cajal  
body  formation  and  function  (Hebert  and  Matera,  2000;;  Tucker  et  al.,  2001).    
  
Loss   of   Cajal   bodies   in   Spinal   Muscular   Atrophy   and   the   association   between  
several  ALS-­linked  proteins  and  Cajal  bodies  suggests  they  could  be  defective  and  
contribute   to   pathology   in   neurodegenerative   disorders   (Boulisfane   et   al.,   2011;;  
Wang  et  al.,  2002).  In  the  previous  chapter,  we  showed  that  C9orf72  interacts  with  
coilin.   Haploinsufficiency   of   C9orf72   is   hypothesised   to   contribute   to   ALS  
pathogenesis,  and  therefore  this  chapter  investigates  the  effect  of  C9orf72  on  Cajal  
bodies.  C9orf72   protein  was   overexpressed   or   depleted   in  HEK293   cells,   primary  
neurons   and   iAstrocyte   patient   cell   lines   and   Cajal   bodies   investigated   by  
immunofluorescence  using  an  anti-­coilin  antibody.    
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5.2   Results  
  
5.2.1   C9orf72  overexpression  reduces  the  number  of  Cajal  bodies  in  
HEK293  cells  
  
To   investigate   the   effect   of   C9orf72   on   Cajal   bodies,   the   short   and   long   C9orf72  
isoforms   were   overexpressed   in   HEK293   cells.   Cells   were   transfected   with   beta-­
galactosidase  (control),  myc-­C9orf72  short  or  myc-­C9orf72  long.  Beta-­gal  was  used  
as   a   control   for   protein   expression   and   was   not   expected   to   repeat   the   effect   of  
transfection  and  overexpression   in  HEK293  cells,   so  we  can  observe  any  specific  
effect   of   C9orf72.   Twenty-­four   hours   post-­transfection,   cells   were   fixed   and  
immunostained   using   an   anti-­beta-­galactosidase   antibody   or   anti-­myc   antibody   to  
confirm   transfections   were   successful.   Co-­immunostaining   with   an   anti-­coilin  
antibody   was   used   to   visualise   Cajal   bodies   in   cells,   which   appeared   as   bright  
spherical   foci   in   the  nucleus   (Figure  5.1A).  To  determine   if  C9orf72  affected  Cajal  
body   numbers,   the   mean   number   of   Cajal   bodies   per   cell   was   quantified.   Cells  
transfected  with  either  myc-­C9orf72S  or  myc-­C9orf72L  had  an  approximate  30%  or  
50%  decrease   in  mean  Cajal   bodies   in   comparison   to   cells   transfected  with  beta-­
galactosidase,   respectively   (Figure   5.1B).   To   visualise   the   effects   of   C9orf72  
expression   on   individual   cells   we   plotted   the   frequency   distribution   of   cells  
containing  between  0-­7  Cajal   bodies.  The   frequency  distributions  were   similar   but  
shifted  to  the  left  with  C9orf72S  or  C9orf72L  transfection,  indicating  cells  had  fewer  
Cajal   bodies   after   C9orf72   overexpression   (Figure   5.1C).   The   frequency  
distributions  suggested  the  myc-­C9orf72  transfected  cell  population  had  more  cells  
with  0  and  1  Cajal  bodies  in  comparison  to  the  beta-­gal  control.  To  confirm  this,  the  
percentage   of   cells   with   <   3   Cajal   bodies   per   cell   was   quantified   for   statistical  
analysis.   Both   myc-­C9orf72S   and   myc-­C9orf72L   had   more   cells   with   <   3   Cajal  
bodies   per   cell   (Figure   5.1D).   Collectively,   these   results   suggest   that  
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5.2.2   C9orf72  knockdown  increases  the  number  of  Cajal  bodies  in  
HEK293  cells  
  
Overexpression  of  C9orf72  was  shown   to  decrease  Cajal  bodies   in  HEK293  cells.  
Next,   the   effect   of   C9orf72   knockdown   on   Cajal   bodies   in   HEK293   cells   was  
investigated.  Cells  were  transfected  with  either  a  non-­targeting  control  (NTC)  siRNA  
or   pooled   C9orf72   siRNAs.   After   72   hours,   cells   were   fixed   and   immunostained  
using  anti-­coilin  and  anti-­SMN  antibodies  as  markers  of  Cajal  bodies.  For  both  the  
NTC   and  C9orf72   siRNA,   coilin   and   SMN   showed   perfect   co-­localisation   in   Cajal  
bodies   (Figure   5.2A).   The   SMN   protein,   which   shuttles   between   the   nucleus   and  
cytoplasm   as   part   of   the   SMN   complex,   was   also   dispersed   throughout   the  
cytoplasm.  Cajal  bodies  were  quantified  as  mean  number  of  Cajal  bodies  per  cell  
from  300  cells  (Figure  5.2B).  Cells  which  were  transfected  with  C9orf72  siRNA  had  
increased   Cajal   bodies   in   comparison   to   the   NTC.   The   frequency   distribution   of  
Cajal   bodies   in   the   NTC   and   C9orf72   siRNA   cells   was   plotted   which   showed  
C9orf72   knockdown   cells   had   fewer   cells  with   0,   1   and   2  Cajal   bodies   per   cell   in  
comparison  to  the  NTC  but  more  cells  with  >  4  Cajal  bodies  per  cell  (Figure  5.2C).  
The   significance   of   the   increase   in   cells   containing   >   4  Cajal   bodies   per   cell  was  
statistically  confirmed  in  Figure  5.2D,  with  30%  of  C9orf72  siRNA  cells  containing  >  
4  Cajal   bodies   per   cell   versus  10%  of  NTC  siRNA  cells,   suggesting  a   loss   of   the  
C9orf72   protein   in   HEK293   cells   can   lead   to   an   increase   in   the   number   of   Cajal  
bodies   in   cells.   C9orf72   knockdown  was   confirmed   by  measuring  C9orf72  mRNA  
levels   by   RT-­qPCR   which   showed   an   average   50%   reduction   across   the   three  
experiments  (Figure  5.2E).    
Figure  5.1.  C9orf72  overexpression  decreases  Cajal  bodies  in  HEK293  cells.  (A)  HEK293  
cells   were   transfected   with   Beta-­Galactosidase   (control),   myc-­C9orf72S   or   myc-­C9orf72L.  
Cells  were  fixed  and  immunostained  using  anti-­Beta-­Gal  antibody  or  anti-­myc  antibody  (9B11)  
(red)   and   anti-­coilin   antibody   (green)   for   Cajal   body   staining.   Scale   bar   =   10   µm.   (B)  
Quantification   of   number   of   Cajal   bodies   per   cell.   Data   represent   mean   ±   SEM;;   One-­way  
ANOVA  with  Dunnett’s   test,   ****   p   ≤   0.0001.   n=300   cells   from   3   replicate   experiments.   (C)  
Frequency  distribution  of  Cajal   bodies.  Data   represent  mean  ±  SEM;;  n=3  experiments   (100  
cells  per  experiment).  (D)  Cells  were  quantified  for  percentage  of  cells  with  <  3  Cajal  bodies.  
Data   represent   mean   ±   SEM;;   One-­way   ANOVA   with   Dunnett’s   test,   *   p   ≤   0.05.   n=3  
experiments  (100  cells  per  experiment).  

































Figure  5.2.  C9orf72  knockdown   increases  Cajal  bodies   in  HEK293  cells.   (A)  HEK293  cells  
were   transfected  with  NTC  or  C9orf72   siRNA.  Cells   were   fixed  and   immunostained  using  anti-­
coilin  antibody  (green)  for  Cajal  body  staining.  Scale  bar  =  10  µm.  (B)  Quantification  of  number  of  
Cajal  bodies  per  cell.  Data  represent  mean  ±  SEM;;  Unpaired  t-­test,  ****  p  ≤  0.0001.  n=300  cells  
from   3   replicate   experiments.   (C)   Frequency   distribution   of   Cajal   bodies.   Mean   ±   SEM;;   n=3  
experiments  (100  cells  per  experiment).  (D)  Cells  were  quantified  for  percentage  of  cells  with  >  4  
Cajal   bodies.   Mean   ±   SEM;;   Unpaired   t-­test,   *   p   ≤   0.05.   n=3   experiments   (100   cells   per  
experiment).  (E)  C9orf72  knockdown  was  confirmed  by  RT-­qPCR.  Mean  ±  SEM;;  Unpaired  t-­test,  
*  p  ≤  0.05.  n=3  experiments.  
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To   confirm   the   increase   in   the   number   of   Cajal   bodies   observed   after   C9orf72  
knockdown  was  specific   to  a   loss  of  C9orf72  protein  as  opposed   to  an  siRNA  off-­
target  effect,   the   two  C9orf72  siRNAs  were   transfected  separately  and  Cajal  body  
numbers   analysed.   The   C9orf72   siRNAs   have   different   sequences   and   target  
different  exons  of  C9orf72,  hence  the  likelihood  of  them  yielding  the  same  off-­target  
effect  is  improbable.  HEK293  cells  were  transfected  with  NTC,  C9orf72  #2,  C9orf72  
#D  or  C9orf72   pooled   siRNA.  Cells  were   fixed   and   immunostained   using   an   anti-­
coilin   antibody   as   a  marker   of  Cajal   bodies   (Figure   5.3A).   The   individual  C9orf72  
siRNAs  as  well  as  the  pooled  transfection  led  to  an  increase  in  the  mean  number  of  
Cajal   bodies   per   cell   (Figure   5.3B).  Analysis   of   the   frequency  distribution  of  Cajal  
bodies  in  the  different  conditions  showed  that  cells  that  received  C9orf72  siRNA  had  
more  cells  with  >  2  Cajal  bodies  per  cell  in  comparison  to  the  NTC.  The  percentage  
of  cells  with  1  or  2  Cajal  bodies  per  cell  was  also  dramatically  decreased  in  C9orf72  
siRNA  cells  versus  the  NTC.  Successful  knockdown  of  C9orf72  was  determined  by  
measuring   the   C9orf72   mRNA   levels   by   RT-­qPCR   which   showed   a   40-­50%  
decrease   in  C9orf72  mRNA   levels  with  all  C9orf72  siRNAs.  Both  C9orf72  siRNAs  
caused  an  increase  in  Cajal  body  number  when  used  individually,  suggesting  a  loss  
of  the  C9orf72  protein  can  directly  influence  Cajal  bodies  in  HEK293  cells.    
  
  


































Figure  5.3.   Individual  C9orf72  siRNA   transfection   increases  Cajal  bodies.   (A)  HEK293  
cells  were  transfected  with  NTC,  C9orf72  #2,  C9orf72  #D  or  C9orf72  pool  siRNA.  Cells  were  
fixed  and  immunostained  using  anti-­coilin  antibody  (green)  for  Cajal  body  staining.  Scale  bar  
=  10  µm.  (B)  Quantification  of  number  of  Cajal  bodies  per  cell.  Data  represent  mean  ±  SEM;;  
One-­way   ANOVA   with   Dunnett’s   test,   ***   p   ≤   0.001,   ****   p   ≤   0.0001.   n=100   cells.   (C)  
Frequency  distribution  of  Cajal  bodies,  n=1.   (D)  C9orf72  knockdown  was  confirmed  by  RT-­
qPCR.  Mean  ±  SEM;;  One-­way  ANOVA  with  Dunnett’s   test,   **  p  ≤  0.01,   ***  p  ≤  0.001.  n=3  
triplicates  from  1  experiment.  
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5.2.3   C9orf72  overexpression  partially  rescues  Cajal  bodies  after  
C9orf72  knockdown  
  
If  the  increase  in  Cajal  bodies  was  specific  to  a  loss  of  C9orf72,  it  was  hypothesised  
that  Cajal  body  numbers  would  be  restored  with  rescue  transfections  of  the  C9orf72  
protein.  HEK293  cells  were  transfected  with  NTC  or  C9orf72  pooled  siRNAs.  After  
72   hours,   cells   were   transfected   with   pCI-­neo   (empty   vector   control),   siRNA  
resistant   myc-­C9orf72S   or   siRNA   resistant   myc-­C9orf72L.   The   generation   of   the  
siRNA   resistant  myc-­C9orf72   constructs   is   described   in  Chapter   3,   Section   3.2.3.    
Cells   were   fixed   and   co-­stained   using   anti-­myc   and   anti-­coilin   antibodies,   for  
detection   of   myc-­C9orf72   and   Cajal   bodies   respectively   (Figure   5.4A).   As   seen  
before,  the  number  of  Cajal  bodies  was  increased  in  C9orf72  siRNA  cells  versus  the  
NTC   (Figure   5.4B).   There   was   a   partial   rescue   with   myc-­C9orf72S   but   not   myc-­
C9orf72L   transfection;;   expression   of   myc-­C9orf72S   significantly   decreased   the  
number  of  Cajal  bodies  per  cell   in  comparison   to  C9orf72  siRNA  cells   transfected  
with   empty   vector   (Figure   5.4B).   The   frequency   distributions   showed   C9orf72  
siRNA/EV  cells  had  considerably  fewer  cells  that  contained  1  Cajal  body  versus  the  
NTC/EV,  consistent  with  previous  results  (Figure  5.4C).  The  frequency  distributions  
of   the   myc-­C9orf72   rescue   transfections   were   more   similar   in   appearance   to   the  
NTC   distribution   than   the   C9orf72   siRNA   distribution,   suggesting   that  
overexpression   of   the   C9orf72   proteins   could   rescue   Cajal   bodies   to   normal  
numbers.  The  exception  to  this  was  a  higher  percentage  of  cells  with  6  Cajal  bodies  
per   cell   in   the   myc-­C9orf72L   rescue   transfection   in   comparison   to   all   other  
conditions.   C9orf72   knockdown   was   confirmed   as   a   60%   reduction   in   C9orf72  
mRNA  by  RT-­qPCR  (Figure  5.4D).  The  results  suggest  loss  of  the  C9orf72  protein  
can   lead   to  an   increase   in  Cajal  bodies   in  HEK293  cells,  and  reintroduction  of   the  
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5.2.4   The  number  of  Cajal  bodies  are  increased  in  a  C9orf72  knockout  
cell  line  
  
Knockdown   of  C9orf72   using   two   individual   siRNAs  was   shown   to   increase  Cajal  
bodies   in   HEK293   cells,   and   overexpression   of   the   C9orf72   proteins   showed   a  
minor  rescue  of  the  number  of  Cajal  bodies.  siRNA  is  an  acute  method  of  reducing  
protein   expression   but   in   ALS   patients   we   would   expect   to   see   a   long-­term  
reduction   in  C9orf72.  To  investigate  the  chronic  effects  of  C9orf72  depletion,  Cajal  
bodies  were  investigated  in  B2  cells.  The  B2  cell  line  was  generated  from  HEK293  
cells   that   underwent   CRISPR/Cas9   gene   editing   to   stably   knockout   the   C9orf72  
gene  and   is   described   in  Chapter   3,  Section   3.2.1.     HEK293   cells   (control)   or  B2  
cells  were   transfected  with  pCI-­neo   (empty  vector  control),  myc-­C9orf72S  or  myc-­
C9orf72L.  Cells  were   fixed  and  co-­stained  with  anti-­myc  and  anti-­coilin  antibodies  
for  myc-­C9orf72  and  Cajal  body  detection  respectively  (Figure  5.5A).  As  expected,  
the  B2  cell  line  had  an  increased  number  of  Cajal  bodies  in  comparison  to  HEK293  
cells   (Figure  5.5B).  The  number  of  Cajal  bodies  was  rescued  with  C9orf72  protein  
expression,   but   the   rescue  was   only   significant   with   C9orf72L   (Figure   5.5B).   The  
frequency   distribution   of   Cajal   bodies   in   the   B2   cell   line   shifted   to   the   right   in  
comparison   to   the   HEK293   distribution,   suggesting   more   cells   contained   higher  
numbers   of  Cajal   bodies   (Figure  5.5C).   Transfection  with   both  myc-­C9orf72S  and  
myc-­C9orf72L  in  the  B2  cell  line  caused  the  frequency  distribution  to  shift  to  the  left  
suggesting   expression   of   the   C9orf72   isoforms   can   rescue   Cajal   body   numbers  
(Figure  5.5C).  Observation  of  the  images  and  frequency  distributions  suggested  the  
biggest  change  in  Cajal  bodies  between  B2  and  HEK293  cells  appeared  to  be  in  the  
number   of   cells   that   contained   >   4   Cajal   bodies   per   cell.   This   was   confirmed   by  
Figure   5.4.   C9orf72   expression   rescues   Cajal   body   numbers   after   C9orf72  
knockdown   in  HEK293  cells.   (A)  HEK293  cells  were   transfected  with  NTC  or  C9orf72  
siRNA.  Post-­knockdown,  cells  were   transfected  with  pCI-­neo  (empty  vector  control;;  EV),  
myc-­C9orf72S   siRNA   resistant   or   myc-­C9orf72L   siRNA   resistant   for   re-­introduction   of  
C9orf72   expression.   Cells   were   fixed   and   immunostained   using   anti-­myc   antibody   (red)  
and   anti-­coilin   antibody   (green)   for   Cajal   body   staining.   Scale   bar   =   10   µm.   (B)  
Quantification  of  number  of  Cajal  bodies  per  cell.  Data  represent  mean  ±  SEM;;  One-­way  
ANOVA  with  Tukey’s  test,  *  p  ≤  0.05,  **  p  ≤  0.01.  n  (cells)  =  NTC/EV:  116,  C9  siRNA/EV:  
116,  C9   siRNA/C9S:  62,  C9   siRNA/C9L:   63.   (C)  Frequency  distribution  of  Cajal   bodies,  
n=1.  (D)  C9orf72  knockdown  was  confirmed  by  RT-­qPCR.  Mean  ±  SEM;;  Unpaired  t-­test,  
**  p  ≤  0.01.  n=3  triplicates  from  1  experiment.  
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quantification  of   the  percentage  of  cells   that  had  >  4  Cajal  bodies  per  cell   (Figure  
5.5D).  The  percentage  of  cells  with  >  4  Cajal  bodies  was  two-­fold  higher  in  the  B2  
cell   line   versus  HEK293   cells.   Interestingly,   expression   of   both   the  C9orf72   short  
and  long  isoform  rescued  the  percentage  of  cells  with  >  4  Cajal  bodies  in  B2  cells  to  
normal   levels   (Figure  5.5D).  However,   there  was  no   statistical   significance  across  
these   differences.   The   increase   in   Cajal   bodies   after   both   transient   and   stable  
C9orf72  knockdown  strongly  suggests  a  role  of  C9orf72  in  Cajal  body  regulation  in  
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5.2.5   C9orf72  has  no  effect  on  the  number  of  Cajal  bodies  in  rat    
primary  neurons  
  
The   results   in   this   chapter   have   so   far   suggested   C9orf72   can   influence   Cajal  
bodies  in  the  HEK293  cell  line.  Of  most  interest,  loss  of  C9orf72  led  to  an  increase  
in  Cajal  bodies   in   the  nucleus.  Haploinsufficiency  of   the  C9orf72  protein  has  been  
proposed   to   contribute   to   motor   neuron   degeneration   in   ALS.   We   therefore   next  
investigated   the  effect  of  C9orf72  on  Cajal  bodies   in  a  primary  neuron  cell  model.  
Rat   cortical   neurons   were   prepared   and   transduced   at   5   DIV   with   4   transducing  
units  of  lentivirus  expressing  GFP  (control),  mVenus-­C9orf72S  or  mVenus-­C9orf72L  
by  Miss  Rebecca  Cohen.  At  12  DIV,  neurons  were  fixed  and  immunostained  using  
an   anti-­coilin   antibody   to   mark   Cajal   bodies.   mVenus-­C9orf72S   formed   nuclear  
speckles   but   these   did   not   show   co-­localisation   with   Cajal   bodies   (Figure   5.6A).  
GFP   and   mVenus-­C9orf72L   appeared   dispersed   throughout   the   neurons.  
Quantification   of   the   number   of   Cajal   bodies   per   cell   showed   there   was   no  
difference  between  mVenus-­C9orf72L  expressing  neurons  and  GFP,  but  suggested  
there   was   a   slight   increase   in   the   number   of   Cajal   bodies   in   mVenus-­C9orf72S  
expressing   neurons   (Figure   5.6B).   However,   the   frequency   distributions   of   Cajal  
bodies  in  GFP,  mVenus-­C9orf72S  and  mVenus-­C9orf72L  neurons  were  very  similar  
(Figure   5.6C),   suggesting   overexpression   of  C9orf72   in   neurons   has   no   effect   on  








Figure  5.5.  C9orf72  expression  rescues  Cajal  body  numbers  in  the  B2  CRISPR  line.  
(A)  Cells  were  transfected  with  pCI-­neo  (empty  vector  control;;  EV),  myc-­C9orf72S  or  myc-­
C9orf72L.   Cells   were   fixed   and   immunostained   using   anti-­myc   antibody   (red)   and   anti-­
coilin   antibody   (green)   for   Cajal   body   staining.   Scale   bar   =   10   µm.   (B)  Quantification   of  
number   of   Cajal   bodies   per   cell.   Data   represent   mean   ±   SEM;;   One-­way   ANOVA   with  
Tukey’s  test,  *  p  ≤  0.05,  **  p  ≤  0.01.  n  (cells  from  3  replicate  experiments)  =  293/EV:  291,  
B2/EV:  314,  B2/C9S:  110,  B2/C9L:  194.  (C)  Frequency  distribution  of  Cajal  bodies.  Mean  
±  SEM;;  n=3  experiments   (D)  Cells  were  quantified   for  percentage  of  cells  with  >  4  Cajal  
bodies.  Mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s  test.  n=3  experiments.  
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Figure  5.6.  Cajal  bodies  in  rat  cortical  neurons  after  C9orf72  overexpression.  (A)  5  DIV  
rat   cortical   neurons   were   transduced   with   GFP   (control),   mVenus-­C9orf72S   or   mVenus-­
C9orf72L.   Neurons   were   fixed   at   12   DIV   and   immunostained   using   anti-­coilin   antibody  
(magenta)   for  Cajal  body  staining.  Scale  bar  =  10  µm.   (B)  Quantification  of  number  of  Cajal  
bodies  per   cell.  Data   represent  mean  ±   SEM;;  One-­way  ANOVA  with  Dunnett’s   test,   ***   p   ≤  
0.001.  n  =  approximately  300  cells  from  3  replicate  experiments  (C)  Frequency  distribution  of  
Cajal  bodies.  Mean  ±  SEM;;  n=3  experiments.  Neurons  were  prepared  and  transduced  by  Miss  
Rebecca  Cohen.  
   183  
  
In  HEK293  cells,  knockdown  of  C9orf72  caused  an  increase  in  Cajal  bodies.  Here,  
C9orf72  was  knocked  down  in  rat  hippocampal  neurons  to  investigate  if  the  result  is  
repeatable   in   a   primary   cell  model.  Rat   hippocampal   neurons  were   prepared   and  
transduced   at   5  DIV  with   4   transducing   units   of   lentivirus   expressing   either  GFP-­
NTC-­miRNA  (control)  or  GFP-­C9orf72-­miRNA  by  Miss  Rebecca  Cohen.  At  12  DIV,  
neurons  were  fixed  and  immunostained  using  an  anti-­coilin  antibody  for  Cajal  body  
detection  (Figure  5.7A).  Quantification  of  the  mean  number  of  Cajal  bodies  per  cell  
showed  there  was  no  difference  in  Cajal  bodies  in  neurons  transduced  with  NTC  or  
C9orf72  miRNA  (Figure  5.7B).  In  addition,  the  frequency  distribution  of  Cajal  bodies  
in   NTC   and   C9orf72   miRNA   neurons   were   the   same,   confirming   knockdown   of  
C9orf72   in   rat   hippocampal   neurons   did   not   change   the   number   of   Cajal   bodies  
(Figure   5.7C).   C9orf72   knockdown   was   confirmed   by   measuring   C9orf72   mRNA  
levels   by   RT-­qPCR   and   on   average   was   reduced   by   approximately   50%   (Figure  
5.7D).   Interestingly,   overexpression   and   knockdown   of   C9orf72   in   primary   rat  
neurons  did  not  appear   to   influence  Cajal  bodies  as  was  observed   in   the  HEK293  
































































Figure  5.7.  C9orf72  knockdown   in  rat  hippocampal  neurons  does  not  change  Cajal  
bodies.   (A)   5   DIV   rat   hippocampal   neurons   were   transduced   with   GFP-­NTC   or   GFP-­
C9orf72   miRNA.   Neurons   were   fixed   at   12   DIV   and   immunostained   using   anti-­coilin  
antibody   (magenta)   for   Cajal   body   staining.   Scale   bar   =   10   µm.   (B)   Quantification   of  
number   of  Cajal   bodies  per   cell.  Data   represent  mean  ±  SEM;;  Unpaired   t-­test.   n   =  210  
cells   from   2   replicate   experiments   (C)   Frequency   distribution   of   Cajal   bodies.   Mean   ±  
SEM;;   n=2   experiments.   (D)   C9orf72   knockdown   was   confirmed   by   RT-­qPCR.   Mean   ±  
SEM;;   Unpaired   t-­test,   **   p   ≤   0.01.   n=2   experiments.   Neurons   were   prepared   and  
transduced  by  Miss  Rebecca  Cohen.  
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5.2.6   Investigating  Cajal  bodies  in  C9orf72-­ALS  iAstrocyte  cell  lines  
  
Manipulation  of  C9orf72  protein  levels  has  been  shown  to  influence  Cajal  bodies  in  
HEK293   cells   but   not   primary   rat   neurons.   To   consider   the   relevance   of   C9orf72  
and   Cajal   bodies   in   ALS,   we   implemented   C9orf72-­ALS   iAstrocyte   cell   lines,  
generously  developed  and  provided  by  Dr  Laura  Ferraiuolo.  The   iAstrocytes  were  
differentiated   from  induced  neural  progenitor  cells   from  three  C9-­ALS  patients  and  
three  non-­ALS  healthy  controls  (Meyer  et  al.,  2014).  The  iAstrocyte  cell  model  was  
selected   because   their   differentiation   protocol   is   fully   optimised   and   can   be  
generated   with   ease.   In   addition,   they   have   been   well   characterised   and   the  
C9orf72-­ALS   patient   cells   have   been   shown   to   recapitulate   C9-­ALS  
neuropathological  hallmarks  e.g.  RNA  foci  and  defective  autophagy  (Webster  et  al.,  
2016).   The   C9-­ALS   iAstrocyte   lines   were   investigated   by   Dr   Laura   Ferraiuolo   for  
their   C9orf72   mRNA   levels   by   performing   RT-­qPCR   on   RNA   extracted   from   the  
iAstrocyte  cells  and  normalising  C9orf72  mRNA  to  GAPDH  mRNA.  All  were  found  to  
have  decreased  C9orf72  mRNA  levels   in  comparison   to  controls   (Table  5.1).  RNA  
foci  have  been  confirmed  in  the  C9-­ALS  iAstrocyte  lines  by  Dr  Adrian  Higginbottom  
and  the  presence  of  DPR  proteins  is  yet  to  be  confirmed  (Hautbergue  et  al.,  2017).  
  
iAstrocyte  line   Sex   Age  at  biopsy  
collection  (years)  






F   69   -­   0.99  
Non-­ALS  control  
155  
M   40   -­   0.99  
Non-­ALS  control  
3050  
M   55   -­   1.02  
C9-­ALS  patient  
201  
F   66   19.4   0.43  
C9-­ALS  patient  
183  
M   50   27   0.35  
C9-­ALS  patient  
78  
M   66   31.7   0.29  
  
Table   5.1.   Age,   sex   and   C9orf72   mRNA   levels   of   iAstrocyte   lines.   Three   non-­ALS  
control  and  three  C9-­ALS  patient  iAstrocyte  lines  were  used.  Sex,  age  at  biopsy  collection,  
onset  to  death  and  relative  C9orf72  mRNA  levels  are  documented.  Relative  C9orf72  mRNA  
levels  were  determined  by  RT-­qPCR  by  Dr  Laura  Ferraiuolo.  
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Non-­ALS  control  209  and  C9-­ALS  patient  201  were  age  and  sex  matched  as  pair  1.  
iAstrocytes  were  transfected  with  pCI-­neo  (empty  vector  control),  myc-­C9orf72S  or  
myc-­C9orf72L.   Cells   were   fixed   and   immunostained   with   anti-­myc   and   anti-­coilin  
antibodies   for  myc-­C9orf72  and  Cajal  body  visualisation  respectively.   Interestingly,  
control   209   iAstrocytes   contained   very   few   or   no   Cajal   bodies   (Figure   5.8A).  
Conversely,  all  patient  201  iAstrocytes,  including  myc-­C9orf72  transfected  cells,  had  
detectable  Cajal  bodies  (Figure  5.8A).  Quantification  of  the  number  of  Cajal  bodies  
per   cell   showed   patient   iAstrocytes   had   significantly   more   Cajal   bodies   in  
comparison   to   control   cells   (Figure   5.8B).   Expression   of   myc-­C9orf72S   had   no  
effect  on  the  number  of  Cajal  bodies  in  these  cells,  but  expression  of  myc-­C9orf72L  
interestingly   appeared   to   increase   Cajal   body   numbers   (Figure   5.8B).   The  
frequency   distribution   of   Cajal   bodies   in   the   control   209   iAstrocytes   showed   that  
most  cells  did  not  contain  Cajal  bodies,  but  approximately  10%  had  1  (Figure  5.8C).  
There  was  no  apparent  difference  in  the  frequency  distributions  between  the  empty  
vector,  myc-­C9orf72S  or  myc-­C9orf72L  transfected  patient  209  iAstrocytes  showing  
C9orf72  protein  expression   in   these  cells  did  not   rescue  Cajal  body  numbers.  The  
results  suggest  in  the  iAstrocyte  pair  1,  Cajal  bodies  are  increased  in  ALS  cells  but  
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Figure  5.8.  Cajal  bodies  are   increased   in  C9ALS   iAstrocyte  cells   from  control/patient  
pair  1.  (A)  iAstrocyte  cells  derived  from  control  (Ctrl  209)  or  C9ALS  patient  (Pat  201)  iPSC’s  
were   transfected  with  pCI-­neo   (empty  vector  control;;  EV),  myc-­C9orf72S  or  myc-­C9orf72L.  
Cells  were  fixed  and  immunostained  using  an  anti-­myc  antibody  (red)  or  anti-­coilin  antibody  
(green)  as  a  Cajal   body  marker.   Scale  bar  =  10  µm.   (B)  Quantification  of   number  of  Cajal  
bodies  per  cell.  Data  represent  mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s  test.  **  p  ≤  0.01,  
****   p   ≤   0.0001.   n   (cells)   =   209/EV:   131,   201/EV:   131,   201/C9S:   30,   201/C9L:   30.   (C)  
Frequency   distribution   of   Cajal   bodies,   n=1.   iAstrocytes   were   generated   by   Dr   Laura  
Ferraiuolo.  
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We  next  looked  at  Cajal  bodies  in  age  and  sex  matched  iAstrocyte  pair  2:  non-­ALS  
control  155  and  C9-­ALS  patient  183.  Control  155   iAstrocytes  did  not  contain  Cajal  
bodies   (Figure   5.9A).  Patient   183   iAstrocytes   had  Cajal   bodies   in  most   cells,   and  
the   Cajal   bodies   remained   after   myc-­C9orf72   transfection   (Figure   5.9A).  
Quantification  of  mean  Cajal  bodies  per  cell  confirmed  patient  183  had  significantly  
more  Cajal  bodies  versus  control  155  (Figure  5.9B).  Of   interest,  overexpression  of  
myc-­C9orf72   short   and   long   proteins   in   the   patient   183   iAstrocytes   led   to   an  
increase   in   the   number   of   Cajal   bodies   per   cell   (Figure   5.9B).   The   frequency  
distribution  of  Cajal  bodies  in  control  iAstrocytes  showed  80%  of  cells  had  no  Cajal  
bodies.  Conversely,  approximately  70%  of  patient  iAstrocytes  contained  1  to  6  Cajal  
bodies  per   cell.   The   frequency  distributions   for   patient   183   iAstrocytes  expressing  
myc-­C9orf72   appeared   similar   to   patient   183   cells   transfected   with   empty   vector,  
but  there  were  fewer  cells  with  0  Cajal  bodies  and  more  cells  with  4+  Cajal  bodies  
per   cell.   Again,   these   results   suggest   Cajal   bodies   are   misregulated   in   C9-­ALS  
patients,   and   expression   of   C9orf72   protein   in   these   cells  may   cause   Cajal   body  
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Figure  5.9.  Cajal  bodies  are   increased  in  C9ALS   iAstrocyte  cells  from  control/patient  
pair  2.  (A)  iAstrocyte  cells  derived  from  control  (Ctrl  155)  or  C9ALS  patient  (Pat  183)  iPSC’s  
were  transfected  with  pCI-­neo  (empty  vector  control;;  EV),  myc-­C9orf72S  or  myc-­C9orf72L.  
Cells  were  fixed  and  immunostained  using  an  anti-­myc  antibody  (red)  or  anti-­coilin  antibody  
(green)  as  a  Cajal  body  marker.  Scale  bar  =  10  µm.   (B)  Quantification  of  number  of  Cajal  
bodies  per  cell.  Data  represent  mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s  test.  *  p  ≤  0.05,  
****   p   ≤   0.0001.   n   (cells)   =   209/EV:   131,   201/EV:   131,   201/C9S:   111,   201/C9L:   111.   (C)  
Frequency   distribution   of   Cajal   bodies,   n=1.   iAstrocytes   were   generated   by   Dr   Laura  
Ferraiuolo.  
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The  final  iAstrocyte  pair  included  non-­ALS  control  3050  and  C9-­ALS  patient  78.  As  
before,   the   cells   were   transfected   with   pCI-­neo   (empty   vector   control),   myc-­
C9orf72S  or  myc-­C9orf72L  before  fixing  and  immunostaining  with  anti-­myc  and  anti-­
coilin  antibodies.  Control  3050   iAstrocytes  had  no  detectable  Cajal  bodies   (Figure  
5.10A).  Most  patient  78  iAstrocytes  had  no  Cajal  bodies,  but  they  could  be  seen  in  a  
small   number   of   cells   (Figure   5.10A).  Quantification   of   the  mean  number   of  Cajal  
bodies  showed  there  was  no  difference  in  Cajal  bodies  between  control  and  patient  
iAstrocytes,   or   after   C9orf72   expression,   although   there   was   a   notable   non-­
significant   increase   in   Cajal   bodies   in   patient   78   iAstrocytes   expressing   myc-­
C9orf72L.   The   frequency   distribution   of   Cajal   bodies   appeared   similar   across   all  
conditions  however  patient  cells  with  C9orf72L  expression  had  a  higher  percentage  
of  cells  containing  >  2  Cajal  bodies  per  cell   (Figure  5.10C).  Here,   it  appeared  C9-­
ALS  patient  78  did  not  have  increased  Cajal  bodies   in  comparison  to  the  non-­ALS  
healthy  controls  but  expression  of  the  C9orf72  long  isoform  may  cause  an  increase  




















































Figure   5.10.   Cajal   bodies   are   unchanged   in   C9ALS   iAstrocyte   cells   from  
control/patient  pair  3.  (A)  iAstrocyte  cells  derived  from  control  (Ctrl  3050)  or  C9ALS  patient  
(Pat  78)  iPSC’s  were  transfected  with  pCI-­neo  (empty  vector  control;;  EV),  myc-­C9orf72S  or  
myc-­C9orf72L.  Cells  were  fixed  and  immunostained  using  an  anti-­myc  antibody  (red)  or  anti-­
coilin   antibody   (green)   as   a  Cajal   body  marker.   Scale   bar   =   10   µm.   (B)  Quantification   of  
number   of   Cajal   bodies   per   cell.   Data   represent   mean   ±   SEM;;   One-­way   ANOVA   with  
Tukey’s  test.  n  =  30  cells.  (C)  Frequency  distribution  of  Cajal  bodies,  n=1.  iAstrocytes  were  
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Figures  5.8-­5.10  represent  the  number  of  Cajal  bodies  in  the  individual  patient  and  
control   iAstrocyte  cells  and  compared  these  within  age  and  sex  matched  pairs.  An  
alternative   representation  of   the  data   can  be   to  group   the   three  non-­ALS  controls  
together   and   compare   these   against   the   combined  C9-­ALS   cell   lines   to   show   the  
difference  between  healthy  vs  disease.  The  same  data  presented   in   this   format   is  
shown   in  Figure  5.11.  As  was  seen   in   the  pairs,  C9-­ALS  patient  cells  contained  a  
significantly   higher   number   of   Cajal   bodies   in   comparison   to   non-­ALS   controls  
(Figure  5.11A).  Overexpression  of   the  C9orf72  short   isoform  had  no  effect  on   the  
number  of  Cajal  bodies  in  C9-­ALS  patients  whereas  expression  of  the  long  isoform  
led  to  an  increase  in  Cajal  bodies  (Figure  5.11A).  The  frequency  distribution  of  Cajal  
bodies   in   non-­ALS   controls   showed   most   cells   had   none   or   only   1   Cajal   body,  
whereas   cells   derived   from   C9-­ALS   patients   had   a   wide   range   of   Cajal   body  















Figure  5.11.  Combined  results  from  the  iAstrocyte  lines.  iAstrocyte  cells  derived  from  non-­
ALS  control  or  C9-­ALS  iPSC’s  were  transfected  with  pCI-­neo  (empty  vector  control;;  EV),  myc-­
C9orf72S  or  myc-­C9orf72L.  Cells  were   fixed  and  immunostained  using  an  anti-­myc  antibody  
(red)  or  anti-­coilin  antibody   (green)  as  a  Cajal  body  marker.   (A)  Quantification  of  number  of  
Cajal  bodies  per  cell.  Data  represent  mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s  test.  *  p  ≤  
0.05,  ****  p  ≤  0.0001.  n  (cells)  =  209/EV:  292,  201/EV:  292,  201/C9S:  171,  201/C9L:  171.  (B)  
Frequency   distribution   of   Cajal   bodies,   n=1.   iAstrocytes   were   generated   by   Dr   Laura  
Ferraiuolo.  
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5.3   Discussion  
  
This   chapter   investigated   the   relationship   between   the   C9orf72   protein   and   Cajal  
bodies.  C9orf72  has  been  shown  to  interact  with  coilin  and  the  best-­known  function  
of   coilin   is   as   the   scaffolding   protein   in   Cajal   bodies.   Hence,   it   was   logical   to  
investigate  whether  there  is  an  effect  on  Cajal  bodies  by  C9orf72.  We  looked  at  this  
relationship   in   three   different   cell  models:  HEK293   cells,   primary   rat   neurons   and  
C9-­ALS  patient   iAstrocytes.   Interestingly,   the   effect   of  C9orf72   on  Cajal   bodies   in  
the  different  cell  models  varied,  suggesting  the  nuclear  function  of  C9orf72  may  be  
cell-­type  specific.    
  
In   the   HEK293   cell   line,   C9orf72   was   shown   to   influence   Cajal   body   numbers.  
Overexpression  of  C9orf72  caused  a  decrease  in  Cajal  bodies  whereas  knockdown  
of  C9orf72  led  to  an  increase  in  Cajal  bodies.  Cajal  bodies  were  increased  in  both  
the  B2  stable  C9orf72  knockout  cell  line  and  in  response  to  transient  knockdown  of  
C9orf72   using   siRNAs.   Expression   of   both   C9orf72   isoforms   in   cells   following  
C9orf72   knockdown   appeared   to   rescue   Cajal   body   numbers,   suggesting   the  
change  in  Cajal  body  numbers  was  a  result  of  a  direct   loss  of  the  C9orf72  protein.  
To   determine   if   the   Cajal   body   phenotype   was   relevant   to   ALS,   anti-­coilin  
immunostaining   was   performed   on   C9orf72-­ALS   iAstrocytes.   Fibroblasts   were  
collected   from   three   non-­ALS   controls   or   three   C9orf72-­ALS   patients   and  
differentiated  into  induced  neural  progenitor  cells.  From  that  stage,  they  were  further  
differentiated   into   iAstrocytes   which   were   shown   to   have   defining   C9-­ALS  
characteristics   such   as   reduced   C9orf72   mRNA   levels   and   RNA   foci   which   was  
personally  communicated  in  house.  Experiments  looking  at  whether  the  iAstrocytes  
produce  DPRs  are  still   to  be  performed.     All  non-­ALS  control   iAstrocytes  had  very  
few   or   no   Cajal   bodies.   Interestingly,   two   of   the   three   C9-­ALS   patients   had  
increased   Cajal   bodies;;   patient   78   had   Cajal   bodies   comparable   to   non-­ALS  
controls.   However,   Cajal   body   numbers   were   not   rescued   with   expression   of   the  
C9orf72   protein,   suggesting   the   increased   Cajal   bodies   were   not   a   response   to  
C9orf72   haploinsufficiency.   Whilst   changes   to   the   number   of   Cajal   bodies   were  
observed   in  HEK293  and   iAstrocyte   cells,   there  was  no  effect   seen   in  primary   rat  
neurons.  Overexpression   and   knockdown  of  C9orf72   in   neurons   had  no   effect   on  
the  number  of  Cajal   bodies.  This   is   likely   due   to   differences   in   the   cells.  HEK293  
and  iAstrocyte  cells  are  mitotically  active  whereas  the  primary  cells  are  post-­mitotic  
neurons  from  rat  cortex  or  hippocampus.  
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Cajal  bodies  are  dynamic  structures  and  their  number  and  appearance  in  cells  has  
been  shown  to  change  in  response  to  a  number  of  different  factors  (Table  5.2).  The  
wide   range   of   Cajal   body   numbers   in   HEK293   cells   suggests   they   are   more  
dynamic  structures  in  transformed  cells.  The  changes  to  Cajal  bodies  listed  in  Table  
5.2  were  all  observed  in  transformed  cell  lines.  Table  5.2  shows  that  manipulation  of  
proteins   that   localise   in  Cajal  bodies  and/or  are   involved   in   the  snRNP  processing  
pathway  can  cause  an  increase  or  decrease  in  Cajal  bodies.  The  integrator  complex  
is   involved   in   the  processing  of   the  3’  end  of  newly   transcribed  snRNAs  (Baillat  et  
al.,   2005).   PHAX   and   CRM1   are   responsible   for   the   nuclear   export   of   snRNAs  
(Fornerod   et   al.,   1997;;   Ohno   et   al.,   2000).   The   SMN   protein   alongside   gemin  
proteins   associates   with   snRNAs   to   form   the   SMN   complex   and   regulate   snRNP  
assembly  in  the  cytoplasm  (Massenet  et  al.,  2002;;  Meister  et  al.,  2001).  Finally,  the  
SmB  protein  is  one  of  the  Sm  proteins  which  forms  the  core  heteroheptameric  ring  
of  snRNPs  (Raker  et  al.,  1996).  Changes  in  these  proteins  influences  Cajal  bodies,  
therefore   it   could   be   that   C9orf72   also   plays   a   part   in   the   snRNP   processing  
pathway.  Fluorescence  imaging  of  C9orf72  in  the  different  cell  lines  does  not  show  
a   concentrated   localisation   in   Cajal   bodies,   therefore   it   is   unlikely   to   be   directly  
involved  in  the  processing  reactions  that  take  place  within  them.  
  
Table  5.2.  Regulating  factors  of  Cajal  bodies.  
Stimulus   Effect  on  Cajal  bodies   Reference  
UV-­C  DNA  damage   Fragmentation   (Cioce  et  al.,  2006)  
Adenovirus  infection   Fragmentation   (Rebelo  et  al.,  1996)  
Serum  starvation   Decrease   (Andrade  et  al.,  1993;;  
Cantarero  et  al.,  2015)  
SMN  overexpression   Increase   (Hao  et  al.,  2007;;  Sleeman  
et  al.,  2003)  
SMN  depletion   Decrease   (Lemm  et  al.,  2006)  
SmB  overexpression   Increase   (Sleeman  et  al.,  2001)  








into  perinucleolar  caps  
(Takata  et  al.,  2012)  
PHAX  depletion   Coilin  mislocalisation  
into  perinucleolar  caps  
(Lemm  et  al.,  2006;;  Takata  
et  al.,  2012)  
CRM1  inhibition   Coilin  mislocalisation  
into  perinucleolar  caps  
(Takata  et  al.,  2012)  
VRK1  depletion   Decrease   (Cantarero  et  al.,  2015)  
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C9orf72   could   be   involved   in   the   nuclear   export   of   snRNAs.   A   study   in  Xenopus  
oocytes   showed   that   U   snRNAs   localise   to   Cajal   bodies   before   export   to   the  
cytoplasm,  and  inhibition  of  the  RNA  exporter  PHAX  caused  an  accumulation  of  the  
U1   snRNA   into  Cajal   bodies   (Suzuki   et   al.,   2010).   The   co-­localisation   of   snRNAs  
with   their  nuclear  export   factors   in  Cajal  bodies  has   led   to   the  wide-­held   idea   that  
Cajal   bodies   act   as   quality   control   sites   where   export   proteins   assemble   onto  
snRNAs  before   trafficking   to   the  cytoplasm.  Failures   in   the  RNA  export  machinery  
therefore   leads  to  an  accumulation  of   immature  snRNAs  which  are   tethered  within  
Cajal  bodies.  A  loss  of  the  C9orf72  protein  could  hence  cause  a  build-­up  of  snRNAs  
in  the  nucleus  which  then  get  ‘stored’  in  Cajal  bodes,  the  number  of  which  increases  
in  response.  In  trying  to  understand  Cajal  body  differences  between  cell   lines,  one  
study   found   overexpression   of   the   SMN   protein,   which   increases   Cajal   bodies   in  
transformed   cells,   did   not   induce   Cajal   body   formation   in   primary   DFSF1   cells  
(Sleeman   et   al.,   2001).   Interestingly   however,   overexpression   of   the  SmB   protein  
did   lead  to  an   increase   in  Cajal  bodies   in  both  primary  and  transformed  cells.  The  
conclusion  drawn  from  these  studies  was  there  must  be  a  signal  requiring  increased  
snRNP   biogenesis   to   upregulate   Cajal   bodies   in   primary   cells.   This   supports   the  
idea   that   the   presence   of   Cajal   bodies   in   neurons   is   due   to   their   increased  
transcription   demand   and   hence   a   greater   need   for   snRNP   production.   This   is  
observed  in  figures  5.6-­5.10  where  wild-­type  neurons  contain  approximately  1  Cajal  
body  per  cell  whereas  wild-­type  iAstrocyte  cells  contain  <  0.5  Cajal  bodies  per  cell.  
Leading   from   this,   the   C9orf72   protein   in   primary   neurons   could   function   in   the  
pathways   discussed   above,   for   example   in   the   trafficking   of   the   snRNA   export  
complex,   but   changes   in   this   pathway   do   not   generate   the   same   Cajal   body  
phenotype.  
  
There  is  evidence  the  C9orf72  protein  may  function  in  nucleocytoplasmic  transport.  
An   interaction   between  C9orf72   and  Ran-­GTPase   has   previously   been   confirmed  
by  co-­immunoprecipitation   (Xiao  et  al.,   2015).   Interestingly,  Ran-­GTPase   interacts  
with  CRM1  and  PHAX  to  form  the  snRNA  export  complex  and  facilitate  transport  of  
snRNAs  from  the  nucleus  to   the  cytoplasm  (Ohno  et  al.,  2000).  C9orf72  has  been  
shown   to   interact  with  Rab-­GTPases  and  several  of   the  proteins   in   the  autophagy  
initiation  complex  to  facilitate  their  trafficking  in  the  cytoplasm  (Sullivan  et  al.,  2016;;  
Webster  et  al.,  2016).  Ran-­GTPase  and  Rab-­GTPases  are  similar  proteins  and  are  
both   part   of   the   Ras   superfamily   of   small   GTPases   (Wennerberg   et   al.,   2005).  
Hence,   it   is   feasible  C9orf72  could   form  part  of   the  snRNA  export  complex  via  an  
interaction   with   Ran-­GTPase.   Expression   of   the   PHAX   or   CRM1   proteins   tagged  
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with   a  photoactivatable   fluorescent   protein  would  allow  us   to   visualise   the   snRNA  
trafficking   from   Cajal   bodies   to   the   cytoplasm   in   real   time,   and   the   effect   loss   of  
C9orf72   has   on   this   pathway.   It   would   also   be   valuable   to   do   co-­
immunoprecipitation   experiments   between   C9orf72   with   CRM1   and   PHAX   to  
determine  if  C9orf72  is  a  protein  component  of  the  snRNA  export  complex.  Finally,  
it  would  also  be   interesting   to   knockdown  Ran-­GTPase  and  observe  Cajal   bodies  
numbers   in   response.   The   increased  Cajal   body   phenotype  we   observe   could   be  
expected  if  Ran-­GTPase  and  C9orf72  are  interacting  in  the  same  protein  complex  in  
the   same   pathway.   Interestingly,   the   arginine-­containing   C9orf72   DPR   proteins  
have   been   demonstrated   to   induce   nuclear   Ran   defects,   suggesting   a   possible  
convergence   between   C9orf72   loss   of   function   and   toxic   DPR   generation  
(Boeynaems  et  al.,  2016;;  Jovičić  et  al.,  2015;;  Shi  et  al.,  2017).  
  
Another  common  regulator  of  Cajal  bodies  is  the  cell  cycle.  Cajal  bodies  have  been  
shown  to  disassemble  during  mitosis  and  reassemble  in  daughter  cells  during  early-­
G1,  with  the  number  of  Cajal  bodies  peaking  during  the  G1/S  phase  (Andrade  et  al.,  
1993;;   Carmo-­Fonseca   et   al.,   1993;;   Dundr   et   al.,   2004).   The   disassembly   and  
reassembly  of  Cajal  bodies   throughout   the  cell  cycle   is   thought   to  be  regulated  by  
coilin  phosphorylation.  Coilin  is  a  phosphoprotein,  with  11  serine  residues  identified  
so   far   as   available   for   phosphorylation   (Toyota   et   al.,   2010).   Mitotic   coilin   is  
hyperphosphorylated  which  has  been  shown  to  decrease  the  ability  of  coilin  to  self-­
interact  and  cause  Cajal  body  disassembly  (Carmo-­Fonseca  et  al.,  1993;;  Hearst  et  
al.,  2009;;  Hebert  and  Matera,  2000).  Dephosphorylation  of  some,  but  not  all,  coilin  
serine  residues  in  the  G1  phase  of  the  cell  cycle  causes  reassembly  of  Cajal  bodies,  
and   interestingly,   the   SMN   protein   shows   preferential   binding   to   a  
hypophosphorylated  coilin  which  may  facilitate  de  novo  Cajal  body  formation  post-­
mitosis   (Carrero   et   al.,   2011).   Complete   dephosphorylation   of   coilin   however,  
ablates   the   ability   for   coilin   to   form   Cajal   bodies,   suggesting   some   coilin  
phosphorylation   is   required   for   Cajal   body   assembly   (Hearst   et   al.,   2009).   The  
phosphorylation  state  of  coilin  is  controlled  by  the  nuclear  kinase  VRK1  which  itself  
is   cell   cycle   regulated   and   can   phosphorylate   coilin   on   eight   of   its   eleven   serine  
residues   (Sanz-­García   et   al.,   2011;;   Valbuena   et   al.,   2008).   VRK1   is   thought   to  
regulate  Cajal  body  dynamics  by  phosphorylating  coilin  in  a  specific  phosphorylation  
pattern   in   a   cell-­cycle   dependent   manner      (Cantarero   et   al.,   2015).   Interestingly,  
VRK1  phosphorylation  of  coilin  has  also  been  shown  to  inhibit  ubiquitination  of  coilin  
and  its  targeting  for  proteasome  degradation.  Knockdown  of  VRK1  or  inhibition  of  its  
kinase  activity  by  serum  starvation  causes  a  decrease  in  Cajal  bodies,  which  can  be  
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rescued  by  the  proteasome  inhibitor  MG132  (Cantarero  et  al.,  2015).  This  suggests  
the   effect   of   coilin   phosphorylation   on   Cajal   body   regulation   is   two-­fold:   (1)   It  
influences  the  binding  affinity   for   the  self-­interaction  of  coilin  or  between  coilin  and  
other  Cajal  body  proteins  and  (2)  coilin  phosphorylation  stabilises  the  coilin  protein  
and   prevents   its   ubiquitination   and   export   to   the   cytoplasm   for   proteasome  
degradation.    
  
Based  on   the   results  presented   in   this  chapter,   there   is  evidence  C9orf72  may  be  
involved  in  cell  proliferation  and/or  post-­translational  modifications  of  coilin.  C9orf72  
influenced   Cajal   bodes   in   HEK293   and   iAstrocyte   cells,   both   of   which   are  
proliferating   cell   lines.   No   effect   was   observed   however   in   non-­dividing   primary  
neurons.   Interestingly,   other   DENN   proteins   which   act   as   GEFs   for   Rab   proteins  
have  been  reported  to  have  functions  in  cell  cycle  regulation  and  proliferation  (Lim  
et   al.,   2004;;   Thayanidhi   et   al.,   2012).  Overexpression   and   knockdown  of  C9orf72  
could   be   performed   on   synchronised   HEK293   cells,   which   would   allow   any   cell-­
cycle   dependent   effect   of   C9orf72   on   Cajal   bodies   to   be   visualised  more   clearly.  
Perhaps   coilin   phosphorylation   is   changing   in   response   to  C9orf72   protein   levels,  
leading   to   increased/decreased   self-­interaction   and   changing   numbers   of   Cajal  
bodies.   One   way   to   test   this   would   to   be   to   implement   mass   spectrometry   to  
determine   which   serine   residues   are   phosphorylated   in   normal   HEK293   cells   or  
cells  overexpressing  or  depleted  in  C9orf72.  Another  approach  could  be  to  subject  
whole   cell   lysates   of   HEK293   cells   after   C9orf72   overexpression/knockdown   to  
electrophoresis  on  a  PhosTag  acrylamide  gel  which  allows  for  greater  separation  of  
phosphoproteins  based  on  their  level  of  phosphorylation.  Immunoblot  with  anti-­coilin  
could   compare   coilin   phosphoisoforms   between   samples.  Basal   numbers   of  Cajal  
bodies   in   the   transformed   versus   primary   cell   lines   in   this   chapter   were   different,  
with   HEK293   cells   commonly   containing   3   or   more   Cajal   bodies   whereas   the  
primary   neurons   typically   had   1-­2  Cajal   bodies   per   cell.  One   study   compared   the  
phosphorylation   levels   of   coilin   in   transformed   HeLa   cells   versus   WI-­38   primary  
cells  and   found  multiple  coilin  phosphoisoforms  existed   in   the  HeLa  cells  whereas  
coilin  in  the  WI-­38  cells  was  stably  hyperphosphorylated  (Hearst  et  al.,  2009).  This  
suggests  the  difference  in  Cajal  body  numbers  could  be  due  to  differences  in  basal  
levels  of  coilin  phosphorylation  in  transformed  versus  primary  cells.    
  
In  addition,  Cajal  bodies  have  been   linked  with   telomere  maintenance.  Telomeres  
are   protein-­bound,   repeated   DNA   sequences   on   the   end   of   linear   chromosomes  
which   shorten   with   each   round   of   cell   division   (Smogorzewska   and   de   Lange,  
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2004).   Once   telomeres   reach   a   certain   length,   they   signal   to   the   cell   to   undergo  
apoptosis   or   enter   senescence,   hence   their   common   association   with   aging  
(McEachern   et   al.,   2000).   To   counter   shortening,   telomeres   are   maintained   and  
synthesised   by   the   telomerase   enzyme,   assembled   from   the   human   telomerase  
RNA   (hTR)   and   human   telomerase   reverse   transcriptase   (hTERT)   (Greider   and  
Blackburn,  1989;;  Mitchell  et  al.,  1999).  The  telomerase  component  hTR  is  found  in  
Cajal   bodies,   which   themselves   have   been   shown   to   directly   associate   with  
telomeres  (Jady  et  al.,  2005;;  Tomlinson  et  al.,  2006).  Interestingly,  coilin,  which  we  
have  shown  interacts  with  C9orf72,  is  responsible  for  the  recruitment  of  telomerase  
to  telomeres  alongside  telomere  Cajal  body  protein  1  (TCAB1)  (Stern  et  al.,  2012).  
Telomere   maintenance   is   essential   in   transformed   cells   such   as   HEK293s   which  
undergo  indefinite  cell  division,  and  it  has  been  suggested  their  high  basal  levels  of  
Cajal   bodies   are   for   telomerase   assembly   (Lafarga   et   al.,   2017).   It’s   possible   the  
C9orf72-­coilin   interaction   facilitates   telomerase   trafficking   to   telomeres   and   hence  
the   Cajal   body   phenotype   was   not   observed   in   primary   neurons   which   are   post-­
mitotic  and  do  not  rely  on  this  pathway.    
  
In   the   C9orf72-­ALS   iAstrocytes,   the   Cajal   body   phenotype   was   not   rescued   with  
C9orf72   protein   expression,   suggesting   other   mechanisms   may   also   be   at   play.  
Overexpression   of   DPR   proteins   GR   and   PR   in   HeLa   cells   has   been   shown   to  
cause  disassembly  of  Cajal  bodies,  therefore  increased  Cajal  bodies  are  unlikely  to  
be   caused   by  DPR  expression   in   the   iAstrocytes   (Lee   et   al.,   2016).  On   the   other  
hand,   it   has   also   been   shown   that   DPR   proteins   GR   and   PR   can   bind   the   U2  
snRNP   and   inhibit   it’s   assembly   which   may   cause   cells   to   upregulate   snRNP  
production   and   indirectly   increase   Cajal   bodies   in   response   to   the   increase   in  
snRNP  demand  (Yin  et  al.,  2017).  The  RNA  foci  in  C9-­ALS  bind  and  sequester  RNA  
binding   proteins   and  may   contribute   to   splicing   defects   seen   in   disease   (Cooper-­
Knock   et   al.,   2014;;   Prudencio   et   al.,   2015).   Cells   may   therefore   increase  
transcription   of   snRNA   genes   to   compensate   for   the   defective   splicing   and  
increased  Cajal  bodies  are  a  visible  phenotype  of  this.  Astrocytes  have  been  shown  
to   exacerbate   degeneration   of   motor   neurons   in   ALS,   therefore   it   is   worthwhile  
understanding   the  molecular  pathology   in   these  cells   (Haidet-­Phillips  et  al.,  2011).  
However,   the   induced   neuronal   progenitor   cells   from   which   the   iAstrocytes   are  
derived,   can   also   be   differentiated   into   iNeurons,   which   are   more   biologically  
relevant   to   ALS.   Work   is   now   being   completed   to   perform   Cajal   body  
immunostaining   on   iNeurons   differentiated   from   these   same   C9-­ALS   patients   to  
look  at  the  behaviour  of  Cajal  bodies  in  these  cells.    
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It  is  difficult  trying  to  discern  the  function  of  C9orf72  from  the  Cajal  body  phenotype,  
which   varies   between   different   cell   models.   In   HEK293   cells,   the   evidence   is  
convincing   that   Cajal   bodies   can   be   influenced   by   the   C9orf72   protein.   The  
mechanism  for  how  C9orf72  exerts  this  effect  is  unknown,  but  it  is  well  documented  
that  the  snRNP  processing  pathway  and  the  cell  cycle  are  the  biggest  regulators  of  
Cajal   bodies,   suggesting   C9orf72   may   be   involved   in   one   of   these.   Many   of   the  
genes  and  molecular  pathways  linked  to  ALS  highlight  defective  RNA  processing  as  
a  major  player  in  disease  pathogenesis.  In  addition,  the  known  cytoplasmic  function  
of  C9orf72  as  a  protein  component  of   trafficking  complexes   fits  best  with  a   role  of  
C9orf72  in  the  snRNP/splicing  pathway.  We  therefore  chose  to  investigate  the  effect  
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6   Investigating  the  effect  of  C9orf72  on  
splicing  
  
6.1   Introduction  
  
We   have   shown   that   C9orf72   interacts   with   coilin   and   can   influence   Cajal   body  
numbers  in  HEK293  cells.  Cajal  bodies  were  also  changed  in  C9orf72-­ALS  patient  
cells,   although   this   was   not   proven   to   be   a   result   of   haploinsufficiency   of   the  
C9orf72  protein.  Cajal  bodies  are  enriched  in  proteins  and  RNAs  that  process  and  
remodel   snRNPs.   These   snRNPs   form   the   splicing   machinery,   or   ‘spliceosome’,  
which  functions  often  co-­transcriptionally  to  remove  introns  from  pre-­mRNA.    
  
There  are  two  splicing  pathways,  each  with  its  own  distinct  spliceosome.  The  major  
spliceosome,  containing  the  U1,  U2,  U4,  U5  and  U6  snRNPs,  splices  major  or  ‘U2-­
type’   introns  from  mRNA  (Will  and  Luhrmann,  2011).  Approximately  99%  of  all   the  
introns   in   the   human   genome   are  U2-­type   introns.   The  major   splicing   pathway   is  
efficient  and   the  splice  site  and  branch  point  sequences  of  U2-­type   introns,  which  
act  as  splicing  signals,  can  be  highly  degenerate  (Burset  et  al.,  2001;;  Mount,  2000).  
Conversely,   the   minor   spliceosome   removes   minor,   or   ‘U12-­type’   introns,   and   is  
comprised   of   the   U11,   U12,   U4atac,   U5   and   U6atac   snRNPs   (Patel   and   Steitz,  
2003).  Only  1%  of  all   introns  are  U12   introns,   and  unlike  U2   introns,   efficiency  of  
splicing   is   low  and   the   sequences  which   define  U12   introns   are   highly   conserved  
(Burge  et  al.,  1998;;  Patel  et  al.,  2002).  
  
Defective   splicing   is   a   common   theme   which   runs   throughout   ALS   and   other  
neurodegenerative   diseases.   ALS-­linked   genes   FUS   and   TDP-­43   are   both   RNA  
binding  proteins  in  which  mutations  lead  to  defects  in  RNA  processing  (Arnold  et  al.,  
2013;;   Reber   et   al.,   2016).   Deficiency   of   the   Cajal   body   protein   SMN   has   been  
shown   to   cause   failings   in   the  minor   splicing   of   U12   introns   and   in   C9orf72-­ALS  
patient   brains,   alternative   splicing   defects,   including   the   retention   of   introns,   has  
been  detected  (Boulisfane  et  al.,  2011;;  Prudencio  et  al.,  2015).  Importantly,  splicing  
defects   in   C9orf72-­ALS   correlate   with   disease   severity,   suggesting   failures   in   the  
splicing   pathway/machinery   may   play   a   significant   role   in   disease   pathogenesis  
(Cooper-­Knock  et  al.,  2015a).    
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In  this  chapter,  we  investigated  the  effect  of  loss  of  the  C9orf72  protein  on  splicing,  
to   determine   whether   haploinsufficiency   of   C9orf72   could   be   contributing   to   the  
splicing  defects  observed   in  C9orf72  ALS.  Reporter  splicing  assays,  which   involve  
the  transfection  of  an  intron-­containing  construct  into  cells,  have  been  described  in  
the   literature   as   an   effective   method   of   investigating   the   splicing   ability   of   cells  
(Cooper,  2005).  We  therefore  implemented  a  reporter  splicing  assay  using  pCI-­neo  
and   P120   constructs,   which   contain   a   major   and   minor   intron   respectively,   and  
which  have  both  been  used  successfully   in  other  studies   (Hall  and  Padgett,  1996;;  
Whittom   et   al.,   2008).   The   constructs   were   transfected   into   cells   depleted   in  
C9orf72,   and   the   removal   of   their   introns   was   used   as   a   measure   of   splicing  
efficiency.      
  
6.2   Results  
  
6.2.1   C9orf72  siRNA  transfection  decreases  splicing  in  HEK293  cells  
  
The   reporter   splicing   assay   involves   transfection   of   a   reporter   which   contains   an  
intron  which  can  be   retained  or   spliced.  RNA   is  extracted   from  cells  and  RT-­PCR  
performed   using   primers   that   flank   either   side   of   the   intron   which   generates   a  
spliced  or  unspliced  product  depending  on  whether   the   intron  was  retained  or  not.  
To  investigate  major  splicing,  a  pCI-­neo  construct  was  used,  which  contains  a  U2-­
type   intron.   To   look   at   minor   splicing,   a   P120   minigene   was   used.   The   P120  
minigene  contained  exons  6  and  7   from  the  P120  gene   flanking  a  U12-­type   intron  
and  was  generously  provided  by  Professor  Richard  Padgett  at  the  Cleveland  Clinic  
(Hall   and  Padgett,   1996).   PCR  primers  were   designed   that   flanked   regions   either  
side  of  the  intron.  Thus,  if  the  reporter  was  unspliced,  a  PCR  product  containing  the  
intron  plus  flanking  sequences  was  amplified.  However,  if  the  reporter  was  spliced,  
a  smaller  PCR  product   lacking   the   intron  was  generated.  Specifically,   the  pCI-­neo  
intron  was  133  base  pairs  (bps).  Primers  were  designed  to  bind  in  the  flanking  pCI-­
neo  construct  such  that  the  unspliced  product  was  388  bps  and  spliced  product  was  
255   bps   (Figure   6.1A).   The  P120  U12-­intron  was   99   base   pairs,   and   the   primers  
were  designed  to  bind  in  flanking  exons  6  and  7  such  that  the  unspliced  and  spliced  
PCR   products   were   250   bps   and   151   bps   respectively   (Figure   6.1B).   The   P120  
plasmid  also  contained  an  additional  two  U2-­type  introns  that  were  not  analysed.  





















The   primers   were   tested   to   confirm   PCR   products   of   the   expected   size   were  
amplified  from  the  constructs.  A  PCR  was  run  using  the  pCI-­neo  or  P120  construct  
as  the  DNA  template  with  their  respective  primers  for  intron  amplification.  The  pCI-­
neo  primers  successfully  amplified  a  PCR  product  of  expected  388  bp  size  from  the  
pCI-­neo  construct,  but  did  not  generate  product  from  a  water  control  (Figure  6.2A).  
Similarly,  P120  primers  successfully  amplified  a  PCR  product  of   the  expected  250  
bp  size   from   the  P120  minigene  but  not   from   the  water  control   (Figure  6.2B).  The  
A  
B  
Figure   6.1.   The   reporter   splicing   assay.   (A)   pCI-­neo   was   used   as   the   reporter   to  
measure  major  splicing.  The  pCI-­neo  plasmid  contains  a  133  base  pair  U2-­intron.  Primers  
were  designed   to  bind   in   the   flanking  pCI-­neo   construct   such   that   the  unspliced  product  
was   388   bps   and   spliced   product   was   255   bps.   (B)   A   P120  minigene  was   used   as   the  
reporter   to   measure   minor   splicing.   The   P120   minigene   contains   a   99   base   pair   U12-­
intron.  Primers  were  designed   to  bind   to  exon  6  and  exon  7  of   the  P120  minigene  such  
that  the  unspliced  product  was  250  bps  and  spliced  product  was  151  bps.  
   203  
PCRs   confirmed   the   primers   amplified   the   correct   products   and   could   be   taken  













Splicing   of   the   pCI-­neo   intron   in   C9orf72-­depleted   HEK293   cells   was   used   to  
investigate   the   effect   of   C9orf72   on   major   splicing.   Coilin   knockdown   has   been  
shown  to  decrease  splicing  of  the  pSI-­CHECK  intron  in  a  similar  reporter  assay,  and  
we   therefore   included   it  as  a  positive  control   (Whittom  et  al.,  2008).  HEK293  cells  
were  transfected  with  NTC,  pooled  C9orf72  or  pooled  coilin  siRNAs.  After  72  hours  
of  knockdown,  cells  were  transfected  with  pCI-­neo.  RNA  was  extracted  and  poly(A)  
RT-­PCR   performed.   Triplicate   cDNA   samples   were   subjected   to   PCR   using   the  
intron-­flanking   pCI-­neo   primers.   PCR   products   were   resolved   by   agarose   gel  
electrophoresis  which   showed  a   faint   unspliced   product   at   388   bps   and   a   spliced  
product   at   255   bps   (Figure   6.3A).   PCR   controls   included  water   only   and   pCI-­neo  
plasmid   as   DNA   templates.   There   appeared   to   be   more   unspliced   product   in  
C9orf72   siRNA  cells   in   comparison   to  NTC,   suggesting   there  was   less   splicing  of  
the   pCI-­neo   intron   after   C9orf72   knockdown   (Figure   6.3A).   Densitometry   was  
performed   on   the   unspliced   and   spliced   bands   and   the   ratio   of   spliced/unspliced  
product   was   generated   as   a   measure   of   splicing   efficiency.   The   densitometry  
analysis  confirmed  there  was  less  pCI-­neo  splicing  in  the  C9orf72  knockdown  cells  
(Figure  6.3B).   Interestingly,   in  our  experiments,   knockdown  of   coilin  had  no  effect  
A  
B  
Figure   6.2.   PCR   amplification   of   introns   from   pCI-­neo   and   P120   constructs.   (A)  
Water   (control)   or   pCI-­neo   plasmid   was   used   as   a   template   to   test   primers   for   PCR  
amplification  of  the  pCI-­neo  intron  (product  size  =  388  bp)  (B)  Water  (control)  or  the  P120  
mini-­gene   plasmid  was   used   as   a   template   to   test   primers   for   PCR   amplification   of   the  
P120  intron  (product  size  =  250  bp).  PCR  products  were  resolved  on  an  agarose  gel  and  
stained  with  ethidium  bromide.  
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on   the  splicing  of   the  pCI-­neo   intron   (Figure  6.3B).  C9orf72  and  coilin   knockdown  
was   confirmed   by  measuring   their  mRNA   levels   by  RT-­qPCR.  C9orf72   and   coilin  
mRNA  was   reduced  by  approximately  80%  and  70%  across   the   four  experiments  
respectively   (Figure   6.3C-­6.3D).   Unexpectedly,   C9orf72   knockdown   appeared   to  
cause  a  small  reduction  in  coilin  mRNA  (Figure  6.3D).  The  results  suggest  that  loss  
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Figure   6.3.   C9orf72   knockdown   decreases   splicing   of   the   pCI-­neo   intron   in   HEK293  
cells.   (A)   In  vivo  splicing  of   the  pCI-­neo   intron   in  HEK293  cells.  Cells  were   transfected  with  
NTC,  C9orf72  or  coilin  siRNA.  Post-­knockdown,  cells  were  transfected  with  pCI-­neo  plasmid.  
RNA  extractions  were  performed  followed  by  RT-­PCR  from  poly(A)  mRNA.  Subsequent  PCR  
amplification  of  the  intron  produced  two  PCR  products:  Unspliced  (388  bp)  or  spliced  (255  bp).  
PCR   products   were   resolved   on   an   agarose   gel   and   stained   with   ethidium   bromide.   (B)  
Splicing  efficiency  of  the  intron  was  quantified  as  the  ratio  of  spliced  product/unspliced  product  
and  normalised   to  NTC.  C9orf72   (C)  and  coilin   (D)  knockdown  was  confirmed  by  RT-­qPCR.  
All  data  represent  mean  ±  SEM;;  One-­way  ANOVA  with  Dunnett’s  test,  *  p  ≤  0.05,  **  p  ≤  0.01,  
****  p  ≤  0.0001.  n=4  experiments.  
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C9orf72   knockdown   appeared   to   decrease  major   splicing.   A   very   small   subset   of  
introns  are  U12-­type  introns,  and  are  spliced  by  the  minor  spliceosome.  The  rarity  of  
U12-­type   introns,   combined   with   their   high   level   of   splice   signal   conservation,  
suggests  they  may  have  essential  functions,  which  are  not  yet  understood  (Turunen  
et  al.,  2013).  The  P120  construct  was  used  to   investigate   the  effect  of  C9orf72  on  
minor  splicing.  HEK293  cells  were  transfected  with  NTC,  pooled  C9orf72  or  pooled  
coilin   siRNAs.   After   72   hours’   protein   knockdown,   cells   were   transfected  with   the  
P120   minigene.   RNA   was   extracted   and   poly(A)   RT-­PCR   performed.   Triplicate  
cDNA  samples  were  subjected  to  PCR  using  the  intron-­flanking  P120  primers.  PCR  
products   were   resolved   by   agarose   gel   electrophoresis   which   showed   a   darker  
unspliced  product  at  250  bps  and  a  spliced  product  at  155  bps  (Figure  6.4A).  The  
unspliced   band   from   the   C9orf72   siRNA   cells   appeared   darker   than   the   NTC  
unspliced  band,  suggesting  there  was  less  splicing  of  the  P120  intron  after  C9orf72  
knockdown   (Figure   6.4A).   Splicing   efficiency   was   quantified   as   the   ratio   of   the  
densitometry  of  spliced/unspliced  bands  (Figure  6.4B).  The  quantification  confirmed  
there   was   less   splicing   of   the   P120   intron   in   C9orf72   knockdown   cells,   but   coilin  
knockdown   had   no   effect   on   P120   splicing   (Figure   6.4B).   RT-­qPCR   confirmed  
C9orf72   and   coilin   mRNA   was   reduced   by   approximately   70-­75%   across   the  
experiments   (Figure   6.4C-­Figure   6.4D).   Again,   C9orf72   knockdown   appeared   to  
cause   a   slight   knockdown   of   coilin   mRNA   (Figure   6.4D).   The   results   suggest  
knockdown  of  C9orf72   in  HEK293  cells   can  decrease   splicing  of  minor   introns,   in  
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Figure  6.4.  C9orf72  knockdown  decreases  splicing  of   the  P120   intron   in  HEK293  cells.  
(A)   In  vivo  splicing  of   the  P120  minigene   intron   in  HEK293  cells.  Cells  were   transfected  with  
NTC,   C9orf72   or   coilin   siRNA.   Post-­knockdown,   cells   were   transfected   with   P120   minigene  
plasmid.   RNA   extractions   were   performed   followed   by   RT-­PCR   from   poly(A)   mRNA.  
Subsequent  PCR  amplification  of  the  intron  produced  two  PCR  products:  Unspliced  (250  bp)  or  
spliced   (151  bp).  PCR  products  were   resolved   on  an  agarose  gel   and   stained  with  ethidium  
bromide.   (B)   Splicing   efficiency   of   the   intron   was   quantified   as   the   ratio   of   spliced  
product/unspliced  product  and  normalised  to  NTC.  C9orf72  (C)  and  coilin  (D)  knockdown  was  
confirmed  by  RT-­qPCR.  All  data  represent  mean  ±  SEM;;  One-­way  ANOVA  with  Dunnett’s  test,  
**  p  ≤  0.01,  ****  p  ≤  0.0001.  n=4  experiments.  
   208  
We  have  shown  that  knockdown  of  C9orf72  using  pooled  siRNA  decreased  splicing  
of   the  U12  intron   in  the  exogenous  P120  minigene.  The  full   length  P120  protein   is  
expressed   from   the   human   nucleolar   protein   P120   (NOL1)   gene.   Therefore,   the  
P120   primers   were   utilised   to   determine   if   C9orf72   knockdown   caused   defective  
splicing  of  the  endogenous  P120  minor   intron.  HEK293  cells  were  transfected  with  
NTC,  C9orf72  pooled  or  coilin  pooled  siRNAs.  After  72  hours’  protein  knockdown,  
RNA   was   extracted   and   RT-­PCR   performed.   Triplicate   cDNA   samples   were  
subjected   to   PCR   using   the   intron-­flanking   P120   primers.   PCR   products   were  
resolved  by  agarose  gel  electrophoresis  which  showed  a  faint  unspliced  product  at  
250  bps  and  a  darker  spliced  product  at  155  bps  (Figure  6.5A).  The  unspliced  band  
in   the   C9orf72   knockdown   samples   appeared   similar   in   intensity   to   the   NTC  
unspliced   bands,   suggesting  C9orf72   knockdown   did   not   influence   splicing   of   the  
endogenous   P120   intron   (Figure   6.5A).   Densitometry   was   performed   on   the  
unspliced   and   spliced   bands   and   the   ratio   of   spliced/unspliced   product   was  
generated  as  a  measure  of  splicing  efficiency.  The  densitometry  analysis  confirmed  
the  amount  of  endogenous  P120  splicing  after  both  C9orf72  and  coilin  knockdown  
was   the   same   as   in   the   NTC   (Figure   6.5B).   Both   C9orf72   and   coilin  mRNA  was  
reduced  by  approximately  70%  across   the  experiments  (Figure  6.5C-­Figure  6.5D).  
C9orf72   knockdown   in   these   experiments   also   appeared   to   reduce   coilin   mRNA  
levels   by   approximately   30%   (Figure   6.5D).   Taken   together,   the   reporter   splicing  
assays  suggest  knockdown  of  C9orf72  can  decrease  both  major  and  minor  splicing  
of   an   exogenous   intron,   but   endogenous   splicing   is   unchanged.   It   also   appeared  
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Figure  6.5.  C9orf72  knockdown  has  no  effect  on  endogenous  P120  splicing  in  HEK293  
cells.   (A)   In   vivo   splicing   of   the   endogenous   P120   intron   in   HEK293   cells.   Cells   were  
transfected  with  NTC,  C9orf72  or  coilin  siRNA.  RNA  extractions  were  performed  followed  by  
RT-­PCR  from  poly(A)  mRNA.  Subsequent  PCR  amplification  of  the  intron  produced  two  PCR  
products:  Unspliced  (250  bp)  or  spliced  (151  bp).  PCR  products  were  resolved  on  an  agarose  
gel  and  stained  with  ethidium  bromide.  (B)  Splicing  efficiency  of   the  intron  was  quantified  as  
the  ratio  of  spliced  product/unspliced  product  and  normalised  to  NTC.  C9orf72  (C)  and  coilin  
(D)   knockdown   was   confirmed   by   RT-­qPCR.   All   data   represent   mean   ±   SEM;;   One-­way  
ANOVA  with  Dunnett’s  test,  **  p  ≤  0.01,  ****  p  ≤  0.0001.  n=4  experiments.  
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6.2.2   Rescue  transfection  of  C9orf72  in  the  P120  splicing  assays  
  
C9orf72  knockdown  led  to  a  decrease   in  splicing  of   the  U2  and  U12   introns   in   the  
pCI-­neo   and   P120   constructs   respectively.   To   confirm   the   defective   splicing   was  
specific   to   a   loss   of   the   C9orf72   protein,   rescue   transfections   with   the   siRNA  
resistant   myc-­C9orf72   constructs   described   in   chapter   3,   section   3.2.3   were  
performed.   First,   the   myc-­C9orf72   constructs   were   subjected   to   PCRs   using   the  
pCI-­neo   and   P120   primers   to   ensure   the   primers   would   not   amplify   product   from  
them.  Unfortunately,   the  pCI-­neo  PCR  generated  a   product   from  both   pRK5-­myc-­
C9orf72  siRNA  resistant  constructs  (Figure  6.6A).  Therefore,  we  could  not  perform  
rescue   transfections   in   the   pCI-­neo   splicing   assay.   However,   the   P120   PCR  was  
clean,   with   no   products   generated   from   either   myc-­C9orf72   constructs   (Figure  
6.6B).  The  myc-­C9orf72  siRNA  constructs  were  therefore  taken  forward  to  perform  






















Figure   6.6.   pCI-­neo   but   not   P120   specific   primers   generate   a   PCR   product   from  
pRK5-­myc-­C9orf72   siRNA   resistant   constructs.   Water   (control),   pCI-­neo   or   P120  
minigene,  pRK5-­myc-­C9orf72S  siRNA  resistant  and  pRK5-­mycC9orf72L  siRNA  plasmids  
were   used   as   templates   in   a   PCR   using   pCI-­neo   specific   primers   (A)   or   P120   specific  
primers   (B).   PCR   products  were   resolved   on   an   agarose   gel   and   stained  with   ethidium  
bromide.  
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To   establish   if   the   decrease   in   exogenous  P120   splicing  was   caused   by  C9orf72  
knockdown,   changes   were   made   to   the   P120   reporter   splicing   assay.   First,  
knockdown   of   C9orf72   was   achieved   by   individual   C9orf72   siRNAs   in   addition   to  
pooled.   Secondly,   siRNA   resistant   C9orf72   constructs   were   transfected   after  
knockdown   to  determine   if   the  splicing  defect  could  be  rescued.  Coilin  knockdown  
was  not  included  as  there  was  no  observable  effect  on  either  major  or  minor  splicing  
in   previous   experiments.   HEK293   cells   were   transfected   with   NTC,   C9orf72   #2,  
C9orf72  #D  or  C9orf72  pooled  siRNA.  After  72  hours’  protein  knockdown,  cells  were  
co-­transfected  with   the  P120  minigene   and   either   pCI-­neo   (empty   vector   control),  
siRNA   resistant   myc-­C9orf72S   or   siRNA   resistant   myc-­C9orf72L.      RNA   was  
extracted  and  poly(A)  RT-­PCR  performed.  Triplicate  cDNA  samples  were  subjected  
to   PCR   using   the   intron-­flanking   P120   primers.   PCR   products   were   resolved   by  
agarose  gel   electrophoresis  which  showed  a  darker  unspliced  product  at   250  bps  
and   a   fainter   spliced   product   at   155   bps   (Figure   6.7A).   In   all   co-­transfection  
conditions,   the   unspliced   product   appeared   darker   after   C9orf72   #D   and  C9orf72  
pooled   siRNA   transfection,   but   not   the   C9orf72   #2   siRNA.   Densitometry   was  
performed   on   the   unspliced   and   spliced   bands   and   the   ratio   of   spliced/unspliced  
product   was   generated   as   a   measure   of   splicing   efficiency.   The   quantification  
showed   there   was   no   statistically   significant   difference   between   any   of   the  
conditions.   However,   there   was   a   small   decrease   in   P120   intron   splicing   that  
occurred  after  C9orf72  #D  or  C9orf72  pooled  siRNA   transfections  but  not  with   the  
C9orf72  #2  siRNA  (Figure  6.7B).  C9orf72  mRNA  was  reduced  by  approximately  50-­
60%  with   all   C9orf72   siRNAs   however,   as  measured   by  RT-­qPCR   (Figure   6.7C).  
This  suggests   the  observed  defect   in  P120  splicing  may  have  been  caused  by  an  
off-­target   effect   of   the  C9orf72  #D   siRNA  and  not   from  a   loss   of  C9orf72  protein.  
Interestingly   however,   transfection   of  myc-­C9orf72S   into   cells   after   knockdown   of  
C9orf72  by  C9orf72  #D  or  pooled  siRNA,  appeared  to  restore  splicing  of   the  P120  
intron  to  normal  levels  (Figure  6.7B).  Transfection  with  myc-­C9orf72L  had  no  effect.  
The  overexpression  of   the  C9orf72  short  and   long   isoforms  was  confirmed  by  RT-­
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The  experiment  was  repeated  to  investigate  splicing  of  the  endogenous  P120  minor  
intron.   HEK293   cells   were   transfected   with   NTC,   C9orf72   #2,   C9orf72   #D   or  
C9orf72  pooled  siRNAs.  After  72  hours’  protein  expression,  cells  were   transfected  
with   pCI-­neo   (empty   vector   control),   siRNA   resistant   myc-­C9orf72S   or   siRNA  
resistant   myc-­C9orf72L.   RNA   was   extracted   and   poly(A)   RT-­PCR   performed.  
Triplicate   cDNA   samples   were   subjected   to   PCR   using   the   intron-­flanking   P120  
primers.  PCR  products  were  resolved  by  agarose  gel  electrophoresis  which  showed  
a  faint  unspliced  product  at  250  bps  and  a  darker  spliced  product  at  155  bps  (Figure  
6.8A).  The  unspliced  band  in  empty  vector  transfected  cells  appeared  visibly  darker  
after   C9orf72   knockdown   using   individual   siRNAs,   but   not   pooled   (Figure   6.8A).    
Densitometry  was  performed  on   the  unspliced  and   spliced  bands  and   the   ratio   of  
spliced/unspliced   product  was   generated   as   a  measure   of   splicing   efficiency.   The  
quantification  showed  there  was  no  statistically  significant  difference  between  any  of  
the  conditions.  However,  the  ratio  of  spliced/unspliced  product  after  C9orf72  #2  and  
C9orf72  #D  siRNA  transfection  was  decreased,  but  not  after  C9orf72  pooled  siRNA  
transfection   (Figure   6.8B).   Expression   of   myc-­C9orf72S   rescued   splicing   in   the  
C9orf72  #D  siRNA  cells  but  not  in  the  C9orf72  #2  siRNA  cells.  Expression  of  myc-­
C9orf72L   rescued   splicing   in   both   C9orf72   siRNA   conditions   (Figure   6.8B).   The  




Figure  6.7.  Decreased  P120  minigene  splicing  in  HEK293  cells  is  C9orf72  #D  siRNA  
specific.   (A)   In   vivo   splicing   of   the   P120   minigene   intron   in   HEK293   cells   following  
individual  C9orf72  siRNA   transfection  and  reintroduction  of  siRNA  resistant  myc-­C9orf72.  
Cells  were   transfected  with  NTC,  C9orf72  #2,  C9orf72  #D  or  C9orf72  pool  siRNA.  Post-­
knockdown,   cells   were   co-­transfected   with   P120   minigene   +   pCI-­neo   (EV),   myc-­C9S  
siRNA  resistant  or  myc-­C9L  siRNA  resistant.  RNA  extractions  were  performed  followed  by  
RT-­PCR   from  poly(A)  mRNA.  Subsequent  PCR  amplification  of   the   intron  produced   two  
PCR  products:  Unspliced  (250  bp)  or  spliced  (151  bp).  PCR  products  were  resolved  on  an  
agarose  gel   and   stained  with  ethidium  bromide.   (B)   Splicing  efficiency  of   the   intron  was  
quantified  as  the  ratio  of  spliced  product/unspliced  product  and  normalised  to  NTC  EV.  (C)  
C9orf72  knockdown  and  overexpression  was  confirmed  by  RT-­qPCR.  All  data   represent  
mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s  test.  n=3  experiments.  











































6.2.3   Investigating  splicing  in  a  stable  C9orf72  knockout  cell  line  
  
In   HEK293   cells,   there   was   a   small   decrease   in   exogenous   P120   splicing   after  
knockdown  of  C9orf72  using  the  C9orf72  #D  siRNA,  but  not  the  C9orf72  #2  siRNA,  
suggesting   the   effect   could   be   from   an   siRNA   off-­target   effect.   Expression   of   the  
C9orf72  protein  in  these  cells  appeared  to  show  some  rescue  of  the  splicing  defect  
however,  which  suggests  loss  of  the  C9orf72  protein  could  be  responsible.  The  high  
variability  observed  in  the  HEK293  cells  makes  it  difficult  to  draw  solid  conclusions  
about  the  involvement  of  C9orf72  in  splicing.  Therefore,  we  performed  the  reporter  
splicing  assays  in  the  B2  C9orf72  knockout  cell  line,  to  remove  the  need  for  siRNA  
transfection.     HEK293   cells   (control)   or  B2   cells  were   transfected  with   pCI-­neo   to  
investigate  the  C9orf72  proteins  involvement  in  major  splicing.  After  24  hours,  RNA  
was   extracted   and   poly(A)   RT-­PCR   performed.   Triplicate   cDNA   samples   were  
subjected   to   PCR   using   the   intron-­flanking   pCI-­neo   primers.   PCR   products   were  
resolved  by  agarose  gel  electrophoresis  which  showed  a  faint  unspliced  product  at  
388   bps   and   a   spliced   product   at   255   bps   (Figure   6.9A).   PCR   controls   included  
water  only  and  pCI-­neo  plasmid  as  DNA  templates.  There  was  no  visible  difference  
in  band  intensity   in  either  unspliced  or  spliced  bands  between  HEK293  or  B2  cells  
(Figure   6.9A).   Densitometry   was   performed   on   the   bands   to   quantify   the   ratio   of  
spliced/unspliced   product,   as   a   measure   of   splicing   efficiency.   Quantification  
showed  there  was  no  difference  in  pCI-­neo  intron  splicing  in  HEK293  and  B2  cells  
Figure  6.8.  Endogenous  P120  splicing  in  HEK293  cells  following  individual  C9orf72  
siRNA  transfection.  (A)  In  vivo  splicing  of  the  endogenous  P120  intron  in  HEK293  cells  
following   individual   C9orf72   siRNA   transfection   and   reintroduction   of   siRNA   resistant  
myc-­C9orf72.  Cells  were  transfected  with  NTC,  C9orf72  #2,  C9orf72  #D  or  C9orf72  pool  
siRNA.   Post-­knockdown,   cells   were   transfected   with   pCI-­neo   (EV),   myc-­C9S   siRNA  
resistant  or  myc-­C9L  siRNA  resistant.  RNA  extractions  were  performed  followed  by  RT-­
PCR   from   poly(A)   mRNA.   Subsequent   PCR   amplification   of   the   intron   produced   two  
PCR  products:  Unspliced  (250  bp)  or  spliced  (151  bp).  PCR  products  were  resolved  on  
an  agarose  gel   and   stained  with  ethidium  bromide.   (B)  Splicing  efficiency  of   the   intron  
was  quantified  as  the  ratio  of  spliced  product/unspliced  product  and  normalised  to  NTC  
EV.   (C)  C9orf72   knockdown  and  overexpression  was   confirmed  by  RT-­qPCR.   All   data  
represent  mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s  test.  n=3  experiments.  
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Figure  6.9.  pCI-­neo  splicing   is  unaffected   in   the  B2  C9orf72  knockout  cell   line.   (A)   In  vivo  
splicing   of   the   pCI-­neo   intron   in   HEK293   and   B2   cells.   Cells   were   transfected   with   pCI-­neo  
plasmid   and   RNA   extracted   followed   by   RT-­PCR   on   poly(A)   mRNA.   Subsequent   PCR  
amplification  of   the   intron  produced   two  PCR  products:  Unspliced   (388  bp)  or  spliced   (255  bp).  
PCR  products  were  resolved  on  an  agarose  gel  and  stained  with  ethidium  bromide.  (B)  Splicing  
efficiency   of   the   intron   was   quantified   as   the   ratio   of   spliced   product/unspliced   product   and  
normalised  to  293.  Data  represent  mean  ±  SEM;;  Unpaired  t-­test.  n=3  experiments.  
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The  P120   reporter   splicing  assay  was  performed  on   the  B2   cell   line   to   determine  
what   effect   a   chronic   loss   of   the  C9orf72   protein   had   on  minor   splicing.   HEK293  
cells  (control)  or  B2  cells  were  transfected  with  the  P120  minigene.  After  24  hours,  
RNA  was  extracted  and  poly(A)  RT-­PCR  performed.  Triplicate  cDNA  samples  were  
subjected   to   PCR   using   the   intron-­flanking   P120   primers.   PCR   products   were  
resolved  by  agarose  gel  electrophoresis  which  showed  a  darker  unspliced  product  
at   250   bps   and   a   faint   spliced   product   at   155   bps   (Figure   6.10A).   The   unspliced  
band  in  the  B2  cells  appeared  visibly  darker  versus  the  unspliced  product  from  the  
HEK293  cells,  suggesting  there  was  less  splicing  of  the  P120  intron  in  the  C9orf72  
knockout  cells.  The  decrease  in  splicing  was  confirmed  by  performing  densitometry  
on  the  bands  and  quantifying  the  ratio  of  spliced/unspliced  product  (Figure  6.10B).  
There  was  a  60%  decrease  in  splicing  of  the  P120  intron  in  B2  cells  in  comparison  
to   HEK293   cells,   however   this   result   was   highly   variable   and   not   statistically  
significant.  To  determine  if  the  decrease  in  splicing  was  specific  to  loss  of  C9orf72,  
rescue  transfections  of  the  C9orf72  isoforms  were  performed.  Co-­transfection  of  the  
myc-­C9orf72  constructs  with  P120  did  not  visibly  appear   to   reduce   the  strength  of  
the  unspliced  product  (Figure  6.10A).  Quantification  of  the  ratio  of  spliced/unspliced  
product   showed   expression   of   both   myc-­C9orf72S   and   myc-­C9orf72L   did   not  
change   splicing   of   exogenous  P120   in   the  B2   cells   (Figure   6.10B).  Expression   of  
myc-­C9orf72S   and   myc-­C9orf72L   in   the   B2   cells   was   confirmed   by   anti-­myc  
immunostaining  on  coverslip-­plated  cells  which  received  the  same  transfection  mix  
(Figure   6.10C).   Unfortunately,   the   images   are   limited   to   showing   myc-­C9orf72  
transfection  efficiency  only,  and  we  cannot  determine  the  co-­transfection  efficiency  
of  P120  with  myc-­C9orf72.  Interestingly,  the  results  suggest  minor  splicing  may  be  
decreased  in  the  B2  C9orf72  knockout  cell  line,  but  expression  of  C9orf72  in  these  













































Figure   6.10.   Splicing   of   the   P120   minigene   intron  may   be   decreased   in   the   B2   C9orf72  
knockout  line.  (A)  In  vivo  splicing  of  the  P120  minigene  intron  in  HEK293  and  B2  CRISPR  cells  
with  myc-­C9orf72  overexpression.  Cells  were  co-­transfected  with  P120  minigene  +  pCI-­neo  (EV),  
myc-­C9orf72S   or   myc-­C9orf72L.   RNA   extractions   were   performed   followed   by   RT-­PCR   on  
poly(A)   mRNA.   Subsequent   PCR   amplification   of   the   intron   produced   two   PCR   products:  
Unspliced   (250   bp)   or   spliced   (151   bp).   PCR   products   were   resolved   on   an   agarose   gel   and  
stained  with  ethidium  bromide.  (B)  Splicing  efficiency  of  the  intron  was  quantified  as  the  ratio  of  
spliced  product/unspliced  product  and  normalised  to  293  EV.  Data  represent  mean  ±  SEM;;  One-­
way  ANOVA  with  Tukey’s  test.  n=3  experiments.  (C)  myc-­C9orf72  overexpression  was  confirmed  
by  immunostaining  on  separately  fixed  cells  using  an  anti-­myc  antibody  (9B11)  (red).  Scale  bar  =  
10  µm.  
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Splicing  of  the  exogenous  P120  intron  appeared  to  be  decreased  in  the  B2  cell  line.  
We  therefore  next  investigated  the  splicing  of  the  endogenous  P120  minor  intron  in  
B2  cells.  HEK293  or  B2  cells  were  transfected  with  pCI-­neo,  myc-­C9orf72S  or  myc-­
C9orf72L.   After   24   hours,   RNA   was   extracted   and   poly(A)   RT-­PCR   performed.  
Triplicate   cDNA   samples   were   subjected   to   PCR   using   the   intron-­flanking   P120  
primers.  PCR  products  were  resolved  by  agarose  gel  electrophoresis  which  showed  
a   faint   unspliced   product   at   250   bps   and   a   prominent   spliced   product   at   155   bps  
(Figure  6.11A).  The  unspliced  band  in  the  B2  cells  appeared  visibly  darker  than  the  
unspliced  band  in  HEK293  cells.  Expression  of  both  C9orf72  isoforms  appeared  to  
decrease   this  unspliced  band   in   the  B2  cell   line   (Figure  6.11A).  Densitometry  was  
performed   on   the   bands   to   quantify   the   ratio   of   spliced/unspliced   product,   as   a  
measure   of   splicing   efficiency.   There   was   a   decrease   in   the   ratio   of  
spliced/unspliced   product   in   the   B2   cells   in   comparison   to   HEK293   cells,   but   the  
experiment  was  not  adequately  powered  for  the  high  levels  of  variability  observed,  
thus  there  was  no  statistical  difference  (Figure  6.11B).  Splicing  of   the  endogenous  
P120  intron  after  myc-­C9orf72S  and  myc-­C9orf72L  expression  in  B2  cells  was  to  a  
similar   level   as   in   the  HEK293   cells   (Figure   6.11B).   Expression   of  myc-­C9orf72S  
and  myc-­C9orf72L   in   the   B2   cells   was   confirmed   by   anti-­myc   immunostaining   on  
coverslip-­plated  cells  which  received  the  same  transfection  mix  (Figure  6.11C).  The  
immunostaining   showed   not   all   cells   were   successfully   transfected   and   thus   non-­
transfected  cells  will  have  been  included  in  the  analysis  of  endogenous  P120  intron  
splicing   in   the  rescue  conditions.  Again,  high  variability   in   the  experiments  make   it  
difficult   to   conclude   whether   there   is   a   minor   splicing   defect   in   the   B2   C9orf72  
knockout   cell   line,   but   there   is   a   slight   trend   in   the   data   which   suggests   loss   of  
C9orf72  could  be  affecting  the  minor  splicing  of  P120.      
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Figure  6.11.  Endogenous  P120  splicing   in   the  B2  C9orf72  knockout  CRISPR   line.   (A)   In  
vivo  splicing  of  the  endogenous  P120  intron  in  HEK293  and  B2  CRISPR  cells  with  myc-­C9orf72  
overexpression.   Cells   were   transfected   with   pCI-­neo   (EV),   myc-­C9orf72S   or   myc-­C9orf72L.  
RNA   extractions   were   performed   followed   by   RT-­PCR   on   poly(A)   mRNA.   Subsequent   PCR  
amplification  of  the  intron  produced  two  PCR  products:  Unspliced  (250  bp)  or  spliced  (151  bp).  
PCR  products  were  resolved  on  an  agarose  gel  and  stained  with  ethidium  bromide.  (B)  Splicing  
efficiency   of   the   intron   was   quantified   as   the   ratio   of   spliced   product/unspliced   product   and  
normalised   to  293  EV.  Data   represent  mean  ±  SEM;;  One-­way  ANOVA  with  Tukey’s   test.  n=3  
experiments.  (C)  myc-­C9orf72  overexpression  was  confirmed  by  immunostaining  on  separately  
fixed  cells  using  an  anti-­myc  antibody  (9B11)  (red).  Scale  bar  =  10  µm.  
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6.3   Discussion  
  
The   aim   of   this   chapter   was   to   determine   if   the   C9orf72   protein   was   involved   in  
major  and  minor  splicing.  The  hypothesis  was  that  loss  of  C9orf72  in  HEK293  cells  
influences  Cajal  bodies,  and  this  would  extend  to  an  effect  on  splicing.  Two  reporter  
splicing  assays  were  used,  which  have  been  described  in  the  literature  as  a  method  
of  semi-­quantitatively  measuring  the  splicing  efficiency  of  cells.  A  pCI-­neo  reporter,  
which   contained   a   U2   intron,   was   used   to   investigate  major   splicing   and   a   P120  
minigene   reporter,   which   contained   a   U12   intron,   was   used   to   investigate   minor  
splicing.  The  P120  gene  is  expressed  in  human  cells,  therefore  we  also  investigated  
the  splicing  of  the  endogenous  P120  U12  intron.  PCR  primers  which  flanked  either  
side  of  the  intron  amplified  two  products,  a  larger  unspliced  product  if  the  intron  was  
present,  and  a  smaller  spliced  product  when  the  intron  had  been  removed.  Changes  
in   the   densitometry   of   these   bands   was   indicative   of   more   or   less   splicing,   and  
calculating  the  ratio  of  spliced/unspliced  product  allowed  us  to  compare  the  amount  
of  splicing  in  comparison  to  controls.    
  
In  the  pCI-­neo  reporter  assay,  there  was  very  little  unspliced  product  in  comparison  
to  spliced,  suggesting  splicing  of  the  U2  intron  was  highly  efficient.  The  snRNPs  that  
make  up  the  major  spliceosome  are  abundant  in  cells,  which  may  facilitate  the  fast  
co-­transcriptional   removal   of   introns   (Khodor   et   al.,   2011).   In   HEK293   cells,  
transfection  of  C9orf72  pooled  siRNAs  caused  a  decrease   in   the  major  splicing  of  
the  pCI-­neo  intron,  suggesting  C9orf72  could  play  a  role  in  splicing  or  in  a  splicing-­
associated   pathway   (Figure   6.3B).   Unfortunately,   we   could   not   perform   rescue  
transfections   of   C9orf72   in   the   pCI-­neo   reporter   assay   because   the   PCR   primers  
amplified   product   from   the  myc-­C9orf72   constructs.  BLAST  analysis   of   the  primer  
sequences   and   alignment   with   the   pRK5-­myc-­C9orf72   sequence   showed   there  
should   be   no   primer   binding   to   these   constructs.   pCI-­neo   is   one   of   the   most  
frequently  prepared  and  used  constructs  within  our   lab  group  due   to   its  use  as  an  
empty  vector  control.  Therefore,  it  is  plausible  that  there  is  pCI-­neo  contamination  of  
other   plasmid   preps   and   equipment   in   the   lab,   leading   to   pCI-­neo   template  
availability   in  the  PCR.  However,  the  pCI-­neo  reporter  assay  was  performed  in  the  
B2  C9orf72  stable  knockout  cell   line  which  showed  there  was  no  effect  on  splicing  
of   the   pCI-­neo   intron   in   the   B2   cell   line   versus   HEK293   cells.   This   suggests   the  
decrease   in   pCI-­neo   splicing   observed   in  HEK293   cells  was  an  artefact   of   siRNA  
transfection,  and  the  C9orf72  protein  is  not  involved  in  major  splicing.  Measuring  the  
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splicing   efficiency   of   a   selection   of   endogenous   major   introns   in   the   B2   cell   line  
would  support  this  result.    
  
The   P120   reporter   assay  was   used   to   investigate   the   effect   of   C9orf72   on  minor  
splicing.  In  these  assays,  there  were  considerably  higher  levels  of  unspliced  product  
due  to  the  slow  removal  of  U12  introns  by  the  minor  spliceosome  (Patel  et  al.,  2002;;  
Niemela  et  al.,  2014).  The  minor  snRNPs  are  found  in  much  lower  numbers  in  cells  
versus  major  spliceosome  snRNPs,  however  one  study  suggests  this  is  not  causal  
of  minor  splicing  inefficiency  (Pessa  et  al.,  2006).  In  addition  to  investigating  splicing  
of   the   exogenous   P120   intron,   the   splicing   of   the   endogenous   P120  minor   intron  
was   also   examined.   There   was   very   little   unspliced   product   generated   from  
endogenous   P120,   suggesting   the   minor   spliceosome   efficiently   removes  
endogenous  introns,  which  are  few  in  number,  but  is  less  able  to  cope  with  the  large  
amount  of  exogenous  P120.    
  
The   results   from   the   P120   reporter   splicing   assays   were   highly   variable   and  
sometimes  contradictory.  In  Figures  6.4  and  6.5,  C9orf72  pooled  siRNA  transfection  
appeared   to   cause   a   small   decrease   in   splicing   of   exogenous   P120,   but   not  
endogenous.   These   results   suggest   the   C9orf72   protein   could   have   some  
involvement   in   minor   splicing   but   loss   of   the   C9orf72   protein   is   not   overly  
detrimental;;  the  splicing  defect  is  only  observed  when  introducing  large  amounts  of  
an   exogenous   intron   thereby   increasing   the   splicing   demand,   but   endogenous  
splicing  is  unaffected.    
  
Rescue  transfections  of  C9orf72  short  and   long   isoforms  after  C9orf72  knockdown  
were  performed  to  determine  if  expression  of  C9orf72  could  restore  splicing.  In  the  
NTC   siRNA   samples,   expression   of   myc-­C9orf72S   and   myc-­C9orf72L   did   not  
appear  to  change  splicing,  suggesting  although  knockdown  of  C9orf72  may  be  able  
to  decrease  splicing,  overexpression  of  the  protein  has  no  effect.  It  has  been  shown  
that  overexpression  of  splicing  factor  proteins  SF2  and  hnRNPA1  leads  to  changes  
in  the  splicing  of  a  reporter  intron  (Cáceres  et  al.,  1994).  Thus,  if  the  C9orf72  protein  
was  a  splicing  factor,   its  overexpression  would  be  expected  to  influence  splicing  in  
the   reporter   splicing  assays.  This   suggests  C9orf72   is   unlikely   directly   involved   in  
splicing  or  RNA  processing.    
  
However,   the   rescue   transfection  experiments   suggest   the   splicing  defect  may  be  
an   siRNA   off-­target   effect   rather   than   specific   to  C9orf72   knockdown   (Figure   6.7-­
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6.8).   It   is  worth  noting   that   there  was  statistically  no  significant  difference  between  
the  different   conditions   in   the   rescue  experiments  and   therefore   this   discussion   is  
based  on  small  changes   in   the  data  only.   In   the  P120  reporter  splicing  assay  with  
C9orf72  rescue,  transfection  of  the  C9orf72  #2  siRNA  did  not  decrease  splicing,  but  
C9orf72  mRNA  levels  were  reduced  by  70%.  There  was  a  non-­significant  decrease  
in  splicing  after  transfection  with  C9orf72  #D  and  C9orf72  pooled  siRNAs  however.  
These   results   suggest   the   decrease   in   splicing   could   be   caused   by   an   off-­target  
effect   of   the   C9orf72   #D   siRNA.   BLAST   analysis   of   the   C9orf72   #D   siRNA  
sequence   suggests   there   should   be   no   non-­specific   binding   to   other   genes.  
However,  nucleotides  2-­7  within  an  siRNA  can  act  as  a  ‘seed  region’,  facilitating  the  
binding   to   other   genes   and  exhibiting   behaviour   similar   to  microRNAs   (Kamola   et  
al.,   2015).   To   determine  whether   the  C9orf72   #D   siRNA   is   targeting   other   genes  
through   a   seed   region,   a   common   method   is   to   mutate   siRNA   base   pairs  
downstream  of  the  seed  region,  thus  making  it  unable  to  knockdown  C9orf72.  The  
reporter  splicing  assay  could  then  be  performed  on  cells  transfected  with  the  mutant  
C9orf72  #D  siRNA  and   if   the  splicing  defect   is  observed,   it   can  be  concluded   it   is  
likely  through  binding  of  the  siRNA  seed  region  to  another  gene,  thus  generating  an  
off-­target  effect.  
  
Interestingly  however,  expression  of  myc-­C9orf72S  in  cells  after  C9orf72  #D  siRNA  
transfection   increased   exogenous   P120   splicing,   suggesting   there   is   some  
involvement   of   the  C9orf72  protein   in  minor   splicing.  Expression  of  myc-­C9orf72L  
had   a   lesser   effect,   but   the   C9orf72   mRNA   levels   show   myc-­C9orf72L   was   not  
expressed  as  highly  as  myc-­C9orf72S.  In  addition,   transfection  of  both  C9orf72  #2  
and   C9orf72   #D   siRNAs   appeared   to   decrease   endogenous   P120   splicing   in   the  
rescue   experiment.   Pooled   C9orf72   siRNA   did   not   decrease   endogenous   P120  
splicing,   but   the   experiment   was   performed   only   twice   and   the   knockdown   of  
C9orf72  mRNA  in  one  of  these  experiments  was  only  20%,  which  may  explain  why  
there   was   no   effect   on   splicing   in   this   sample.   There   also   appeared   to   be   some  
rescue   of   splicing   with   C9orf72   expression   in   the   endogenous   P120   experiment.  
Taken  together,  these  results  do  implicate  a  role  for  C9orf72  in  minor  splicing.    
  
There   was   contrasting   evidence   from   the   HEK293   experiments   as   to   how   the  
decrease   in   splicing  was   occurring;;   knockdown  of  C9orf72   or   an   off-­target   siRNA  
effect.   Transfection   of   siRNAs   also   appeared   to   introduce   variability   into   the  
experiments   as   the   knockdown   of   C9orf72   was   inconsistent   across   repeated  
experiments.   Therefore,   the   reporter   splicing   assays   were   performed   in   the   B2  
   224  
stable  C9orf72  knockout  cell   line,   thus   removing  need   for  siRNA   transfections.  As  
with  the  previous  assays,  the  results  in  the  B2  cell  line  were  highly  variable,  and  all  
changes   were   non-­significant.   However,   there   was   an   observable   increase   in  
unspliced   product   from   both   exogenous   and   endogenous   P120   in   B2   cells   in  
comparison   to   HEK293   cells.   The   ratio   of   the   densitometry   of   spliced/unspliced  
bands  confirmed  there  was  a  decrease  in  P120  minor   intron  splicing  in  the  B2  cell  
line  (Figure  6.10B-­6.11B).  This  suggests  that  loss  of  the  C9orf72  protein  can  cause  
a  defect   in  minor  splicing.  However,  splicing  of  exogenous  P120  was  not   rescued  
with   co-­transfection   of   myc-­C9orf72   protein.   In   co-­transfecting   P120   and   myc-­
C9orf72,   we   assume   cells   are   transfected  with   both   constructs.   However,   we   are  
unable   to   confirm   that   the   cells   transfected   with   P120   were   successfully   co-­
transfected  with  myc-­C9orf72.  Therefore,   there   is   a   chance   that  we  are  analysing  
P120  splicing   in  cells   that  do  not  express  C9orf72,  which  could  explain   the   lack  of  
splicing  rescue.  It  is  also  possible  that  the  minor  splicing  defect  is  caused  by  an  off-­
target   effect   introduced   with   the   CRISPR   editing   of   the   cell   line.   However,   as  
discussed  in  Chapter  3,  Section  3.2.1,  two  guide  RNAs  were  used  in  the  CRISPR-­
Cas   9   nickase   editing   of   the   C9orf72   gene,   which   significantly   reduces   the  
probability  of  off-­target  effects  (Shen  et  al.,  2014).  
  
As   discussed,   C9orf72   overexpression   has   no   effect   on   splicing,   therefore   is  
unlikely  to  be  actively  involved  in  the  removal  of  introns.  The  interaction  with  minor  
spliceosome   components   could   be   investigated   to   consider   whether   C9orf72   is  
exerting   its   effect   on   minor   splicing   through   a   direct   interaction   with   the   splicing  
machinery.  The  C9orf72  protein,  unlike  the  other  ALS-­linked  genes  that  have  been  
shown   to   interact  with   the  minor  snRNPs,  does  not  appear   to  be  an  RNA  binding  
protein   (RBP)   because   of   its   lack   of   a   RNA-­recognition   motif,   supporting   that  
C9orf72   is   unlikely   to   be  directly   involved   in  RNA  processing.   In   keeping  with   the  
Cajal   body   data,   a   decrease   in   splicing   could   be   expected   to   occur   if   C9orf72   is  
involved  in  the  trafficking  of  snRNAs  and  snRNPs.  Loss  of  the  C9orf72  protein  could  
cause  an  accumulation  of  immature  snRNPs  in  the  nucleus,  causing  an  increase  in  
Cajal  bodies  and  fewer  functional  snRNPs  available  for  splicing.  The  more  efficient  
major  spliceosome  may  have  more  scope   for  compensating   for  a   loss  of  C9orf72,  
whereas   the   less   efficient   minor   spliceosome   may   be   affected.   In   addition,  
overexpression  of  C9orf72  would  not  be  expected  to  influence  splicing  if  involved  in  
snRNP   trafficking.  However,   this   is   supposition  based  on  non-­significant   data  and  
more   experiments   are   required   to   narrow-­down   the   actual   mechanism   for   how  
C9orf72  loss  generates  the  Cajal  body  and  minor  splicing  phenotype.    
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Other  groups  who  have  utilised  the  same  assay  often  report  8  biological  replicates,  
whereas   we   had   only   3-­4   repeats   (Reber   et   al.,   2016;;   Whittom   et   al.,   2008).  
Therefore,   it   appears   the   assay   is   subject   to   high   variation   and   we   were   likely  
lacking  power  to  observe  statistically  significant  changes.  More  repeats  would  allow  
us   to   say   with   more   confidence   if   we   are   observing   a   true   effect   or   not.   More  
quantitative   methods   of   measuring   splicing,   such   as   qPCR   or   RNA   sequencing,  
would   help   support   the   data   in   this   chapter.   These  methods   are   also  more   high-­
throughput,  which  would  allow  investigation  of  multiple  minor  introns  after  loss  of  the  
C9orf72  protein,  as  opposed  to  the  single  P120  intron.  It  would  also  be  of  value  to  
repeat   the   reporter  splicing  assays  with  a  more  appropriate  positive  control.  Coilin  
was   initially   included   as   a   control,   as   it   has   been   reported   that   knockdown  
decreases   splicing   (Whittom   et   al.,   2008).   However,   it   has   also   been   shown   that  
coilin   depletion   can   increase   splicing   of   a   reporter   gene   in   plants   (Kanno   et   al.,  
2016).   In  our  studies,  coilin  knockdown  had  no  effect  on  the  splicing  of  either  pCI-­
neo  or  P120,  hence  a  different  positive  control  is  required.  Knockdown  of  a  splicing  
factor,  such  as  the  SF2  protein,  would  be  an  ideal  positive  control  as  it  should  give  a  
definite  decrease  in  both  major  and  minor  splicing  and  would  confirm  the  assays  are  
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7   Discussion  
  
7.1   Summary  
  
The  GGGGCC  hexanucleotide  repeat  expansion  in  the  C9orf72  gene  is  the  leading  
genetic   cause   of   familial   and   sporadic   ALS   (DeJesus-­Hernandez   et   al.,   2011;;  
Renton   et   al.,   2011).   Three   non-­mutually   exclusive   disease   mechanisms   are  
proposed   to  occur   from   the  mutation.  First,   toxic  RNA   foci  sequester  RNA-­binding  
proteins   and   disrupt   RNA   metabolism.   Second,   RAN   translation   of   the   repeat  
expansion  generates  DPR  proteins  which  form  cytoplasmic  and  nuclear  aggregates  
and   have   been   shown   to   disrupt   multiple   cellular   functions   such   as   the   UPS,  
nucleocytoplasmic   transport   and   stress   granule   formation.   Third,   the   expansion  
causes  an  approximate  50%  reduction   in  C9orf72  mRNA  and  haploinsufficiency  of  
the  C9orf72  protein.  Loss-­of-­function  of  the  C9orf72  protein  might  cause  disruption  
to  the  pathways  it  is  normally  involved  in.  Our  group  and  others  have  discovered  a  
role  for  the  C9orf72  protein  in  autophagy  (Sellier  et  al.,  2016;;  Webster  et  al.,  2016).  
There  are  also  suggestions  in  the  literature  that  C9orf72  may  have  a  distinct  nuclear  
function;;   the   C9orf72   interaction   network   includes   nuclear   proteins   and  
immunostaining   of   C9orf72   has   found   it   to   exhibit   some   nuclear   localisation  
(Blokhuis  et   al.,   2016;;  Sellier   et   al.,   2016;;  Xiao  et   al.,   2015).  Many  of   the  nuclear  
proteins   identified   from  the  different  screens  as  C9orf72   interactors  have  functions  
in   RNA   metabolism   and   gene   expression,   for   example   splicing   factors   and  
heterogeneous   nuclear   RNPs   are   specifically   enriched   in   the   list   (See   appendix).  
However,  a  function  for  C9orf72  in  the  nucleus  remains  elusive.    
  
The  aim  of  this  project  was  to  better  understand  the  nuclear  function  of  C9orf72  and  
its   relevance   to  ALS.  Chapter  4   focused  on  characterising   the   interaction  between  
C9orf72  and  the  nuclear  protein  coilin.  Coilin  was  initially  identified  as  an  interacting  
partner  of   the  C9orf72   long  protein   in  an  unbiased  yeast   two-­hybrid  screen  (Table  
4.1).   The   interaction   was   confirmed   by   applying   three   different   methods   for  
investigating   protein-­protein   interactions.  An   in   vitro  GST-­binding   assay   confirmed  
coilin  directly  binds  to  both  the  C9orf72  short  and  long  protein  isoforms  (Figure  4.4).  
Co-­immunoprecipitation  experiments  showed  that  the  interaction  could  be  detected  
in   HEK293   cells   and   is   therefore   physiologically   relevant   (Figure   4.5).   Lastly,   the  
proximity   ligation   assay   allowed   visualisation   of   the   close   proximity   between  
   227  
C9orf72  and  coilin   in  situ,  which  suggested  C9orf72  and  coilin   interact   in  both   the  
nucleus  and  the  cytoplasm  (Figure  4.7).    
  
Coilin  is  the  major  protein  component  of  Cajal  bodies,  nuclear  suborganelles  which  
are   linked   with   snRNP   processing,   snRNA   gene   regulation   and   telomere  
maintenance.   Chapter   5   therefore   investigated   the   relationship   between   C9orf72  
and   Cajal   bodies.   The   number   of   Cajal   bodies   was   increased   in   HEK293   cells  
following   transient  C9orf72  knockdown  and   in   the  B2  stable  C9orf72  knockout   line  
(Figure  5.2,  Figure  5.5).  Overexpression  of  C9orf72  appeared  to  reduce  the  number  
of  Cajal  bodies  (Figure  5.4-­Figure  5.5).  In  contrast,  overexpression  or  knockdown  of  
C9orf72  in  rat  cortical  or  hippocampal  neurons  did  not  change  the  number  of  Cajal  
bodies  (Figure  5.6-­Figure  5.7).  Lastly,  Cajal  bodies  were  increased  in  C9orf72-­ALS  
iAstrocyte   cells,   but   rescue   of   Cajal   body   numbers   with   C9orf72   expression   was  
unsuccessful,  suggesting  a  mechanism  unrelated  to  C9orf72  haploinsufficiency  was  
causal  of  the  Cajal  body  increase  in  these  cells  (Figure  5.8-­Figure  5.10).  The  results  
presented   in   this   chapter   suggest   the  C9orf72   protein   can   influence  Cajal   bodies  
and  may  be  involved  in  a  pathway  linked  with  their  regulation  in  HEK293  cells.    
  
Finally,  Chapter  6  investigated  the  effect  of  C9orf72  on  the  major  and  minor  splicing  
pathways.  The  best-­known  function  of  Cajal  bodies  is  the  processing  of  the  snRNPs  
that   form   the   splicing   machinery.   In   addition,   RNA   splicing   defects   have   been  
reported   in   C9orf72-­ALS   patients   (Cooper-­Knock   et   al.,   2015a;;   Prudencio   et   al.,  
2015).   We   therefore   investigated   whether   changes   in   splicing   in   HEK293   cells  
occurred   in   response   to   loss   of   the   C9orf72   protein.   Transient   knockdown   of  
C9orf72  in  HEK293  cells  generated  mixed  results.  C9orf72  knockdown  appeared  to  
cause   a   small   decrease   in   major   and   minor   splicing,   but   there   was   evidence   to  
suggest   this  may  have  occurred   from  an  siRNA  off-­target  effect   (Figure  6.3-­Figure  
6.8).  In  the  B2  stable  C9orf72  knockout  line,  major  splicing  was  unaffected  but  there  
was  a  non-­significant  decrease  in  minor  splicing  (Figure  6.9-­Figure  6.11).  However,  
C9orf72  expression  in  B2  cells  did  not  rescue  the  minor  splicing  defect  (Figure  6.10-­
Figure   6.11).   The   results   presented   in   Chapter   6   suggested   there   was   a   trend  
towards   decreased   minor   splicing   in   response   to   loss   of   the   C9orf72   protein.  
Unfortunately,  high  variability  across  the  assay  combined  with  a  lack  of  power  in  the  
biological  repeat  number  limits  the  confidence  with  which  statements  can  be  made  
from  the  data.  
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7.2   Discerning  C9orf72  function  from  phenotype  
  
  
7.2.1   Nucleocytoplasmic  transport  and  RNA  processing  
  
We  have  shown  that  C9orf72  interacts  with  coilin  and  can  influence  the  number  of  
Cajal   bodies   in  HEK293   cells.   This   hints   at   a   potential   role   for  C9orf72   in   snRNP  
processing   or   a   similarly   related   pathway.   Published   evidence   demonstrates   that  
the   C9orf72   protein   may   be   involved   in   nucleocytoplasmic   transport.   The  
endogenous  C9orf72   short   protein  displays  nuclear   envelope   localisation   in  motor  
neurons   and   both   C9orf72   isoforms   exhibit   both   nuclear   and   cytoplasmic  
localisation   in   transfected   cell   lines   (Xiao   et   al.,   2015).   The   results   presented   in  
Chapter  4  support  this  finding.  Overexpression  of  either  C9orf72  protein  resulted  in  
one  of  three  cellular  localisation  patterns:  equal  diffusion  throughout  the  whole  cell,  
strong   nuclear   localisation   or   strong   cytoplasmic   localisation   (Figure   4.1).   These  
localisation  patterns  support  a  role  for  C9orf72  actively  moving  between  the  nucleus  
and  cytoplasm.  Indeed,  the  C9orf72S  staining  pattern  in  motor  neurons  co-­localises  
with   known   nucleocytoplasmic   transport   proteins,   and   co-­immunoprecipitation  
experiments   in   N2a   cells   showed   C9orf72S   interacted   with   Ran-­GTPase   and  
Importin-­β   (Xiao   et   al.,   2015).   The   interaction   between  C9orf72   and  Ran-­GTPase  
was   also   identified   in   a   mass   spectrometry   screen   of   C9orf72   protein   interactors  
(See   appendix).   Interestingly,   the   C9orf72S   nuclear   speckles   we   observed   in   a  
subset   of   cortical   neurons  are   similar   in  appearance   to   the   staining  pattern  of   the  
Ran-­GTPase   activating   protein   1   (RanGAP1)   using   an   anti-­RanGAP1   antibody  
(ab204650)   (unpublished).   These   results   suggest   the   C9orf72   protein   may   be  
involved   in   Ran-­GTPase   mediated   nucleocytoplasmic   transport.   The   Ran   protein  
exists   in   two   forms,   GTP-­bound   or   GDP-­bound.   In   the   nucleus,   Ran-­GTP   binds  
exportin  proteins,  for  example  CRM1,  and  facilitates  the  translocation  of  their  cargo  
through   the   nuclear   pore   complex.   In   the   cytoplasm,   Ran-­GTP   interacts   with  
RanGAP1  and  hydrolyses  the  GTP  to  GDP  (Görlich  and  Mattaj,  1996;;  Nigg,  1997).  
Ran-­GDP   is   then   imported  back   into   the  nucleus  where   it   interacts  with   the  RCC1  
protein.  The  RCC1  protein  acts  as  a  GEF  for  Ran,  and  mediates  the  substitution  of  
GTP   for   GDP,   generating   Ran-­GTP   and   allowing   the   cycle   to   begin   again.   For  
translocation   of   cargo   from   the   cytoplasm   into   the   nucleus,   importin   proteins   bind  
their   cargo  and  mediate   translocation  across   the  NPC  directly.   In   the  nucleus,   an  
interaction   with   Ran-­GTP   releases   the   cargo   and   facilitates   translocation   of   the  
importin  proteins  back  to  the  cytoplasm  in  the  manner  described  above  (Görlich  and  
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Mattaj,  1996;;  Nigg,  1997;;  Weis,  2003).  Ran  is  part  of  the  same  family  of  GTPases  
as   Rab   proteins,   and   they   share   evolutionary   similarities   in   their   structure   and  
function   (Wennerberg   et   al.,   2005).   C9orf72   has   been   reported   to   bind   Rabs  
preferentially   in   their   GTP-­bound   conformation,   thus   behaving   as   an   effector  
(Webster   et   al.,   2016).   We   therefore   reason   that   C9orf72   may   be   involved   in  
nucleocytoplasmic  shuttling  via  an  interaction  with  Ran-­GTP.    
  
Chapter  3  showed   that  both  C9orf72   isoforms   interact  with   the  Cajal  body  protein  
coilin.   In   addition,   we   have   demonstrated   that   both   acute   and   chronic   loss   of  
C9orf72  in  HEK293  cells  led  to  an  increase  in  the  number  of  Cajal  bodies,  whereas  
its  overexpression  caused  a  decrease  in  the  number  of  Cajal  bodies.  As  reviewed  in  
Chapter  1,  snRNPs  go  through  a  long  maturation  pathway  which  involves  entry  into  
and   processing   in   Cajal   bodies.   Many   of   the   coilin-­interacting   proteins   in   Cajal  
bodies  are  involved  in  the  snRNP  processing  pathway.  We  have  therefore  analysed  
the   snRNP   processing   pathway   to   determine   whether   C9orf72   could   fit   in   this  
pathway  based  on  the  results  presented  in  this  thesis.        
  
One   of   the   early   steps   in   the   snRNP  maturation   pathway   is   the   assembly   of   the  
snRNA   export   complex.   Nascent   snRNAs   are   bound   on   their   5’   end   by   the   cap  
binding  complex  (CBC)  and  are  recruited  to  Cajal  bodies.  Here,  the  export  proteins  
PHAX  and  CRM1  are   assembled   sequentially   onto   the   snRNA   to   form   the  export  
complex   (Boulon   et   al.,   2004).   After   the   snRNA   export   complex   is   assembled,   it  
exits   Cajal   bodies   into   the   nucleoplasm   where   it   is   bound   by   Ran-­GTP   to   be  
translocated   to   the  cytoplasm   for   further  modifications.  Both   the  PHAX  and  CRM1  
proteins  have  been  detected  in  Cajal  bodies,  whereas  Ran-­GTP  is  only  found  in  the  
nucleoplasm.   PHAX   binding   of   snRNA   is   essential   for   the   snRNA   to   exit   Cajal  
bodies,   suggesting   the   Cajal   body   behaves   as   a   quality   checkpoint.  We   suggest  
that   the   evidence   presented   in   Chapters   4   and   5   support   a   role   for   C9orf72   in  
trafficking   the   snRNA   export   complex   from   Cajal   bodies   to   the   cytoplasm   via   an  
interaction   with   coilin   and   Ran-­GTP   (Figure   7.1).   A   study   in   frog   oocytes   has  
demonstrated  coilin  can  shuttle  between   the  nucleus  and  cytoplasm,  and   the  PLA  
experiments  in  Chapter  4  suggest  C9orf72  and  coilin  interact  in  both  compartments,  
suggesting  they  both  may  be  translocating  across  the  nuclear  membrane  as  part  of  
the   same   complex   (Bellini   and   Gall,   1999).   We   did   not   detect   C9orf72   in   Cajal  
bodies  as   is   the  case  for  Ran-­GTP,  suggesting   its  position   in   the  pathway   is  post-­
snRNA  export  complex  formation  in  Cajal  bodies.  Depletion  of  C9orf72,  if   indeed  it  
is  involved  in  the  trafficking  of  snRNA  from  Cajal  bodies  to  the  cytoplasm,  may  lead  
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to   an  accumulation  of   snRNA   in   the  nucleus,  which   in   turn   could   cause   the  Cajal  
body  phenotype  we  report   in   this  work   (Figure  7.1).  This   is  supported  by  a  similar  
Cajal   body   phenotype   observed   after   depletion   of   PHAX   in   Xenopus   oocytes.  
Inhibition  of  PHAX  activity   inhibits   snRNA  export   to   the   cytoplasm  and  causes  an  
increase   in   their   accumulation   in   Cajal   bodies   (Suzuki   et   al.,   2010).   In   addition,  
knockdown  of  PHAX  using  siRNA   in  HeLa  cells  has  been  demonstrated   to   cause  
mislocalisation   of   coilin   to   the   nucleolus   (Takata   et   al.,   2012).   These   studies   are  
evidence  that  inhibition  of  snRNA  export  can  influence  the  localisation  of  coilin  and  
appearance  of  Cajal  bodies,  and  the  phenotype  can  be  cell-­type  specific.  
  
Interestingly,   if  snRNA  trafficking  is  a  function  of  C9orf72,   it  could  also  be  involved  
in   the   intranuclear   trafficking   of   snoRNA   from   Cajal   bodies   to   the   nucleolus.  
snoRNAs   briefly   visit   Cajal   bodies   for   RNA   processing   before   trafficking   to   the  
nucleolus,  where  they  catalyse  RNA  modifications  of  ribosomal  RNA  (Narayanan  et  
al.,   1999a,   1999b).   In   addition   to   interacting   with   coilin,   C9orf72   has   also   been  
shown   to   interact  with  nucleolus  proteins   fibrallarin  and  nucleolin   in  both   in  house  
and   published   proteomic   screens   (Blokhuis   et   al.,   2016).   Cajal   bodies   often  
associate  with   the  nucleolus  and  coilin  also  shows  nucleolar   localisation,   reviewed  
in   (Trinkle-­Mulcahy   and   Sleeman,   2017).   As   is   the   case   for   snRNA   export,   the  
PHAX  and  CRM1  proteins  are  responsible  for  routing  snoRNA  from  Cajal  bodies  to  
the  nucleolus.  Knockdown  of  the  CRM1  protein  leads  to  accumulation  of  snoRNA  in  
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Figure  7.1.  Hypothesised  role  for  C9orf72   in  snRNA  trafficking.   In  wild-­type  cells,  C9orf72  
may  be  involved  in  the  trafficking  of  the  snRNA  export  complex.  After  PHAX  and  CRM1  bind  in  
Cajal  bodies,  an  interaction  with  C9orf72  which  may  be  mediated  by  coilin,  allows  for  trafficking  
to   the   nuclear   pore   complex   and   interaction   with   Ran-­GTP   for   nuclear   export.   In   C9orf72  
depleted   cells,   snRNAs   accumulate   in   the   nucleus   and   Cajal   bodies.   The   accumulation   of  
snRNA  nucleates  new  Cajal  bodies  thus  leading  to  the  increased  Cajal  body  phenotype.    
   232  
In  Chapter   6,  we   investigated   the  effect   of  C9orf72  depletion  on  major   and  minor  
splicing.  Transfection  of  C9orf72  siRNA  appeared  to  have  some  off-­target  effects  on  
splicing,   therefore   I   have   chosen   to   focus   on   discussing   the   results   from   the   B2  
C9orf72   stable   knockout   cell   line   and   how   they   may   link   with   C9orf72   in  
nucleocytoplasmic   transport   and   the   snRNP  processing   pathway.   Statistically,   the  
reporter  splicing  assays  showed  there  was  no  effect  of  loss  of  C9orf72  on  splicing.  
However,   there  was  a  non-­statistically  significant  decrease   in  minor  splicing   in   the  
B2   cells.   As   previously   discussed,   with   an   n   number   of   3   we   were   likely  
underpowered   to   observe   a   statistically   significant   result.   Performing   a   power  
calculation  suggests  a  minimum  sample  size  of  5  would  be  required  to  give  an  80%  
probability   of   observing   an   effect   in   the   splicing   assay.   If   haploinsufficiency   of  
C9orf72   does   disrupt   the   snRNP   processing   pathway,   fewer   functional   snRNPs  
would   be   available   and   a   decrease   in   splicing   could   be   expected.   Indeed,  
knockdown  of   the  PHAX  protein  has  been  shown  to  cause  a  decrease   in  snRNPs  
which   in   turn   led   to   mis-­splicing   events   in   a   Drosophila   model,   confirming  
disruptions  to  snRNP  biogenesis  at  the  snRNA  export  step  can  lead  to  dysfunctional  
RNA  processing  (Garcia  et  al.,  2016).  Interestingly  however,  the  splicing  defect  we  
observed  in  this  project  was  minor  splicing  specific.  It  may  be  that  in  our  cell  model,  
the   major   spliceosome   has   greater   capacity   to   cope   with   reductions   in   snRNP  
biogenesis.  The  minor  spliceosome  which  has  a  low  abundance  of  snRNPs  to  begin  
with,  may  be  more  vulnerable   to  changes   in  snRNP  levels  (Pessa  et  al.,  2006).   In  
addition,  studies   that  have   investigated   inhibition  of  snRNP  biogenesis  on  splicing  
have  reported  the  effect  on  splicing  to  be  specific  to  a  subset  of  introns  and  exons,  
as  opposed  to  global  changes  (Garcia  et  al.,  2016;;  Pleiss  et  al.,  2007;;  Saltzman  et  
al.,   2011).   Therefore,   it   may   be   coincidental   in   our   experiments   that   the   pCI-­neo  
(major)  intron  is  unaffected  by  the  decrease  in  snRNPs,  whereas  the  P120  (minor)  
intron   is   targeted.   We   would   need   to   analyse   more   major   and   minor   introns   to  
determine  if  the  effect  is  transcript  or  spliceosome  specific.    
  
Conversely,  there  is  also  evidence  against  the  hypothesis  that  C9orf72  may  function  
in   snRNP   biogenesis.   First,   the   snRNA   export   complex   has   been   thoroughly  
researched  and  its  molecular  pathway  is  well  understood.  There  are  no  suggestions  
in   the   literature   for   a   role   of   another   unidentified   protein   in   this   pathway.  Second,  
this   pathway   is   presumably   ubiquitous   across   different   cell   types,   therefore   one  
could  expect  the  Cajal  body  phenotype  to  be  replicated  in  primary  neurons  as  well  
as  HEK293  cells.  It   is  worth  noting  however,  that  the  experiments  investigating  the  
molecular   pathway   of   snRNA   maturation   have   mostly   been   performed   in  
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transformed  cell  lines  and  differences  in  the  pathway  in  neurons  is  possible.  Thirdly,  
a  2012  study  demonstrated  depletion  of  CRM1  and  PHAX  export  proteins  caused  
loss  of  Cajal  bodies  and  mislocalisation  of  coilin  to  the  nucleolus,  which  contradicts  
the  increased  Cajal  body  phenotype  we  observe  (Takata  et  al.,  2012).  Lastly,  if  the  
C9orf72   protein   is   involved   in   the   snRNA   export   complex,   one  would   expect   it   to  
indirectly   interact  with   the  PHAX  and  CRM1  proteins   yet  neither  of   these  proteins  
have  been  identified  in  the  C9orf72  proteomic  screens  (See  appendix).    
  
  
7.2.2   Cell  cycle  
  
A   second   plausible   role   for   nuclear   C9orf72   could   be   an   involvement   in   the   cell  
cycle.   The   results   presented   in   Chapter   5   indicated   C9orf72   regulation   of   Cajal  
bodies  was  specific  to  dividing  cells,  suggesting  its  function  may  be  linked  with  cell  
proliferation.  Neurons  are  regarded  as  permanently  post-­mitotic,  hence  the  absence  
of   an   effect   of   C9orf72   protein   overexpression   or   knockdown   in   the   primary   rat  
neurons   may   be   explained   by   differences   in   the   cell-­cycle   biochemistry   between  
differentiated  and  proliferating  cells.  The  number  of  Cajal  bodies  is  increased  during  
mid-­G1,   followed   by   their   disassembly   at   entry   into  mitosis   (Andrade   et   al.,   1993;;  
Carmo-­Fonseca  et  al.,  1993).  It  has  been  hypothesised  that  the  changing  number  of  
Cajal   bodies   is   in   response   to   the   transcription   and   splicing   demand   of   the   cell.  
During   mitosis,   transcription   and   splicing   are   halted,   therefore   there   is   less   of   a  
requirement  for  snRNP  biogenesis.  On  the  other  hand,  transcription  and  splicing  are  
prevalent  during  G1,   thus  Cajal  bodies  are   increased.  The  regulation  of  Cajal  body  
numbers   during   cell   cycle   progression   is   controlled   by   phosphorylation   of   coilin  
(Carmo-­Fonseca  et  al.,  1993;;  Chan  et  al.,  1994;;  Hearst  et  al.,  2009).  Low  levels  of  
coilin   phosphorylation,   as   detected   in   G1,   favour   Cajal   body   assembly   and  
hyperphosphorylation   of   coilin   during   mitosis   causes   Cajal   body   disassembly  
(Figure  7.2)  .    
  
In  chapter  4,  C9orf72  was  shown  to  directly  interact  with  coilin.  We  therefore  reason  
C9orf72  may  be   involved   in   regulating  Cajal   body  numbers  via   its   interaction  with  
coilin,  and  could  do  so  by  affecting  coilin  phosphorylation  and/or  protein  levels.  The  
VRK1   protein   is   a   cell-­cycle   regulated   nuclear   kinase   that   is   involved   in   coilin  
phosphorylation   (Sanz-­García   et   al.,   2011).   Phosphorylation   of   coilin   by   VRK1  
promotes  Cajal  body  assembly  from  two  predicted  mechanisms.  First,  specific  coilin  
phosphorylation   patterns   enhance   protein-­protein   interactions   and   increase   Cajal  
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body   nucleation   events.   Second,   coilin   phosphorylation   prevents   its   ubiquitination  
by   the  Mdm2  E3  ubiquitin   ligase  and  degradation  by   the  UPS.  Coilin   can  also  be  
phosphorylated   by   the  CDK2-­cyclin   E   complex,   which   shows   localisation   to   Cajal  
bodies  and   is   responsible   for   transition   from   the  G1   to  S  phase   (Liu   et   al.,   2000).  
There   is   little  evidence  to  currently  support  a  role   for  C9orf72   in  directly  regulating  
coilin  phosphorylation   levels.  Hyperphosphorylation  or  complete  dephosphorylation  
of  coilin  completely  abolishes  its  ability  to  form  Cajal  bodies,  therefore  it  is  probable  
that   coilin   in   the   C9orf72   knockout   and   knockdown   HEK293   cells   exists   in   the  
hypophosphorylated  state  that  favours  Cajal  body  formation.    
  
From   our   current   knowledge   of   C9orf72,   the   protein   does   not   exhibit   kinase   or  
phosphatase  enzymatic  activity.  This  would  therefore  suggest  the  protein  kinases  or  
phosphatases   responsible   for   managing   coilin   phosphorylation   are   influenced   by  
loss  of  C9orf72.  Because   these  proteins  appear   to  be   regulated  by   the   cell-­cycle,  
we   cannot   say  whether   they  are  affected  directly   through   loss  of  C9orf72  protein,  
e.g.   loss   of   a   C9orf72-­kinase   interaction,   or   by   a   change   in   the   cell   cycle,   e.g.  
stalling   in   a   particular   phase   of   the   cell   cycle.   The   table   of   proposed   nuclear  
interactors   of   C9orf72   in   the   appendix   shows   a   lack   of   detected   interactions  
between   C9orf72   and   nuclear   serine/threonine   kinases.   However,   analysis   of   the  
C9orf72   protein   sequence   shows   it   contains   four   potential   sites   for   CDK2-­cyclin  
binding,   which   follow   the   XK/RXL   motif:   248VRTL,   407RKAL,   427FKSL,   430LRNL  
(Takeda  et  al.,  2001;;  Wohlschlegel  et  al.,  2001).  As  mentioned,  the  CDK2-­cyclin  E  
complex   can   phosphorylate   coilin   and   joins   Cajal   bodies   at   the   G1/S   boundary,  
presumably   where   it   performs   phosphorylation   of   coilin   and   other   Cajal   body-­
localised  substrates  (Liu  et  al.,  2000).  Hence,  C9orf72  may  interact  with  both  coilin  
and  the  CDK2-­cyclin  E  complex  and  mediate  the  G1  phosphorylation  of  coilin.  The  
CDK2-­cyclin   binding  motifs   found   in  C9orf72   are   located  within   the   central  DENN  
and  downstream  DENN  domains,  and  are  therefore  not  present  in  the  C9orf72  short  
isoform.   We   have   shown   that   both   the   C9orf72   short   and   long   protein   isoforms  
interact   with   coilin,   suggesting   the   longin   domain   of   C9orf72   is   responsible   for  
mediating   this   interaction.   It   is   therefore  possible   for  C9orf72   to   interact  with  coilin  
via  its  longin  domain  and  bridge  an  interaction  with  the  CDK2-­cyclin  E  complex  via  
its   C-­terminal   domain.   In   this   scenario,   the   C9orf72   short   protein   would   lack   this  
function.  However,   in  the  experiments  presented  in  this  thesis,   transfection  of  both  
C9orf72   isoforms   rescued   Cajal   body   numbers,   questioning   the   relevance   of   the  
CKD2-­cyclin  binding  motifs   to  Cajal  body   regulation.   It  may  be   that   the  motifs  are  
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not   involved   in   cyclin   binding   but   are   hydrophobic   stretches   of   residues   that  
contribute  to  proper  dDENN  domain  folding.    
  
It   is   not   illogical   to   assume   the   regulation   of   Cajal   bodies   by  C9orf72   in  HEK293  
cells  requires  the  interaction  with  coilin.  However,  there  is  evidence  to  suggest  there  
is  a  link  between  the  cell  cycle  regulation  of  Cajal  bodies  and  C9orf72’s  previously  
discussed   predicted   functioning   in   Ran-­GTP   nucleocytoplasmic   transport.  
Disruptions  to  the  Ran-­GTPase  network  has  been  found  to  disrupt  multiple  steps  in  
the   cell   cycle   (Moore,   2000).   Of   most   relevance   to   this   project,   depletion   of   the  
RCC1  protein,  which   is  a  GEF  for  Ran-­GTP,  can  cause  cells   to  arrest  at   the  G1/S  
boundary  (Nishimoto  et  al.,  1978).  In  addition,  expression  of  a  mutant  Ran-­GTPase  
protein  that  cannot  catalyse  the  conversion  of  GTP  to  GDP,  also  leads  to  cell  cycle  
arrest  at   the  G1/S  boundary  or  G2/M  boundary   (Ren  et  al.,  1994).   In   line  with   this,  
one   could   expect   to   observe   an   increase   in   the   number   of   Cajal   bodies   in   cells  
arrested   at   the   G1/S   transition.   One   interpretation   of   these   results   is   that   loss   of  
C9orf72   inhibits  Ran-­GTP   driven   nucleocytoplasmic   transport,   as   proposed   in   the  
previous  section.  It  has  been  hypothesised  that  loss  of  nucleocytoplasmic  transport  
may   then   indirectly   influence   the   cell   cycle   (Dasso,   1995;;  Moore,   2000).  Faults   in  
the   nuclear   export/import   pathways   can   lead   to   mislocalisation   of   both   RNA   and  
protein,  including  the  CDK-­cyclin  complexes  required  for  cell  cycle  regulation.  Loss  
of   these  proteins   then  signal   for  cells   to  arrest  at   the  boundary  between  G1  and  S  
(Figure  7.2).    
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There  is  also  some  evidence  to  suggest  the  minor  spliceosome  has  some  cell-­cycle  
regulated   activity,   perhaps   explaining  why  we   detect   a   decrease   in  minor   but   not  
major  splicing  following  C9orf72  depletion,  should  the  above  hypothesis  prove  true.  
A  study   in  2007   reported   that   the  minor  and  major  spliceosomes  may  be  spatially  
segregated  in  vertebrates,  with  minor  splicing  in  the  cytoplasm  and  major  splicing  in  
the   nucleus   (König   et   al.,   2007).   As   reviewed   in   Chapter   1,   Section   1.7.2.1,   the  
inefficiency  of  the  minor  spliceosome  in  comparison  to  the  major  spliceosome,  often  
causes   generation   of   mRNA   transcripts   that   contain   a   single   minor   intron.   The  
König  paper  reports  that  these  minor-­intron  mRNAs  can  undergo  nuclear  export  and  
minor   snRNPs   can   catalyse   the   removal   of   the   intron   in   the   cytoplasmic  
environment.  Interestingly,  splicing  activity  of  the  P120  minor  intron  was  detected  in  
cells  arrested   in  mitosis  when   transcription  and  major  splicing  are   typically  halted,  
and  depletion  of   the  minor  snRNPs  caused  cell  cycle  arrest  at   the  G1/S   transition,  
suggestive  of  a   role   for  minor  splicing   in   the  cell  cycle   (König  et  al.,  2007).  Taken  
together,   these   results   suggest   minor   splicing   may   be   regulated   by   and/or   have  
Figure   7.2.   Haploinsufficiency   of   C9orf72   may   lead   to   cell   cycle   arrest   at   the   G1/S  
transition.  Coilin   is  hypophosphorylated  during  the  G1,  S,  and  G2  phases  of   interphase  which  
promotes  Cajal  body  assembly.  Mitotic  coilin   is  hyperphosphorylated  which  causes  Cajal  body  
disassembly  during  mitosis.  Loss  of  C9orf72  causes  an  increase  in  the  number  of  Cajal  bodies  
and  a  decrease  in  minor  splicing,  suggestive  of  cell-­cycle  arrest  at  the  G1/S  transition.  
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regulatory   control   of   the   cell   cycle.   We   have   suggested   that   loss   of   C9orf72  
nucleocytoplasmic   transport   may   lead   to   cell   cycle   arrest   in   the   G1/S   boundary,  
which   in   turn  may  decrease  minor  splicing  activity  which  may  have  a  different  cell  
cycle  activity  and   localisation  pattern   to  major   splicing.   It  may  also  be   that   loss  of  
C9orf72  nucleocytoplasmic   transport   leads   to  a  decrease   in  snRNP  biogenesis  as  
discussed  in  the  previous  section.  Loss  of  the  snRNPs  may  then  signal  for  cells  to  
arrest  before  DNA  synthesis  can  occur.  
  
In   summary,   we   reason   the   Cajal   body   phenotype   and   minor   splicing   defect   we  
have   reported   in   this   thesis   could   occur   through  multiple   converging  mechanisms  
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Figure  7.3.  Converging  disease  mechanisms  caused  by  C9orf72  haploinsufficiency.  There  
is   evidence   to   suggest   the  C9orf72   protein   has   an   involvement   in   nucleocytoplasmic   transport  
based   on   its   interaction   with  Ran-­GTP   and   importin-­B,   and   it’s   subcellular   localisation   pattern.  
C9orf72  haploinsufficiency   therefore  may  cause  dysfunctional  nucleocytoplasmic   transport.  This  
may   lead   to  mislocalisation   of   RNA  and  proteins   involved   in   cell   cycle   regulation  which   in   turn  
signals  for  cell  cycle  arrest.  Cajal  bodies  and  minor  splicing  can  both  be  regulated  by  cell  cycle,  
and   will   therefore   be   affected   by   stalling   at   the   G1/S   phase.   Dysfunctional   nucleocytoplasmic  
transport  may  also  affect   snRNP  biogenesis,  which   relies  on  nuclear   export   and   import   for   the  
maturation   pathway.   This   may   lead   to   an   accumulation   of   immature   snRNA   in   the   nucleus   of  
cells,  which  could  nucleate  Cajal  body  assembly.  We  also  propose   that  a  decrease   in  available  
snRNPs  could  directly  lead  to  a  minor  splicing  defect  and  can  also  cause  cell  cycle  arrest.    
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7.3   Cajal  bodies  in  ALS  
  
One  of  the  main  findings  of  this  project  was  that  loss  of  the  C9orf72  protein  can  lead  
to  an  increase  in  Cajal  bodies.  A  proposed  mechanism  for  how  this  occurs  has  been  
discussed  (Figure  7.3).   In  Chapter  5  we  observed  that   the  number  of  Cajal  bodies  
was   increased   in  C9orf72-­ALS  patient   iAstrocytes   in  comparison   to   their  age-­  and  
sex-­matched   healthy   controls.   This   suggests   an   increase   in   the   number   of   Cajal  
bodies  may  be  a  pathological  hallmark  of  C9orf72-­ALS.    
  
Cajal   bodies   have   links   with   neurodegenerative   disorders,   however   it   is   normally  
their   loss   which   is   thought   to   be   pathogenic,   and   the   loss   of   snRNP  
biogenesis/splicing  that  goes  with  this.  It  is  not  known  whether  an  increase  in  Cajal  
bodies   can   have   related   toxic   side   effects,   therefore   more   work   is   needed   to  
investigate   the   downstream   consequences   of   an   increase   in   the   number   of   Cajal  
bodies   in   cells.   From   the   current   knowledge   of   the   function   of   Cajal   bodies,   we  
hypothesise   that   the   increase   in  Cajal   bodies   themselves   are   not   pathogenic,   but  
are  a  visible  consequence  of  a  separate  pathomechanism.    
  
Interestingly,  the  number  of  Cajal  bodies  in  the  patient  iAstrocyte  cell  lines  was  not  
rescued  by  exogenous  C9orf72  expression,  suggesting  in  these  cells  there  may  be  
another  pathway  involved  that  leads  to  the  same  Cajal  body  phenotype  as  C9orf72  
protein   haploinsufficiency.   We   have   hypothesised   that   the   C9orf72   protein   may  
have   a   role   in   nucleocytoplasmic   transport,   and   Figure   7.3   demonstrates   how   a  
disruption  to  this  function  may  lead  to  misregulation  of  Cajal  bodies.  As  reviewed  in  
Chapter  1,  both  the  RNA  foci  and  DPRs  generated  from  the  C9orf72  mutation  have  
been   reported   to   interfere   with   nucleocytoplasmic   transport.   RNA   foci   are  
hypothesised   to   exert   toxicity   via   sequestration   of   RNA-­binding   proteins.  
Interestingly,   the   RanGAP1   protein   which   functions   within   the   Ran-­GTP   network,  
interacts  with   the  C9orf72  repeat  expansion  RNA  and  colocalises  with  RNA  foci   in  
C9orf72-­ALS   derived   neurons   and   patient   tissue   (Zhang   et   al.,   2015).   The   same  
study   described   a   consequence   of   RanGAP1   sequestration   was   Ran-­GTP  
mislocalisation   to   the   cytoplasm   and   significant   disruption   to   the   translocation   of  
proteins   across   the   nuclear   membrane   (Zhang   et   al.,   2015).   In   another   study,  
expression  of   58  GGGGCC  hexanucleotide   repeats   in  both   flies  and  cells   caused  
the  nuclear  accumulation  of  RNA,  suggestive  of  disrupted  RNA  export  (Freibaum  et  
al.,   2015).   The   authors   reported   only   a   fraction   of   the   retained  RNA  was  mRNA,  
suggesting  other  small  non-­coding  RNAs  may  also  have  been  retained.  There  are  a  
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number   of   publications   suggesting   arginine-­containing   DPRs   can   also   directly  
interact   with   the   NPC   and   disrupt   RNA   and   protein   nucleocytoplasmic   transport  
(Boeynaems  et  al.,  2016;;  Jovičić  et  al.,  2015;;  Shi  et  al.,  2017).  Knockdown  of  both  
the  RCC1  and  RanGAP1  proteins   in   a  Drosophila  model   expressing   the  Poly-­GP  
protein  enhanced  neurodegeneration  of   the  fly  eye  and  toxicity  (Boeynaems  et  al.,  
2016).  In  C9orf72-­ALS  derived  induced  neurons,  the  RCC1  protein  was  also  shown  
to   be   mislocalised   to   the   cytoplasm   (Jovičić   et   al.,   2015).   Taken   together,  
disruptions   to   the  Ran-­GTP   network   and   nucleocytoplasmic   transport  may   be   the  
end  target  from  three  individual  but  converging  disease  mechanisms  that  occur  from  
the  C9orf72  mutation  in  ALS.  If  this  hypothesis  proves  true,  it  may  be  expected  that  
in   the   presence   of   C9orf72   haploinsufficiency,   blocking   DPR   or   foci   generation  
might   also   fail   to   rescue   Cajal   bodies   and   Ran-­mediated   nucleocytoplasmic  
transport.  
  
Disruption   to   the   nuclear   export   and   import   of   RNA   and   protein   could   have  
widespread   repercussions.   The   changes   to   alternative   splicing   in   C9orf72-­ALS  
patients  have  been  attributed   to  RNA  foci  sequestration  of  splicing   factor  proteins,  
but   the  mislocalisation   of   snRNA   and   proteins   involved   in   splicing   from   disrupted  
nucleocytoplasmic  transport  may  also  be  a  contributing  factor  (Cooper-­Knock  et  al.,  
2015a;;  Prudencio   et   al.,   2015).   In   addition,   researchers   have   questioned  whether  
defective   nucleocytoplasmic   transport   in   ALS   could   also   be   causal   of   the  
mislocalisation  of  proteins  such  as  TDP-­43.  Interestingly,  inhibition  of  nuclear  import  
leads  to  mislocalisation  of  FUS  into  cytoplasmic  aggregates  and  overexpression  of  
the   transportin   1   protein,   responsible   for   FUS-­nuclear   import,   suppresses   DPR-­
related  toxicity  in  both  yeast  and  flies  (Boeynaems  et  al.,  2016;;  Reber  et  al.,  2016;;  
Sun  et   al.,   2015).  Pathogenic  FUS-­related   splicing   defects   have  been   reported   to  
occur  through  loss  of  the  nuclear  function  of  FUS  and  sequestration  of  snRNPs  by  
FUS   aggregates   (Reber   et   al.,   2016;;   Sun   et   al.,   2015).   Hence,   defective  
nucleocytoplasmic  transport  may  be  an  underlying  causal  factor  for  FUS  pathology  
in   ALS   and   FTD.   In   support,   DPR   pathology,   and   presumably   also   RNA   foci  
formation,   has   been   shown   to   precede   TDP-­43   neuronal   cytoplasmic   inclusion  
pathology   in  C9orf72-­FTLD  patients   (Baborie  et   al.,   2015;;  Proudfoot  et   al.,   2014).  
ALS   is   an   aging   disease,   and   there   is   evidence   to   suggest   nucleocytoplasmic  
transport  efficiency  decreases  with  age  (Mertens  et  al.,  2015).  Motor  neurons,  which  
do   not   undergo  mitosis,   do   not   have   regular   break   down  of   the   nuclear   envelope  
and   nuclear   pore   complex   disassembly.   A   consequence   of   this   is   the   proteins  
involved   in  nucleocytoplasmic   transport   in  neurons  are   recycled  at  a  much  slower  
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rate  and   therefore  could  be  more  prone   to  damage  and  deterioration   (D’Angelo  et  
al.,  2009;;  Toyama  et  al.,  2013).  Motor  neurons,  which  have  a  higher  dependency  on  
splicing  and  metabolism  than  other  post-­mitotic  cells,  may  then  be  more  vulnerable  
to  defects  in  RNA  and  protein  import/export.    
  
The   iAstrocyte   Cajal   body   results   are   interesting   when   thinking   about   the  
implications   for   ALS   and   future   treatments.   Anti-­coilin   antibodies   that   exhibit   both  
high   sensitivity   and   specificity   are   commercially   available.   We   reason   that   after  
further   validation   studies   to   confirm   increased  Cajal   bodies  are  a   consequence  of  
dysfunctional  nucleocytoplasmic  transport,  their  immunostaining  could  be  used  as  a  
useful   biomarker   for   investigating   the   usefulness   of   drugs   targeting   this   pathway.  
For  example,  if  the  increased  Cajal  bodies  in  patient  iAstrocytes  are  caused  by  RNA  
foci   sequestration   of   the   RanGAP1   protein   and   disrupted   nucleocytoplasmic  
transport,   then   a   decline   in   Cajal   bodies   could   be   a   relatively   high-­throughput  
readout   to  measure   the   efficiency   of   drugs   targeting  RNA   foci.   In   line  with   this,   it  
would   be   particularly   interesting   to   perform   Cajal   body   immunostaining   from  
different  cells,  animals  and  patient  tissue  that  model  the  three  different  C9orf72-­ALS  
disease   mechanisms   to   investigate   this   further.   As   ALS   causes   the   specific  
degeneration  of  motor  neurons,   the  regulation  of  Cajal  bodies   in   these  cells  would  
be  most   important.  Unfortunately,  we   did   not   observe   a   change   in   the   number   of  
Cajal  bodies  in  primary  neurons  following  C9orf72  protein  knockdown,  although  it  is  
worth   noting   these   were   not   motor   neurons.   In   addition,   the   level   of   C9orf72  
knockdown  in  neurons  was  determined  by  measuring  C9orf72  mRNA  levels,  which  
had   limitations.   The   miRNA   transduced   into   neurons   to   knockdown   C9orf72   was  
tagged   with   GFP,   and   immunofluorescence   images   suggest   there   was   100%  
transduction  efficiency,  whilst  C9orf72  mRNA  was  reduced  approximately  by  50%,  
suggesting  miRNA  may  not  be   the  most  effective  method   for  C9orf72  knockdown.  
Immunoblot  of  C9orf72  from  neuronal  lysate  following  C9orf72  miRNA  transduction  
would  allow   for  better   characterisation  of  C9orf72  knockdown   in   the  primary  cells.  
Should   the   C9orf72   protein   be   reduced   in   neurons   without   the   Cajal   body  
phenotype,  this  suggests  either  (1)  C9orf72  haploinsufficiency  alone  does  not  cause  
disruption  enough   to  generate   the  Cajal  body  phenotype   in  neurons  or   (2)   loss  of  
C9orf72  is  pathogenic  in  neurons  but  differences  in  their  biochemistry  means  Cajal  
body  numbers  do  not  respond  as  they  would  in  different  cell  models.    
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7.4   C9orf72  haploinsufficiency  in  ALS  
  
If  the  Cajal  body  phenotype  is  a  consequence  of  a  disrupted  molecular  pathway  in  
the   iAstrocyte   patient   cells,   then   the   experiments   included   in   this   thesis   suggest  
overexpression  of   the  C9orf72  protein  alone  may  not  be  enough  to  restore  normal  
function.  This  would  suggest,  at  least  in  the  iAstrocyte  cells,  that  haploinsufficiency  
of  the  C9orf72  protein  is  not  the  only  cause  of  ALS  pathogenesis.  This  would  need  
to   be   confirmed   however   by   rescuing   iAstrocyte   C9orf72   protein   levels   whilst  
simultaneously  blocking  DPRs  and  RNA  foci.    
  
In  chapter  6,  we  found  that  loss  of  the  C9orf72  protein  may  directly  lead  to  a  small  
defect   in   minor   splicing,   suggesting   loss   of   function   may   have   some   pathogenic  
consequences,  although  these  results  are  variable  and  need  to  be  further  validated.  
We   cannot   conclude   from   the   reporter   splicing   assays   the   size   of   the   effect   of  
C9orf72  haploinsufficiency  on  splicing.  However,  the  decrease  in  minor  splicing  was  
small,  and  there  was  no  effect  to  major  splicing.  It   is  therefore  unlikely  to  be  solely  
responsible   for   the   widespread   changes   to   alternative   splicing   events   found   in  
C9orf72-­ALS   patient   brains,   but   may   still   contribute   to   the   intron   retention  
(Prudencio  et  al.,  2015).  
  
In  summary,  we  propose  that  loss  of  this  nuclear  function  of  C9orf72  does  not  have  
a   large  enough  effect   to  cause  severe  pathogenesis  by   itself.  This   is  supported  by  
the  relatively  minor  neurodegeneration  in  C9orf72  loss  of  function  animal  models  in  
comparison   to  C9orf72  gain-­of-­function  models   (Jiang  et  al.,  2016;;  Koppers  et  al.,  
2015;;   Liu   et   al.,   2016;;   O’Rourke   et   al.,   2016;;   Peters   et   al.,   2015).   However,   in  
combination  with  gain  of   toxic   functions   from  RNA  foci  and  DPRs,   loss  of  C9orf72  
could   have   a   detrimental   effect   by   enhancing   the   neurodegeneration   caused   by  
these   disease   mechanisms,   such   as   RNA   processing   and   nucleocytoplasmic  
transport.  That  is  not  to  say  reintroduction  of  the  C9orf72  protein  would  not  provide  
some  advantage  to  patients,  as  there  is  compelling  evidence  to  suggest  it  could  be  
beneficial   to   restoring  C9orf72-­haploinsufficiency   related  autophagy  problems   (Shi  
et   al.,   2018;;   Webster   et   al.,   2016),   but   its   impact   on   nuclear-­associated   disease  
pathways,   such  as  RNA  processing  and  nucleocytoplasmic   transport,   is   still   to  be  
determined.  Overexpression  of  nucleocytoplasmic  transport  proteins,  such  as  Ran-­
GAP1   or   KPNA3,   have   been   reported   to   partially   alleviate   the   neurodegeneration  
caused   by   the   toxic   gain-­of-­function   mechanisms   suggesting   restoration   of   this  
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pathway  has  therapeutic  benefit  (Jovičić  et  al.,  2015;;  Zhang  et  al.,  2015).  However,  
the   literature  suggests  several  proteins   in  nuclear  export/import  can  be  affected   in  
C9orf72-­ALS.   As   such,   expression   of   a   singular   protein   may   provide   some  
therapeutic   benefit,   but   would   be   limited   to   a   partial   rescue.   In   addition   to   this,  
expression  of  wild-­type  proteins  in  motor  neurons  to  overcome  their  loss-­of-­function  
would  require  implementing  gene  therapy  techniques  which  has  had  limited  success  
so   far   in   modern   treatments.   Antisense   oligonucleotides   that   target   the   C9orf72  
repeat  expansion  RNA  have  shown  promise  and  could  inhibit  the  generation  of  both  
RNA  foci  and  DPRs  (Lagier-­Tourenne  et  al.,  2013;;  Zhang  et  al.,  2015).    
  
7.5   Future  directions  
  
The   work   completed   towards   this   thesis   has   set   the   groundwork   for   some  
interesting  future  experiments  to  build  upon.  The  two  most  important  things  to  lead  
on   from   this  project  are   to   (1)   validate   the  splicing   results  presented   in  Chapter  6  
and   (2)   design   experiments   to   determine   a   mechanistic   understanding   of   the  
nuclear  function  of  C9orf72.  
  
Chapter  4  showed  an  interaction  between  C9orf72  and  coilin.  We  have  shown  that  
C9orf72   interacts  with  coilin  via   its   longin  domain,  as   the   interaction  was  detected  
with  both  the  short  and  long  protein  isoforms.  It  would  be  interesting  to  confirm  this  
result   by   including   a  C9orf72  mutant   protein   lacking   the   longin   domain   in   the   co-­
immunoprecipitation   experiment.   Coilin   deletion   mutants   could   also   be   used   to  
investigate  where  on  coilin  C9orf72  is  binding.  Deletion  mutants  of  particular  interest  
would  be  coilin  lacking  the  N-­terminal  self-­association  domain,  the  C-­terminal  tudor  
domain,  the  C-­terminal  RG-­box  and  a  double  tudor  domain/RG  box  deletion  mutant.  
Both  C9orf72  protein  isoforms  were  shown  to  rescue  the  number  of  Cajal  bodies  in  
Chapter   5,   suggesting   the   C9orf72   longin   domain   is   sufficient   for   Cajal   body  
regulation.  Overexpression  of  a  ∆longin-­C9orf72  protein  in  the  B2  C9orf72  knockout  
cells  would   not   be   expected   to   rescue   the   number   of  Cajal   bodies.  Currently,   the  
significance   of   the  C9orf72-­coilin   interaction   for   the   ability   of  C9orf72   to   influence  
Cajal  body  numbers  is  not  clear.  If  we  could  further  narrow  down  the  interaction  to  
the   exact   binding   residues   on  C9orf72,  we   could   generate   a  C9orf72  mutant   that  
cannot   bind   coilin.   It   would   then   be   interesting   to   determine   if   expression   of   the  
C9orf72  protein  that  lacks  coilin  binding  can  regulate  the  number  of  Cajal  bodies.  
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In   chapter   6,   the   effect   of   loss   of   C9orf72   on   major   and   minor   splicing   was  
presented.   Issues  with   variability   in   the   reporter   splicing  assays  has  already  been  
discussed   in   detail.   Others   who   have   implemented   these   assays   have   often  
included  8  biological  repeats,  therefore  we  suggest  performing  sufficient  repeats  of  
our   assays   to   determine   if   C9orf72   has   a   significant   effect   on  minor   splicing;;   the  
power   calculation   referred   to   earlier   in   this   discussion  would   suggest   another   two  
repeats  are  needed   to  observe  a  significant  effect   (Reber  et  al.,  2016;;  Whittom  et  
al.,  2008).  In  addition,  we  were  limited  in  these  assays  by  analysing  the  splicing  of  
just   one   major   and   minor   intron,   therefore   making   it   difficult   to   conclude   if   the  
decrease  in  splicing  was  transcript  specific  or  loss  of  spliceosome-­specific  splicing.  
Therefore   the   assay   should   be   performed   using   additional   major   and   minor  
reporters  such  as  SMS,  MAPK3,  and  MAPK12,  which  contain  both  minor  and  major  
introns   and   can   therefore   be   used   as   reporters   for   both   splicing   pathways  
(Markmiller  et  al.,  2014).  RNA  sequencing  after  C9orf72  depletion  would  generate  
the  most   informative   data   on   the   effect   of   C9orf72   haploinsufficiency   on   splicing.  
Mis-­splicing   of   targets   shared   between   the   transient   C9orf72   knockdown   and  
C9orf72   knockout   cells   are   likely   to  be   true  mis-­splicing  events   caused  by   loss  of  
C9orf72   protein   rather   than   an   off-­target   effect   from   siRNA   transfection   or  
CRISPR/Cas9  editing.  Confirmation  of   these  effects   in  cerebellum  and  cortex  from  
the   brains   of   C9orf72   haploinsufficient  mice,   as   has   been   performed   on  C9orf72-­
ALS  patient  brains  (Prudencio  et  al.,  2015),  would  allow  separation  of   the  effect  of  
C9orf72  protein  haploinsufficiency  on  splicing  from  RNA  foci  and  DPR  contributions.  
  
The   effect   of   C9orf72   on   Cajal   bodies   and   minor   splicing,   combined   with   the  
localisation  pattern  of  C9orf72  in  Chapter  3,   led  to  predictions  of  C9orf72  having  a  
nuclear   function   in   nucleocytoplasmic   transport   and   snRNA   export.   There   is  
evidence   to   suggest  C9orf72   interacts  with  Ran-­GTPase.   To   investigate  C9orf72-­
Ran-­GTPase  binding,  one  could  perform  an  in  vitro  GST-­binding  assay  to  measure  
the  direct   interaction  between  the  proteins  (Xiao  et  al.,  2015).  Further   from  this,   to  
determine   if   the   interaction   is   physiologically   relevant,   co-­immunoprecipitation  
experiments  between  C9orf72  and  export  adaptor  proteins  PHAX  and  CRM1  could  
determine   if   an   interaction   is   present   in   cells.   If   C9orf72   haploinsufficiency   does  
cause  a  defect  in  nucleocytoplasmic  transport,  one  could  expect  an  accumulation  of  
RNA   in   the   nucleus,   as   has   been   detected   in   HEK293   cells   following   DPR  
transfection   (Freibaum  et  al.,  2015).  To   test  whether  C9orf72  depletion  causes  an  
RNA   export   defect,   one   could   perform   RNA   in   situ   hybridisation   of   C9orf72-­
knockdown   HEK293   cells   to   measure   RNA   accumulation   in   the   nucleus.   To  
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investigate   whether   said   RNA   accumulation   contributes   to   the   increase   in   the  
number   of   Cajal   bodies,   coilin   immunostaining  may   be   performed   to   determine   if  
there  is  a  correlation  between  RNA  accumulation  and  Cajal  body  numbers.  Many  of  
the  studies   into  nucleocytoplasmic  transport   in  ALS  suggest  disruption  to   the  Ran-­
GTP  gradient   across   the   nuclear  membrane   is   disrupted   (Zhang   et   al.,   2015).   To  
test   if   there   is   a   disruption   to   the   nuclear   to   cytoplasmic   ratio   of   Ran   in   C9orf72  
depleted   cells,   one   could   perform   immunofluorescence   or   nuclear   fractionation   of  
cells  followed  by  immunoblot  for  Ran  to  measure  the  relative  Ran  proteins  levels  in  
the  different  subcellular  localisations.  
  
Earlier  we  discussed  a  mechanism  for  how  C9orf72  haploinsufficiency  could  cause  
cell   cycle   arrest   in   HEK293   cells.   This   was   based   on   the   Cajal   body   and   minor  
splicing   results,  both  of  which  have   links  with  cell-­cycle   regulation   (Andrade  et  al.,  
1991;;  Carmo-­Fonseca  et  al.,  1993;;  König  et  al.,  2007).  However,  this  hypothesis  is  
based  on  circumstantial  evidence  only  and  needs  to  be  assessed  further.  One  way  
of  investigating  this  would  be  determining  the  frequency  of  wild-­type  versus  C9orf72  
knockout  cells  at  different  stages  in  the  cell  cycle.  As  discussed,  the  cyclin  E  protein  
localises  to  Cajal  bodies   in  mid  G1  and  exits  during  the  S  phase  (Liu  et  al.,  2000).  
Co-­staining  for  coilin  and  the  cyclin  E  protein  after  C9orf72  siRNA  transfection  or  in  
the  B2  C9orf72  knockout  cells  could  therefore  inform  if  cells  are  stalled  at  the  G1/S  
by   an   observable   increase   in   the   percentage   of   cells   with   coilin-­cyclin   E  
colocalisation.  Similarly,  DNA  incorporation  of  BrdU  is  frequently  implemented  as  a  
marker  of  DNA  synthesis  during   the  S  phase  of   the  cell  cycle   (Nowakowski  et  al.,  
1989).   We   also   predict   coilin   in   C9orf72   depleted   cells   to   show   a   different  
phosphorylation   pattern   to   coilin   from   wild-­type   cells.   As   coilin   has   11  
phosphorylation  sites,  it  would  prove  difficult  using  phospho-­site  specific  antibodies  
to  track  the  post-­translational  modifications  to  all  individual  sites.  Mass  spectrometry  
analysis   on   immunoprecipitated   coilin   from   C9orf72   knockout   cells   would   be   the  
most  suitable  option  for  investigating  this  further.    
  
Further   investigation   is   also   required   into   the   relevance   of   C9orf72  
haploinsufficiency   in   ALS.   Chapter   5   included   interesting   results   in   C9orf72-­ALS  
iAstrocytes  which  displayed  elevated  numbers  of  Cajal  bodies.  Work  is  now  ongoing  
to  determine   if   the  Cajal  body  phenotype   is  also  present   in   iNeurons  derived   from  
the  same  patient  fibroblasts.  This  result  will  hopefully  answer  some  of  the  questions  
arising   from   the   lack   of   effect   of   C9orf72   knockdown   on   Cajal   bodies   in   primary  
neurons.   If   Cajal   bodies   are   increased   in   the   iNeurons,   this   would  more   strongly  
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Protein   Uniprot  protein  function   Reference  
ADCY10   Adenylate  cyclase  type  
10  
cAMP  biosynthesis   In  house  
ANXA7   Annexin  A7   Ca/GTP  regulated  
exocytosis  
Yeast  two-­hybrid  





BEX1   Protein  BEX1   Signalling  adaptor  
molecule  
Yeast  two-­hybrid  
C9orf72   Chromosome  9  open  
reading  frame  72  
Autophagy;;  Trafficking   In  house,  Sullivan  
et  al.  2016  
CACTIN   Cactin   Transcriptional  activator   Yeast  two-­hybrid  
CAD   CAD  protein   Pyrimidine  pathway   In  house;;  Blokhuis  
et  al.  2016  
CAND1   Cullin-­associated  
NEDD8-­dissociated  
protein  1  
F-­box  protein  exchange  
factor  
In  house  
CBX3   Chromobox  protein  
homolog  3  
Chromatin  organisation   In  house  




CXXC5   CXXC-­type  zinc  finger  
protein  5  
Transcription  regulation;;  
DNA  damage  response  
Yeast  two-­hybrid  
DDX21   Nucleolar  RNA  helicase  2   RNA  helicase   In  house  
DDX50   ATP-­dependent  RNA  
helicase  DDX50  
RNA  helicase   In  house  
DEK   Protein  DEK   Chromatin  organisation   In  house  






ERH   Enhancer  of  rudimentary  
homolog  
Cell  cycle   In  house  
ERI1   3’-­5’  exoribonuclease  1   RNA  exonuclease   Yeast  two-­hybrid  
EXOSC10   Exosome  component  10   3’-­5’  exoribonuclease  
activity;;  Maturation  of  
rRNA,  snRNA  and  
snoRNA  
Yeast  two-­hybrid  
FBL   Fibrallarin   rRNA  processing;;  
Nucleolar  protein  
In  house  
FUS   RNA-­binding  protein  FUS   RNA  processing   In  house  




factor;;  Cyclin  D1  
expression  regulation  
In  house  





HNRNPA1   Heterogenous  nuclear  
ribonucleoprotein  A1  
RNA  processing   In  house  
HNRNPC   Heterogenous  nuclear  
ribonucleoprotein  C  
RNA  processing   In  house  
HNRNPF   Heterogenous  nuclear  
ribonucleoprotein  F  
RNA  processing   Blokhuis  et  al.  
2016  
HNRNPH   Heterogenous  nuclear  
ribonucleoprotein  H  
RNA  processing   Blokhuis  et  al.  
2016  
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HNRNPK   Heterogenous  nuclear  
ribonucleoprotein  K  
RNA  processing   In  house  
HNRNPM   Heterogenous  nuclear  
ribonucleoprotein  M  
RNA  processing   In  house  
HNRNPU   Heterogenous  nuclear  
ribonucleoprotein  U  
RNA  processing   In  house  
HUWE1   E3  ubiquitin-­protein  
ligase  HUWE1  
Protein  ubiquitination   Sellier  et  al.  2016  
ILF2/3   Interleukin  enhancer-­














MATR3   Matrin-­3   Transcription  regulation;;  
RNA  processing  
In  house  
NCL   Nucleolin   Major  nucleolar  proteins;;  
Pre-­rRNA  transcription;;  
Ribosome  assembly  
In  house,  Blokhuis  
et  al.  2016  
NOTCH3   Neurogenic  locus  notch  
homolog  protein  3  
Transcriptional  activator   In  house  
NPM1   Nucleophosmin   Ribsome  biogenesis;;  
Centromsome  duplication  
In  house  
NR1D2   Nuclear  receptor  
subfamily  1  group  D  
member  2  
Circadian  rhythm   Yeast  two-­hybrid  





PKM   Pyruvate  kinase  PKM   Glycolysis;;  Cell  death  
induction  
In  house  
PPP1CA   Serine/Threonine  protein  
phosphatase  PP1-­alpha  
catalytic  subunit  
Protein  phosphatase   Blokhuis  et  al.  
2016  
PRKAA1   5’AMP-­activated  protein  
kinase  catalytic  subunit  
alpha-­1  
Transcription  regulation   Sellier  et  al.  2016  
PSIP1   PC4  and  SFRS1-­
interacting  protein  
RNA  processing   In  house  
PSMA4   Proteasome  subunit  
alpha  type-­4  
Protein  degradation   Sellier  et  al.  2016  
PSMD8   26S  proteasome  non-­
ATPase  regulatory  
subunit  8  
Protein  degradation   Sellier  et  al.  2016  
PSMD10   26S  proteasome  non-­
ATPase  regulatory  
subunit  10  
Protein  degradation   Sellier  et  al.  2016  
PTBP1   Polypyrimidine  tract-­
binding  protein  1  
RNA  processing   In  house  
RAD54B   DNA  repair  and  
recombination  protein  
RAD54B  
DNA  repair;;  Mitotic  
recombination  
Yeast  two-­hybrid  









In  house;;  Sellier  et  
al.  2016  
RBMX   RNA-­binding  motif  
protein,  X  chromosome  




RLIM   E3  ubiquitin-­protein   Protein  ubiquitination   Sellier  et  al.  2016  
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ligase  RLIM  
RNF126   E3  ubiquitin-­protein  
ligase  RNF126  
Protein  ubiquitination   Sellier  et  al.  2016  




RSL1D1   Ribosomal  L1  domain-­




SENP6   Sentrin-­specific  protease  
6  
Protein  desumoylation   Yeast  two-­hybrid  
SETX   Probable  helicase  
senataxin  
RNA/DNA  helicase;;  RNA  
metabolism  
Sellier  et  al.  2016  
SFPQ   Splicing  factor,  proline-­  
and  glutamine-­rich  
RNA  processing;;  DNA  
repair  
In  house  
SNX6   Sorting  nexin-­6   Intracellular  trafficking   Sellier  et  al.  2016  
SQSTM1   Sequestosome-­1   Autophagy   Sellier  et  al.  2016  
SRSF3   Serine/arginine  rich  
splicing  factor  3  
RNA  processing   In  house  
SRSF7   Serine/arginine  rich  
splicing  factor  7  
RNA  processing   In  house  
STK38   Serine/Threonine  protein  
kinase  38  
MAP3K1/2  signalling   In  house  
STUB1   E3  ubiquitin-­protein  
ligase  CHIP  
Protein  ubiquitination   Sellier  et  al.  2016  
TARDBP   TAR  DNA-­binding  protein  
43  
Transcription  and  splicing  
regulation  
Sellier  et  al.  2016  





Blokhuis  et  al.  
2016  
TJP2   Tight  junction  protein  ZO-­
2  
Tight  junctions  and  
adhere  junctions  
Yeast  two-­hybrid  
TOX4   TOX  high  mobility  group  
box  family  member  4  
Chromatin  structure;;  Cell  
cycle  
Blokhuis  et  al.  
2016  
UACA   Uveal  autoantigen  with  
coiled-­coil  domains  and  
ankyrin  repeats  
Apoptosis  signalling   In  house  
UBR4   E3  ubiquitin-­protein  
ligase  UBR4  
Protein  ubiquitination   In  house;;  Sellier  et  
al.  2016  
USP48/8   Ubiquitin  carboxyl-­
terminal  hydrolase  48/8  
Protein  deubiquitination   Yeast  two-­hybrid  
WAC   WW  domain-­containing  
adaptor  protein  with  
coiled-­coil  
Transcription  regulation;;  
DNA  damage  response  
Yeast  two-­hybrid  
XRCC6   X-­ray  repair  cross-­
complementing  protein  6  
DNA  helicase;;  DNA  
damage  response  
In  house  
YBX1   Nuclease-­sensitive  
element  binding  protein  1  
RNA  processing   In  house  
ZC3H14   Zinc  finger  CCCH  
domain-­containing  
protein  14  
Poly(A)  RNA  binding  and  
regulation  
In  house  
ZNF551   Zinc  finger  protein  551   Transcription  regulation   In  house  
ZNF585A   Zinc  finger  protein  585A   Transcription  regulation   Yeast  two-­hybrid  
Table  8.1.  C9orf72  nuclear   interactors.  Where   ‘In  house’   refers   to  mass   spectrometry   identification  of  C9orf72  
protein  interactors  after  immunoprecipitation  of  exogenous  C9orf72  protein  from  HEK293  cell  lysates.  Performed  by  
Dr  Guillaume  Hautbergue  and  Dr  Matthew  Walsh.  Where  ‘Yeast  two-­hybrid’  refers  to  the  screen  detailed  in  Section  
4.2.3.  
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